



HEALTHIER LIFE **OUR COMMITMENT**

Integrated Annual Report 2019-20



In Search of Excellence



Orion Pharma Limited believes that improving quality is a continuous process and it is our commitment, prime responsibility and priority to make lives better by ensuring proper health. All our business practices and efforts are in consistency with our key aim – Healthier Life, Our Commitment.

As a part of this commitment, we are morally obligated to deliver quality medicines to patients in need. This year we successfully launched 9 (nine) medicines of which 5 (five) were introduced in the face of the Covid-19 pandemic. We feel proud to be able to help our people during this time of crisis, which again supports our ultimate motive of making lives healthier.

We are a reliable pharmaceutical company in Bangladesh and dedicated in contributing to the improvement of human health. 'Pharmacovigilance' is a system whereby we monitor and manage the safety of our medicines all over the country. In the reporting financial year, '0' adverse event was reported under pharmacovigilance that ensured best quality of our products.

Our company has a holistic approach towards corporate responsibility and believes in building a long-term sustainable business by also considering our impacts on the environment in which we operate. Pharmaceutical waste affects the environment and those living near production plant. Therefore, taking steps towards nurturing the environment brings us closer to our aim of making lives healthier. Our key initiatives in this regard were installation of ETP with neutralizing capacity of 3,75,000 litre/day for liquid waste and installation of incinerator including wet scrubbing technology with incineration capacity of 100 kg/hr for solid waste. We try to operate as a responsible business in all aspects which enables us to continue taking a step closer to our promise of making lives healthier.



Please scan the above QR code instead of printing the report. It contains the digital version of the Integrated Annual Report 2019-20 of Orion Pharma Limited.

Letter of transmittal

All Shareholders
Registrar of Joint Stock Companies and Firms
Bangladesh Securities and Exchange Commission
Dhaka Stock Exchange Limited and
Chittagong Stock Exchange Limited

Dear Sir/Madam (s):

ANNUAL REPORT FOR THE YEAR ENDED JUNE 30, 2020

We are pleased to inform you that the Board of Directors of Orion Pharma Ltd. has taken the decision, in its Board meeting held on November 08, 2020, to hold 55th Annual General Meeting of the Company on December 23, 2020.

In accordance with the requirement of Bangladesh Securities and Exchange Commission, we are enclosing a copy of the Annual Report together with the Audited Financial Statements including Statement of Financial Position as at June 30, 2020, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity and Statement of Cash Flows for the year ended June 30, 2020 along with notes as well as the Directors' Report of the Company thereon for your record/necessary measures.

Yours sincerely

Sd/-

Md. Ferdous Jaman

Company Secretary

Dated: December 01, 2020



AVAILABILITY OF THE REPORT

We ensure that the printed version of the Integrated Annual Report is forwarded to the shareholders before holding the Annual General Meeting. Also the hard copy of the report is available at the company's registered office and the electronic version of the report is available online at www.orionpharmabd.com

REQUEST FOR FEEDBACK

We would appreciate the views, comments, questions and opinions from all stakeholders on the Integrated Annual Report 2019-20. The stakeholders can share their observation; ask for any information requirements or any query at the following addresses:

Corporate Address

Orion House
153-154 Tejgaon I/A,
Dhaka-1208, Bangladesh

Contact

Phone: +88 02 8870133
Fax: +88 02 8870130

E-mail Address

orion@orion-group.net
orion.share@orion-group.net

Facebook

www.facebook.com/OrionPharmaLtdbd/
www.facebook.com/oriongroup.dhaka.bangladesh/

Website

www.orionpharmabd.com
www.orion-group.net



In Search of Excellence

Registered office:

ORION HOUSE

153-154, Tejgaon I/A, Dhaka-1208, Bangladesh

NOTICE OF THE 55TH ANNUAL GENERAL MEETING

Notice is hereby given that the 55th Annual General Meeting (AGM) of the Shareholders of Orion Pharma Limited will be held on **Wednesday, December 23, 2020 at 04.00 PM** on a Digital Platform, to transact the following businesses :-

Agenda

- To receive, consider and adopt the Audited Financial Statements of the Company for the year ended June 30, 2020 together with the Auditors' Report and Directors' Reports thereon.
- To approve dividend for the year ended June 30, 2020.
- To elect/re-elect Directors who will retire by rotation as per the relevant provisions of Articles of Association.
- To consider and approve the appointment of Managing Director with post facto effect.
- To consider and approve the appointment of the Independent Director.
- To appoint Statutory Auditors and to fix their remuneration for the financial year 2020-2021.
- To appoint Corporate Governance Compliance Auditors and to fix their remuneration for the financial year 2020-2021.
- To transact any other business with the permission of the Chair.

By Order of the Board

Date: December 01, 2020
Dhaka

Sd/-
Md. Ferdous Jaman
Company Secretary

Note

- Shareholders whose names appeared in the Depository/Members Register on the Record Date (November 29, 2020) are eligible to join the meeting and will qualify for Dividend.
- A member entitled to join and vote at the Annual General Meeting may appoint a proxy to join and vote on his/her behalf. The Proxy Form, duly stamped (BDT 20.00), must be sent to the Company's Corporate Office or through e-mail (orion.share@orion-group.net) not later than 48 hours before the time fixed for the meeting and in default, Proxy Form will not be treated as valid.
- Annual Report and Proxy Form along with the notice will be sent to all the members through post/courier/e-mail. The members may also collect the Annual Report or the Proxy Form from the webpage (www.orionpharmabd.com) of the Company. AGM joining procedure will be notified later through E-mail/SMS.
- Members are requested to update their BO ID contact information i.e. address, mobile no. and e-mail address through their concerned DP.

INSIDE THIS REPORT

Notice of the 55 th Annual General Meeting	3
Contribution to the Sustainable Development Goals	6
Our approach to integrated reporting	7
Materiality assessment & reporting	10

Corporate Overview

Performance highlights	12
The values we created	13
About our Group	14
Company information	18
Company philosophy	20
Our company at a glance	21
Chronicle of events	26
Awards & recognition	28
Board of Directors	31
Management team	39

Our governance

Message from the Chairman	48
Message from the Chairman in Bangla	50
Message from the Managing Director	52
Governance structure	54
Audit Committee report	67
Nomination & Remuneration Committee report	72
Risk Management Committee report	79
Code of conduct & business ethics	93
Organizational chart	98
Compliance with laws, rules, regulations & standards	99
Shareholders' grievance redressal system	100
Directors' report	104
Management discussion & analysis	114
Certification by the MD & CFO to the Board	116
Certificate of compliance on the corporate governance code	117
Checklist on compliance of corporate governance code	118
The pattern of shareholding	130
Compliance report on IAS/IFRS	132

Our capitals

Financial capital	134
Manufactured capital	138
Intellectual capital	146
Human capital	160
Social & relationship capital	176
Natural capital	196



Sustainable business strategy

Operating context analysis	204
Business model for value creation	208
Value chain model	210
Our strategic objectives	212
Opportunities & outlook	219
Stakeholder engagement strategy	222
Competitive edge with our value proposition	224

Performance & Financials

Five years' highlights - consolidated	226
Horizontal & vertical analysis - consolidated	227
Graphical presentation - consolidated	228
Contribution to national exchequer	230
Human resource accounting	231
Value added statement - consolidated	232
Share performance	233
Independent Auditors' Report	235
Consolidated Statement of Financial Position	240
Statement of Financial Position	241
Consolidated Statement of Profit or Loss and Other Comprehensive Income	242
Statement of Profit or Loss and Other Comprehensive Income	243
Consolidated Statement of Changes in Equity	244
Statement of Changes in Equity	245
Consolidated Statement of Cash Flows	246
Statement of Cash Flows	247
Notes to the Financial Statements	248

Orion Power Meghnaghat Limited

Directors' report	286
Independent Auditors' Report	289
Statement of Financial Position	291
Statement of Profit or Loss and Other Comprehensive Income	292
Statement of Changes in Equity	293
Statement of Cash Flows	294
Notes to the Financial Statements	295

Dutch Bangla Power & Associates Limited

Directors' report	310
Independent Auditors' Report	313
Statement of Financial Position	315
Statement of Profit or Loss and Other Comprehensive Income	316
Statement of Changes in Equity	317
Statement of Cash Flows	318
Notes to the Financial Statements	319

Proxy form & shareholders' attendance slip	335
--	-----

Contribution to the Sustainable Development Goals

The United Nations adopted 17 (seventeen) Sustainable Development Goals (SDGs) as a set of collective targets for the world with the aim of solving global problems and attaining these goals by 2030. In our endeavors, we are actively committed to contributing to the achievement of the SDGs and accordingly we have identified 10 (ten) goals based on the evaluation of impacts of our business operation on SDGs across the entire value creation model. How we are contributing towards achievement of SDGs are illustrated below:



Our approach to integrated reporting

We are proud to be one of the early adopters of Integrated Reporting particularly in the manufacturing sector of Bangladesh and presenting our 5th Integrated Annual Report demonstrating our governance structure, business strategy, risks and opportunities, as well as operational performance for the financial year ended June 30, 2020.

This Integrated Report concisely depicts the general picture of the company including how it creates values through its normal course of business in the context of its strategy, opportunities and risks and gives stakeholders a holistic view of the organization's financial and non-financial performance for the financial year ended June 30, 2020. This report is prepared based on the information which is material, useful, relevant and meaningful to stakeholders for their understanding of the company's ability to build value in the short, medium and longer term.

Scope & boundary

This report covers the activities and performance of Orion Pharma Limited including global operations and its operating subsidiaries with a view to providing a true and transparent picture of the company to all stakeholders, with a particular focus on those stakeholders who are the providers of financial capital. This report demonstrates the overview of the performance of the company and its subsidiaries, value created for stakeholders and contribution to the society. For facilitating proper decision-making by our stakeholders, the company's separate as well as the consolidated audited financial statements are presented here. For better understanding of the performance of the subsidiaries, a separate subsidiary report comprising of the Directors' Report as well as the audited financial statements of each subsidiary for the reporting financial year are included in this report. This Integrated Report is prepared in line with the guidelines of Integrated Report issued by the Institute of Chartered Accountants of Bangladesh (ICAB) referred to as the 'Integrated Reporting Checklist' which is along the lines of Integrated Reporting Framework issued by the International Integrated Reporting Council (IIRC).

There have not been any significant changes to the scope, boundary and reporting basis since the last reporting date and therefore, this report has been prepared on the same basis as the 2018-19.



Reporting period

Orion Pharma Limited presents its 2019-20 Integrated Annual Report for the financial year from July 01, 2019 to June 30, 2020 with comparative prior period information where applicable. In addition to this, subsequent events upto the issuance of this report have also been described in various sections of the report.



Reporting framework

Integrated reporting

- Integrated Reporting Framework issued by the International Integrated Reporting Council (IIRC)

Financial reporting

- International Financial Reporting Standards
- International Accounting Standards

Corporate governance reporting

- Corporate Governance Code issued by BSEC in 2018

Regulations

- Companies Act, 1994
- Securities and Exchange Ordinance, 1969
- BSEC's Laws, Orders, Notifications, Directives, Guidelines etc.
- The Income Tax Ordinance, 1984
- Other relevant laws and regulations of the land



Cross-reference

Throughout the report, we have used cross-reference in order to limit repetition.

Capitals of value creation

As we focus on building a sustainable business, we demonstrate the performance and activities related to the 6 (six) capitals of value creation, described in the Integrated Reporting Framework. These capitals are financial, manufactured, intellectual, human, social and relationship and natural capitals.

The business model presented on page 208 details the integration of our 6 (six) capitals into the business for value creation. The following icons are used as an identifiable visual reference to these 6 (six) capitals throughout this report.



Financial capital
(Page 134)



Manufactured capital
(Page 138)



Intellectual capital
(Page 146)



Human capital
(Page 160)



Social & relationship capital
(Page 176)



Natural capital
(Page 196)

Key elements of our Integrated Report



Corporate governance
(Page 47)



Strategic objectives
(Page 212)



Business model
(Page 208)



Stakeholder relationship
(Page 222)



Operating context
(Page 204)



Performance
(Page 225)



Opportunities & outlook
(Page 219)



Risks
(Pages 82)

Key qualitative attributes of our Integrated Report



External assurance of the integrity of the report

The company has applied combined assurance practices from various independent external assurers on the following reports:

Assurance on	Assurance provider
Consolidated and separate financial statements of Orion Pharma Limited	S.F. Ahmad & Co. Chartered Accountants
Financial statements of Orion Power Meghnaghat Limited	S.F. Ahmad & Co. Chartered Accountants
Financial statements of Dutch Bangla Power & Associates Limited	S.F. Ahmad & Co. Chartered Accountants
Corporate governance compliance	ARTISAN Chartered Accountants
Provident fund	Habib Sarwar Bhuiyan & Co. Chartered Accountants
Credit rating	Credit Rating Agency of Bangladesh Ltd.

The Board has approved the Directors' Report of the company to be published in the Integrated Annual Report for the financial year 2019-20 in its meeting held on November 08, 2020

Forward looking statements

Certain statements in this report particularly under the points "Opportunities & outlook" contain forward looking statements which are highly based on assumptions and predictions. Some of the major issues highlighted under this point are future financial performance, growth in production and sales, achievement of international certification, new markets etc. These statements do not guarantee any future outcome rather demonstrate our current expectations. However, actual results might differ significantly from forecasts made in any forward looking statements because of some future events and circumstances which are beyond the company's control. Therefore, the readers are recommended to use caution when interpreting any forward looking statement of this report.

Responsibility over the integrity of the Integrated Report

The Board and the management acknowledge their responsibility to apply their collective endeavour to the preparation and presentation of this report and ensure that all material matters have been addressed and fairly presented in this Integrated Report. In addition, the Board states that the Integrated Report has been prepared as per the stated reporting frameworks.



Disclaimer

This disclaimer sets out the conditions for use of contents in this Integrated Annual Report. This report's contents are for information for the company's stakeholders including shareholders and is not intended to endorse, promote or recommend products listed in it which are for representation purpose only.

Materiality assessment & reporting

We always believe that issues which have impact on our performance and help our stakeholders derive at a decision are material and therefore, need to be identified and addressed. Identifying and reporting these material issues is an integral part for preparation of our annual report because it helps to make the report both concise and rich, in terms of providing appropriate insight into the past performance and future outlook of the entity.

Issues highly material for both internal & external stakeholders

- Maintain quality products
- Monitor safety of products through pharmacovigilance
- Sustained financial performance
- Strong research and development
- New product development assessment
- Corporate governance
- Business ethics and code of conduct
- Compliance
- Broader market with strong foundation
- Occupational health and safety

Issues highly material for internal stakeholders

- Improved productivity
- Strict cost control and management
- Strong brand image
- Knowledge based professional team
- Global footprint expansion
- Talent management through training and education
- Employee engagement
- Monthly appraisal
- Eco-friendly staff practices
- Conservative use of natural resources

Issues highly material for external stakeholders

- Respond to customers within a reasonable time
- Community engagement
- Environment-friendly production plan
- Efficient waste management
- Safe expired product destruction

Materiality assessment process

Identification

The management team and the representatives of functional departments go through extensive consultation and document review based on the previous year's material topics to derive at the issues that are of major importance and have substantial impact on the company's value creation for its stakeholders. Regular communication and engagement with potential stakeholders is conducted to obtain inputs in the process of identifying material issues.

Prioritization

Identified issues are prioritized based on their relative importance to value creation. Both financial and qualitative risks, opportunities and strategic objectives of the company are considered when prioritizing the material aspects and determining how they affect stakeholders and their goal of attaining maximum utility from our business operations.

Disclosure & reporting

Identified material issues are disclosed and reported for stakeholders' information and their decision making purposes.

Review & monitoring

The materiality assessment process and identified material topics are reviewed periodically by key functional heads and top management to enrich our materiality analysis process.




**Corporate
overview**
2019-20

• Board of Directors • Management team • Performance highlights • The values we created • About our Group • Company Information



Performance highlights

2019-20



<p>Patients </p> <ul style="list-style-type: none"> • Particle size analyzer and impurity profile checking of API were introduced to enhance the product quality • 9 new products were launched under antifungal, antidiabetic, hand rub preparations, anti-malarial and anti-viral portfolio • '0' adverse event was reported under pharmacovigilance ensuring best quality of product 	<p>Shareholders </p> <ul style="list-style-type: none"> • BDT 2.84 earnings per share • 10% cash dividend proposed • 35.21% profit payout • 3.47% return on equity • 5.13% return on capital employed 	<p>Regulators </p> <ul style="list-style-type: none"> • BDT 517.31 million contributed to national exchequer • BDT 167.35 million at import stage • BDT 349.96 million at local stage
<p>Employees </p> <ul style="list-style-type: none"> • 368 employees received trainings • 646 employees purchased the medicines at a discounted price • 6 deceased employees' families were benefited under the scheme "Donation on Death" • Covid-19 test facility, doctor's chamber and medicine corner were arranged • Health checkup program on World Diabetes Day was arranged 	<p>Society </p> <ul style="list-style-type: none"> • 27 Chronic Myeloid Leukemia patients are getting Enliven capsule at a discounted price • 29 medical students are receiving scholarship • 3,000 iftar packets were distributed to the distressed people of the society • 30,000 packets of relief were distributed to underprivileged in Covid-19 pandemic • Health awareness campaigns and programs were undertaken in print and social media 	<p>Environment </p> <ul style="list-style-type: none"> • Structural layout of building facilitates maximum utilization of natural light • Annual paper, natural gas and water consumption were reduced • ETP and incinerator were installed for treatment of both liquid and solid waste before discharging to environment

The values we created

2019-20



BDT 2,701.41 million
wealth created for our shareholders and the society in which we operate



About our Group

Founded over almost 4 (four) decades ago, Orion Group is a recognized and diversified conglomerate in Bangladesh. Initially established as one of the front-runners in the pharmaceutical industry, Orion later diversified into many other sectors and has leadership positions in many of the most demanding and attractive industries including power & energy, infrastructure development, real estate, cosmetics & toiletries. The Group is built on a strong foundation of determination, excellence, integrity and a firm promise to deliver value to its key stakeholders. The Group is highly committed in bringing great changes in the socio-economic development of the country as well as in making a future which is more productive, secure and sustainable.

The Group has grown into a large conglomerate through revealing valuable new growth opportunities after starting its journey back in early 80's. It has undergone potential expansion in multiple sectors due to its responsible business practices. The Group mainly operates in 11 (eleven) sectors containing pharma & healthcare, power & energy, infrastructure development, real estate, cosmetics & toiletries, high-tech agro & consumer products, textiles & garments and home appliances.

There are 3 (three) publicly-listed companies of Orion Group namely; Orion Pharma Limited, Orion Infusion Limited and Kohinoor Chemical Company (Bangladesh) Limited; with a combined market capitalization of BDT 20,838.22 million as on June 30, 2020.

The Group is ranked among the most important multidisciplinary Groups and advocates for the principles of care for the future, high professionalism, employee-centric approach, financial stability, transparency, safety and leadership. It is striving to strengthen its market access, formulating its competitive strategies and putting emphasis on productivity enhancement, thus playing a pivotal role in the country's commerce & trade sectors. Orion Group will continue to adopt coherently set strategies and objectives to contribute to all our stakeholders. The strategies also focus on addressing the economic and social development along with its long-term commitments to the citizen of the country. The Group will keep working to foster sustainable economic development of the country.



Group Vision

To transform communities by blending the mix of integrity, teamwork and creativity of our people

Corporate

Ethos



Customer

- Exceeding customer satisfaction and granting trust through quality services



Product & Process

- Assuring quality products from advanced manufacturing facilities
- Introducing new and innovative products and technologies



People & Performance

- Continuous development of people competency
- Recognizing individual contribution

Group Mission Group Values



Sustainability

- Quality in everything we do
- Transparent and fair in all our dealings



Leadership

- Take initiative to exceed standards




Co-operation

- Trust and respect for each other
- Work as a team



Responsibility

- Share social responsibility



INFRASTRUCTURE DEVELOPMENT



TEXTILES & GARMENTS




HOME APPLIANCES



PHARMA & HEALTHCARE

Group



POWER

Landmark projects



The LONGEST Flyover

The first successful PPP project of the country is ORION's 11.80 km long Elevated Expressway "Mayor Mohammad Hanif Flyover" operational since October 2013 and connecting Dhaka with 40 (forty) districts.



The MOST TECHNOLOGICALLY ADVANCED HFO Power Plants

The 3 (three) HFO based power plants - the 100 MW Dutch Bangla Power & Associates Ltd. at Narayanganj, the 100 MW Orion Power Meghnaghat Ltd. at Narayanganj and the 105 MW Orion Power Rupsha Ltd. at Khulna were completed in just 9 (nine) months each.



Kohinoor Chemical Company (Bangladesh) Ltd.

COSMETICS & TOILETRIES



City Centre



Orion Properties Ltd.

REAL ESTATE

SBU's



Jafflong Tea Company Ltd.



ORION CONSUMER PRODUCTS LIMITED



Orion Tea Company Ltd.

CONSUMER PRODUCTS



Orion Footwear Ltd.

FOOTWEAR



MEDIA



Orion Gas Ltd.



Orion Oil & Shipping Ltd.

ENERGY



The TALLEST Building

The 37-storied "City Centre" is the tallest building and the most prestigious landmark in country's skyline. This building is the first commercial cum multistoried parking complex at Motijheel, Dhaka and is managed through Building Management System.



The MOST MODERN Pharma Park

ORION is implementing one of the biggest Pharma Parks of the country at Narayanganj where a complete array of pharmaceutical facilities and solutions will be incorporated within a single complex, following all latest global standards.



The ULTRA SUPER-CRITICAL Coal Power Plants

The 630 MW Orion Power Dhaka Ltd. and the 635 MW Orion Power Unit -2 Dhaka Ltd. are two of the largest IPP based single unit coal based Ultra Super-Critical power plants being implemented in Munshiganj.

Company information

Section A General information about the company

Legal Form

Incorporated as a Private Limited Company on June 21, 1965; converted into a Public Limited Company on June 24, 2010 under the Companies Act, 1994

Listing Status

Listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited since 2013

Corporate Office

ORION HOUSE
153-154, Tejgaon Industrial Area
Dhaka-1208, Bangladesh
Tel: +88 02 8870133
Fax: +88 02 8870130

Factory Address

Sumilpara, Siddhirganj
Narayanganj, Bangladesh

Company E-mail

orion@orion-group.net
orion.share@orion-group.net

Company Website

www.orionpharmabd.com
www.orion-group.net

No. of Employees

2,696

Section B Board & Committee information

Board of Directors

- Mr. Mohammad Obaidul Karim
- Mrs. Arzuda Karim
- Mrs. Zareen Karim
- Mr. Salman Obaidul Karim
- Mrs. Hasina Begum
- Mr. Md. Shafiqur Rahman
- Mr. A. N. M. Abul Kashem

Audit Committee

- Mr. Md. Shafiqur Rahman
- Mr. A. N. M. Abul Kashem
- Mr. Salman Obaidul Karim

Nomination & Remuneration Committee

- Mr. Md. Shafiqur Rahman
- Mr. A. N. M. Abul Kashem
- Mr. Salman Obaidul Karim

Risk Management Committee

- Mr. A. N. M. Abul Kashem
- Mrs. Arzuda Karim
- Mrs. Zareen Karim

Company Secretary

Mr. Md. Ferdous Jaman

Chief Financial Officer

Mr. Samaresh Banik

Head of Internal Audit & Compliance

Mr. Md. Ibrahim Khalil

Section C Financial details of the company

Authorized Capital

BDT 5,000,000,000

Paid-up Capital

BDT 2,340,000,000

No. of Shareholders

35,481

Section D Other details

Statutory Auditors

S. F. Ahmed & Co.
Chartered Accountants
House - 51 (2nd & 3rd Floor), Road - 9, Block - F, Banani
Dhaka - 1213, Bangladesh

Corporate Governance Compliance Auditor

ARTISAN
Chartered Accountants
Shah Ali Tower (7th Floor), 33, Kawran Bazar
Dhaka-1215, Bangladesh

Subsidiaries

- Orion Power Meghnaghat Limited
- Dutch Bangla Power & Associates Limited

Associate

Orion Infusion Limited

Bankers

- Agrani Bank Limited
- Sonali Bank Limited
- Rupali Bank Limited
- National Bank Limited
- Social Islami Bank Limited
- Bank Asia Limited
- Premier Bank Limited
- City Bank Limited
- AB Bank Limited
- Al-Arafah Islami Bank Limited

Insurers

- Islami Commercial Insurance Co. Limited
- Phoenix Insurance Company Limited
- Green Delta Insurance Co. Limited

Company philosophy

Our VISION

To be regarded as a world-class pharmaceutical company in the field of generic finished products



Our MISSION

To improve people's health and achieve stakeholders' satisfaction by manufacturing and marketing pharmaceutical finished products

Our CORE VALUES



INTEGRITY

We act with integrity, honesty and transparency



QUALITY

We are committed to excellence of quality of our products



RESPECT

We treat each other with respect and uphold the dignity of people



MOTIVATION

We value, develop, encourage and motivate every member of our company



SAFETY

We value safety to be the utmost priority in all our decision making process and activities



TEAMWORK

We encourage and nurture the culture of teamwork



COLLABORATION

We collaborate to strengthen the communities in which we operate



SUSTAINABILITY

We believe in sustainable business from economic, environment and social aspects

Our company at a glance

Established in 1965, Orion Pharma Limited (OPL) is a pharmaceutical company focused on improving the health of patients through its reliable and affordable pharmaceutical products. Based on this, the company emphasizes on responsible and sustainable growth through wide generic portfolio and strong customer relationships across both local and global markets. Being active at every stage of the value chain, maximizing the value we create for our business and its diverse stakeholders is our focal area.



Orion Pharma Park

Orion Pharma Park

Orion Pharma Limited is constructing a new pharmaceutical manufacturing plant named Orion Pharma Park, which is going to be one of the biggest and finest pharmaceutical complexes of the country. The Orion Pharma Park is located in Siddhirganj, Narayanganj. The construction of the General Pharma Building – 1 (GPB-1) is complete. We will start the commercial operation in this new manufacturing plant very soon. The plant is well designed and equipped with all latest facilities and state-of-the-art technologies.



More information about the plant is discussed elaborately in the 'Manufactured capital' of this Integrated Annual Report.

OPL Annual Report 2019-20

We focus on 203 products under 7 dosage forms



96

Tablets



23

Capsules



16

Powder for suspensions



31

Liquids & suspensions



30

Injections



05

Creams/ointments



02

Hand rubs

Our portfolio

Our company produces capsules, tablets, syrups, suspensions, injections, dry powder for syrups/suspensions, creams/ointments, hand rubs etc. under different classifications including anticancer, cardiovascular, antibiotics, anti-diabetics, anxiolytics, antihistamines, antiulcerants, NSAIDs, vitamins & minerals and many others. With growing markets and an increasing reach, this pharmaceutical powerhouse is operating with 104 brands and 203 presentations with the anticipation of rapid growth and innovation. OPL always strives to come up with new ways of using existing medicines, new dosage combinations, new indications, different flavors and enhanced packaging that improve patient adherence. We are continually focused on increasing the breadth and depth of our therapeutic portfolio and have been working on various new products including cephalosporin and oncology categories. During the reporting year, Orion Pharma Limited has introduced 9 (nine) new products of anti-malarial, antifungal, anti-viral, antidiabetic and hand rub preparations therapeutic areas under 5 (five) different brand names.

112

Generics

104

Brands


36

Therapeutic areas



Our global presence

OPL believes that in order to grow and develop in the future and to provide our healthcare facility globally, we must also expand beyond borders and go international. As of now, we have overseas marketing network in Asia, Middle-East, Europe and Africa.



- 📍 Afghanistan
- 📍 Armenia
- 📍 Bhutan
- 📍 Cambodia
- 📍 Fiji
- 📍 Iraq
- 📍 Kosovo
- 📍 Lesotho
- 📍 Myanmar
- 📍 Nepal
- 📍 Somalia
- 📍 Somaliland
- 📍 Sudan
- 📍 Sri Lanka
- 📍 Yemen

Associate

OPL owns 21.76% of shares in Orion Infusion Limited (OIL), another concern under the banner of Orion Group. OIL produces Large Volume Parenteral (LVP) & other life-saving injectable products.

Orion Infusion Ltd.

Orion Infusion Limited (OIL) was incorporated in 1983 as a state-of-the-art Large Volume Parenterals (LVP) manufacturing company. In 1994, the company became a public limited company and was listed in DSE. Subsequently in 1996, the company was enlisted with CSE as well.

OIL is one of the leading pharmaceutical companies in Bangladesh with cutting edge technologies for manufacturing and marketing of IV Fluid, lifesaving intravenous and intravascular saline like Rehydration Solution, Electrolyte Solution, Amino Acid Solution, Antimicrobial products viz. Ciprofloxacin IV, Metronidazole IV, Ceftriaxone IV & Plazma Substitute viz. Hydroxyethyl Strach Solution.



Subsidiaries

OPL owns 95% of shares in Orion Power Meghnaghat Limited (OPML) and 67% of shares in Dutch Bangla Power & Associates Limited (DBPAL), 2 (two) concerns of Orion Group. OPML is a 100 MW HFO power plant on quick rental basis in Meghnaghat, Narayanganj. DBPAL is another 100 MW HFO power plant on quick rental basis in Siddhirganj, Narayanganj.

Orion Power Meghnaghat Ltd.

Orion implemented a 100 MW HFO based power plant, under the Government's Quick Rental Power Plant (QRPP) policy, situated in the power village of Meghnaghat, Narayanganj, near the bank of river Meghna. The construction of the plant was completed in a record time of just 9 (nine) months with brand new European machineries and equipment. It is connected with National Grid, Sonargaon Substation. The plant has been distributing electricity to the national grid on regular basis since 2011 and BPDB has renewed the contract with the company to generate and distribute electricity for 5 (five) more years till 2021.



Dutch Bangla Power & Associates Ltd.

Dutch Bangla Power & Associates Limited was implemented as a 100 MW HFO Quick Rental Power Plant (QRPP) policy, situated in Siddhirganj, Narayanganj, beside the bank of river Shitalakshya, with brand new European machineries and equipment. This construction was also completed in only 9 (nine) months due to the use of world class equipment and deployment of world class EPC contractor. The generated output is regularly being supplied to national grid since 2011. It is connected with National Grid through Siddhirganj Substation. This plant has also been renewed to operate for further 5 (five) years till 2021.



Chronicle of events

Foundation Phase (1965-2004)

- Incorporation of the company with the name - Orion Laboratories Limited
- Commencement of production
- 1st time production of following generics in Bangladesh-
 - Zinc Sulphate (Brand name - Pep)
 - Vitamin E + Vitamin C (Brand name - EC - Plus)
 - Furosemide + Spironolactone (Brand name - Frulac)
 - Desloratadine (Brand name - Deslor)
- 1st time locally manufacturing of Mecobalamin Generic in Bangladesh (Brand name - Nervex)

Growing Phase (2005-2012)

- First entry into the international market; export to Nepal and Myanmar
- 1st time locally manufacturing of Tiemonium Methylsulphate Generic in Bangladesh (Brand name - Onium)
- 1st time production of following generics in Bangladesh-
 - Alverine Citrate (Brand name - Alve)
 - Magaldrate + Simethicone (Brand name - Novelta)
 - Acemetacin (Brand name - Tendonil)
 - Cefditoren (Brand name - Cefditor)
- Achievement of ISO 9001:2008 Certificate
- Conversion to public limited company
- Change of company name to Orion Pharma Limited
- Start of commercial operation of 2 (two) subsidiaries (Power generation plants)



Expansion Phase (2013-2020)

- Listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited
- Export to Srilanka, Lesotho, Armenia, Bhutan, Cambodia, Afghanistan, Sudan, Somalia, Somaliland, Fiji, Iraq, Yemen and Kosovo.
- Successful achievement of ISO 9001: 2015 certification
- Achieved 2nd position for best presented Annual Report from ICAB in 2014 and 2016
- Achieved 2nd runner-up position for best presented Annual Report from SAFA in 2016
- Achieved 3rd (joint) position for best presented Annual Report from ICAB in 2017 and 2018
- Achieved Certificate of Merit for best presented Annual Report from SAFA in 2018
- Achieved Silver award for Corporate Governance Excellence from ICSB in 2018
- Completion of construction of the General Pharma Building-1 of Orion Pharma Park



Awards & recognition

Achievements in 2019-20



Mrs. Zareen Karim, Managing Director and Mr. Md. Ferdous Jaman, Company Secretary of Orion Pharma Limited receiving award from the Hon'ble Commerce Minister, Mr. Tipu Munshi, MP for securing the joint 3rd position under Manufacturing Sector category for "Best Presented Annual Report-2018" at the 19th ICAB National Award ceremony.

Mrs. Zareen Karim, Managing Director and Mr. Md. Ferdous Jaman, Company Secretary of Orion Pharma Limited receiving award from the Hon'ble Commerce Minister, Mr. Tipu Munshi, MP for winning the Certificate of Merit in South Asian Federation of Accountants (SAFA) Best Presented Annual Report Awards 2018 under Manufacturing Sector category.



Mr. Md. Mamunur Rashid, Manager, Company Affairs of Orion Pharma Limited receiving Silver Award and Certificate from former Adviser of the Caretaker Government, Mr. A B Mirza Azizul Islam and former Principal Secretary of Government of the People's Republic of Bangladesh, Mr. Md. Abdul Karim at the 6th ICSB National Award for Corporate Governance Excellence, 2018 under Pharmaceutical and Chemical Companies category.

Recognition over the years



3rd (joint) position in 19th ICAB National Award for Best Presented Annual Report 2018



Certificate of Merit in South Asian Federation of Accountants (SAFA) Best Presented Annual Report Awards 2018



Silver award in 6th ICSB National Award for Corporate Governance Excellence, 2018



Certificate of Silver award in 6th ICSB National Award for Corporate Governance Excellence, 2018



3rd (joint) position in 18th ICAB National Award for Best Presented Annual Report 2017



2nd position in 17th ICAB National Award for Best Presented Annual Report 2016



2nd Runner Up in South Asian Federation of Accountants (SAFA) Best Presented Annual Report Awards 2016



2nd position in 15th ICAB National Award for Best Presented Annual Report 2014

Orion Pharma Limited

a company of many firsts



Board of Directors

MR. MOHAMMAD OBAIDUL KARIM

Chairman &
Non-Executive Director

MRS. ZAREEN KARIM

Managing Director

MRS. ARZUDA KARIM

Non-Executive Director

MR. SALMAN OBAIDUL KARIM

Non-Executive Director

MRS. HASINA BEGUM

Non-Executive Director

MR. MD. SHAFIQR RAHMAN

Independent Director

MR. A. N. M. ABUL KASHEM

Independent Director



MR. MOHAMMAD OBAIDUL KARIM

Chairman

Appointment as Director

Mr. Mohammad Obaidul Karim has been a Director of the company since 1984 and was unanimously appointed as the Chairman of the Board in 2014.

Educational Qualification(s)

Mr. Karim graduated from University of Dhaka.

Board Committee(s) served on

Mr. Karim does not hold membership in any sub-committee of the Board.

Directorship(s) in other companies

Currently Mr. Karim is also the Chairman of Orion Infusion Limited, Kohinoor Chemical Co. (BD) Limited, Digital Power & Associates Limited, Dutch Bangla Power & Associates Limited, Orion Power Meghnaghat Limited, Orion Power Dhaka Limited, Orion Power Unit-2 Dhaka Limited, Orion Power Sonargaon Limited, Orion Power Rupsha Limited, Orion Infrastructure Limited, Orion Infrastructure Development Company Limited, City Centre, Orion Gas Limited, Orion Oil & Shipping Limited, Orion Hospitals Limited, Orion Holdings Limited, Orion Knit Textiles Limited, Orion Footwear Limited, Orion Agro Products Limited, Orion Capital Limited, Orion Natural Care Limited, Orion Tea Company Limited, Orion Quaderia Textiles Limited and Orion Consumer Products Limited.

Responsibilities and achievements

Mr. Mohammad Obaidul Karim is a distinguished self-achieved industrialist & businessman. Mr. Karim's business career started in the early 1980s with his first pharmaceutical company named Orion Laboratories Limited, which is now

known as Orion Pharma Limited. He turned the company into one of the most successful businesses of the country. Inspired by the success of this company, Mr. Karim founded another company in the same business sector named Orion Infusion Limited.

He is the Founder of Orion Group and established the Group into one of the largest conglomerates in Bangladesh with his futuristic attitude, determined will and a burning passion. He heads the Group through his rich experience in diversified sectors. All concerns of Orion Group were formed under his dynamic leadership and management which have received various industrial recognitions.

Mr. Karim is one of the first entrepreneurs in the country to recognize the importance of Public Private Partnership (PPP). Under his leadership, Orion Group constructed and owns the 11.8 km long Mayor Mohammad Hanif Flyover, the longest flyover and the first ever successful PPP project of the nation. Also, Orion Group built City Centre, the tallest commercial complex cum car parking in Motijheel, Bangladesh. Mr. Karim's success went further up when the Group became successfully involved in private sector power generation of the country, when it signed the biggest contract with Bangladesh Power Development Board (BPDB) of 4 (four) supercritical coal based power plants of 3000 MW total under IPP (apart from 500 MW current generation under HFO), under the Ministry of Power of the Government of Bangladesh.

Mr. Karim is the Founder Chairman of Tejgaon Industrial Owners Association. He is also the former President of Dhaka Mohamedan Sporting Club Ltd., a century old legendary and most successful sporting club of the country.

MRS. ZAREEN KARIM

Managing Director



Appointment as Director

Mrs. Zareen Karim has been serving as the Director of the Board since 2010 and was appointed as the Managing Director in 2020.

Educational Qualification(s)

Mrs. Zareen Karim holds an MBA in Marketing from North South University.

Board Committee(s) served on

Mrs. Zareen Karim is the member of the Risk Management Committee since 2020.

Directorship(s) in other companies

Mrs. Zareen Karim sits on the Board of Orion Infusion Limited, Orion Holdings Limited and The Business Standard. She is also the Director of Star Associates Limited and Zeysa Fashionwear Limited.

Responsibilities and achievements

Mrs. Zareen Karim is one of the successful entrepreneurs of the country and she is the daughter of Mr. Mohammad Obaidul Karim, Chairman of the company. In order to comply with the corporate governance code issued by Bangladesh Securities and Exchange Commission on June 03, 2018 (BSEC/CMRRCD/2006-158/207/Admin/80), the Board of Directors of the company decided to appoint Mrs. Zareen Karim as Managing Director in place of Mr. Salman Obaidul Karim, as the MD of a listed company cannot hold the same position in any other listed company.

The Board entrusts Mrs. Zareen Karim with this new role and is confident that she will be able to take the business to new heights with her leadership. She has strong insights and research skills and a deep understanding of customer and consumer strategy.

Apart from her active involvement in the management and executive decision making of the company, she is the leading force of the Marketing Department and has taken the responsibility to revolutionize it. OPL continues to move forward with her expertise in strategic marketing and brand development.

Mrs. Karim believes in utilizing & fostering the talent, integrity, creativity and teamwork of people in achieving sustainable business results. She is more inclined towards a holistic approach of business where it directly contributes to the transformation of communities across the country and actively plays its role to socio-economic and socio-cultural enrichment of the country.

Mrs. Karim oversees the management of Orion Pharma Ltd. as the Managing Director with her professional, creative and result-driven approach. She is actively managing the project implementation of Orion Pharma Park, one of the largest pharmaceutical plants of Bangladesh at Siddhirganj, Narayanganj.



MRS. ARZUDA KARIM

Non-Executive Director

Appointment as Director

Mrs. Arzuda Karim joined the Board of Directors of the company in 1985.

Educational Qualification(s)

Mrs. Karim holds a Master's degree in Social Science from University of Dhaka.

Board Committee(s) served on

Mrs. Karim is the member of the Risk Management Committee since 2018.

Directorship(s) in other companies

Mrs. Karim is the Chairman of Jafflong Tea Company Limited and Intergral Energy Limited and also holds the directorship of Orion Infusion Limited, Kohinoor Chemical Company (BD) Limited, Digital Power & Associates Limited, Dutch Bangla Power & Associates Limited, Orion Power Meghnaghat Limited, Orion Power Dhaka Limited, Orion Power Unit-2 Dhaka Limited, Orion Power Sonargaon Limited, Orion Infrastructure Limited, Orion Infrastructure Development Company Limited, City Centre, Orion Gas Limited, Orion Oil & Shipping Limited, Orion Renal & General Hospital, Orion Hospitals Limited, Orion Holdings Limited, Orion Footwear Limited, Orion Agro Products Limited, Orion Natural Care Limited, Orion Tea Company Limited, Orion Quaderia Textiles Limited and Orion Consumer Products Limited.

Responsibilities and achievements

Mrs. Arzuda Karim has been one of the successful women entrepreneurs in Bangladesh over the years. She is the wife of Mr. Mohammad Obaidul Karim, Chairman of the company. Mrs. Karim has been associated with the company as well as with Orion Group since its inception. She has vast working experience of almost 40 (forty) years in diverse areas including production, commercial and administration. She leads several business units of Orion Group with her expertise in the areas of leadership, corporate management, organizational development, marketing and human resource management.

Mrs. Karim is one of those rare people who combine professionalism with warmth and humanity. Besides holding directorship in many companies, Mrs. Karim is actively involved in various religious and philanthropic activities in the fields of education, human resources and disaster relief. Mrs. Karim is also involved with the Orion Renal and General Hospital, which provides partly free medication to the underprivileged of the country.

MR. SALMAN OBaidul KARIM

Non-Executive Director



Appointment as Director

Mr. Salman Obaidul Karim was appointed as the Director of the Board in 2010.

Educational Qualification(s)

Mr. Salman Obaidul Karim graduated in Business & Computing Management from Brunel University, UK.

Board Committee(s) served on

Mr. Salman Obaidul Karim is the member of the Audit Committee and the Nomination and Remuneration Committee since 2020.

Directorship(s) in other companies

Mr. Salman Obaidul Karim is currently the Managing Director of Orion Infusion Limited, Digital Power & Associates Limited, Dutch Bangla Power & Associates Limited, Orion Power Meghnaghat Limited, Orion Power Dhaka Limited, Orion Power Unit-2 Dhaka Limited, Orion Power Sonargaon Limited, Orion Power Rupsha Limited, Orion Infrastructure Limited, Orion Infrastructure Development Company Limited, Orion Properties Limited, Orion Gas Limited, Orion Oil & Shipping Limited, Intergral Energy Limited, Orion Hospitals Limited, Orion Holdings Limited, Orion Knit Textiles Limited, Orion Footwear Limited, Jafflong Tea Company Limited, Orion Agro Products Limited, Orion Natural Care Limited, Orion Tea Company Limited, Orion Quaderia Textiles Limited, Orion Consumer Products Limited and The Business Standard.

Responsibilities and achievements

Mr. Salman Obaidul Karim is a visionary, dynamic and ingenious businessman in Bangladesh. Being guided by his father, Mr. Mohammad Obaidul Karim, he has become one of the most young and successful entrepreneurs of the country. He was the Managing Director of OPL from 2014 to 2020. In order to comply with the corporate governance code issued by Bangladesh Securities and Exchange Commission on June 03, 2018 (BSEC/CMRRCD/2006-158/207/Admin/80), the Board of Directors of the company decided to appoint Mrs. Zareen Karim as Managing Director in his place.

After completing his study in the UK, he came back to Bangladesh and started his career in Orion Group as the Director of most of the concerns of Orion Group since 2005. Besides his graduation, he experienced a couple of professional trainings in the Brunel University, UK and Harvard University, USA. Under his leadership, Orion's sustainability efforts were given outstanding shapes through his unique business concepts and visionary leadership skills.

From the beginning of his tenure in Orion, Mr. Salman Obaidul Karim proved his inherent talent for efficient management. He integrated versatile management system in the corporate culture of Orion Group bringing in a fresh perspective towards portfolio diversification. He helped the Group win some of the largest contracts in its history, to name a few- Mayor Mohammad Hanif Flyover (completed), City Center (completed), 5 HFO fueled power generation projects of 500 MW (completed), 4 Coal Fired Power generation Projects of 3000 MW (under construction).



MRS. HASINA BEGUM

Non-Executive Director

Appointment as Director

Mrs. Hasina Begum holds the position of the Nominated Director of Panbo Bangla Mushroom Limited in the Board of Orion Pharma Limited since 1997.

Educational Qualification(s)

Mrs. Hasina Begum is a graduate from a reputed university of Bangladesh.

Board Committee(s) served on

Mrs. Hasina Begum does not hold membership in any sub-committee of the Board.

Directorship(s) in other companies

Mrs. Hasina Begum has no directorship in any other company.

Responsibilities and achievements

Mrs. Hasina Begum started her business career from scratch with her late husband and achieved an outstanding level of success in the pharmaceutical industry. She is a distinguished and self-committed businessperson and has been involved with the Orion Pharma Limited for a long time and played a pivotal role in the start-up years of the company.

Beside her involvement in business areas, she is a social entrepreneur which has given her an opportunity to grow and make a difference in the society in which she lives.

MR. MD. SHAFIQR RAHMAN

Independent Director



Appointment as Director

Mr. Md. Shafiqur Rahman was appointed as an Independent Director of the company in 2018.

Educational Qualification(s)

Mr. Rahman holds a Master's degree (M.Com) in Accounting from University of Dhaka.

Board Committee(s) served on

Mr. Rahman is the Chairman of the Audit Committee and the Nomination and Remuneration Committee since 2018.

Directorship(s) in other companies

Mr. Rahman does not hold any directorship in any other company except being the Independent Director of Orion Infusion Limited.

Responsibilities and achievements

Mr. Md. Shafiqur Rahman had an illustrious career in banking sector of Bangladesh for more than 40 (forty) years experience with expertise in investment, trade finance, Branch in-Charge. Just before being appointed as the Independent Director of Orion Pharma Limited and Orion Infusion Limited, Mr. Rahman was an Advisor in Bangladesh Finance and Investment Company Limited (BD Finance Ltd.) and before that he was the Managing Director and CEO of Social Islami Bank Limited. Mr. Rahman has undergone many national and international training sessions. He has acquired significant experience in banking sector while working at various positions and carrying out various assignments.



MR. A. N. M. ABUL KASHEM

Independent Director

Appointment as Director

Mr. A. N. M. Abul Kashem joined the company in 2020 as an Independent Director.

Educational Qualification(s)

Mr. Kashem has successfully completed his graduation and post-graduation from the University of Dhaka.

Board Committee(s) served on

Mr. Kashem is the Chairman of Risk Management Committee, the member of the Audit Committee and Nomination and Remuneration Committee since 2020.

Directorship(s) in other companies

Mr. Kashem does not hold any directorship in any other company.

Responsibilities and achievements

Mr. A. N. M. Abul Kashem has a long and illustrious career of more than 30 (thirty) years in the Banking industry. He started his career in 1988 in Agrani Bank in the Loan & Advance section. Later he joined Bangladesh Bank and lastly served as an Executive Director of the Central Bank. He was responsible for Bangladesh Bank Khulna Office, Foreign Exchange Investment Dept. and Human Resource Dept. He is also vastly experienced in CBSP, Banking inspection, Expenditure Management and Accounts dept. He has acquired versatile knowledge by working in different departments at the Central Bank of Bangladesh and this extensive knowledge and long professional experience in Banking sector will be a great addition to the Board of Directors of Orion Pharma Limited. He has also been involved in many local and foreign trainings including Credit Risk Management, Core Banking Module and Training on Investment Climate of Bangladesh.

Management team

MRS. ZAREEN KARIM

Managing Director

MR. MD. RUHUL AMIN

Executive Director - Regulatory Compliance and Quality Assurance

MR. MD. FERDOUS JAMAN

Company Secretary

MR. SAMARESH BANIK

Chief Financial Officer

MR. MD. ASHFAQUL ALAM

Vice President - Corporate Affairs

MR. MAHBUBUR RAHMAN

Vice President - Sales

MR. MD. IBRAHIM KHALIL

Vice President - Internal Audit & Compliance

MR. MD. ABU SAYED KHONDOKER

Vice President - Plant

MR. MD. ZAKIR HOSSAIN

Vice President - Production

MRS. AYESHA AKHTER

Vice President - Commercial, TSD & PPIC

MR. MD. FAKHRUL ISLAM

Manager - Distribution

MR. MD. FORHAD HOSSAIN

Manager - Administration

DR. SINTHIA ALAM

Deputy Manager - Medical Services

MR. ABU MD. NAYEEM SARKER

Assistant Manager - Product Management



MRS. ZAREEN KARIM
Managing Director

Mrs. Zareen Karim is one of the successful young entrepreneurs of the country and has been involved in different management roles in different business activities since her early career. She is the daughter of Mr. Mohammad Obaidul Karim, Chairman of the company.

As 'Women Entrepreneur' she accepts challenging roles and has proven her worth beyond any doubt. She has expertise in the areas of strategic marketing, brand development across a wide variety of consumer products. She has strong insights and research skills and a deep understanding of customer and consumer strategy. She is currently responsible for the overall operations of the company with emphasis on strategic business planning as well as for developing the company's business and investment plans and execution of business strategies. She is also acting as the bridge between the Board of Directors and the management to link expectations, accountability and performance.

Along with being the Managing Director of Orion Pharma Limited, she also has extensive and diverse experience in various industries and she is also holding the senior management position in many companies.



MR. MD. RUHUL AMIN
Executive Director
Regulatory Compliance and Quality Assurance

Mr. Md. Ruhul Amin has 30 (thirty) years of experience in the Directorate General of Drug Administration (DGDA) of Bangladesh. He left DGDA with honor as a Director and was instrumental in many pharmaceutical regulations at the DGDA.

Mr. Amin joined OPL in 2020 as an Executive Director in the Regulatory Compliance and Quality Assurance Department. Md. Ruhul Amin is a competent pharmacist and has got vast knowledge and experience in implementation of GMP and establishment of Quality Risk Management system for manufacturing of Pharmaceutical Products. He has also huge knowledge in documentation system and evaluation of pharmaceutical manufacturing facilities. He oversees the quality policy and quality management system of OPL to comply with cGMP and to ensure the quality, stability and safety of products. He is entrusted to supervise the development activities of new Pharmaceutical Manufacturing Projects in Orion Pharma Park and to provide guidance for establishing Quality Management System for new projects in line of WHO GMP and other international GMP/cGMP guidelines.

Mr. Md. Ruhul Amin has completed both his graduation and post-graduation in Pharmacy from the University of Dhaka.



MR. MD. FERDOUS JAMAN
Company Secretary

Mr. Jaman is a very dynamic and competent individual ensuring secretarial compliances as per the Companies Act 1994 of Bangladesh & other regulatory rules and regulations. He has the experience of attending meetings with company shareholders and the Board of Directors and acts as a point of communication between them. A very well presented and highly personable individual, Mr. Jaman has a deep knowledge of acts, rules and regulations related to company affairs and statutory requirements. He possesses excellent organizational skills with a good eye for detail. He is an expert in handling IPO's shareholder acquisition and raising funds in challenging environment. In addition to his secretarial profile, he is actively involved with the Finance Department and responsible for timely availability of fund for successful implementation of project.

Mr. Jaman is an accounting professional having experience spanning over more than 25 (twenty five) years in various big business groups in the complex finance intensive industries in Bangladesh. He hails from the new generation of professionals who have entered into the then nascent corporate world of Bangladesh. His commendable work over more than 2 (two) decades have made significant contributions towards his generation's effort to transform the business houses of Bangladesh into world class corporate organizations.



MR. SAMARESH BANIK
Chief Financial Officer

Mr. Banik has more than 25 (twenty five) years of experiences in Finance and Accounts Departments of the company with a proven track record of leading financial strategies to facilitate the company's ambitious growth plans. He is also responsible to ensuring compliance and statutory reporting. Mr. Banik possesses the ability to provide a high standard of financial control and ensuring legal & regulatory compliance relating to taxation. He is also accountable for expenditure tracking, operating budgets and preparing long range financial plans for the company. As CFO, he also works in assisting business units in their budgeting and planning process. Ensuring preparation and dissemination of timely and accurate financial information to allow for efficient use and control over financial resources of the company also fall under some of his major tasks.

He is partly qualified Cost and Management Accountant from the Institute of Cost and Management Accounts of Bangladesh. He also holds a degree in Master of Commerce from the Department of Management of the University of Dhaka. He has attended many training sessions for his career ranging from institutes such as International Development under British Government, Institute of Chartered Secretaries and Managers of Bangladesh, Briddhi and many more.



MR. MD. ASHFAQUL ALAM
Vice President - Corporate Affairs

Mr. Md. Ashfaqul Alam is a resourceful corporate leader with more than 20 (twenty) years of work experience. He started working with OPL since 2005 as a Senior Executive, Project Management and was gradually promoted to the position of Vice President, Corporate Affairs.

Mr. Alam has become a key member for the organization due to his accomplishments in managing projects, representing organization and management, liaison with regulatory bodies and maintaining public relationships. His efforts and successes led him to be the Head of Corporate Affairs Department making him responsible of managing and taking care of all corporate and regulatory issues. He has integrated versatile management system in the corporate culture of the organization and is known to lead by example and setting standards for his subordinates.

Mr. Alam has obtained his Post-Graduation degree in the year 1995 in Management from the University of Rajshahi. He also holds an MBA degree in Management. During his long course of career, he has undergone many trainings on Effective Performance Management, Relationship building & Corporate Management, Credit Management & Debt Collection Strategies, Balanced Scorecard management and many more.



MR. MAHBUBUR RAHMAN
Vice President - Sales

Mr. Mahbubur Rahman is a pharmacy professional with more than 30 (thirty) years of work experience. He joined Orion Pharma Limited in 2016 in the Sales Department.

As the Head of Sales, Mr. Rahman mostly concentrates on strategy planning and analytics towards OPL's mission to serve the ailing humanity around the globe through proliferation into manufacturing and marketing of generic drugs. He leads and monitors the Sales team at OPL. He is further involved with prescription monitoring, sales monitoring and maintaining balance between sales team and PMD. Training, Script writing, Marketing Management, Market Research, Brand Building, Sales Force Effectiveness, Strategic planning & Management are his forte.

Mr. Hossain attained his M. Sc from the University of Dhaka in the year 1983. During his long course of career, he has undergone many trainings on Sales-force effectiveness, Internal QMS auditing, Sales management, Pharmaceuticals regional planning, Marketing strategies and many more.



MR. MD. IBRAHIM KHALIL

Vice President - Internal Audit & Compliance

Mr. Ibrahim is an accounting professional having a wide range of work experience spanning over more than 20 (twenty) years. In Orion Pharma Limited, he is responsible for developing and implementing risk based audit plan, policy/procedure giving priority of sensitive areas. He also works to identify deficiencies during audits and notify the significant audit findings to the Management and Audit Committee of the Board. He is also responsible for implementing, directing and overseeing the auditing and compliance programs and conduct and direct audits and ongoing reviews of organizational controls and operating procedures with policies and regulations. He also reviews and appraises the soundness, effectiveness, and proper application of accounting process and assesses the adequacy and extent of programs designed to safeguard organization assets. He also creates and improves homogenous Compliance Culture throughout the organization that aligns with the control and business objectives of the company.

Mr. Ibrahim has a degree in Chartered Accountancy of Intermediate from Institute of Chartered Accountant in Bangladesh. He also has a degree in Master of Commerce. His expertise lies in Fraud and Operational risk knowledge along with Policy and Regulation interpretation and implementation. His outstanding analytical and effective decision making skill with advanced financial management knowledge are an asset for the company.



MR. MD. ABU SAYED KHONDOKER

Vice President - Plant

Mr. Md. Abu Sayed Khondoker is one of the vastly experienced engineers in the pharmaceutical industry in Bangladesh having over 24 (twenty four) years of experience working at several local pharmaceutical companies. Currently, Mr. Sayed serves as the VP of Plant. He joined the company in 2018. Since then, he is responsible for the implementation of entire Orion Pharma Park including civil, mechanical and electrical works.

Currently, Mr. Sayeed oversees the construction of General Pharma Building-2 and General Pharma Building-3 (Cephalosporin). He is involved with the upcoming projects including manufacturing plants of Supplement and Oncology.

Mr. Sayed has enormous experience in the installation and operation of HVAC, Boiler, generator, Fire Detection & Protection, Sandwich panel, PW & WFI plant and many other production related machineries.

Mr. Sayed Khondoker is a B.Sc engineer having graduated from RUET (then BIT, Rajshahi) majoring in Mechanical engineering in 1993. During his long professional career, he has successfully completed several trainings including Sterile process validation from APC, Industrial accident and safety devices from B.I and Occupational safety and health from Nipson.



MR. MD. ZAKIR HOSSAIN
Vice President - Production

Mr. Md. Zakir Hossain has ample knowledge in the sphere of manufacturing and with his dedication he has become the leading person of the production unit of Orion Pharma Limited. He has a work experience of 25 (twenty five) years. He joined OPL as a Production Officer in 2001 and was gradually promoted to the position of Vice President under Production Department.

Some of Mr. Hossain's major job responsibilities are to approve standard procedures for Cleaning & Sanitation of production area, machine and utensils, Standard Operating Procedures of production machine and control equipment along with overseeing Batch Manufacturing Instruction and Batch Packaging Instruction. He is also responsible to ensure manufacturing of medicines as per standard procedure to obtain required quality. Mr. Hossain also ensures appropriate manufacturing conditions of products and their storage with proper documents.

Mr. Hossain has completed his Master of Pharmacy from Jahangirnagar University in the year 2001 and registered himself as an 'A' grade member of the Pharmacy Council of Bangladesh. He also holds an MBA degree and has undergone many trainings such as Good Manufacturing Practice, Quality Control, EHS Management in Pharmaceutical Industry, Awareness and Internal Audit Course on ISO 9001:2015, Team Building & Leadership Skill and many more.




MRS. AYESHA AKHTER
Vice President - Commercial, TSD & PPIC

Mrs. Ayesha Akhter looks after the activities of Commercial, Technical Services and Procurement Planning & Inventory Control Departments of OPL. She has a work experience of more than 25 (twenty five) years and has made her mark in the organization with her strong determination and hardwork.

Mrs. Akhter is responsible for planning, monitoring and supervising material requirement, export requirements, new product launching requirements and controlling inventory management & functioning. She is also responsible for sourcing materials as well overseeing comparative statement for import along with documentation for receiving materials in the port.

Mrs. Akhter has a Master's degree in Chemistry from the University of Dhaka in 1993. She broke the glass ceilings of the society at a time when very few women were serious about their educational aspirations and thought of pursuing a career in the corporate world. Mrs. Akhter was always persistent and decided to use her intelligence and skills in order to contribute in the economy. With a view to improving her skills, Mrs. Akhter has undergone various trainings like Leadership & Change Management, Internal Quality Audits, Total Quality Management, Good Manufacturing Practice and many more.



MR. MD. FAKHRUL ISLAM

Manager - Distribution

Mr. Md. Fakhrul Islam has 24 (twenty four) years of experience serving in local pharmaceutical companies of Bangladesh. He joined OPL in 1996 and since then has become an important part of the company for his vast knowledge and deep insight on the pharmaceutical industry.

As Manager of Distribution Department, Mr. Islam is heavily involved in supervising and regulating the distribution activities of the company. He facilitates the distribution channel to ensure smooth operation of all the drugs and medicines manufactured at the company. He ensures effective supply chain management through detailed planning and execution of distribution. He is also responsible for creating, implementing and managing strategies and processes to guarantee all products are sent and received on time.

Mr. Islam has completed his Masters from University of Rajshahi in Social Science in 1985. He also has an MBA in Marketing and International Business. During his long course of career, he has undergone many training programs on Internal Quality Audit, Internal QMS Audit, Supply Chain Management and many more.



MR. MD. FORHAD HOSSAIN

Manager - Administration

Mr. Md. Forhad Hossain has a work experience of over 20 (twenty) years and is in charge of OPL's Admin Department. He joined the organization as an Officer under Administration Department in 2005 and was gradually promoted to the position of Manager.

Mr. Hossain is responsible for the day-to-day functions of OPL as well as planning, coordinating and supervising administrative procedures and systems along with devising ways to streamline processes. He looks after office administration, transport management, protocol and other logistic support. Mr. Hossain further ensures the smooth and adequate flow of information within the company to facilitate other business operations. He also maintains liaison with outside agencies including government departments associated with the operational requirement.

Mr. Hossain attained his Master's degree from Dhaka College in 1996. He also holds an MBA degree and has undergone many trainings such as Leadership & Change Management, Effective Communication and many more.



DR. SINTHIA ALAM

Deputy Manager - Medical Services

Dr. Sinthia Alam is a medical professional with over 7 (seven) years of work experience. She joined Orion Pharma Limited in 2015 and has been assigned with the accountability of Head of Medical Services Department.

As the Head of Medical Services, Dr. Sinthia leads and monitors the PMD, MIS, Field Admin and Sales Training teams at OPL. She is further involved with territory development, market development and planning for new product launching. She is responsible for organizing Scientific Seminars, Round Table Meetings, Rural Promotional Campaigns etc. which are knowledge sharing programs with healthcare professionals of the country.

Dr. Sinthia attained her MBBS from Dhaka National Medical College in the year 2013. Originally being from the medical sector, Dr. Sinthia has undergone many trainings during her career to adapt to the corporate world.



MR. ABU MD. NAYEEM SARKER

Assistant Manager - Product Management

Mr. Nayeem Sarker is a pharmaceutical professional with over 5 (five) years of work experience. He joined Orion Pharma Limited in 2017 in the Product Management Department under Marketing Division. As a Pharmaceutical Marketer, Mr. Sarker is mostly involved with the marketing team to deal with the marketing strategy and overseeing the implementation of it.

Mr. Sarker is responsible to execute product promotional activities and other marketing strategies. He is also responsible to introduce new products in the market and manage the existing product life cycles. He maintains the balance among the departments of PPIC, Commercial, Production, R&D, MIS, Audit, Training, Sales and Distribution.

Mr. Sarker attained his M.Pharm in 2015. During his course of career, he has undergone many trainings on Brand Management, Market Mapping, IMS, Sales Management, Risk Assessment & many more.



Our
Governance
2019-20

- Directors' report
- Governance structure
- Committee reports
- Code of conduct
- Organogram
- Compliance

Message from the Chairman



“Even in such difficult times of Covid-19, along with maintaining the normal course of business activities, we successfully launched time demanded medicines for the society and undertook many measures for the safety of our employees and environment.”

Dear Shareholders,

Assalamualaikum Wa Rahmatullah

It is an honor and privilege for me to welcome all of you to the 55th Annual General Meeting (AGM) of Orion Pharma Limited (OPL) and present the Integrated Annual Report for the financial year ended June 30, 2020. The last financial year brought numerous challenges for our economy but we as a nation remained resilient and managed those challenges very well. The Covid-19 pandemic paralyzed the world but due to the timely initiatives and efforts of the Government of Bangladesh, we were able to come out stronger from this unprecedented situation. I am happy to say that even in such difficult times, along with maintaining the normal course of business activities last year, we also successfully launched time demanded medicines for the society and undertook many measures for the safety of our employees and environment.

My dear Shareholders, you are all aware that we strive to provide the society medicines of the finest quality. During the reporting year, we feel proud to have successfully launched 9 (nine) medicines of which 5 (five) were introduced in the face of the Covid-19 pandemic.

I am delighted to declare that during the reporting financial year, OPL started exporting to 2 (two) new countries – Kosovo and Yemen. We are exporting medicines of CNS, Antibiotic, Cardiovascular and Vitamin - Minerals & Hematinic portfolio to these countries.

My dear friends, it is a matter of great prestige for me to inform you all that our company was awarded 2 (two) national and 1 (one) international honor:

- The joint 3rd position for the "Best Presented Annual Report – 2018" under the category: Manufacturing Sector by the Institute of Chartered Accountants of Bangladesh (ICAB);
- The Silver Award and Certificate for Corporate Governance Excellence, 2018 under Pharmaceutical and Chemical Companies category by the Institute of Chartered Secretaries of Bangladesh (ICSB); and
- The Certificate of Merit for the "Best Presented Annual Report 2018" under Manufacturing Sector category by the South Asian Federation of Accountants (SAFA).

Dear Shareholders, let me take you all over the financial particulars now. Against the tough business scenario during the year under review, your company put its best efforts at bringing best possible return from its core business through wise business practices and practical cost control. The company attained a Consolidated Net Revenue of BDT 7,647.70 million, Consolidated Gross Profit of BDT 2,577.84 million and the Consolidated Net Profit of BDT 665.69 million. Even though the Consolidated Net Revenue decreased compared to last year, the Standalone Net Revenue of the company increased to BDT 2,297.74 million compared to BDT 2,222.54 million in the last year. The Consolidated Earnings per Share for this year is

BDT 2.84 and taking into account the financial performance of the company the Board has recommended 10% Cash Dividend subject to the approval of shareholders.

Dear friends, every year we make a significant contribution to the National Exchequer in the form of Corporate Tax, Value Added Tax (VAT) and different other duties. This year your company has contributed an amount of BDT 517.31 million which is equivalent to 22.51% of the company's Standalone Net Revenue.

Dear Shareholders, there was a change in the composition of the Board. Lt. Col. Kamal Ahmed, PSC (Retd.) was an Independent Director of the company since 2014 and completed his second tenure successfully. Now in compliance with the corporate governance code of BSEC, the Board appointed Mr. A. N. M. Abul Kashem as the new Independent Director of the company and the proposal of his appointment is placed for your approval. Mr. Kashem has an illustrious long career of more than 30 (thirty) years in the banking industry and I am sure his vast knowledge and experience will be a great asset for the company.

Dear friends, we highly value the safety of our employees and always take measures to ensure a safe workplace. Your company undertook additional initiatives in light of the Covid-19 pandemic. We arranged to conduct Covid tests for suspected employees. We also have Doctor's Chamber and Medicine Corner to ensure their wellbeing. We are also providing transport facilities to all employees so that they can avoid public transport and stay safe.

Your company also undertook social awareness programs through online campaigns and interactive sessions with prominent doctors. We feel proud to be able to serve the society through the Orion Shastho Barta and Telemedicine service. In Shaa Allah, we will continue such endeavors to help our country people even in the future.

Dear Shareholders, I would now like to take the opportunity to thank you for your never-ending support and confidence. I also appreciate all our valued stakeholders including business partners, customers, bankers, suppliers, government agencies and regulatory authorities. I am grateful to the management and employees for their determination, dedication and hard work in such tough times.

I am optimistic that with support from all of you, together we will rise even further towards success.

Thank you

Sd/-

Mohammad Obaidul Karim
Chairman

চেয়ারম্যান-এর প্রতিবেদন

প্রিয় শেয়ারহোল্ডারবৃন্দ

আসসালামু আলাইকুম ওয়া রাহ্মাতুল্লাহ

ওরিয়ন ফার্মা লিমিটেড-এর ৫৫তম বার্ষিক সাধারণ সভায় আমি আপনাদের সকলকে স্বাগত জানাচ্ছি এবং ৩০শে জুন, ২০২০ সমাপ্ত অর্থ বছরের Integrated Annual Report উপস্থাপন করছি। বিগত অর্থ বছরে আমাদের দেশের অর্থনীতি বিভিন্ন প্রতিকূলতার সম্মুখীন হয়েছে কিন্তু জাতিগতভাবে আমরা অত্যন্ত দক্ষতার সাথে তা মোকাবেলা করতে সক্ষম হয়েছি। কোভিড-১৯ মহামারীটি যখন সারা বিশ্বকে ছবির করে দিয়েছে, তখন বাংলাদেশ সরকারের সময়োচিত উদ্যোগ এবং প্রচেষ্টার ফলে আমরা এই কঠিন সময় প্রাথমিকভাবে কাটিয়ে উঠতে পেরেছি। আপনাদের কোম্পানীও ব্যবসায়িক কার্যক্রমের স্বাভাবিক ধারা অব্যহত রাখার পাশাপাশি প্রয়োজনীয় নতুন ঔষধ বাজারে এনেছে এবং কর্মকর্তা ও কর্মচারীদের জন্য বিভিন্ন নিরাপত্তা ব্যবস্থা সুনিশ্চিত করেছে।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

আপনারা সকলেই অবগত আছেন যে, আমরা সর্বদাই সর্বোচ্চ মানের ঔষধ উৎপাদন ও বাজারজাত করে থাকি। বিগত অর্থ বছরে আমরা ৯টি নতুন ঔষধ বাজারে এনেছি যার মধ্যে ৫টি কোভিড-১৯ এর চিকিৎসায় ব্যবহৃত হচ্ছে।

আমি আনন্দের সাথে জানাতে চাই যে, আপনাদের কোম্পানী আলোচ্য অর্থ বছরে কসোভো এবং ইয়েমেনে ঔষধ রপ্তানি শুরু করেছে। এই দেশগুলোতে আমরা CNS, Antibiotic, Cardiovascular and Vitamin - Minerals ও Hematinic পোর্টফলিও অন্তর্ভুক্ত ঔষধ রপ্তানি করছি।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

আমি গর্বের সাথে জানাচ্ছি যে, বিগত অর্থ বছরে আপনাদের কোম্পানী নিম্নোক্ত ২টি জাতীয় ও ১টি আন্তর্জাতিক পুরস্কার অর্জন করেছে, যা সকলের জন্য অত্যন্ত সম্মানের বিষয়।

- Institute of Chartered Accountants of Bangladesh (ICAB) কর্তৃক “Manufacturing Sector” বিভাগের অধীনে “Best Presented Annual Report – 2018” এর জন্য তৃতীয় পুরস্কার (মৌখ);
- Institute of Chartered Secretaries of Bangladesh (ICSB) কর্তৃক “Pharmaceuticals and Chemical Company” বিভাগের অধীনে Corporate Governance Excellence, 2018 এ সিলভার অ্যাওয়ার্ড ও প্রশংসাপত্র; এবং
- South Asian Federation of Accountants (SAFA) কর্তৃক “Manufacturing Sector” বিভাগের অধীনে “Best Presented Annual Report – 2018” এর জন্য সার্টিফিকেট অফ মেরিট পুরস্কার।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

আমি এখন সমাপ্ত অর্থ বছরের নিরীক্ষিত আর্থিক বিবরণী উপস্থাপন করছি। আলোচ্য অর্থ বছরে ব্যবসায়িক প্রতিকূলতা থাকা সত্ত্বেও আপনাদের কোম্পানী একীকৃত নীট বিক্রয় করেছে ৭,৬৪৭.৭০ মিলিয়ন টাকা, একীকৃত মোট মুনাফা অর্জিত হয়েছে ২,৫৭৭.৮৪ মিলিয়ন টাকা এবং একীকৃত নীট মুনাফার পরিমাণ ৬৬৫.৬৯ মিলিয়ন টাকা। যদিও গত বছরের তুলনায় একীকৃত নীট বিক্রয় হ্রাস পেয়েছে, কিন্তু কোম্পানীর নিজস্ব বিক্রয় ২,২২২.৯৪ মিলিয়ন থেকে ২,২৯৭.৭৪ মিলিয়ন টাকায় উন্নীত হয়েছে। আলোচ্য অর্থ বছরে শেয়ার প্রতি একীকৃত আয় হয়েছে ২.৮৪ টাকা এবং কোম্পানীর সার্বিক আর্থিক অবস্থা বিবেচনা করে পরিচালনা পর্ষদ সমাপ্ত অর্থ বছরের জন্য আপনাদের অনুমোদন সাপেক্ষে ১০% নগদ লভ্যাংশ প্রস্তাব করেছে।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

সমাপ্ত অর্থ বছরে আপনাদের কোম্পানী কর্পোরেট ট্যাক্স, ভ্যাট এবং অন্যান্য শুল্ক বাবদ জাতীয় কোষাগারে ৫১৭.৩১ মিলিয়ন টাকা জমা করেছে, যা কোম্পানীর নিজস্ব নীট বিক্রয়ের প্রায় ২২.৫১%।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

এই বছর কোম্পানীর পরিচালনা পর্ষদে একটি পরিবর্তন এসেছে। লেঃ কর্ণেল কামাল আহমেদ, পিএসসি (অবসরপ্রাপ্ত), ২০১৪ সাল হতে কোম্পানীর স্বতন্ত্র পরিচালক হিসাবে দায়িত্ব পালন করে এসেছেন এবং এ বছর তিনি তার দ্বিতীয় মেয়াদ শেষ করেছেন। পরিচালনা পর্ষদ জনাব এ.এন.এম আবুল কাশেম-কে নতুন স্বতন্ত্র পরিচালক হিসেবে নিয়োগ দিয়েছে এবং উক্ত নিয়োগের প্রস্তাবটি আপনাদের অনুমোদনের জন্য রাখা হয়েছে। জনাব এ.এন.এম আবুল কাশেম ব্যাংকিং খাতে ৩০ বছরেরও বেশি অভিজ্ঞতা সম্পন্ন। আমরা আশা করছি তার দীর্ঘ অভিজ্ঞতা ও বিস্তৃত জ্ঞান আপনাদের কোম্পানীকে আরও সফলতার দিকে এগিয়ে নিয়ে যাবে।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

আমরা আমাদের সকল কর্মকর্তা ও কর্মচারীদের জন্য সর্বোচ্চ নিরাপত্তার জন্য সর্বদা সচেতন থাকি। তারই ধারাবাহিকতায় আমরা কোভিড-১৯ সময়কালীন আরও অতিরিক্ত সুরক্ষা ব্যবস্থা গ্রহণ করছি। আমরা প্রয়োজনের ভিত্তিতে কর্মীদের কোভিড পরীক্ষা করার ব্যবস্থা করছি। পাশাপাশি আমাদের অফিসে ডাক্তার চেম্বার ও মেডিসিন কর্নার বিদ্যমান আছে। তাছাড়াও, গণপরিবহনের ব্যবহার এড়াতে আমরা আমাদের কর্মীদের জন্য নিরাপদ পরিবহন ব্যবস্থা সুনিশ্চিত করতে সক্ষম হয়েছি।

কোভিড-১৯ সময়কালীন আপনাদের কোম্পানী অনলাইনে বিশিষ্ট চিকিৎসকদের সাথে ইন্টারএকটিভ সেশনের মাধ্যমে সামাজিক সচেতনতামূলক কর্মসূচী ধারাবাহিকভাবে পালন করে আসছে। ওরিয়ন স্বাস্থ্য বার্তা (টেলিমেডিসিন) এই সমাজ সেবামূলক কার্যক্রমের একটি অংশ। ইনশাআল্লাহ ভবিষ্যতে এই সামাজিক পরিষেবার ধারাবাহিকতা বজায় থাকবে।

প্রিয় শেয়ারহোল্ডারবৃন্দ,

আপনাদের সহযোগিতা, আন্তরিকতা, বিশ্বাস ও সক্রিয় সমর্থনের জন্য বিশেষভাবে ধন্যবাদ জানাচ্ছি। এছাড়াও আমাদের সম্মানিত গ্রাহক, ব্যাংকার, সরবরাহকারী, সরকারী সংস্থা, নিয়ন্ত্রনকারী কর্তৃপক্ষ সহ সকল স্টেকহোল্ডারদেরকে আন্তরিকভাবে ধন্যবাদ জ্ঞাপন করছি। কোভিড-১৯ মহামারীর কারণে যে সংকটময় সময় আমরা অতিবাহিত করছি, এ সময়ে আমাদের পাশে থাকার জন্য সকল কর্মকর্তা ও কর্মচারীদের প্রতি কৃতজ্ঞতা প্রকাশ করছি। আমি আশাবাদী যে, আপনাদের সকলের সহযোগিতায় আমরা সফলতার দিকে এগিয়ে যাব।

ধন্যবাদান্তে

স্বা/-

মোহাম্মদ ওবায়দুল করিম

চেয়ারম্যান



Message from the Managing Director



“ We strive to do even better towards ensuring a sustainable environment because we believe that sustainability of business is directly related to sustainability of the environment. ”

Dear Shareholders,

Assalamualaikum Wa Rahmatullah

On behalf of the Management, I am pleased to present the Statement of the Managing Director of Orion Pharma Limited for the year ended June 30, 2020. With great honor and pleasure, I take this opportunity to be presenting this statement for the first time after taking-over the responsibility to act as the Managing Director of the company in the beginning of this year.

Overcoming the unique challenges

At the start of my role as the Managing Director of Orion Pharma Limited, I came across unprecedented challenges owing to the Covid-19 global pandemic. We faced both short-term and long-term hurdles in the reporting period, ranging from health and safety of the employees, supply-chain disruption, timely availability of cash-flow, overtly cautious consumer demand etc. The socio-economic impacts of the country wide lockdown affected our business operations and performance. But I am proud to state that, in tackling this unique crisis, I got full support and co-operation from all my colleagues and the company was able to remain strong by implementing the time-appropriate strategies of the management.

Launching new medicines

In the reporting financial year, our company has successfully launched 9 (nine) medicines, of which 5 (five) were introduced in the face of the Covid-19 pandemic. The following medicines were launched in the last financial year which also had a very good response in the market:

Brand name	Generic name	SKU
Terbiderm	Terbinafine 250 mg	Terbiderm 250 mg
Linastar	Linagliptin 5 mg	Linastar 5 Tab
	Linagliptin 2.5 + Metformin 850 mg	Linastar M 2.5/500 Tab
	Linagliptin 2.5 + Metformin 500 mg	Linastar M 2.5/850 Tab
Hexion	0.5% Chlorhexidine Gluconate + 70% Isopropyl alcohol	Hexion 50 ml
		Hexion 250 ml
Oxiquin	Hydroxychloroquine 200mg	Oxiquin 200
	Hydroxychloroquine 400mg	Oxiquin 400
Fravir	Favipiravir 200 mg	Fravir 200 mg Tab

The year in review

Our company attained a Consolidated Net Revenue of BDT 7,647.70 million in the reporting financial year compared to BDT 8,705.17 million last year. A reduction in revenue from power generation (our subsidiaries) resulted in the decrease of the Consolidated Net Revenue. However, the Standalone Net Revenue stood at BDT 2,297.74 million compared to BDT 2,222.54 million registering a positive growth of 3.38%. OPL attained a Consolidated Gross Profit of BDT 2,577.84 million and Standalone Gross Profit of BDT 1,281.10 million. The

Consolidated Net Profit is BDT 665.69 million and Standalone Net Profit is BDT 194.34 million. Consolidated EPS resulted in BDT 2.84 and Standalone EPS stood at BDT 0.83.

Striving for sustainability

Our company always focuses on adopting initiatives towards protecting the environment along with endeavors to minimize any negative impact that we might have on it. During the last financial reporting period, our key initiatives in regards to environmental sustainability were installation of an ETP with neutralizing capacity of 3,75,000 litre/day for liquid waste and an installation of an incinerator with incineration capacity of 100 kg/hr for solid waste. In the upcoming days we will strive to do even better to improve our initiatives focusing towards a sustainable environment because we believe that sustainability of business is directly related to sustainability of the environment.

Looking ahead

Orion Pharma Limited is constructing one of the biggest and finest pharmaceutical complexes of the country named Orion Pharma Park, located in Siddhirganj, Narayanganj. The plant is well designed and equipped with all latest facilities and state-of-the-art technologies. The construction of the 1st manufacturing unit General Pharma Building – 1 is complete. The construction of 2nd and 3rd manufacturing units General Pharma Building – 2 and General Pharma Building – 3 are also under construction. We firmly believe that the strong brand value and recognition that our company has will be strengthened further with the inception of the Orion Pharma Park. We also will be able to pivot our position and tap into new international markets with the advent of production in our world-class Orion Pharma Park.

I would like to end by thanking all our stakeholders for their immense support and belief on our company during the changing business dynamics we witnessed in the last reporting year. We have a dedicated team that works tirelessly to achieve the set goals and targets. I am very grateful to every member of the Orion family for their hard work, loyalty and integrity.

Thank you

Sd/-

Zareen Karim
Managing Director

Governance structure

Corporate governance is an important set of principles incorporated into every part of our organization to obtain sustainable success. We are committed to ensuring the highest standards of governance designed to protect the interest of all stakeholders to generate goodwill among business partners, customers and investors which ultimately creates value for them.

Governance practices & reporting framework

The laws, policies, rules and regulations adopted by Orion Pharma Limited for maintaining sound corporate governance are outlined below:

- The Companies Act, 1994;
- Notification on corporate governance imposed by Bangladesh Securities and Exchange Commission (BSEC);
- Listing regulations imposed by Stock Exchanges;
- Related laws of the Land;
- Company's internal standards of code of conducts, ethics and compliances;
- Company's risk management system;
- Company's different types of committee's terms of reference and their statements with recommendations; and
- National and international best practices applicable in consistent with the company's nature of business.

The above mentioned laws, policies, rules and regulations are the basis of standards of disclosures and throughout the year, the company has always been adherent to and applied or, if not applied, explained, these frameworks. The review of the corporate governance framework is done from time to time to assure that our applied governance structure is always consistent, relevant with the best practices of the corporate world and effective in addressing upcoming business challenges.

In addition to this, the sub-committees of the Board with the direction of Board as well as the management team are always responsive to the regulatory requirements of different authorities like obtaining certification, periodic reporting of respective issues and transparency issues.

OPL regularly submits accurate and periodic documents including financial statements to the Bangladesh Securities and Exchange Commission, Stock Exchanges, National Board of Revenue, Registrar of Joint Stock Companies and Firms and other relevant regulatory authorities.

Governance structure as on June 30, 2020



The governing Board

The Board of Directors has the highest degree of authority, control and leadership and lays out the code of conduct and corporate governance in our company. The Board acknowledges the importance of corporate governance for the accomplishment of sustainability in business. The Board further ensures that the company is going ahead in the right direction so that the value of all stakeholders is maximized and there is a positive impact of the entity's operations on the society as well as on the environment.

The Board of Directors of OPL constitutes of different multidimensional individuals whose broad and diverse range of knowledge, experiences and competencies perfectly align with the context of our company as well as with the statutory requirements. The Board members have the right combination and balance of business, entrepreneurial, financial and technical skills that OPL considers as one of its greatest assets. In order to further ensure the independence of the Board, 2 (two) qualified Independent Directors have also been included in this board.

The governing Board ensures that all business strategies are formulated and all operations are carried out according to the conditions of corporate governance code and other

notifications and directives imposed by BSEC. The Board confirms that OPL adopts and applies the aforesaid code, other regulatory requirements and also the company's own policies and principles to deliver shareholders' value and to be transparent to all potential stakeholders.

Board composition


The company has an appropriate mix of Executive, Non-Executive and Independent Directors. At present the Board consists of 7 (seven) Directors, of which 1 (one) is Executive, 4 (four) including the Chairman are Non-Executive and 2 (two) are Independent Non-Executive Directors. The combination of Executive, Non-Executive and Independent Directors in the Board of OPL adheres to the corporate governance code issued by the BSEC.

The current composition of the Board reflects an appropriate mix of skill sets, experience and qualifications that are relevant to the company's business. The Board composition is reviewed regularly to ensure the combination of diversity is maintained and that the Board retains its effectiveness by performing its functions.

The Board of OPL as on the reporting date is as follows:

Name	Status			
	BoD	AC	NRC	RMC
Mr. Mohammad Obaidul Karim	Chairman, Non-Executive Director	-	-	-
Mrs. Zareen Karim	Managing Director, Executive Director	-	-	M
Mrs. Arzuda Karim	Non-Executive Director	-	-	M
Mr. Salman Obaidul Karim	Non-Executive Director	M	M	-
Mrs. Hasina Begum	Non-Executive Director	-	-	-
Mr. Md. Shafiqur Rahman	Independent Director	C	C	-
Mr. A. N. M. Abul Kashem	Independent Director	M	M	C

Note: BoD denotes Board of Directors
 AC denotes Audit Committee
 NRC denotes Nomination and Remuneration Committee
 RMC denotes Risk Management Committee
 C denotes Chairman of the Committee and
 M denotes Member of the Committee



Board diversity

Diversifying the Board in terms of the inclusion of a wide variety of knowledge, skills and experiences in the Board brings new thinking, insights and perspectives and assists us to move towards the achievement of our long term goals. It is the responsibility of our Nomination and Remuneration Committee to identify Board member candidates, if required, to be proposed to and to get approved by the shareholders. Our existing Board is the combination of different personal characteristics including gender, age, background, experience, expertise and other technical and interpersonal skills.

Board charter

The Board of Orion Pharma Limited assumes supreme leadership, responsibility and control for the overall strategic direction of the company along with its operations and activities through appropriate delegation of authority to the management and decisions in subsidiaries. The main role of the Board is to direct the company towards its vision and supervise the management according to the strategies and decisions set by them which are made in the best interest of the stakeholders. At OPL, the Board delegates certain duties to the sub-committees, enabling them to work in an efficient manner and focus on decision-making.

The Board at OPL is governed by a formal Board charter setting out its composition, processes and responsibilities. The main duties and responsibilities of the Board are to:

- Formulate corporate strategies, business policies along with major plans of action and monitor management in implementing these plans and strategies;
- Retain full and effective control of the company and take decisions concerning budgets, capital budgeting, business plan and major capital expenditures;
- Identify and regularly monitor key risk areas, major performance indicators and performance objectives of the business;
- Endeavour that the company complies with relevant laws, regulations and code of business practices and evaluate the effectiveness of the company's governance practices;
- Appoint/remove the Executive and Non-Executive Directors, CEO, CS, CFO, HIAC and top executives of the company and ensure their compensation, performance evaluation and proper succession when required keeping in consideration the best interest of the company;

- Establish a formal and transparent procedure for appointment of the Board members along with their orientation and assess the performance of the Board along with the effectiveness of its sub-committees;
- Ensure that the company regularly communicates with shareholders and relevant stakeholders openly and promptly, protecting the interest of minority shareholders;
- Review the company's integrated performance and ensure the integrity of the company's accounting and financial reporting system, including independent audit; along with corresponding the financial results to the interested users;
- Monitor and manage potential conflicts of interest of management, Board members and shareholders; and
- Review the reports provided by the sub-committees.

In order to fulfill their responsibilities, Directors always have unrestricted access to information including financial data, documents and records of the company.

Appointment, retirement & rotation of Directors

Orion Pharma Limited abides by all rules and regulations of different relevant regulatory authorities including Companies Act, 1994 along with its own Articles of Associations, regarding the appointment, retirement and re-appointment of Directors.

In terms of the Companies Act, 1994, one third of the Directors are required to retire by rotation at each year's Annual General Meeting (AGM). Upon retirement the Directors may offer themselves for re-election by shareholders at AGM, if they are deemed to be eligible.

For the reporting financial year, Mrs. Arzuda Karim, Director and Mrs. Hasina Begum, Director of the company will retire by rotation from the Board and also offered themselves for re-appointment at the ensuing AGM.



Brief profiles of the Directors seeking re-appointment are disclosed on pages 34 & 36

OPL Annual Report 2019-20

Appointment of Managing Director

The company appointed Mrs. Zareen Karim as its Managing Director for a period of 5 (five) years on January 08, 2020. Since 2014 Mr. Salman Obaidul Karim had been holding the

position of Managing Director of all concerns of Orion. As per the corporate governance code issued by Bangladesh Securities and Exchange Commission on June 03, 2018 (BSEC/CMRRCD/2006-158/207/Admin/80); the Managing Director of a listed company cannot hold the same position in any other listed company. Therefore, in order to comply with the mentioned corporate governance code, the Board of Directors of the company decided to appoint Mrs. Zareen Karim, who has been associated with the company for a long time, as Managing Director in place of Mr. Salman Obaidul Karim. The Board entrusts Mrs. Zareen Karim with this new role and is confident that she will be able to take the business to new heights with her leadership.



Brief profile of the newly appointed Managing Director is disclosed on page 33

OPL Annual Report 2019-20

Induction of Directors

The new Director(s) including the Independent Director(s) are provided with a formal orientation program, so that they can perform their roles in an efficient manner within the shortest practicable time. To understand about the company they are provided specific information about the company's mission, strategies, activities etc. New Board members are also introduced to their basic roles and responsibilities.

Independent Directors

The Board of Directors of OPL consists of 2 (two) qualified Independent Directors who ensure independence of the Board and also bring more competencies on the table. The Independent Directors are Non-Executive Directors who have been appointed in compliance with the corporate governance code of BSEC. At our company, both the Independent Directors have successfully established trusting relationships with the other Board members and provide adequate time to their responsibilities.

As per the corporate governance code, the term of an Independent Director is 3 (three) years which may be prolonged for another 3 (three) years. Also the post of Independent director cannot remain vacant for more than 90 (ninety) days. However, the appointment / re-appointment of the Independent Director is subject to the approval by shareholders at the first AGM after their appointment following the recommendation from Board.

Lt. Col. Kamal Ahmed, PSC (Retd.), Independent Director, completed his second tenure with great success and Mr. A. N. M. Abul Kashem has been appointed as the new Independent Director, in compliance with the Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80 dated June 03, 2018 issued by BSEC, subject to the approval of the shareholders in the ensuing AGM.

Qualification of Independent Directors

Both the Independent Directors fulfill the conditions specified in the corporate governance code of BSEC and can make meaningful contribution to the business of the company.

Mr. Md. Shafiqur Rahman

Mr. Md. Shafiqur Rahman obtained his B.Com (Hon's) and M.Com degree from the University of Dhaka. He was the Managing Director and CEO of Social Islami Bank Limited. His experience spans over more than 4 (four) decade of illustrious career in the banking sector.

Mr. A. N. M. Abul Kashem

Mr. A. N. M. Abul Kashem has a long and illustrious career of more than thirty (30) years in the Banking industry. He last served as an Executive Director of the Central Bank, where he oversaw the Khulna Office, Foreign Exchange Investment Department and Human Resource Department. He is also vastly experienced in CBSP, Banking inspection, Expenditure Management and Accounts Departments. He has acquired versatile knowledge by working in different departments at the Central Bank of Bangladesh and this extensive knowledge and long professional experience is a great asset for the Board of the company.

Separation of work for the Chairman & the Managing Director

The main purposes of splitting the position and roles of the Chairman from that of the Managing Director are to strengthen the overall integrity of the company by means of avoiding the conflict of interest and to improve the ability of the Board of Directors to oversee management.

Mr. Mohammad Obaidul Karim has been acting as the Chairman of the Board and elected by the Board since September 10, 2014. He does not participate in the operational and regular affairs of the company.

Mrs. Zareen Karim has been appointed as the Managing

Director on January 08, 2020. She is responsible for all day to day management decisions and for the routine business operation of the company.

Both the Chairman and the Managing Director are collectively accountable for the leadership of the company and for exercising the highest standards of ethics, integrity and governance.

The respective and distinctive roles and responsibilities of the Chairman and the Managing Director are clearly defined by the Board. The separation of both of these positions and roles & responsibilities meets the criteria of corporate governance code of BSEC and also a balance of authority with regard to the Board's decision-making processes.

Major roles & responsibilities of the Chairman are as follows:

- Provides leadership to the Board and assesses whether the Board is functioning in accordance with the Memorandum and Articles of Association of the company and other applicable laws, rules and regulations;
- Fixes Board, committee and general meeting schedule including date, time and location of meetings and develops agendas in consultation with the MD and the Company Secretary;
- Acts as Chair at meeting of members, meeting of Board of Directors and reviews and signs minutes of Board meeting and general meeting;
- Promotes open discussion and constructive dialogue among the Directors inside or outside the Board meeting and between the Directors and the management team;
- Works with the MD to ensure that Directors are properly informed and key issues are discussed by the Board in a timely manner, so that the Board has adequate support and all required information to make necessary decisions;
- Provides supports, independent advice and counsel to the MD;
- Represents the company as its figurehead to the relevant stakeholders;
- Acts as a direct liaison between the Board and the management of the company, through the MD; and
- Reviews the Board's sub-committees performance to make sure that they work effectively.

Major roles & responsibilities of the Managing Director are as follows:

- Formulates and successfully implements company policy;
- Develops strategic operating plans that reflect the longer-term objectives and priorities established by the Board and also directs strategy towards the profitable growth and operation of the company;
- Represents the company to major stakeholders;
- Maintains the operational performance of the company and closely monitors the operating and financial results against plans and budgets;
- Builds and maintains an effective management team;
- Assess the principal risks of the company to ensure that these risks are being monitored and managed;
- Ensures effective internal controls and management information systems are in place;
- Ensures that the company maintains high standards of corporate citizenship and social responsibility wherever it does business; and
- Keeps the management and the Board informed about all material activities of the company and all material external factors affecting the company.

Company Secretary (CS)

The Company Secretary, Mr. Md. Ferdous Jaman, plays a proactive and crucial role in the governance of the company. He works at the centre point of the decision making process and is a management personnel of the company responsible for providing guidance to the Chairman and Board of Directors in respect to their responsibilities, authorities and power. He is directly accountable to the Board, through the Chairman and has been serving as a dedicated and resourceful personnel for a long time. Mr. Jaman does not hold any executive position in any other company.

Major duties & responsibilities of the Company Secretary are as follows:

- Responsible to advice on the corporate governance and other rules and regulations imposed by different regulatory authorities including RJSC, BSEC, DSE, CSE;
- Most notably, the responsibility for developing and implementing processes to promote and sustain good corporate governance has fallen largely within the remit of the Company Secretary;

- Facilitates the distribution of information to the concerned office or person in a timely manner like agenda items for Board and committee meetings, investor communications and any other corporate announcement including Price Sensitive Information which may have significant material impact on the performance of the company;
- Attends all the meetings of the Board, its sub-committees, meeting of the members and records the minutes of such meetings;
- Maintains the necessary link and liaison with the internal organs like Board, Management, different divisions and department and also with the external agencies; and
- Performs company secretarial and legal matters-compliance with Companies Act, 1994, listing regulations, securities law and Memorandum & Articles of Association; arranging and holding the Board meeting, annual general meeting, extra ordinary general meeting as well as taking correct record of proceedings; maintaining statutory books.

Chief Financial Officer (CFO)

Mr. Samaresh Banik is the Chief Financial Officer of the company. He is the Executive Vice President and also the Head of Finance & Accounts of the company. As one of the key members of management team, he reports to the MD and has a strategic role in the overall management of the company. He has been serving as a credible, knowledgeable and trusted resource to the MD. Mr. Banik does not hold any executive position in any other company.

Major duties & responsibilities of the Chief Financial Officer are as follows:

- Responsible for directing finance and accounts team to carry on the financial functions of the company in accordance with the applicable rules and regulation;
- Works with management team on the strategic vision of the organization including cultivating and fostering strategic relationships and potential alliances;
- Responsible for oversight of financial internal controls and coordination of all financial audits;
- Collaborates with the MD and other senior leaders on operational and strategic issues as they arise; provides strategic recommendations based on financial analysis and projections, and revenue/expense analysis;

- Oversees all financial transactions, including billing, finance, accounting and reporting; and prepares and communicates monthly, quarterly, half yearly and annual financial statements;
- Develops and supervises the budget or financial forecasting for upcoming year considering the long-term budgetary planning and cost management in alignment with the strategic plan;
- Develops and promotes a framework to drive financial acumen and accountability across the organization; and
- Reviews and certifies the financial statements together with the MD and submit the same to the Board of Directors of the company.

Head of Internal Audit & Compliance (HIAC)

One of the important members of our management team, Mr. Md. Ibrahim Khalil is the Head of Internal Audit and Compliance. He is not holding the same position in any other company at present. He is an extremely self-driven and clearheaded person who strives to be a diligent professional through team work and relationships with the colleagues. He is responsible for developing and implementing risk based Audit plan, policy/procedure giving priority of sensitive areas. He also works to identify deficiencies during Audits and notify the significant audit findings to the management and Audit Committee of the Board. Other than this, he is also responsible for implementing, directing and overseeing the auditing and compliance programs and conducts and directs audits and ongoing reviews of organizational controls and operating procedures with policies and regulations.

Major duties & responsibilities of the Head of Internal Audit & Compliance are as follows:

- Responsible for evaluating the adequacy of the system of internal controls and recommending improvements in controls;
- Assesses compliance with policies and procedures and sound business practices;
- Assesses compliance with the laws, rules, regulations, guidelines etc.;
- Reviews operations/programs to ascertain whether results are consistent with established objectives and whether the operations/programs are being carried out as planned;

- Reviews and appraises the soundness, effectiveness, and proper application of accounting process and assesses the adequacy and extent of programs designed to safeguard organization assets; and
- Issues reports to the Audit Committee regarding planning of adequate internal control and financial reporting.

The Directors' Report to shareholders

The Directors' Report to shareholders is prepared in compliance with the corporate governance code of BSEC. This report has been duly approved by the Board of Directors in its Board meeting held on November 08, 2020.



Detailed Directors' Report is articulated on pages 104-132

OPL Annual Report 2019-20

Board meetings & procedures

The meetings of the Board of Directors of OPL occur regularly as per schedules but often the Board members also meet to discuss and deal with urgent matters that require attention. Therefore, additional meetings are convened on an ad hoc basis. In this case reasonable notice period for such emergency meeting is given before holding the meeting to facilitate planning of Directors' schedule. The Company Secretary finalizes the agenda for meetings in consultation with the Chairman and the same is circulated to the Board members well in advance to ensure meaningful participation in the meetings. In the meetings, the Board of Directors discusses about critical issues as per the set agendas; reviews sub-committees' reports and takes appropriate decisions. These meetings provide an opportunity for both Executive and Non-Executive Directors to articulate ideas.

Orion Pharma Limited complies with the provision mentioned under Section 96 of the Companies Act, 1994 which states that a meeting of the Board of Directors shall be held at least once in every 3 (three) months and at least 4 (four) such meetings shall be held in every year. The CS, CFO and HIAC attend the meetings regularly.

Number of Board meetings held & attendance of Directors

During the financial year ended June 30, 2020, 7 (seven) Board meetings were held. Other than Directors, the CS, CFO and HIAC of the company also attended all the Board meetings. Information about the attendance of Directors at the Board meetings during the reporting year and at the last AGM is stated in the table below:

Name	Board meetings held	Board meetings attended	Attendance at the last AGM (held on 15.12.2019)
Mr. Mohammad Obaidul Karim	7	6	Yes
Mrs. Zareen Karim	7	6	Yes
Mrs. Arzuda Karim	7	6	No
Mr. Salman Obaidul Karim	7	6	Yes
Mrs. Hasina Begum	7	5	No
Lt. Col. Kamal Ahmed, PSC (Retd.)*	7	5	No
Mr. Md. Shafiqur Rahman	7	7	Yes

Name	Attendance at the Board meetings						
	05.09.2019	05.10.2019	06.11.2019	12.11.2019	08.01.2020	28.01.2020	20.05.2020
Mr. Mohammad Obaidul Karim	√	√	√	√	√	-	√
Mrs. Zareen Karim	√	-	√	√	√	√	√
Mrs. Arzuda Karim	-	√	√	√	√	√	√
Mr. Salman Obaidul Karim	√	√	√	√	√	√	-
Mrs. Hasina Begum	√	√	√	-	-	√	√
Lt. Col. Kamal Ahmed, PSC (Retd.)*	√	√	-	√	-	√	√
Mr. Md. Shafiqur Rahman	√	√	√	√	√	√	√

*Mr. A. N. M. Abul Kashem has been appointed as the Independent Director in place of Lt. Col. Kamal Ahmed, PSC (Retd.) after the end of the financial year 2019-20. Therefore, Lt. Col. Kamal Ahmed, PSC (Retd.) attended the Board Meetings as the Independent Director during the reporting financial year.

Boards of subsidiary companies

Orion Pharma Limited is the parent (holding) company of 2 (two) unlisted subsidiary companies:

- Orion Power Meghnaghat Limited and
- Dutch Bangla Power & Associates Limited



Detailed discussions on the operation and performance of the subsidiaries are disclosed on pages 25 & 286-333

OPL Annual Report 2019-20

Both the subsidiaries have their own Board of Directors with the authority to manage the companies for the best interest of the companies as well as the shareholders. The Board is aware of the fact that any material issue of the subsidiary companies might have an effect on both the parent company as a whole and on its subsidiaries. Therefore, OPL oversees the operation and performance of the subsidiaries to ensure effective control over the decision making process of the subsidiaries. One of the Independent Directors of the parent company, Mr. Md. Shafiqur Rahman, was appointed as the Nominated Director of both the subsidiary companies through a Board meeting held on June 14, 2018 in order to ensure governance of Board of Directors of subsidiary companies. The minutes of all the Board meetings of the subsidiary companies are placed and reviewed at the following Board meetings of OPL.

Board's sub-committees

For ensuring good governance in the company, the Board established the following sub-committees:

- Audit Committee;
- Nomination and Remuneration Committee; and
- Risk Management Committee.

The responsibility of such sub-committees is to divide up the work amongst Board members, allowing Board members with specific expertise to focus on key areas and which allows committee members to better serve the Board's needs.

Audit Committee

The Board has an Audit Committee as a sub-committee to enable the Board to carry out its responsibilities and duties

effectively. The Audit Committee is comprised of 1 (one) Non-Executive Director and 2 (two) Independent Directors. The Chair of the committee is an Independent Director, Mr. Md. Shafiqur Rahman, as required under the corporate governance code of BSEC. He was duly appointed by the Board as the Chairman of the committee. Other members are Mr. Salman Obaidul Karim, Non-Executive Director and Mr. A. N. M. Abul Kashem, Independent Director. The Company Secretary of the company acts as the Secretary to the Audit Committee.

The committee assists the Board with respect to internal control, financial reporting, auditing matters, monitoring process, related party transactions etc. The committee also has the responsibility to make sure that all the rules and regulations issued by the regulatory authorities have been complied with and they are directly responsible and report to the Board.



The detailed activities of the Audit Committee are disclosed on pages 67-71

OPL Annual Report 2019-20

Nomination & Remuneration Committee

The Board of Directors has a Nomination and Remuneration Committee for the company in compliance with the corporate governance code of BSEC. The committee is composed of 3 (three) members of the Board of Directors. Mr. Md. Shafiqur Rahman, Independent Director is the chair of the committee. Other members are Mr. Salman Obaidul Karim, Non-Executive Director and Mr. A. N. M. Abul Kashem, Independent Director. The Company Secretary serves as the Secretary to the Nomination and Remuneration Committee.

The committee supports the Board in formulating the nomination criteria or policy for identifying and recommending the qualified candidates to become members of Board of Directors and top Executives as well as sets policy for formal process of considering remuneration of the Directors and top Executives of the company.



The detailed activities of the Nomination and Remuneration Committee are disclosed on pages 72-78

OPL Annual Report 2019-20

Risk Management Committee

In order to ensure effective risk management within the company, the Risk Management Committee is formed as another sub-committee of the Board. The Risk Management Committee focuses on the overall process of risk management of the company. The committee comprises of 3 (three) members from the Board. Mr. A. N. M. Abul Kashem, Independent Director is the Chairman of the Committee. Other members are Mrs. Zareen Karim, Managing Director and Mrs. Arzuda Karim, Non-Executive Director.



Details on Risk Management Committee are disclosed on pages 79-92

OPL Annual Report 2019-20

Evaluation of the Board's performance

The Board members always take decisions for the benefit of the company as well as for the stakeholders including the shareholders and always perform their duties accordingly. However, at Orion Pharma Limited, an annual evaluation of the performance of the Board, Board members as well as the committees is carried out as the Directors believe that this assessment measures how the Board, Board members and its committees have performed on the parameters of strategic direction, management control and support. The responsibility of evaluation of the Board, Board members and its Committees is conducted under the stewardship of Nomination and Remuneration Committee.

Code of conduct for Directors & Chief Executive Officer

All the Directors are required to abide by and conduct their fiduciary responsibilities towards the company as well as towards the shareholders in accordance with the code of conduct set for them as per the guidelines of corporate governance code of BSEC. The Chief Executive Officer also adheres to the code of conduct for the CEO while performing her duties with care, skill and diligence.



Please refer to the following URL for detailed Code of Conduct:

http://www.orionpharmabd.com/public/corporate_governance/replace/Code_of_Conduct_OPL.pdf

OPL Annual Report 2019-20

Independence of Board of Directors

At Orion Pharma Limited, the Board of Directors is independent of management and has no association that can interfere with their judgment or scope of work. The Nomination and Remuneration Committee has been assigned to assist the Board to review the independence of the Directors as well as the sub-committee members. Both the Independent Directors have submitted a signed and dated declaration to demonstrate their independence to the Board of Directors. The Board determines and declared at the end of the year that all of its members along with those of its sub-committees are independent.

External or statutory auditors

OPL follows the Companies Act, 1994, Securities and Exchange Rules 1987 and BSEC's notification with regard to the appointment and re-appointment of statutory auditors. Complying with the rules, the Audit Committee recommends to the Board to appoint or re-appoint statutory auditors and the Board recommends the same for the approval of shareholders at the next AGM. Also the remuneration of the statutory auditors is fixed by the shareholders in the AGM. In addition to this, Orion Pharma Limited conforms to the laws that the statutory auditors can hold the office for a maximum period of 3 (three) consecutive years and they act independently to provide audited financial statements. S.F. Ahmed & Co., Chartered Accountants, was appointed as the statutory auditors of the company in the last Annual General Meeting and will retire in the forthcoming Annual General Meeting.

Meanwhile, they have confirmed their eligibility and willingness to accept their office as the statutory /external auditors of the company for the next financial year, if re-appointed. In this regard, subject to the approval of shareholders in this forthcoming Annual General Meeting, the Board, as per the recommendation of the Audit Committee, has recommended to appoint S. F. Ahmed & Co., Chartered Accountants, as the statutory auditors of the company for the financial year to be ended June 30, 2021.

Maintaining a website

OPL maintains an official website and the website address is www.orionpharmabd.com. The company's website has a wealth of information and there is a section in the website named "Investor Relations" designed specifically for investors. It includes detailed coverage of the Board of Directors, share information, PSI, financial news and investor contact. Quarterly, half-yearly and the annual financial statements are posted at company's website to keep all the stakeholders informed about the company's financial results.



This year's Annual Report as well as the reports of prior years can be viewed at:

<http://www.orionpharmabd.com/investor/annualreport>

OPL Annual Report 2019-20

Appointment of compliance auditors

OPL assures compliance on corporate governance by obtaining a Certificate on compliance on the conditions of the corporate governance code from ARTISAN, Chartered Accountants, who provides certification based on audit that we have duly complied with all regulatory requirements of BSEC. Also the Board has recommended to appoint ARTISAN Chartered Accountants, as the corporate governance compliance auditors for the next financial year subject to the approval of shareholders at the ensuing AGM.

Dealing of securities

The Board of Directors of Orion Pharma Limited, in their declared code of conduct, has forbidden any kind of insider trading. All Directors and management personnel are prohibited from dealing with own securities during closed periods. The Board ensures that members of the Board of Directors, the Board's sub-committees or the management and their family members were not involved in any insider trading.



Details on share dealing is described in the Code of Conduct for the Directors and the Chief Executive Officer under section Insider Trading and please refer to the following URL for detailed Code of Conduct:

http://www.orionpharmabd.com/public/corporate_governance/replace/Code_of_Conduct_OPL.pdf

OPL Annual Report 2019-20

Succession planning

At Orion Pharma Limited, the Board of Directors through its Nomination and Remuneration Committee is responsible for overseeing the succession planning. The management team is particularly assigned to assist the Board and the committee with senior leadership succession planning when necessary. The company always plans ahead the succession keeping factors such as skills and knowledge, diversity, professional background, expertise etc. into consideration.

Corporate culture

Orion Pharma Limited has a flexible corporate culture which is always open to improvement. We are a team-oriented company and our human resource practices are one of the best in the country. We are committed for establishing equal employee opportunity for our valued employees. Integrity is one of our core values and we believe in being transparent and fair in all our dealings by providing the best quality to the customers along with fulfilling our responsibility towards the society.

Communication with shareholders and stakeholders

The Board of Directors of the company pays great importance to its investors' community and their information requirements. With the sincere desire to stay close with investors' community, the company always tries to bridge the gap between investors' and the company. The company aims to be transparent with all stakeholders, including the owners of the company – the shareholders.

The AGM of OPL is held each year as per law. Extraordinary general meetings are called as often as necessary by a decision of Board of Directors, or by the written notice of shareholders of the company. The purpose of the AGM is to enable the company to report on its activities during the previous financial years to its shareholders. We at OPL aim to be accountable and transparent with all our stakeholders, through proper and timely dissemination of information on the company's financial performance and major developments. The AGM is a platform for the Board and shareholders to effectively communicate on company's performance.

We give a lot of importance to the participation of shareholders in the AGM and also try to ensure their presence in this meeting to notify them about how their company is performing. This is because we at OPL follow the opinion that regular and transparent communication can help our shareholders feel connected to the company.

A notice of AGM is sent to the exchanges and simultaneously to the shareholders at least 21 (twenty one) days prior to AGM and any resolutions containing price sensitive information send to the exchanges within half an hour in compliance with the Listing Regulations, 2015. The annual reports are circulated and published in the company's website as per the provisions of Listing Regulations, 2015, so that shareholders can get sufficient time to go through the report and freely provide their valuable comments and suggestions during the AGM. When selecting the time and venue for the AGM, the convenience of maximum shareholders is considered by the company. The Chairman and other members of the Board answer the questions of the shareholders and note the views and suggestions of them offered at the AGM with utmost seriousness. A shareholder of the company is entitled to attend and vote at the general meeting or may appoint a proxy to attend and vote in his/her stead. OPL also provides updated information on its website regularly for the shareholders of the company.

Human Capital

OPL ensures high standard business practices by engaging competent work force in every department of the organization. OPL considers human resources as the source of creativities and innovations in continuing and/or upgrading organizational overviews towards excellence which is the ultimate objective of the company.



A detailed report on our human capital is disclosed in our human capital report on pages 160-175

OPL Annual Report 2019-20

Denouement

Responsible and fair corporate governance is fundamental to the success of OPL. It is an integral part of our corporate culture and the reason why employees, customers, shareholders, business partners and the general public place their trust in us.

The Board, management and employees of OPL are obliged to act responsibly and in compliance with applicable laws and regulations of the corporate governance. Our company strives to set benchmark in the corporate world by obtaining the most efficient form of management with the aid of our Board Members, stakeholders and the employees. Therefore, it is the sole responsibility of our members and employees to adhere with good corporate governance for the sake of company's success in all aspects. OPL envisions to achieve excellence in the field of pharmaceutical industry through effective execution of corporate governance policies. With the aim to adopt transparency and accountability in corporate governance, our company conducts surveillance on a regular basis ensuring a law abiding and appropriate implementation of corporate governance. As a result, OPL is undoubtedly recognized as an ideal organization in maintaining fair governance along with its potential and reliable Board members and employees.

Audit Committee report

Part One: Statement by the Chairman of the Audit Committee

I, the undersigned Independent Director and Chairman of Audit Committee, on behalf of the members of committee, do hereby declare that the committee has pleasure in submitting its report to the shareholders as required in terms of the condition No.5.6 of the Notification No.BSEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018 issued by Bangladesh Securities and Exchange Commission under section 2CC of the Securities and Exchange Ordinance, 1969 (XVII of 1969).

The committee is satisfied that it has met its responsibilities for the reporting year and to the date of this report in accordance with its terms of reference as set down in its charter. The table below depicts the activities carried out by the committee and the outcomes of these activities as on the reporting date:

Activities	Outcomes
Oversight of financial statements and its reporting process	<ul style="list-style-type: none"> • Reviewed the quarterly, half yearly and annual financial statements of the company and its subsidiaries together with the Chief Financial Officer and the Managing Director; • Considered the quarterly, half yearly and annual financial statements of the company and recommend the same to the Board of Directors for their approval; • Confirmed that the financial statements reflect true and fair view of the state of affairs of the company and its subsidiaries; • Oversaw the financial reporting process, the application of accounting policies and principles; • Concluded that no material deviation, discrepancies or adverse findings in the areas of reporting and disclosures were found during the reporting financial year; and • Verified compliance with all applicable laws and matters related to the preparation and presentation of financial statements.
Assurance of internal control and internal audit	<ul style="list-style-type: none"> • Reviewed the statement of significant re-current related party transactions entered into by the company throughout the year; • Monitored the overall internal audit and compliance process, audit plans and audit reports at each of its quarterly meetings and approves the annual internal audit plans; • Worked with the internal auditors on the reports issued by the internal audit to ensure that proper actions have been taken to address the internal audit recommendations; • Assessed the adequacy of internal audit and internal control function; and • Played a role along with the Risk Management Committee in the company's overall risk management process in the context of its responsibilities for internal control.

Activities	Outcomes
Engagement with the statutory auditors	<ul style="list-style-type: none">• Ensured that the appointment of the statutory auditors complies with the Companies Act 1994, guidelines imposed by the BSEC relating to the appointment of the statutory auditors;• Concluded that the statutory auditors did not provide any non-audit services to the company;• Oversaw the determination of audit fees to be paid to the statutory auditors;• Monitored the overall performance of the statutory auditors;• Recommended to the shareholders to appoint S. F. Ahmed & Co., Chartered Accountants as the statutory auditors of the company;• Held meeting with the statutory auditors, with and/or without the presence of any members of management team, to review the company's annual financial statements; and• Reviewed the statutory auditors' findings, their letters or response to ensure that all these issues or findings have been addressed and concluded that no management letter or letter of internal control weakness was issued by the statutory auditors.
Preparation of report	Prepared a report of Audit Committee for publishing in the Annual Report 2019-20 of the company.

Part Two: The report of Audit Committee

Introduction

The Board of Directors of Orion Pharma Limited has always prioritized the assurance of protection of the interest of stakeholders by means of maintaining integrity of financial reporting, effectiveness of risk management and internal control systems and related corporate governance and compliance matters. The responsibility of ensuring these important matters is exclusively delegated to the Audit Committee, a sub-committee of the Board, appointed by and responsible to the Board of Directors.

The committee reports regularly to the Board on the performance of the activities it has been assigned and also lends confidence to the quality of the audit and the credibility of the financial statements.

Composition of the committee

In order to conform to the corporate governance code imposed by BSEC, the Board of Directors of OPL changed the composition of the committee on January 28, 2020 by including Mr. Salman Obaidul Karim, Non-Executive Director in place of Mrs. Zareen Karim, Managing Director and Mr. A. N. M. Abul Kashem in place of Lt. Col. Kamal Ahmed, PSC (Retd.). The committee also consists of another Independent Director, Mr. Md. Shafiqur Rahman.

The members of the committee are financially literate and competent in financial matters and the committee as a whole has adequate relevant knowledge and experience to equip the committee to carry out its responsibilities.

The committee is chaired by Mr. Md. Shafiqur Rahman, Independent Director of the company. The Board is confident that the leadership of Mr. Md. Shafiqur Rahman as Chairman of the Audit Committee is in the best interests of the company, based on his extensive knowledge on specific areas of responsibilities of the committee. Mr. Md. Shafiqur Rahman will attend the ensuing AGM to answer shareholder questions on the committee's activities. During the reporting year, no such situation arose making the number of committee members lower than 3 (three) persons. Other than the committee members, the Company Secretary, Mr. Md. Ferdous Jaman, functioned as the Secretary of the committee and attended all the meetings of the committee.




The biographical details of each member are shown on pages 35, 37 & 38

OPL Annual Report 2019-20

The members of the Audit Committee of OPL as on the reporting date are as follows:

Name	Joined the committee	Status with the committee	Status with the Board
Mr. Md. Shafiqur Rahman	2018	Chairman	Independent Director
Mr. A. N. M. Abul Kashem	2020	Member	Independent Director
Mr. Salman Obaidul Karim	2020	Member	Non-Executive Director
Secretary: Mr. Md. Ferdous Jaman, Company Secretary			



Meetings & attendance

Name	Audit Committee meetings held	Audit Committee meetings attended
Mr. Md. Shafiqur Rahman	5	5
Lt. Col. Kamal Ahmed, PSC (Retd.)*	5	5
Mr. Salman Obaidul Karim (from 28.01.2020)	5	1
Mrs. Zareen Karim (till 27.01.2020)	5	4

Name	Attendance at the Audit Committee meetings				
	28.09.2019	03.11.2019	09.11.2019	25.01.2020	17.05.2020
Mr. Md. Shafiqur Rahman	√	√	√	√	√
Lt. Col. Kamal Ahmed, PSC (Retd.)*	√	√	√	√	√
Mr. Salman Obaidul Karim (from 28.01.2020)	-	-	-	-	√
Mrs. Zareen Karim (till 27.01.2020)	√	√	√	√	-

*Mr. A. N. M. Abul Kashem has been appointed as the Independent Director in place of Lt. Col. Kamal Ahmed, PSC (Retd.) after the end of the financial year 2019-20. Therefore, Lt. Col. Kamal Ahmed, PSC (Retd.) attended the committee meetings as the member of the committee during the reporting financial year.

The company held Audit Committee meetings at regular intervals. During the financial year ended June 30, 2020 the committee held 5 (five) meetings and all members were present in all meetings of the committee. Mr. Md. Ferdous Jaman, Company Secretary also attended all the meetings to act as the Secretary of the committee.

Terms of reference

The Audit Committee discusses and reviews company's financial disclosures with the Board and statutory auditors and oversees the organization's internal controls. The committee reports that it operates within the terms of reference defining the role and responsibilities of Audit Committee as set out in its charter which is governed by the BSEC's corporate governance code. The committee's principal responsibilities include, but not limited to, the following matters:

Financial statements & its reporting process

- Supporting the Board particularly in monitoring the financial reporting process, and submitting recommendations or suggestions to the Board on ensuring the integrity of the financial reporting process;

- Review of the quarterly, half yearly and annual financial statements and accounting policies and principles for the company and all of its subsidiaries; and
- Meeting with the management on quarterly financial statements or with the statutory auditors on the annual financial statements and upon satisfaction of the review, recommendation of the same statements to the Board for approval.

Internal control arrangement

- Review of the management letter and letter of internal control weakness issued by the statutory auditors on the effectiveness of the systems designed for internal financial control and management response thereon; and
- Review of statement of significant related party transactions submitted by management;
- Review of and recommendation to the Board regarding disclosures to be published in the annual report concerning internal control, risk management and the Management's Discussion and Analysis; and

- Discharge of the committee's fiduciary responsibilities to consider the major findings on internal investigations and management's response.

Statutory auditors

- Review of the audit plan and methodology proposed by the statutory auditors to carry out the audit as well as holding meeting with them for review of the annual financial statements before submission for Board's approval;
- Oversight of the nomination, determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit, assessment of the statutory auditors' performance, qualifications, findings and recommendation;
- Recommendation of the appointment, re-appointment or replacement of the statutory auditors and preparation the proposal of the Board to the annual general meeting for the election of the statutory auditors;
- Discussion of the problems, irregularities and reservation arising from the statutory audit and any matters the statutory auditors may wish to discuss; and
- Assurance of the independence of statutory auditors from any material non-audit services including appraisal or valuation service or fairness opinions, financial information systems design and implementation, book-keeping, broker-dealer services, actuarial services and internal audit services.

Internal audit function

- Oversight of the performance, adequacy and effectiveness of internal audit function and compliance process to make sure that the internal audit and compliance process is adequately resourced and review of their report stating major findings of the internal investigations and management response and where necessary, making sure that the appropriate actions are taken.

In addition, the committee:

- Submits the minutes of all committee meetings and reports on the matters discussed at each committee meeting to the Board on quarter basis, as appropriate;
- Reports annually to the shareholders on the activities carried out by the committee;
- Reviews and assesses the performance and effectiveness of the Audit Committee; and
- Performs any other activities consistent with the regulatory law as the committee or the Board deems necessary or appropriate.

Reporting of the Audit Committee

Board of Directors

The committee Chairman reports formally to the Board on its proceedings after each meeting on all matters within its duties and responsibilities including any material defects in internal control or in internal audit and compliance process or in the financial statements, any conflict of interest, any infringement of laws or regulatory compliances and any other matters necessary to ensure the true and fair view of the financial statements.

During the year under review, the committee met 5 (five) times and accordingly forwarded their reports to the Board. The Board is of the view that there was no issue having significant material impact on the company's financial statements which needed to be disclosed to the Board or the regulatory authorities.

Regulatory authorities

Apart from reporting to the Board, it also have the authority to report to the regulatory authorities regarding any issue having material financial impact on the financial condition and results of operation if the Board and the management have unreasonably ignored such issues without making any rectification.

Shareholders & general investors

The committee prepares report on its activities to shareholders and other interested parties of the company on annual basis by means of presenting a summary of its activities in the form of a "Statement by the Chairman of the Audit Committee" in first part and the Report of Audit Committee in second part.

Recommendation of Audit Committee report for approval by the Board

This Audit Committee report was recommended by the committee on November 05, 2020 for approval by the Board of Directors of Orion Pharma Limited which was granted on November 08, 2020.

On behalf of the committee

Sd/-

Md. Shafiqur Rahman
Chairman

Nomination & Remuneration Committee report


Part One: Statement by the Chairman of the Nomination & Remuneration Committee

I, the undersigned Independent Director and Chairman of Nomination and Remuneration Committee on behalf of the members of Committee, do hereby declare that the committee has pleasure in submitting its report to the shareholders for the financial year ended June 30, 2020. When performing its duties, the committee has taken into account the requirements set by the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018 issued by Bangladesh Securities and Exchange Commission under section 2CC of the Securities and Exchange Ordinance, 1969 (XVII of 1969).

The committee is of the opinion that the disclosure provided in this integrated annual report on the nomination and remuneration policies and the evaluation criteria and activities of the committee are adequate to present a transparent and independent view of the company's approach to its human resources and are in line with business strategy and well-aligned to shareholder interest. The table below depicts the activities carried out by the committee and the outcomes of these activities as on the reporting date:

Activities	Outcomes
Proposal for re-election of Directors	Proposed Mrs. Arzuda Karim and Mrs. Hasina Begum, Directors of the company for retirement by rotation and for re-election (being eligible) by the shareholders in this upcoming Annual General Meeting.
Appointment of Managing Director	Proposed to appoint Mrs. Zareen Karim as the Managing Director of the company for the next 5 (five) years evaluating her strong business development skills, managing capability and eligibility as per applicable laws, rules and regulations, subject to the post-facto approval of the shareholders in this upcoming Annual General Meeting.
Appointment of Independent Director	Selected Mr. A. N. M. Abul Kashem as the Independent Director of the company for the next 3 (three) years considering his qualification, skills, experience, expertise, positive attributes and eligibility as per corporate governance code issued by BSEC, subject to the approval of the shareholders in the upcoming Annual General Meeting.
Evaluation of performance	Evaluated the performance of the Board, its committees, individual members of the Board, Key Managerial Personnel and other senior executives of the company, with the assistance of HR department as and when required, and satisfied with their performance.

Activities	Outcomes
Review of remuneration and other fees	Reviewed the annual remuneration package of the Executive Director, Key Managerial Personnel and other senior executives of the company, with the assistance of HR department as and when required, and ensured that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate them to run the company as per company goals.
Succession planning	Reviewed the succession plan to ensure that the potential individuals are ready with proper skills, experience, ownership and engagement to fill gaps when necessary.
Review of HR and training policy	Reviewed human resources and training policies for the future leaders of the company.
Disclosure of remuneration	Considered and confirmed that the remuneration disclosed in this integrated annual report is accurate, complete and transparent.
Preparation of report	Prepared a Nomination and Remuneration Committee Report for publishing in the Annual Report 2019-20 of the company.



Part Two: The report of Nomination & Remuneration Committee

Introduction

The Nomination and Remuneration Committee, a sub-committee of the Board has been duly constituted with one primary objective-supporting the Board by setting policies for nomination and remuneration functions. The charter clearly sets out the terms of reference or scopes of the committee's responsibilities. The committee may be supported by an independent expert as advisor who does not have voting power like the member of the committee. The committee has been constituted by the Board of Directors and it reports regularly to the Board on the performance of the activities it has been assigned.

Composition of the committee

The Nomination and Remuneration Committee is comprised of 3 (three) members of whom 2 (two) are Independent Directors with a minimum requirement of 1 (one) such member. All the members are Non-Executive Directors, nominated and appointed by the Board. The committee is headed by Mr. Md. Shafiqur Rahman, Independent Director of

the company. The Board is confident that the leadership of Mr. Md. Shafiqur Rahman as Chairman of the committee is in the best interests of the company, based on his extensive knowledge of the specific areas of responsibilities of Nomination and Remuneration Committee. Mr. Md. Shafiqur Rahman will attend the ensuing AGM to answer shareholder questions on the committee's activities. To conform to the corporate governance code imposed by BSEC, the Board of Directors of OPL changed the composition of the committee during the reporting financial year, by including Mr. Salman Obaidul Karim, Non-Executive Director in place of Mrs. Zareen Karim, Managing Director. Other member of the committee is Mr. A. N. M. Abul Kashem, Independent Director. Other than the committee members, the Company Secretary, Mr. Md. Ferdous Jaman, functions as the Secretary of the committee.




The biographical details of each member are shown on pages 35, 37 & 38

OPL Annual Report 2019-20

The members of Nomination and Remuneration Committee of OPL as on the reporting date are as follows:

Name	Joined the committee	Status with the committee	Status with the Board
Mr. Md. Shafiqur Rahman	2018	Chairman	Independent Director
Mr. A. N. M. Abul Kashem	2020	Member	Independent Director
Mr. Salman Obaidul Karim	2020	Member	Non-Executive Director
Secretary: Mr. Md. Ferdous Jaman, Company Secretary			



Meetings & attendance

Name	Nomination and Remuneration Committee meetings held	Nomination and Remuneration Committee meetings attended
Mr. Md. Shafiqur Rahman	4	4
Lt. Col. Kamal Ahmed, PSC (Retd.)*	4	4
Mr. Salman Obaidul Karim (from 28.01.2020)	4	-
Mrs. Zareen Karim (till 27.01.2020)	4	4

Name of Directors	Attendance at the Nomination and Remuneration Committee meetings			
	01.09.2019	23.10.2019	01.01.2020	25.01.2020
Mr. Md. Shafiqur Rahman	√	√	√	√
Lt. Col. Kamal Ahmed, PSC (Retd.)*	√	√	√	√
Mr. Salman Obaidul Karim (from 28.01.2020)	-	-	-	-
Mrs. Zareen Karim (till 27.01.2020)	√	√	√	√

*Mr. A. N. M. Abul Kashem has been appointed as the Independent Director in place of Lt. Col. Kamal Ahmed, PSC (Retd.) after the end of the financial year 2019-20. Therefore, Lt. Col. Kamal Ahmed, PSC (Retd.) attended the committee meetings as the member of the committee during the reporting financial year.

This table demonstrates the attendance records of members at committee meetings during the financial year ended June 30, 2020. The committee held 4 (four) meetings and all members were present in all meetings of the committee. Mr. Md. Ferdous Jaman, Company Secretary also attended all the meetings to act as the Secretary of the committee.

Terms of reference

The committee has formal terms of reference which is governed by the BSEC corporate governance code. The charter governs the procedures and guidelines of nominating a candidate to the position of Director as well as nominating persons to become members of the company Key Managerial Personnel. This charter also outlines the procedures and guidelines in relation to the remuneration of Directors, Key Managerial Personnel and other senior executives of the company. The committee's principal responsibilities include, but not limited to, the following matters:

Functions related to nomination

- Establishing a policy formalizing the company's approach to Board diversity (including diversity in gender, age, socio-economic background, skills, experience and independence);
- Formulating criteria for determining qualifications, positive attributes and independence of Directors as well as the criteria for evaluation of performance of the Board of Directors including the Independent Directors;
- Evaluating and reviewing the appropriate size of the Board, required mix of skills, experience and other qualities on annual basis;
- Identifying the company's need for employees at different levels and determining their selection, transfer or replacement and promotion criteria;
- Recommending qualified candidates to the Board to appoint/re-appoint as members of the Board, subject to the approval of shareholders in the Annual General Meeting;

- Considering the need to identify persons who may be appointed in senior management in line with the criteria laid down and recommending to the Board regarding their appointment or removal; and
- Developing, recommending and reviewing annually the company's human resource and training policies.

Functions related to remuneration

- Reviewing and recommending to the Board a formal and transparent remuneration policy and framework for the Board members and senior management and other employees of the company. In doing so, the committee considers the following:
 - The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable Directors as well as top level executives to run the company successfully;
 - Relationship of remuneration to performance is clear and meets appropriate performance benchmarks;
 - Remuneration to Directors, Key Managerial Personnel and senior management involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to corporate governance code imposed by BSEC and the goals of the company;
 - Assessing and proposing to the Board for approval of annual bonus and salary increment framework of the company; and
 - Preparing and presenting a report for disclosing in the Annual Report describing the nomination and remuneration policy

Part Three: The nomination & remuneration report

Nomination & remuneration policy

The committee formulated and recommended and the Board approved a nomination and remuneration policy as per the guidelines to determine attributes and qualifications for appointment as well as appropriate pay package for the Board Members and top executives including the Key Managerial Personnel (KMP) and other senior executives of the company. The nomination and remuneration policy consists of 3 (three) sections.

- The first section describes the matters to be dealt with, pursued and recommended to the Board by the committee;
- The second section is related to the determination of the criteria of nomination, appointment, performance evaluation and removal of Directors, KMP and Other senior executives; and

the remunerations and other benefits awarded to Directors and Key Managerial Personnel.

- Evaluating annually the structure, policies and amount of remuneration for the Directors and top level executives.

Reporting of the Nomination & Remuneration Committee

Board of Directors

It is mandatory for the committee to report and inform the Board of Directors from time to time about its regular activities and to ensure that the Board is aware of the activities carried out by the committee. The committee's Chair on behalf of the committee, reports to the Board following each meeting and prepares any report on the matters as outlined in its charter for the approval of the Board.

Shareholders and other interested parties

It reports to Board and the Board discloses the nomination and remuneration policy and the evaluation criteria and activities of NRC to the shareholders and other interested parties by means of presenting a summary of its activities in the form of a "Statement by the Chairman of the Nomination and Remuneration Committee" in first part, the report of Nomination and Remuneration Committee in second part and the nomination and remuneration policy and the remuneration report in the third part.

- The third section deals with the remuneration structure for Directors, KMP and other senior executives.



Please refer to the following URL for detailed Nomination and Remuneration Policy:

http://www.orionpharmabd.com/public/corporate_governance/replace/Nomination_and_Remuneration_po_icy_OPL.pdf

OPL Annual Report 2019-20

Appointment of Managing Director

As per the corporate governance code issued by Bangladesh Securities and Exchange Commission on June 03, 2018, the Managing Director of a listed company cannot hold the same position in any other listed company. As Mr. Salman Obaidul Karim holds the position of Managing Director of Orion Infusion Limited, he expressed his unwillingness to hold the office of the Managing Director of OPL but is willing to continue the position of the Sponsor Director of the company.

On the other hand, another Sponsor Director of the company, Mrs. Zareen Karim, has been involved with Orion Pharma Limited for a very long period, had expressed her willingness to hold the office of the Managing Director of the company. Moreover, as Mrs. Zareen Karim does not hold the position of Managing Director in any other company, her appointment as Managing Director of Orion Pharma Limited will comply with the above mentioned corporate governance code issued by BSEC. Thereafter, by considering experience, strong business development skills, managing capability of Mrs. Zareen Karim and eligibility as per applicable laws, rules and regulations, the committee has recommended to appoint her as the Managing Director of the company for the next 5 (five) years from the date of her appointment which was approved by the Board of Directors on January 08, 2020 and recommended by the Board for the post-facto approval of the shareholders at the ensuing AGM.

Re-appointment of Directors

With regard to the appointment, retirement and re-appointment of Directors, the company is governed by the Companies Act, 1994, its Articles of Association, and other related legislations. In order to comply with the provision mentioned under Section 91(2) of the Companies Act, 1994 and Clause no. 126 to 130 of the Articles of Association of the OPL, at least one third of the Directors shall retire from the office in the Annual General Meeting. Pursuant to the above, Mrs. Arzuda Karim and Mrs. Hasina Begum, Directors of the company, will retire by rotation from the Board, but being

eligible, have offered themselves for re-appointment. Therefore, the committee has recommended to the Board of Directors to re-appoint Mrs. Arzuda Karim and Mrs. Hasina Begum as the Directors of the company which was also recommended by the Board for the approval of the shareholders at the forthcoming AGM.

Appointment of Independent Director

Lt. Col. Kamal Ahmed, PSC (Retd.), the Independent Director, has completed his second tenure with great success and now, among the shortlisted candidates considering their qualification, skills, experience, expertise, positive attributes, the NRC has recommended to the Board of Directors to appoint Mr. A. N. M. Abul Kashem as the new Independent Director, in compliance with the Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80 dated June 03, 2018 issued by BSEC, subject to the approval of the shareholders in the ensuing AGM.

Total remuneration composition of Executive Director

Mrs. Zareen Karim was appointed as the Managing Director on January 08, 2020 and before her Mr. Salman Obaidul Karim held the position. Therefore, Mr. Salman Obaidul Karim received remuneration as Executive Director from July 01, 2019 to January 07, 2020. As he became Non-Executive Director after January 08, 2020; he was not eligible for further remuneration. On the other hand, being a Non-Executive Director, Mrs. Zareen did not receive any remuneration from July 01, 2019 to January 07, 2020. But after being appointed as the Managing Director and becoming an Executive Director, Mrs. Zareen Karim received remuneration from January 08, 2020 to June 30, 2020.



Details on remuneration received by Executive Director is disclosed on page 270, note 30.a of the financial statements

OPL Annual Report 2019-20

Remuneration received by Executive Director consists of monthly salary and there was no change in the remuneration structure during the last 2 (two) financial years. The following remuneration payment was made during the last 2 (two) years:

Name	Amount in BDT	
	2019-20	2018-19
Mrs. Zareen Karim (from 08.01.2020)	1,800,000	-
Mr. Salman Obaidul Karim (till 07.01.2020)	1,800,000	3,600,000

Total fees of Non - Executive Directors & Independent Directors

All the Non-Executive Directors and the Independent Directors have been remunerated by way of only Board and committee meeting attendance fees during the financial year 2019-20. From July 01, 2019 to January 07, 2020 Mrs. Zareen Karim being a Non-Executive Director received Board and committee meeting attendance fees but upon her appointment as the Managing Director and becoming an Executive Director on January 08, 2020; she did not receive any such fees from that time. On the other hand, Mr. Salman Obaidul Karim did not

receive any Board and committee meeting attendance fees being the Managing Director and Executive Director from July 01, 2019 to January 07, 2020. But upon being Non-Executive Director from January 08, 2020; he has become eligible to receive such fees after that date.



Total fees received by the Non- Executive Directors and Independent Directors is disclosed on page 270 note 30.a of the financial statements

OPL Annual Report 2019-20

The following table demonstrates the meeting attendance fees received by each Director for the reporting year:

Amount in BDT

Name	2019-20		2018-19	
	Board meeting attendance fee	Committee meeting attendance fee	Board meeting attendance fee	Committee meeting attendance fee
Mr. Mohammad Obaidul Karim	60,000	-	52,500	-
Mrs. Zareen Karim (till 07.01.2020)	40,000	80,000	52,500	35,000
Mrs. Arzuda Karim	60,000	20,000	52,500	-
Mr. Salman Obaidul Karim (from 08.01.2020)	10,000	20,000	-	-
Mrs. Hasina Begum	50,000	-	45,000	-
Lt. Col. Kamal Ahmed, PSC (Retd.)*	50,000	110,000	60,000	35,000
Mr. Md. Shafiqur Rahman	70,000	90,000	52,500	35,000
Total	340,000	320,000	315,000	105,000

*Mr. A. N. M. Abul Kashem has been appointed as the Independent Director in place of Lt. Col. Kamal Ahmed, PSC (Retd.) after the end of the financial year 2019-20. Therefore, Lt. Col. Kamal Ahmed, PSC (Retd.) received the Board and committee meeting attendance fee during the reporting financial year.

Total payments/ perquisites to Key Managerial Personnel

Key Managerial Personnel (KMP) consist of Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance, Vice Presidents and Assistant Vice Presidents. In the reporting financial year, the KMP received BDT 31.52 million as payments/ perquisites which was BDT 28.18 million in previous year.



Total payments/ perquisites received by Key Managerial Personnel is disclosed on page 274 note 38.2 of the financial statements

OPL Annual Report 2019-20

Recommendation of Nomination & Remuneration Committee report for approval by the Board

This Nomination and Remuneration Report was recommended by the committee on November 01, 2020 for approval by the Board of Directors of Orion Pharma Limited which was granted on November 08, 2020.

On behalf of the committee

Sd/-

Md. Shafiqur Rahman
Chairman

Risk Management Committee

report

Part One: Statement by the Chairman of the Risk Management Committee

I, the undersigned, Independent Director and Chairman of Risk Management Committee, on behalf of the members of the committee, do hereby declare that the committee has pleasure in presenting Risk Management Committee report to the shareholders for the financial year ended June 30, 2020. The committee is satisfied that it has met its responsibilities for the reporting year and to the date of this report in accordance with its terms of reference as set down in its charter. The table below reflects the principal activities undertaken by the committee in liaison with management and the outcomes of these activities as on the reporting date:

Activities	Outcomes
Assessment of risk management system	<ul style="list-style-type: none"> • Evaluated, on annual basis, the adequacy of the charter along with reviewing and assessing the quality, integrity and effectiveness of the risk management systems; • Reviewed, when required, together with the statutory auditors, the risks associated with financial instruments that could affect the company's result and the measures planned for reducing those risks; • Conducted assessment of material risks facing the company taking into account different sources of assurance including management, internal audit and external audit; • Monitored the implementation of effective risk management policies, strategies and practices by management; • Ensured that risk considerations are incorporated into management responsibilities and decision making; and • Played a role along with the Audit Committee in the company's overall risk management process in the context of its responsibilities for internal control.
Assurance in respect of risk management, mitigation and monitoring processes	<ul style="list-style-type: none"> • Opined that the disclosure provided in this integrated annual report on the risk management strategies & policies along with the evaluation criteria and activities of the committee are adequate to present a transparent and independent view of the company's approach to identifying risks and taking necessary steps against them; and • Confirmed that the company's risk management, mitigation and monitoring processes have been effective in limiting the potential impact of risks on the business during the year under review.
Preparation of report	<ul style="list-style-type: none"> • Prepared a Risk Management Committee report for publishing in the Annual Report 2019-20 of the company.

Part Two: The report of Risk Management Committee

Introduction

The Board of Orion Pharma Limited set up a Risk Management Committee (RMC), a sub-committee of the Board, to oversee and drive improvement in risk management practices of the company. The committee has been duly constituted with one primary objective - supporting the Board by looking after the total process of risk management of the company. The charter clearly sets out the terms of reference or scopes of the committee's responsibilities. The committee reports regularly to the Board regarding its activities and performance. The Board also encourages the presence of executives, Head of Internal Audit and Compliance as well as representatives of the statutory auditors; in the meetings of the RMC so that they may be able to provide valuable input for effective decision making.

Composition of the committee

The Risk Management Committee is comprised of 3 (three) members of whom 1 (one) is Independent Director, Mr. A. N. M. Abul Kashem and he is the Chairman of this committee. The other members are Mrs. Zareen Karim, Managing Director and Mrs. Arzuda Karim, Non-Executive Director. Other than the committee members, the Company Secretary, Mr. Md. Ferdous Jaman, functions as the Secretary of the committee.




The biographical details of each member are shown on pages 33, 34 & 38

OPL Annual Report 2019-20

The members of Risk Management Committee of OPL as on the reporting date are as follows:

Name	Joined the committee	Status with the committee	Status with the Board
Mr. A. N. M. Abul Kashem	2020	Chairman	Independent Director
Mrs. Arzuda Karim	2018	Member	Non-Executive Director
Mrs. Zareen Karim	2020	Member	Executive Director

Secretary: Mr. Md. Ferdous Jaman, Company Secretary



Meetings & attendance

The following table demonstrates the attendance records of members at committee meetings during the financial year ended June 30, 2020. The committee held 2 (two) meetings and all members were present in the meeting of the committee. Mr. Md. Ferdous Jaman, Company Secretary also attended the meetings to act as the Secretary of the committee.

Name	Risk Management Committee meetings held	Risk Management Committee meetings attended
Lt. Col. Kamal Ahmed, PSC (Retd.)*	2	2
Mrs. Arzuda Karim	2	2
Mrs. Zareen Karim (from 28.01.2020)	2	-
Mr. Salman Obaidul Karim (till 27.01.2020)	2	2

Name	Attendance at the Risk Management Committee meetings	
	09.09.2019	25.01.2020
Lt. Col. Kamal Ahmed, PSC (Retd.)*	√	√
Mrs. Arzuda Karim	√	√
Mrs. Zareen Karim (from 28.01.2020)	-	-
Mr. Salman Obaidul Karim (till 27.01.2020)	√	√

*Mr. A. N. M. Abul Kashem has been appointed as the Independent Director in place of Lt. Col. Kamal Ahmed, PSC (Retd.) after the end of the financial year 2019-20. Therefore, Lt. Col. Kamal Ahmed, PSC (Retd.) attended the committee meetings as the member of the committee during the reporting financial year.

Terms of reference

The committee reports that it operates within the terms of reference defining the role and responsibilities of Risk Management Committee as set out in its charter. The charter governs the procedures of the RMC and outlines the procedures and code for the total process of risk management of the company. The committee's responsibilities include, but not limited to, the following matters:

- Assisting the Board in framing risk strategy policies and ensure that these strategies are effectively administered by the management;
- Setting the risk tolerance and appetite levels of the company and ensure that the risks are taken within the agreed tolerance and appetite limit;
- Ensuring that the management formulates a policy for a system of risk management which is circulated throughout the company and annually assess the quality, integrity and effectiveness of the risk management plan;
- Establishing an effective ongoing process to identify risk and work out a plan for outcomes surrounding key risks;
- Overseeing and assessing formal reviews of activities associated with the effectiveness of internal control processes; and
- Presenting an independent and objective oversight and view of the information presented by management on corporate accountability along with assisting the Board in its responsibility for disclosure in relation to risk management in the annual report.

Reporting of the Risk Management Committee

Board of Directors

It is mandatory for the committee to report and inform the Board of Directors from time to time about its regular activities and to ensure that the Board is aware of any matter relating to the committee which may significantly impact the financial condition or other affairs of the company. The committee Chair, on behalf of the committee, reports to the Board following each meeting and prepares any report on the matters as outlined in its charter for the approval of the Board.

Part Three: Risk management framework

Overview of risk management

The Board of Orion Pharma Limited assumes the importance of maintaining and following an effective risk management and internal control system for the interest of the financial capital providers. They define the risk appetite and tolerance level, along with framing risk strategy policies.

The Risk Management Committee, with the Audit Committee's support is responsible to design, implement and monitor the risk management framework at all levels of the organization. The management team is responsible with the tasks of implementing the strategies of the Board and notifying the committees immediately regarding any risks or violation of internal control that come to their attention.

The internal control, compliance and the statutory auditors are also integral parts of the framework reviewing audit and internal control.

We have categorized 19 (nineteen) risks under 4 (four) classifications to better focus upon them through structural and systematic targeting of common areas that have room of improvements. The Board ensures that this classification will make our risk management framework more efficient.

We focus on 19 risks
under 4 categories



Strategic risks



Compliance risks



Operational risks



Financial risks

Governance of risk management

Board of Directors

- Defines OPL's risk appetite and tolerance
- Frames risk strategy policies along with RMC
- Reviews risk management key outcomes

Risk Management Committee

- Identifies key risks and develops systems to manage them
- Facilitates and monitors the implementation of strategies and policies by management
- Oversees and reviews effectiveness of internal control processes along with AC
- Reviews risk reports from management, internal audit and external audit
- Provides independent and fair disclosure on risk management in Annual Report
- Continuously improves risk management policy and supporting framework

Audit Committee

- Maintains effectiveness of risk management and internal control systems along with RMC
- Reviews assurance reports from management, internal audit and external audit

Management team

- Implements and complies with Board and committee risk policies and procedures
- Identifies, assesses and manages risks within the organization regularly
- Fosters a culture where risks are identified and mitigated following the policies of Board

Internal control

- Reviews the effectiveness of the internal financial control systems and management responses
- Oversees the performance, adequacy and effectiveness of internal audit function and compliance process

Compliance


- Supports management policies, defines roles and responsibilities and sets goals for implementation of risk management processes

Statutory auditors

- Reviews the audit plan and provides assurance on the financial statements solving key financial reporting risks and problems

Risk management cycle

The risk management framework at OPL falls in 3 (three) stages: design, implementation and monitoring stages. The steps in our risk management cycle under our framework are as follows:



A. Design stage

Policy formulation/ Establish the context

The Risk Management Committee and Audit Committee establish the context considering the internal (mission, vision, goals and objectives) and external (overall business environment including stakeholders’ objectives and perception) consideration, the basis upon which risks will be evaluated. In this regard they define a framework for the process and agenda for identification and analysis.

B. Implementation stage

Risk identification

Risk identification provides the foundation of any risk management process. Any failure at this stage to identify risk may cause a major loss for us. The management is constantly engaged in identifying possible potential risks that may affect, either negatively or positively, the objectives and performance of our business.

Risk analysis

Assessing risk is a major part of our risk management process where we determine which risks have a greater consequence or impact than others. The probability of our risks are assessed according to their occurrence, probability and the potential impact of the risks.

Risk evaluation

Risk evaluation involves comparing the level of risk found during the analysis process with previously established risk criteria, and deciding whether these risks are acceptable or require treatment. Ultimately, at this stage we will have a prioritized list of risks that require further action. A risk may be acceptable for any of the following reasons-

- The cost of treatment far exceeds the benefit;
- The level of the risk is so low;
- The opportunities presented outweigh the threats to such a degree that the risks justified; and
- The risk is such that there is no treatment available.

C. Monitor/Review Stage

Risk mitigation







OPL works for identifying options for treating or controlling risk, in order to reduce negative consequences, or to reduce the likelihood of an adverse occurrence. The Management, Internal Audit, Compliance and External Auditors help in risk mitigation and aim to enhance positive outcomes. Risks are transferred, avoided, retained or controlled to minimize the negative risks.


Monitoring & review of risks & framework




The RMC periodically monitors risks and reviews the effectiveness of our risk management system to ensure changing circumstances do not alter the risk priorities set previously. Our risk management process is regularly repeated with the objective of evaluating whether the previously selected control measures are still applicable and effective, and ensuring that new risks are captured in the process and effectively managed.

Potential risks

Below is a list of key risks having significant impact on the operation of the company and also the procedures to mitigate or control those risks. The list of mitigation measures is only illustrative and not exhaustive.

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Strategic risks				
1. Market demand and competition				
Presence of significant number of pharmaceutical companies and also the availability of same generic products from different companies results in tough competition that we are already facing.	 Financial capital  Intellectual capital	<ul style="list-style-type: none"> Market presence Product specific strategy 		<ul style="list-style-type: none"> Promotional activities for generic brand through right channel Adoption of effective and efficient marketing strategies Healthcare professionals engagement Strong systems and processes to monitor and manage the performance of each product
2. Potential conflict of interest				
The Directors of OPL are also involved with Orion Infusion Limited (both the companies are member concerns of Orion Group), which falls in the pharmaceutical sector that might cause a conflict of interest.	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Even though both companies belong to the pharmaceutical sector, their product lines are completely different



Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Strategic risks (Contd.)				
3. Supply disruption				
<p>Disruption due to machinery breakdown, fire and explosion, faulty design and manufacturing, operating error, interruption of power of suppliers can cause material shortages and production can be hampered at great extent.</p>	 Manufactured capital  Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Adoption of strong supply chain management Inventory management Planning, development and implementation of contingency plan
4. Product pipeline and development				
<p>Failure to establish bioequivalence may lose us international markets. Also, development of new products taking longer time and being more costly than estimation may create hindrance in capturing the potential market.</p>	 Financial capital  Intellectual capital	<ul style="list-style-type: none"> Product specific strategy Patient health and safety 		<ul style="list-style-type: none"> We offset this risk by going for regular market surveys and always develop new medicines as per market's medicinal need Continuous monitoring of product development progress Robust business strategies developed for selected upcoming products
5. Corporate reputation				
<p>If the reputation falls, it will be difficult for OPL to recover it and sustain in the long run.</p>	 Social and relationship capital	<ul style="list-style-type: none"> Operational excellence Market presence 		<ul style="list-style-type: none"> Compliance with standards and regulations applicable for the company Proper disclosure of necessary data for govt., shareholders, customers and other stakeholders Alignment of CSR with our values

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Strategic risks (Contd.)				
6. Stakeholder relationship				
If stakeholder relationship is not maintained well, OPL will lose its trust and the market also. The stakeholders may not step forward if proper relationship is missing.	 Social and relationship capital	<ul style="list-style-type: none"> Ethical behavior and governance Patient health and safety 		<ul style="list-style-type: none"> Regular communication to related stakeholders Supply of necessary data and fulfillment of their legitimate needs to maintain smooth and reliable relation
 Compliance risks				
7. Product quality				
Serious adverse event with consumers and potential product quality risks in use of products can damage our image and decline the quantity of sale.	 Financial capital  Social and relationship capital	<ul style="list-style-type: none"> Patient health and safety Operational excellence 		<ul style="list-style-type: none"> Compliance with rules and regulations including ISO, WHO, DGDA etc. Enforcing quality standards on vendors Pharmacovigilence Customer complaint form Import of APIs from best sources and using USDMF grade raw materials Regular quality inspection Computerized product testing
8. Compliance issues				
OPL may lose its market, face damage to corporate image and financial penalty if it does not conform to relevant compliances issues and certification.	 Financial capital  Social and relationship capital	<ul style="list-style-type: none"> Ethical behavior and governance 		<ul style="list-style-type: none"> Compliance in every aspect of health and safety, financial and reporting, quality of product, production and plant, international business and so on Disclosure of a statement of compliance in annual report

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Compliance risks (Contd.)				
9. Environmental consideration				
<p>Failure to make positive contribution to the environmental dimension of sustainability reporting will damage our corporate image.</p>	 Natural capital  Social and relationship capital	<ul style="list-style-type: none"> Eco-friendly environment practices 		<ul style="list-style-type: none"> Maintenance of effective waste management Adoption of air pollution control mechanism Maximum usage of daylight Conservative use of natural resources Adoption of paperless office concept
 Operational risks				
10. Political instability				
<p>Instability and turbulence of the political condition severely disrupt the operation and cause downturn of sales of the business. Sales decreased, production hampered are some risks arising from political instability.</p>	 Financial capital  Manufactured capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Keeping up to date information about volatile political climate, macro and micro political risk environment, change in government, new laws and regulations etc. Careful analysis and evaluations of the situations
11. People and talent				
<p>Risks can come from failure of attracting and retaining sufficient number of quality staff. Again lack of right person in the right place at right time can cause huge loss and fail to achieve the planned growth.</p>	 Human capital  Social and relationship capital	<ul style="list-style-type: none"> Employee well-being and engagement 		<ul style="list-style-type: none"> Fair and transparent recruitment process Arrangement of succession planning Regular training and development programs Remuneration structure based on the industry analysis

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Operational risks (Contd.)				
12. Health and safety				
<p>Failure to comply with health and safety laws and industry standards, injury to employees that causes legal liability and failure to safely and appropriately handle hazardous and toxic materials may have adverse impact on our operations and business.</p>	 Human capital  Social and relationship capital  Financial capital	<ul style="list-style-type: none"> Employee well-being and engagement 		<ul style="list-style-type: none"> Precautionary equipment and safety measures Training of workers and employees on health and safety Availability of group insurance benefit Availability of full time doctors Ensuring balanced diet of employees Providing transport facility to employees
13. Information technology failure				
<p>With the office being adapted to a paper-less office, disruptions or failures in our information technology systems and network infrastructure will result into operational disruption, loss of data, financial loss and damage to corporate image.</p>	 Intellectual capital  Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Development of a strong access security to the server Protective measures such as firewalls, antivirus, data encryption, routine back-ups, disaster recovery procedures etc Awareness campaign
 Financial risks				
14. Liquidity crisis				
<p>If we have inability to meet our obligations and expense in time, it will threaten our financial position and our strong existence.</p>	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Mitigation of the risk by developing strategies and taking appropriate actions designed to ensure that necessary funds and collateral are available when needed Monitoring of cash flow regularly

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Financial risks (Contd.)				
15. Credit risk				
<p>Credit Risk is the risk that may arise if customers fail to make required payments on due time.</p>	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Effort to make collections faster by constantly being in touch with our customers
16. Interest in subsidiaries				
<p>OPL has 2 (two) subsidiaries in the power sector from where a significant portion of revenue is achieved. This might have a negative impact on the company.</p>	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Contract signed with BPDB for a fixed number of years ensures payment
17. Value of investment				
<p>Risk in investing in the marketable securities being offered with comparison to other available investment option.</p> <p>This risk may arise from making any capital investment through business expansion.</p>	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Maintenance of a diversified investment portfolio As for our business expansion through the Pharma Park, our marketing team constantly surveys the market trend and gives feedback upon which our production will take place Survey of market trend and analysis of future requirements
18. Interest rate risk				
<p>Risk that arises from fluctuating interest rates that occur due to macroeconomic reasons might have a negative impact on the company.</p>	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> Maintainance of low debt/equity ratio; and accordingly, adverse impact of interest rate fluctuation is insignificant

Principal risks and their importance	Impact on capital	Link to material issues	Status	Mitigation process
 Financial risks (Contd.)				
19. Exchange rate risk				
OPL has offshore markets and receives revenue in the form of foreign currencies. Any unforeseen deviations in the exchange rates might have a negative impact on the company.	 Financial capital	<ul style="list-style-type: none"> Operational excellence 		<ul style="list-style-type: none"> The products of the company are sold mostly in local currency. Therefore, volatility of exchange rate will have no impact on profitability of the company



Internal control framework


The Board of Directors is ultimately responsible for the system of internal control. They delegate the tasks of establishing, operating and monitoring the system to the management of the company. The Board with assistance from Audit Committee and Risk Management Committee set appropriate policies on internal control and the Management works based on those policies adopted by the Board. The charge of annual review of the efficiency and effectiveness of the internal control system rests with the Audit Committee to assure that internal control system is functioning properly and it is up-to-date with the changing business environment.

Internal audit

Our Internal Audit Department performs a very specific job that is designed to assist in financial audit and inventory audit function. Within the company, 2 (two) types of internal audit functions are carried out:

- Pre-Audit: Bills are sent by the concerned employees of respective department to the Pre-Audit Department, including software entry through e-bill processing, before making any payment, If any change or correction is required, the bill is revert back to the concerned employee. After all necessary corrections, the bill is submitted again to this department. Subsequent to this, if the department is satisfied with the fact that the bill is acceptable, they send the bill to the Accounts Department for making payment.
- Post Audit: Following the payment made by the Accounts Department, all necessary documents are sent to the Post Audit Department for final checking and verification.

Moreover, they also conduct inventory audit at CDC and every depot on a regular basis. A monthly report is also prepared and delivered to the Managing Director regarding their activities and findings.



Financial reporting control

In order to provide assurance on the reliability of the financial statements, the company has placed different policies, practices and control mechanism which are designed to identify and solve key financial reporting problems including the risks of changes in accounting standards. The statutory auditors also provide assurance about the financial statements. The Chief Executive Officer and the Chief Financial Officer is required to provide their certification on the true and fair view of the financial statements. Further to that the integrity of the financial statements are supported by the review and recommendation of the Audit Committee and approved by the Board of Directors.

Recommendation of Risk Management Committee report for approval by the Board

This Risk Management Committee report was recommended by the committee on November 01, 2020 for approval by the Board of Directors of Orion Pharma Limited which approval was granted on November 08, 2020.


On behalf of the committee

Sd/-

Lt. Col. Kamal Ahmed, PSC (Retd.)
Chairman

Code of conduct & business ethics

Orion Pharma Limited is committed to maintaining the highest standards of business conduct and ethics. The code of conducts and business ethics of OPL is applicable to all employees (whether regular, contractual or casual) of the company, its subsidiaries and others who perform services for OPL. The code of conduct for the Board members and the CEO has been duly approved by the Board of Directors and posted the same in the company's website.



Compliance with the standard of ethical code is a key element for OPL in establishing itself as an organization by forming an ideal corporate ambience. Conflict of interests, intellectual property, corporate responsibilities and various other corporate segments are ensured to fully adhere with the rules and regulations associated with the business activities. OPL also maintains an equal opportunity environment and mutual respects among the employees to retain the dignity of our valued employees and Board members. Management is aware about the company's image, hence motivate the employees to perform with honesty and utmost diligence.

Code of conduct & business ethics

Failure to comply with the code, the required certification process or failure to cooperate with an internal investigation of an actual or apparent violation of this code may constitute grounds for disciplinary action, up to, and including, termination.

01 Our commitment to each other

Mutual respect

OPL respects everyone as individuals and treat them with dignity. By treating each other with respect, dignity, courtesy and fairness, OPL continues to succeed through effective teamwork and collaboration.

Equal opportunity

OPL provides equal opportunity in employment to all employees and applicants. Equal opportunity rights are applicable to recruitment, employment, and employment-related decisions including, but not limited to, hiring, firing, transfers, promotions, financial benefits etc.

Families & relatives

In our company employment is done on a basis of merit. Immediate family members of employees may be hired only if the appointment is based on qualification, performance, skill and experience and provided that there is no direct or indirect reporting relationship between the employee and his or her relative. These principles of fair employment apply to all aspects of the employment, including compensation, promotion and transfer, even if the relationship develops after joining the company.

Free of discrimination & harassment

The company is committed to maintaining a workplace free of discrimination, harassment, intimidation or inappropriate conduct based on gender, race, color, religion, age, disability and/or any other category.

Therefore, the company does not tolerate any behavior, whether verbal or physical that creates an intimidating, offensive or hostile work environment, or that interferes with work performance. If employees experience or are aware of any conduct being violated this section, they are encouraged to raise their concern through the human resources department immediately.

Workplace safety

OPL believes that workplace safety is of utmost importance in any organization as it benefits both the company and the employees. Human loss and suffering is immeasurable. Occupational injuries and illnesses can provoke major crises for the families in which they occur. In addition to major financial burdens, they can impose substantial time demand on rest of the family members. Safety transforms a company and the employees into an instinctive team of people with a common goal.

When a company prioritises their employees first and implements proper safety training and education and then enforces it, several positive results happen. Our company has taken many initiatives to ensure safety such as safe equipment and a healthy working environment.

We have metal detectors to ensure no one is bringing guns, knives or any other dangerous weapons into the workplace. Also proper record is maintained whenever outsiders pay a visit to the company. Time and again, it has been established that companies that put safety first turn out higher quality products and our company is no exception to this thought.

Prudent conduct & behavior

Behind every successful company there is role of employees and management who are responsible for their honesty, performance and discipline they have shown to the company for a considerable span of time. OPL believes in the same notion and gives high importance to these factors and keep motivating the employees to maintain prudent conduct and behavior in compliance with the ethical standards of behavior. In addition, HR continues to analyze how to boost the performances and incorporate more rules and regulations to keep the employees to act in a more disciplined manner and provide various incentives to retain the loyalty of the employees towards the company. Our HR department focuses on personnel development and therefore conducts regular trainings and management co-ordination meetings.

02 Our commitment to our company & shareholders

Conflict of interest

A conflict of interest occurs when personal interests of an employee or the interests of a third party compete with the interests of the company. In such a situation, it can be difficult for the employee to act fully in the best interests of company. If a situation that may involve or lead to a conflict of interest, the employees at OPL disclose it to the Line Manager and/or the divisional head to resolve the situation in a fair and transparent manner.

Corporate business opportunities

Employees of OPL are prohibited from taking for themselves opportunities that are discovered through the use of company property, information or position, for personal gain, and/or competing with the company. The extent that an employee learns of an investment opportunity because of their position with the company, they must not misuse fund or client accounts by personally taking advantage of the private business opportunity. In compliance with the ethical code of conduct OPL protects the company's assets and ensures they are used for legitimate business purposes instead of investing in private interests or activities.

Protection & proper use of company assets

Everyone at OPL is conscious and committed to ensuring the efficient use of the company assets and always tries to protect these from misappropriation, loss and destruction.

We safeguard and make only proper and efficient use of company property and seek to protect property from loss, damage, misuse, theft, fraud, embezzlement and destruction. These obligations cover both tangible and intangible assets, including trademarks, know-how, confidential or proprietary information and information systems.

Confidentiality

Confidential business information is a valuable company asset. "Confidential business information" includes trade secrets, business, marketing and service plans, consumer insights, engineering and manufacturing ideas, product recipes, designs, databases, records, salary information and

any non-published financial or other data. Also, our customers, suppliers and others also may share their confidential and proprietary information with us. We have the duty to properly use and safeguard business information belonging to and shared with the company.

Accuracy & retention of business records and documents

All business information including financial records of OPL are reported in a timely and accurate manner. Financial information of our company reflects actual transactions. Business documents and records include paper documents such as letters and printed reports.

They also include electronic documents such as e-mail and any other medium that contains information about our company and/or its business activities. We encourage all employees to use all of this information wisely and carefully to get the best value from it.

Inside information & securities trading

Employees of OPL who have access to confidential (or "inside") information are not permitted to use or share that information for stock trading purposes or for any other purpose except to conduct our business. All nonpublic information about the company or about companies with which we do business is considered inside information. Such information may include new marketing initiatives, sales and earnings results or projections, major contracts with customers or suppliers, potential acquisitions or mergers, other significant developments or any other information that a reasonable investor would consider important in deciding whether to buy, sell or hold securities. To use material nonpublic information in connection with buying or selling securities, or "tipping" others including friends and family who might make an investment decision on the basis of this information, is not only unethical, it is illegal. Our employees exercise the utmost confidentiality when handling material inside information.

02 Our commitment to our company & shareholders (contd.)

Intellectual property

Intellectual property is considered to be reserved with utmost sincerity as it plays a significant role in promoting a creative and competitive environment. Keeping company related information, trade mechanisms, production techniques, technological development confidential and using the public domain like newspaper or websites as source for gathering general information. OPL ensures to protect its intellectual property by maintaining confidentiality, not allowing any data which is irrelevant to the company and can put the company to risk and taking legal consultations if there is any default in the intellectual property.

Competition

OPL ensures to promote a fair competitive environment and maintain the quality of employees and the products simultaneously. OPL believes free market economy competition is the key to progress. Market prices, selling of products, production are all operated fairly so that no injustice is done to the customers and the employees. In case of any misuse through competition, legal department must be informed to seek necessary actions against the failure in compliance with the ethical code of fair competition.

Information, communication & media

Information is an essential tool for OPL. Effective utilization and dissemination of information can play a crucial role in determining company's potential and its image in the industrial arena. Communication with the appropriate source in a suitable time with the help of right media is the objective of OPL from the very beginning of its journey. Employees of OPL remain updated with all information necessary to be circulated in the market through media by staying compliant with the ethical standards of communication.

Cooperating with auditors

Standards require auditors to state whether, in their opinion, the financial statements are presented in conformity with International Accounting Standards or International Financial Reporting Standards and to identify those circumstances in which such Standards have not been consistently observed in the preparation of the financial statements of the current year in relation to those of the preceding period. OPL is responsible for adopting sound accounting policies and for establishing and maintaining internal control so that it assists auditors in their responsibilities.

Accurate disclosure to the public

OPL realizes the significance of accurate and timely information disclosure to its stakeholders. We are committed to ensure that timely and accurate disclosure is made regarding all material matters concerning the company, including its financial situation and results.

Maintain relationship with regulators

OPL understands the importance of sound regulatory relationships and acknowledges that getting along with your regulators really does matter for the company. We have a close interaction with regulators in every stage of our development. We maintain a free-flowing relationship with them.

Compliance with laws, rules & regulations

Complying with the prevailing laws, rules and regulations and being in conformity with social norms are the basics of our business. Nationally and internationally where ever we do business we obey the relevant laws and regulations and avoid any action that can discredit the company.

03 Our commitment to our customers & business partners

Bribery & corruption

Bribery occurs when things of value are provided directly or indirectly to individuals, including government officials, business partners, clients or prospective clients to influence a discretionary decision. This is strictly prohibited at OPL. Employees are discouraged to directly or through intermediaries, offer or promise any personal or improper financial or other advantage in order to obtain or retain a business or other advantage from a third party, whether public or private. Moreover, employees refrain from any activity or behavior that could give rise to the appearance or suspicion of such conduct or the attempt thereof. Employees over here are aware that the offering or giving of improper benefits in order to influence the decision of the recipient, may not only entail disciplinary sanctions but also result in criminal charges.

Gifts, meals & entertainment

Employees shall not be influenced by receiving favors nor shall they try to improperly influence others by providing favors. Employees may only offer or accept reasonable meals and symbolic gifts which are appropriate under the circumstances, and they shall not accept or offer gifts, meals, or entertainment if such behavior could create the impression of improperly influencing the respective business relationship.

Fair dealings

We respect all people and have a reputation of trust through all of our relationships. Therefore, we do not disclose to a third party any contractual information in terms of our business relationships with others. All concerned employees are trained to deal fairly with company's customers, suppliers, partners and competitors and anyone else with whom have to contact in the course of performing the job.

Sales, marketing & communications practices

OPL take pride in the quality of our services and are committed to competing fairly by employing ethical business practices. We present only accurate and truthful information about our products in presentations, discussions with clients, our advertising, promotional literature and public announcements.

Selecting suppliers

OPL believes that supplier relationships are critically important to the health of the business and so the company follows a competitive bid process whenever selecting suppliers and never compromises on quality. We always attain high quality API from world renowned suppliers. We place a lot of emphasis on selecting suppliers who provide good quality goods in a timely manner.

04 Our commitment to our communities


Political contributions & activities

OPL is prohibited to participate in any political activities and donations to maintain a fair corporate environment within the company. Involvement in political activities shall be perceived as compromising employees' performance of their duties in an impartial manner. In order to maintain a nonpolitical environment inside the organization and to retain the pure corporate culture employees are bounded with certain restrictions.

Protection of environment

OPL has an ethical responsibility to protect the environment and comply with environmental laws and regulations. Responsible environmental actions are not only important to our customers, vendors and other key stakeholders; it is the right thing to do. Our goal is to avoid any situation that may lead to unacceptable environmental or health hazards for the employees, the public or the environment.

Organizational chart



Compliance with laws, rules, regulations & standards

We are committed to prove ourselves as a compliant company and assure our stakeholders that we conduct our operations and run our business in compliance with all the relevant laws, rules, regulations and standards applicable to our company including but not limited to the following:

Company affairs

- Companies Act, 1994
- Rules and regulations of RJSC
- Securities and Exchange Ordinance, 1969
- Bangladesh Securities and Exchange Commission Act, 1993
- Listing Regulations, 2015
- Notifications, guidelines, directives and orders of BSEC

Financial & reporting

- Companies Act, 1994
- Securities and Exchange Ordinance, 1969
- Securities and Exchange Rules, 1987
- Bangladesh Securities and Exchange Commission Act, 1993
- Listing Regulations, 2015
- Notifications, guidelines, directives and orders of BSEC
- Income Tax Ordinance, 1984
- Income Tax Rules, 1984
- Value Added Tax and Supplementary Duty Act, 2012
- Value Added Tax and Supplementary Duty Rules, 2016
- Customs Act, 1969
- SRO related to Tax, VAT and Customs
- International Accounting Standards
- International Financial Reporting Standards

Product

- Rules of Directorate General of Drug Administration (DGDA)
- Compliances with WHO Good Manufacturing Practices (GMP)

Labor & employment

- Bangladesh Labor Act, 2006
- Bangladesh Labor Rules, 2015

Plant & production

- ISO 9001:2015
- Bangladesh Environment Conservation Act, 1995

International Business

- Value Added Tax and Supplementary Duty Act, 2012
- Value Added Tax and Supplementary Duty Rules, 2016
- Customs Act, 1969
- SRO related to Tax, VAT and Customs
- Import and export policies and orders
- Rules of the DGDA
- Bangladesh Bank guidelines for foreign exchange transactions

Shareholders' grievance redressal system

Investor Grievance Redressal process of OPL aims at empowering the investors by providing them an effective and efficient process to resolve their complaints or quarries. OPL accords highest priority for resolving of investor complaints/disputes and therefore the company has a dedicated grievance redressal team, as a part of Share Department, to ensure that complaints received from investors are redressed at the earliest and without any delays. The grievance redress team protects the rights of the shareholders.



SHAREHOLDERS

They are redressed promptly and fairly within the regulatory framework

We follow these principles with regard to shareholders' grievance redressal system:

- All shareholders be treated equally
- All queries raised by investors be dealt promptly and with courtesy
- All queries be resolved efficiently and fairly within the regulatory framework

Procedure of submitting grievance/queries



The company has a designated e-mail ID:

orion.share@orion-group.net

on which investor(s) can lodge their grievance / complaint. The designated person of the share department monitors the said e-mail ID on a daily basis to check whether any new complaint has been lodged.



The company also has a designated telephone number:

+88-02-8870133 (Ex. 160 & 161)

of share department for receiving verbal complaints and grievances of the investors.



An investor may make a written complaint through fax of the company on fax number:

+88-02-8870147




An investor can make a written complaint through a letter to the mailing address:

**Share Department
Orion Pharma Limited
Orion House
153-154, Tejgaon Industrial Area,
Dhaka -1208, Bangladesh**

Redressal of investor queries

- The Share Department obtains all information available on the complaint received from investors through email, post, telephone or fax which is considered necessary for a proper investigation and take necessary steps to resolve them as soon as possible;
- Personal calls and proactive follow-ups are made to resolve grievance of the investors to enhance shareholders' confidence; and
- The Company Secretary also monitors the status of pending complaints along with the settlement status on a regular basis.



Investor grievance redressal process

Queries received and redressed during the reporting year are as follows:

Queries/ Grievances	Received	Redressed
To receive copies of the Quarterly and Annual Report(s)	19	19
To re-issue dividend warrants	72	72
To inspect the minute books of the general meetings and to receive copies thereof	6	6
To issue Income Tax Certificate deducted at source on Cash Dividend	267	267
Total	364	364

In addition, OPL holds Annual General Meeting (AGM) regularly as per law. A notice of that meeting and other supporting documents are dispatched to shareholders and the invitation to the AGM contains information and guidelines relevant to the meeting, including the voting procedure for the shareholders.

In case shareholders cannot personally attend the meeting, they may appoint a proxy through filling out the proxy form provided along with the other documents or may download the same from the company's website, to appoint any person as proxy to attend and vote at the AGM.

Shareholders are welcome to attend the company's interactive and informative AGM at which they have the opportunity to ask questions. The Chairman and other members of the Board answer the questions of the shareholders and note the views and suggestions offered at the AGM with utmost seriousness.



The Board of Directors, Company Secretary and Chief Financial Officer at the 54th Annual General Meeting



The Board of Directors, Company Secretary and Chief Financial Officer at the Extra-Ordinary General Meeting



The Chairman of the company giving his speech at the 54th Annual General Meeting



General Shareholders at the 54th Annual General Meeting



Our shareholders expressing their views at the 54th Annual General Meeting

Directors' report

The Directors of Orion Pharma Limited present their report, together with the audited financial statements, on the consolidated entity consisting of Orion Pharma Limited and the entities it controlled at the end of, or during the financial year ended June 30, 2020.

Industry scenario

Pharmaceutical industry in Bangladesh has grown tremendously since the beginning of its journey in late 80's of the last century. A few decades ago, the country was dependent on imported medicines as well as drugs produced by multinational companies for meeting domestic demands. Now, Bangladesh pharma industry is capable of meeting 98% of the domestic demand that amounted to around USD 3 billion in 2019. The market share of the local manufacturers is currently around 90% and 10% is controlled by foreign producers. Bangladesh is now the only least-developed country among 47 nations that has a well-developed pharmaceutical sector that can produce medicines for cancer diseases and biological products such as insulin and vaccines.

After meeting local demand, key players of this industry have successfully managed to continue the upsurge of international exports. Market researchers have said that achieving global certification of the medicines and responding promptly to adopt new technologies used in worldwide from the domestic companies along with receiving cash incentives against exports of medicine are the key reasons for the sharp rise in exports earnings. According to Export Promotion Bureau, Bangladesh, the sector's earning from 151 overseas market jumped 4.49% to USD 135.79 million in FY2020 from USD 129.95 million in FY 2019.

A key strength of the industry is to deliver quality products that are produced with ultra-modern technology and to comply the international requirements. Another competitive advantage of Bangladesh in the global stage is its cheap labor (almost 4 times cheaper than that of India or China). Bangladesh has also been enjoying a vast amount of skilled manpower in this sector. But the cherry on top is the Trade-Related Aspects of Intellectual Property (TRIP) agreement. TRIP agreement allows Bangladesh to produce and export patent-free generic version of a patented drug without taking the permission from the original innovator.

However, despite the many merits of Bangladesh's pharmaceutical industry, Bangladesh's large import dependence on China for API which is almost 50% has become a significant threat to the growth of Bangladesh's healthcare manufacturing and global supply chain. Any disruption in supply chain of APIs can result in significant shortages in the supply of essential drugs in Bangladesh which is clearly happening since the outbreak of Coronavirus in March. Pharmaceutical industry is heavily dependent on China's API for high-burden disease categories like cardiovascular diseases, diabetes and tuberculosis and also many antibiotic APIs like penicillin, cephalosporins and macrolides. India has also posted ban on API exports which is giving more hard times to the import-dependent market like Bangladesh, potentially pushing towards facing API shortage in near future.

Pharmaceutical industry during Covid-19 pandemic

Due to the ongoing Covid-19 pandemic, the government enforced lock-down has disrupted production (factory closure), distribution and marketing for a couple of months. However, the industry is not expected to suffer from any potential lockdown as medicine is one of the most important necessities of human life. Patients with certain health conditions like high blood pressure (hypertension), high cholesterol, diabetes and some other life threatening diseases need to take medicines for the rest of the life even though whatever the situation is. Beside this, the sales of certain medicines related to the treatment of corona virus has increased significantly.

On other hands, despite the fall of country's total export due to coronavirus in the FY 2019-20, Bangladesh's medicine exports recorded 4.49% growth. But the industry is now facing dire consequence of corona pandemic. One major setback caused due to ongoing lockdown over Coronavirus pandemic in worldwide is being halt the process of registration of local brands in global market. The process of drug registration is itself very difficult which sometimes might take more than 5 (five) years to complete all the process in European countries. Besides, separate registrations are needed against each drug product in different developed countries. Moreover, drug

manufactures now fear that novel coronavirus or COVID-19 has caused severe supply chain disruptions and the earnings might be declined by 10-15% because of it. But the industry is now bouncing back which is not only true for Bangladesh, but globally too.

Outlook of Bangladesh pharmaceutical industry in post-pandemic era

The ongoing battle between the US and China has opened up opportunities for growing international markets like Bangladesh to invest in building up API production capacity and take a big chunk of market share of US which is currently dominated by India remaining a key exporter to the US for generic drugs. In a survey conducted in April 2020 by the Confederation of Indian Industry and KPMG, it is reported that 90% of American's prescriptions are filled by generic drugs and one in every three pills are produced by Indian manufacturers. According to the US International Trade Commission, US has imported USD 127 billion pharmaceutical products in 2019 of which India and China accounted for USD 7.5 billion and USD 1.5 billion respectively. On the contrary, Bangladesh's export of pharmaceutical products to the US is merely USD 13 million for FY19. So, in order to succeed in the long run to penetrate US market amidst ongoing trade war, Bangladesh needs to be self-sufficient and achieve cost-effectiveness in the manufacturing process of drugs as soon as possible. The completion of the API Park would make Bangladesh a serious prospect for the US to consider. In addition, the API Park will also give the opportunity for US pharmaceuticals to import APIs from Bangladesh which opens up many possible revenue streams.

Highlights on financial results

This point provides a snapshot of some of our key performance indicators (on consolidated figure) regarding our financial performance of the financial year 2019-20 along with the preceding financial year:

Particulars	Amount in BDT		
	2019-20	2018-19	% increase (decrease)
Net turnover	7,647,703,031	8,705,172,867	(12.15)
Cost of sales	(5,069,865,088)	(6,159,489,430)	(17.70)
Gross profit	2,577,837,943	2,545,683,437	1.26
Net profit before tax	795,530,136	1,028,310,756	(22.64)
Net profit after tax	665,686,161	882,354,974	(24.55)
Earnings per Share	2.84	3.77	(24.67)

Principal activity

Orion Pharma Limited is a publicly listed pharmaceutical company focused on the development, manufacture and marketing of a broad range of generic and branded pharmaceutical products in solid, semi-solid, powder, liquid and injectable final dosage forms. The company's pharmaceutical operations are conducted in both local and international markets. The majority of the company's export business are in non-regulated markets but we have plans to enter into regulated pharmaceutical market after full completion of the construction of Orion Pharma Park.

Product status

The status of products of Orion Pharma Limited available at the end of the financial year has been shown here under 7 (seven) product categories:

Product categories	No. of products
Tablet	96
Capsule	23
Liquid & suspension	31
Injection	30
Powder for suspension	16
Cream & ointment	5
Hand rub	2
Total	203

Segment wise or product wise performance

Orion Pharma Limited itself is operating its business in a single economic segment i.e. the pharmaceutical industry within and outside the territory of Bangladesh. The company is the parent company of another 2 (two) power generation companies i.e. Orion Power Meghnaghat Limited and Dutch Bangla Power & Associates Limited. These 2 (two) revenue generating subsidiary companies have been in operation in the power sector of our country since 2011.

The breakup of consolidated sales figure (pharmaceutical and power sector) and sales figure of Orion Pharma Limited into local and export sales are as described here.

Sector wise sales

Amount in BDT

Year	Pharmaceutical	Power	Total revenue
2019-20	2,297,740,301	5,349,962,730	7,647,703,031
2018-19	2,222,541,814	6,482,631,053	8,705,172,867

Local and export pharma sales

Amount in BDT

Year	Local	Export	Total revenue
2019-20	2,144,549,213	153,191,088	2,297,740,301
2018-19	2,048,430,562	174,111,252	2,222,541,814

Pharma cost of goods sold & profit margin

The cost of goods sold compared to net turnover has remained almost same, which is 44.25% in reporting year and 44.37% in last year. The breakup of cost of goods sold along with the percentage of each element of COGS in terms of total COGS are as described here.

COGS	Amount in BDT		% of total COGS	
	2019-20	2018-19	2019-20	2018-19
Raw materials	440,014,412	423,581,407	43.28	42.95
Packing materials	192,825,828	222,552,717	18.97	22.57
Factory overhead	431,014,446	314,316,780	42.39	31.87
Manufacturing cost	1,063,854,686	960,450,905	104.64	97.40
WIP (Opening-Closing)	(3,312,521)	1,475,111	(0.32)	0.15
FG (Opening-Closing)	(31,094,429)	36,624,882	(3.06)	3.71
Cost of physician sample	(12,802,715)	(12,431,262)	(1.26)	(1.26)
Cost of goods sold	1,016,645,021	986,119,636	100.00	100.00

Pharma sales
BDT **2,297.74** million

Cost of goods sold
BDT **1,016.65** million
% of sales **44.25%**

Gross profit
BDT **1,281.10** million
Margin **55.75%**

Net profit
BDT **194.34** million
Margin **8.46%**

Utilization of production capacity

Item	Production capacity		Actual production	
	2019-20	2018-19	2019-20	2018-19
Tablet & capsule	694.26	694.26	523.20	508.87
Oral liquid, injection, PFS, cream & ointment	23.68	23.68	17.27	15.49

Capacity utilization (%)			
Tablet & capsule		Oral liquid, injection, PFS, cream & ointment	
2019-20	75.36	2019-20	72.93
2018-19	73.25	2018-19	65.42

Additional investments


The fund capitalized for acquisition of fixed assets and for construction work in progress by Orion Pharma Limited and its subsidiaries during the reporting period is as follows:

Amount in BDT

Additional investment	2019-20	2018-19
Land and land development	127,957,031	4,000,000
Factory and office building	1,899,698,457	15,633,633
Plant and machinery	249,755,124	464,726,665
Furniture and fixtures	9,910,291	52,738,958
Office equipment	16,115,555	49,333,485
Vehicles	12,619,453	30,032,643
Road and road development	588,230,892	-
Total	2,904,286,804	616,465,384

Declaration of dividend

With the recommendation of Directors for a cash dividend of 10% (BDT 1.00 per share) for the financial year 2019-20, the company will have a payout of BDT 234,000,000 subject to approval of the Shareholders at the 55th Annual General Meeting. The dividend will be applicable for the shareholders whose names will appear in the depository register of CDBL as on Record Date i.e. November 29, 2020.



Appropriations of profit

Considering the financial statements of Orion Pharma Limited and also the interest of the Shareholders, the Board of Directors has proposed and recommended following appropriation of profit for the financial year 2019-20:

	Amount in BDT	
Net profit for the Period (2019-20)	194,342,150	
Add: Adjustment for depreciation on revaluation surplus	11,114,051	
Profit brought forward from previous year	252,094,738	
Profit available for distribution		457,550,939
Less: Appropriation proposed:		
Cash Dividend @ 10%		234,000,000
Transfer to retained earnings		223,550,939

Operation of subsidiaries

Orion Power Meghnaghat Limited (OPML)

During the financial year ended June 30, 2020, Orion Power Meghnaghat Limited earns total revenue of BDT 2,704.91 million broken up into BDT 1,322.88 million as Reference Rental Price, BDT 64.59 million as Reference Energy Price (Variable O&M), BDT 1,323.59 million as sales revenue from HFO OOSL. The total revenue is derived after considering foreign exchange loss of BDT 6.15 million. Its net profit is BDT 384.75 million during the period under report. Since the company is not listed, its market price cannot be determined. The Earnings and the NAV as on 30 June, 2020 stands at BDT 3.85 and BDT 48.61 per share respectively.

Dutch Bangla Power & Associates Limited (DBPAL)

During the financial year ended on June 30, 2020, the turnover of Dutch Bangla Power & Associates Limited is BDT 2,645.05 million broken up into BDT 1,322.88 million as Reference Rental Price, BDT 60.35 million as Reference Energy Price (Variable O&M), BDT 1,268.01 million as sales revenue from HFO OOSL and BDT 6.19 million as foreign exchange loss. The company has made a net profit of BDT 157.96 million and consequently EPS stands at BDT 15.80. It is not a listed company and the NAV is BDT 297.86 per shares as on 30 June, 2020.

Risks & concerns

The company is always aware of that business is subject to variety of risks and uncertainties e.g. industry risk, liquidity risk, market risk, operational risk, interest rate risk, exchange rate risk and potential changes in global or national policies etc.

In this respect, Orion Pharma Limited has well defined its risk management policies and introduced periodic monitoring system that act as an effective tool in mitigating various risks to which our businesses are exposed to in the course of its day-to-day operations as well as in its strategic actions.



A detailed discussion on the risk management system of OPL is mentioned on pages 82-91 and in Note 4 of the financial statements on pages 256-257

OPL Annual Report 2019-20

Continuity of any extra-ordinary gain or loss

There is no extra-ordinary gain or loss in the financial statements prepared for the financial period 2019-20 as well as for the financial period 2018-19.

Disclosure on related party transactions

The Directors and other key management personnel are very much cautious to avoid any conflicts of interest inconformity with the prevailing rules and regulations. Related party transactions, when undertaken in the normal course of business, are carried out on an arm's length basis without any special benefit to the related party. All such transactions during the reporting period was approved by the Board of Directors and the same will be placed before the shareholders for approval in the ensuing Extra-ordinary General Meeting (EGM).



A statement of all related party transactions containing the name of related parties, nature of related parties, nature of transactions and total transaction values is mentioned under notes 3.15 and 38.1 of the audited financial statements as per IAS 24: Related Party Disclosure on pages 255 & 274

OPL Annual Report 2019-20

Utilization of proceeds from public issues, right issues and/or through any other instrument

Initial Public Offering (IPO) of Orion Pharma Limited was made in 2013 and it mobilized a fund of BDT 2.40 billion with the allocation of 40.00 million shares. The main purpose of raising this fund was to construct an expansion project of Orion Pharma Limited named as Orion Pharma Park at Sumilpara, Siddhirganj, Narayanganj in terms of the expansion of existing production capacity as well as the addition of new products line.

However, the fund raised thereby has been being utilized for the said Pharma Park and reported accordingly to the regulators about the status of the fund utilization on a regular basis. No other issue of any instrument including right share was made during the year.

Explanation if financial results deteriorate after the company goes for IPO, RPO, right share offer & direct listing

Orion Pharma Limited went for IPO in 2013 and after that the company did not raise any fund by any sort of public offerings upto June 30, 2020. Therefore, no explanation is required in this connection.

Explanation about significant variance between quarterly & annual financial statements

Significant variation has occurred between the quarterly and annual financial statements of the company during the year for net operating cash flow per share. It increased because cash received from customers increased compared to cash payments for operating expenses. Furthermore, for confirming more appropriate presentation from quarterly unaudited financial statements to annual financial statements, some expenses under operating activities were rearranged with investing activities.

Significant deviation from the operating results of last year

During the year, significant deviation has occurred from the operating results of last year of the company. Earnings per share decreased because operating expenses increased as compared to revenue than from previous year and financial expenses increased also as compared to last year.

Again net operating cash flow per share increased due to huge cash received from customers compared to cash paid to suppliers.

Key operating & financial data of preceding five years

A summarized statement stating the key operating and financial data of preceding (5) five years have been disclosed in this annual report. Various financial information in terms of Consolidated Statement of Profit or Loss and Other Comprehensive Income and Consolidated Statement of Financial position, ordinary share related information and different financial ratios for preceding 5 (five) years are included in this statement.



Key operating and financial data of preceding 5 (five) years have been disclosed on page 226

OPL Annual Report 2019-20

Remuneration paid to Directors including Independent Directors

The Directors excluding the Managing Director of Orion Pharma Limited do not receive any facilities or perquisites except Board meeting and committee meeting attendance fees which are reviewed annually and approved by the Board of Directors. Total remuneration expenses of the Directors of Orion Pharma Limited is BDT 3.60 million during the reporting financial year and the amount has been disclosed as an expense under the head of General and Administrative Expenses in the note 30.a of the financial statements.



Details on Directors' remuneration have been described on pages 77 & 78

OPL Annual Report 2019-20

Corporate & financial reporting

The Directors are pleased to conform the following:

- The financial statements of the company present true and fair view of its state of affairs, the result of its operation, cash flows and changes of equity.
- Books of accounts have been maintained properly as required by the law.
- Appropriate accounting policies have been consistently applied in preparation of the financial statements and the accounting estimates were reasonable and prudent.
- The financial statements were prepared in accordance with International Accounting Standards (IAS) / International Financial Reporting Standards (IFRS), as applicable in Bangladesh. Any departure therefrom has been adequately disclosed.



Compliance report on IAS/IFRS is presented in Annexure E on page 132

OPL Annual Report 2019-20

- Internal control system is sound in design and implemented and monitored effectively.
- Minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress.
- No Bonus share or stock dividend has been or shall be declared as interim dividend.

Shareholding structure of the company

A report on the pattern of shareholding as on June 30, 2020 is presented in terms of the aggregate number of shares held by-

- Parent or Subsidiary or Associated Companies and other related parties;
- Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children;
- Executives; and
- Shareholders holding ten percent (10%) or more voting interest in the company;



The present shareholding structure of the company is shown in annexure D on pages 130-131

OPL Annual Report 2019-20

Going concern

Subsequent to the conduction of appropriate enquiries and analysis of the significant operating and financials, the Board ensures that the company has the ability to continue its operation for a foreseeable future. The Directors have a reasonable anticipation that the resources are adequate to continue its operation without any major interruptions. Therefore, all these analysis qualify the company as a going concern and consequently the financial statements are also prepared on the basis of going concern assumption.

Consolidation of accounts

As per BSEC Regulations, the company has prepared consolidated financial statements following the codes of IFRS 10. For the preparation of consolidated statements of OPL, the audited financial statements of 2 (two) subsidiaries have been taken into consideration.

Contribution to national economy

The total contribution to the national exchequer by Orion Pharma Limited as on June 30, 2020 was BDT 517.31 million in the form of import duty, import VAT, import tax, supplementary duty and other duty on raw materials, packing materials, spare parts, machineries & other assets, tax on sale

of makeable securities, VAT on sales and income tax. The contribution constitutes 22.51% of the net revenue.



Details on contribution to national economy have been described on page 230

OPL Annual Report 2019-20

Environmental consideration

Orion Pharma Limited is committed to providing a healthy and pollution free environment for its employees, customers, suppliers, and all other parties with whom it interacted to conduct its business. The company follows GMP Regulations, WHO standards and Governmental rules and regulation in order to maintain a pollution free environment.



A detailed report on this is set out on pages 196-202

OPL Annual Report 2019-20

Board meetings held

A total of 7 (seven) Board meetings were held during the financial year ended June 30, 2020. In addition to the Directors, the Chief Financial Officer (CFO), the Company Secretary (CS) and the Head of Internal Audit and Compliance (HIAC) also regularly attended the meetings.



A detailed report on Board meeting is set out on page 62

OPL Annual Report 2019-20

Appointment or re-appointment of Directors

With regard to the appointment, retirement and re-appointment of Directors, the company is governed by its Articles of Association, the Companies Act 1994 and other related legislations. In order to comply with the provision mentioned under Section 91(2) of the Company Act 1994 and Clause no. 126 to 130 of the Articles of association of the OPL, at least one third of the Directors shall retire from the office in the Annual General Meeting.

Pursuant to the above, Mrs. Arzuda Karim and Mrs. Hasina Begum, Directors of the company, will retire by rotation from the Board, but being eligible, have offered themselves for re-election which was also recommended by the Board for the approval of the shareholders.



Brief profile of the Directors being proposed for re-election are set out on pages 34 & 36

OPL Annual Report 2019-20

Appointment of Managing Director

As per the corporate governance code published by BSEC, the Managing Director of a listed company can not hold the same position in another listed company. Therefore, the Board of the company appointed Mrs. Zareen Karim as its Managing Director in place of Mr. Salman Obaidul Karim for a period of 5 (five) years on January 08, 2020 because Mr. Salman Obaidul Karim is the Managing Director of Orion Infusion Limited which is also a listed company. The Board recommended Mrs. Zareen Karim's appointment as the Managing Director for next 5 (five) years with post facto effect subject to the approval of shareholders in the ensuing AGM.



Brief profile of the Managing Director being proposed for appointment is set out on page 33

OPL Annual Report 2019-20

Appointment of Independent Director

Lt. Col. Kamal Ahmed, PSC (Retd.), the Independent Director, has completed his second tenure with great success and now, among the shortlisted candidates considering their qualification, skills, experience, expertise, positive attributes, the NRC has recommended to the Board of Directors to appoint Mr. A. N. M. Abul Kashem as the new Independent Director, in compliance with the Notification No. BSEC / CMRRCD / 2006-158 / 207 / Admin / 80 dated June 03, 2018 issued by BSEC, subject to the approval of the shareholders in the ensuing AGM.



Brief profile of the Independent Director being proposed for appointment is set out on page 38

OPL Annual Report 2019-20

Management Discussion & Analysis

Detailed analysis of the company's position and operations have been presented in a Management Discussion and Analysis signed by Mrs. Zareen Karim, Managing Director of the company. The statement depicts a brief discussion of changes in the financial statements, among others, focusing on:

- accounting policies and estimation for preparation of financial statements;
- changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;
- comparative analysis of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;
- compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;
- briefly explain the financial and economic scenario of the country and the globe;
- risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the company; and
- future plan or projection or forecast for company's operation, performance and financial position.



Management's Discussion and Analysis has been presented on pages 114-115

OPL Annual Report 2019-20

Declaration or certification by the MD & the CFO

As per the corporate governance code prescribed by BSEC, it is the responsibility of both MD and CFO to certify to the Board on the preparation of financial statements as per the applicable IAS and IFRS and the presentation of true and fair view of company affairs.



Declaration or certification by the MD and the CFO has been disclosed in Annexure A on page 116

OPL Annual Report 2019-20

Appointment of statutory auditors

The Directors hereby report that as per the Companies Act 1994 and the Articles of Association of the company, the existing auditors, S. F. Ahmed & Co., Chartered Accountants, who were appointed as statutory auditors of the company in the last Annual General Meeting, has carried out the audit for the reporting year ended June 30, 2020, will retire at the conclusion of the ensuing Annual General Meeting.

However, they have expressed their willingness to the Board to be appointed as statutory auditors of the company for the financial year to be ended June 30, 2021 and to continue till the next AGM, subject to the approval of the shareholders in the upcoming AGM.

Status of compliance

OPL recognizes that the sustainability of the company as well as the relationship and trust between the company and the stakeholders relies on the application and adherence to the standard corporate governance. It is the Company Secretary who is responsible and accountable to make sure of full compliance with all applicable rules and regulations and to assure the stakeholders that OPL is doing everything to maximize the value of the shareholders by safeguarding the interest of other stakeholders.

Appointment of compliance auditors

In compliance with the Bangladesh Securities and Exchange Commission's Notification No. SEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018, a listed company requires to appoint compliance auditors on the corporate governance code and collect the compliance report thereon, who shall be appointed by the shareholders in the AGM. However, ARTISAN, Chartered Accountants, has been appointed as the compliance auditors for the financial year under report and they have provided report as well as certificate regarding compliance of conditions of this code.



Certification and checklist on compliance on the corporate governance code have been published in Annexure B and C respectively on pages 117-129

OPL Annual Report 2019-20

Considering the conditions imposed by the code and necessary expertise, the Board has recommended to appoint ARTISAN, Chartered Accountants, as the compliance auditors of the company for the next financial year to be ended June 30, 2021, subject to the approval of the shareholders in the ensuing AGM.

Sustainability

Doing something extra to improve our society or environment is a way to show our true commitment to a cause. Our corporate social responsibility programs include providing scholarship to medical students and providing our oncology medicine 'Enliven' at subsidized price to underprivileged blood cancer patients in Bangladesh under the program named 'Enliven Patients Assistance Program (EPAP)'. Under the EPAP Program, the company has enlisted and renewed 27 (twenty seven) patients in the reporting financial year. Providing relief during Covid-19 pandemic, new clothes to orphan children, ifter to the underprivileged during the month of Ramadan are other initiatives for the betterment of the society we live in. We also perform responsibilities towards our employees by providing them opportunity to perform Holy Hajj and Umrah at company's expense, supporting the family of deceased employee under the donation on death benefit scheme and many other which have already been depicted in human capital chapter.

We are aware of the fact that climate and environment conservation is an issue of great importance to us. We know that Bangladesh is one of the vulnerable countries in the world due to the negative impact of climate change and global warming; and accordingly take steps towards our commitment to help society to achieve sustainable balance. All the information in this regards has been described in natural capital chapter.

Company outlook

Orion Pharma Limited is dedicatedly working towards completing the construction work of Orion Pharma Park at Narayanganj. Innovation in molecule and dosage form is going to be emphasized in every step at the new plant. The installed production capacity will be increased significantly with the implementation of this park and it will help us to meet the untapped demand of our medicines. At present we are not able to fulfill customer demand due to the limitation of our existing production capacity. We are optimistic about the future outlook, as with the increased production capacity, we will be able to enhance productivity and revenue income not only from local market but also from our export markets.

Our company is also determined to position itself better in the local market as well as the export-market. In order to grow and develop in the future and to provide our healthcare facility globally, the company has no alternative to expanding beyond borders and go international. New strategies have been formed to explore new markets and generate income from there.

Acknowledgement

The Board of Directors appreciates the hard work, determination and guidance of the Board, Management team and all the staffs and employees of the company. The Board of Directors also record with deep appreciation the efforts made by the customers, creditors, suppliers, banks, insurance companies, government agencies, and the Government in particular.

The Directors would also like to express profound gratitude to all other stakeholders of the company for their trust and confidence on the company by supporting the activities of the company and look forward to their continued support and cooperation in future.

On behalf of the Board

Sd/-

Mohammad Obaidul Karim

Chairman

ANNEXURE LIST:

- A. Certification by the MD and CFO to the Board
- B. Certificate from ARTISAN, Chartered Accountants regarding compliance on the corporate governance code
- C. Checklist on compliance of corporate governance code
- D. The pattern of shareholding
- E. Compliance report on IAS/IFRS

Management discussion & analysis

Guiding principles

The preparation and presentation of the financial statements and the relevant disclosures therein have been made in accordance with the requirements of the Companies Act 1994, the Securities and Exchange Rules 1987, the Listing Regulations of Stock Exchanges as applicable and International Accounting Standards (IAS) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB) and International Financial Reporting Standards (IFRS) as applicable to the company.

The company has applied IFRS-16 Leases for the first time with the date of initial application of July 01, 2019. The company has applied IFRS-16 using the modified retrospective approach and therefore the comparative information has not been restated. IFRS-16 introduces new or amended requirements with respect to lease accounting. It introduces significant changes to lessee accounting by removing the distinction between operating and finance lease and requiring the recognition of a right-of-use asset and a lease liability at commencement for all leases.

Economic scenario of the world

Let us start with a few words regarding the economic conditions in which our business is operating. The COVID-19 pandemic spread very quickly while infecting millions and bringing economic activity to a near-standstill causing an unprecedented disruption to the global economy. According to the World Economic Situation and Prospects, the world economy is projected to shrink by 3.2% in 2020. economic activities across the globe were paralyzed due to lockdowns and the closing of national borders, making millions of workers worldwide unemployed. Governments rolled out stimulus packages to fight the pandemic and minimize the impact of a catastrophic economic downturn.

Economic scenario of the country

After the world scenario, we may take a look at the condition of our country. The global health crisis caused by COVID-19 has hit Bangladesh's economy hard and jeopardized the country's impressive achievements in poverty reduction. Over the last decade, the economy has been growing at around 7% per annum, yet according to the Bangladesh Bureau of Statistics (BBS), 20.5% of the population lives below the poverty line. The pandemic has worsened the situation by making many people unemployed especially in the informal sector. Decreasing oil

prices in the Middle-east and lockdowns imposed in Europe have negatively affected the expatriate Bangladeshi workers abroad. The RMG sector faced unprecedented humanitarian and business catastrophe as international buyers cancelled orders worth USD 3.16 billion. Even the banking sector and manufacturing sector was adversely affected by the pandemic. Hon'ble Prime Minister Sheikh Hasina announced a timely stimulus package for the fast recovery of the country. As per analysts and economic trends, the economy will rebound from this situation with the right strategies of the Government and all other working forces of the society.

Pharmaceutical industry scenario

The pharmaceutical industry is one of the most technologically advanced sectors currently in existence in Bangladesh. A few decades ago, the country was dependent on imported medicines as well as drugs produced by multinational companies for meeting domestic demands. Now, Bangladesh pharma industry is capable of meeting 98% of the domestic demand that amounted to around USD 3 billion in 2019. The market share of the local manufacturers is currently around 90% and 10% is controlled by foreign producers. Bangladesh is now the only least-developed country among 47 nations that has a well-developed pharmaceutical sector that can produce medicines for cancer diseases and biological products such as insulin and vaccines.

However, Bangladesh's large import dependence on China for API which is almost 50% has become a significant threat to the growth of Bangladesh's healthcare manufacturing and global supply chain. Any disruption in supply chain of APIs can result in significant shortages in the supply of essential drugs in Bangladesh which is clearly happening since the outbreak of Coronavirus in March. India has also posted ban on API exports which is giving more hard times to the import-dependent market like Bangladesh, potentially pushing towards facing API shortage in near future.

Risk management framework

Let me take you all over the different risks that we face. The management has overall responsibility for the establishment and oversight of the company's risk management framework. The company has exposure to credit risk, liquidity risk, market risk, currency risk, interest-rate risk etc. Risk management policies, procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities.

Company performance

Dear shareholders, below is a comparative analysis of the financial performance and financial position of our company over the last 5 (five) years:

Particulars	Amount in BDT million				
	2019-20	2018-19	2017-18	2016-17	2015-16
Net Sales Revenue	7,647.70	8,705.17	10,423.10	9,534.35	14,799.74
Gross Profit	2,577.84	2,545.68	2,376.20	2,419.25	3,861.26
Net Profit after Tax	665.69	882.35	801.76	794.50	1,323.07
EBITDA	2,459.68	2,347.49	2,343.97	2,377.60	3,763.93
Gross Profit Ratio (%)	33.71	29.24	22.80	25.37	26.09
Current Ratio (times)	4.04	3.00	2.23	1.84	2.30
Debt Equity Ratio (times)	0.98	0.71	0.70	0.66	0.61
Return on Equity (%)	3.47	4.71	4.42	4.52	7.69

Peer industry analysis

Now let us take a look at the peer industry scenario and have a comparison with them in regards to our performance. If we look at the industry, we will find that there are many competitors. We have selected 4 (four) of the listed companies for the sake of comparison. We have used ratio analysis as it is one of the best tools for assessing and comparing the financial performance of a company with others.

Year	2018-19					2017-18				
	OPL	Square	Acme	Beximco	Renata	OPL	Square	Acme	Beximco	Renata
Current Ratio (times)	3.00	12.93	0.93	1.04	2.67	2.23	4.91	1.11	1.26	2.20
Return on Equity (%)	4.71	0.17	0.08	0.10	0.21	4.42	0.18	0.08	0.09	0.21
Net Asset Value per Share (BDT)	75.19	77.07	86.69	73.00	227.04	72.88	59.14	83.38	67.00	187.83
Net Operating Cash flow per Share (BDT)	6.19	15.96	7.81	7.30	51.60	9.38	12.02	7.46	4.49	32.42
Earnings per Share (BDT)	3.77	13.39	6.81	7.48	47.47	3.43	10.42	6.74	6.25	39.70

Future plan

Dear Stakeholders, I am pleased to inform you that in the last financial year we were focused upon starting operation in our world-class Pharma Park in Siddhirganj, Narayanganj and will soon start the production of medicines over there. I hereby ensure that with the start of commercial operation of Pharma Park we will see more success and prosperity both nationally and in the international arena.

Thank you

Sd/-

Zareen Karim
Managing Director

Annexure A

Certification by the MD & CFO to the Board

Orion Pharma Limited
Declaration by MD and CFO

Date: November 05, 2020

The Board of Directors
Orion Pharma Limited
153-154, Tejgaon I/A
Dhaka-1208

Subject: Declaration on Financial Statements for the year ended June 30, 2020

Dear Sirs,

Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No.SEC/CMRRCD/2006-158/207/Admin/80 dated June 03, 2018 under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

1. The Financial Statements of Orion Pharma Limited for the year ended June 30, 2020 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;
2. The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;
3. The form and substance of transactions and the company's state of affairs have been reasonably and fairly presented in its financial statements;
4. To ensure above, the company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;
5. Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the company were consistently followed; and
6. The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern.

In this regard, we also certify that: -

- (i) We have reviewed the financial statements for the year ended June 30, 2020 and that to the best of our knowledge and belief:
 - (a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
 - (b) these statements collectively present true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws.
- (ii) There are, to the best of knowledge and belief, no transactions entered into by the company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

Sd/-
Zareen Karim
Managing Director

Sd/-
Samaresh Banik
Chief Financial Officer

Annexure B



**REPORT TO THE SHAREHOLDERS
OF
ORION PHARMA LIMITED
ON COMPLIANCE ON THE CORPORATE GOVERNANCE CODE**

We have examined the compliance status to the Corporate Governance Code of **ORION PHARMA LIMITED** for the year ended 30th June, 2020. This Code relates to the Notification No. BSEC/CMRRCD/2006-158/207/Admin/80 dated 3rd June, 2018 of Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we require, and after due scrutiny and verification thereof, we report that, in our opinion:

- a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above mentioned Corporate Governance Code issued by the Commission.
- b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code.
- c) Proper books and records have been kept by the Company as required under the Companies Act, 1994, the securities laws and other relevant laws; and
- d) The Governance of the Company is satisfactory.

Place: Dhaka
Dated: 17th November, 2020


Md. Selim Reza CA FCS
Partner
ARTISAN-Chartered Accountants

Shah Ali Tower (7th Floor) 33, Kawran Bazar, Dhaka-1215 Bangladesh.
Phone : 8189883-7, 8180183-6, Fax : 8180187, E-mail: info@artisan-ca.com, afmalamgir28@gmail.com, Web : www.artisan-ca.com

Annexure C

Checklist on compliance of Corporate Governance Code

Status of compliance with the conditions imposed by the Commission's Notification No. BSEC/CMRRCD/2006-158/207/Admin/80, dated June 03, 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969.

(Report under Condition No. 9)

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.	Board of Directors (BOD) :			
1.1	Board's Size :			
	[The total number of members of a Company's Board of Directors (hereinafter referred to as "Board") shall not be less than 5 (five) and more than 20 (twenty)].	✓		The Board of Orion Pharma Limited is comprised of 7 (seven) Directors.
1.2	Independent Directors :			
1.2(a)	At least one fifth (1/5) of the total number of Directors shall be Independent Directors;	✓		The Board of Orion Pharma Limited is comprised of 7 (seven) Directors including 2 (two) Independent Directors.
1.2(b)	Independent Director means a Director :			The Independent Directors have declared their compliances.
1.2(b) (i)	Who either does not hold any share in the Company or holds not less than one percent (1%) shares of the total paid-up shares of the Company;	✓		
1.2(b) (ii)	Who is not a sponsor of the Company and is not connected with the Company's any sponsor or Director or shareholder who holds one percent (1%) or more shares of the total paid-up shares of the Company on the basis of family relationship. His/her family members also should not hold above mentioned shares in the Company;	✓		
1.2(b) (iii)	Who has not been executive of the Company in immediately preceding 2 (two) financial years;	✓		
1.2(b) (iv)	Who does not have any other relationship, whether pecuniary or otherwise, with the Company or its subsidiary/associated companies;	✓		
1.2(b) (v)	Who is not a member or TREC (Trading Right Entitlement Certificate) holder director or officer of any stock exchange;	✓		
1.2(b) (vi)	Who is not a shareholder, director excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market;	✓		
1.2(b) (vii)	Who is not a partner or executive or was not a partner or an executive during the preceding 3 (three) years of the concerned Company's statutory audit firm or audit firm engaged in internal audit services or audit firm conducting special audit or professional certifying compliance of this code;	✓		

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.2(b) (viii)	Who shall not independent director in more than 5 (Five) listed companies;	✓		
1.2(b) (ix)	Who has not been convicted by a court of competent jurisdiction as a defaulter in payment of any loan or advance to a bank or Non-Bank Financial Institution (NBFII);	✓		
1.2(b) (x)	Who has not been convicted for a criminal offence involving moral turpitude;	✓		
1.2 (c)	Independent Director(s) shall be appointed by the board of directors and approved by the shareholders in the Annual General Meeting (AGM);	✓		Mr. A. N. M. Abul Kashem has been appointed by the Board in place of Lt. Col. Kamal Ahmed, PSC (Retd.), which will be placed for approval of the shareholders in the ensuing AGM.
1.2 (d)	The post of Independent director(s) cannot remain vacant for more than 90 (ninety) days;	✓		There was no vacancy in the position of Independent Directors during the reporting period.
1.2 (e)	The tenure of office of an Independent Director shall be for a period of 3 (three) years, which may be extended for 1 (one) tenure only. Provided that a former independent director may be considered for reappointment for another tenure after a time gap of one tenure, i.e., three years from his or her completion of consecutive two tenures [i.e. six years].	✓		
1.3	Qualification of Independent Director (ID) :			
1.3(a)	Independent Director shall be a knowledgeable individual with integrity who is able to ensure compliance with financial laws regulatory requirements and corporate laws and can make meaningful contribution to business.	✓		The qualification and background of Independent Directors justify their ability as such.
1.3(b)	Independent director shall have following qualifications :			
1.3(b)(i)	Business Leader who is or was a promoter or director of an unlisted Company having minimum paid-up capital of Tk.100.00 million or any listed Company or a member of any national or international chamber of commerce or business association;	N/A		N/A
1.3(b)(ii)	Corporate Leader who is or was a top level executive not lower than Chief Executive Officer or Managing Director or Chief Financial Officer or Head of Finance Or Accounts or Company Secretary or Head of internal Audit and Compliance or Head of Legal Service or a candidate with equivalent position of an unlisted Company having minimum paid up capital of TK 100.00 million or of a listed Company;	✓		Independent Directors are Corporate Leaders with more than 30 years of experience.
1.3(b)(iii)	Former official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, Who has at least educational background of bachelor degree in economics or commerce or business or Law;	N/A		N/A
1.3(b)(iv)	University teacher who has educational background in Economics or Commerce or Business Studies or Law;	N/A		N/A

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.3(b)(v)	Professional who is or was an advocate practicing at least in the High Court Division of Bangladesh Supreme Court or a Chartered Accountant or Cost and Management Accountant or Chartered Financial Analyst or Chartered Certified Accountant or Certified Public Accountant or Chartered Management Accountant or Chartered Secretary or equivalent qualification;	N/A		N/A
1.3(c)	The independent director shall have at least 10 (ten) years of experience in any filed mentioned in clause (b);	✓		Independent Directors are Corporate Leaders with more than 30 years of experience.
1.3(d)	In special cases, the above qualification or experiences may be relaxed subject to prior approval of the Commission.			No such situation has occurred during the year.
1.4	Duality of Chairperson of the Board of Directors and Managing Directors or Chief Executive Officer :			
1.4(a)	The position of the Chairperson of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) of the Company shall be filled by different individuals;	✓		Chairperson of the Board and CEO are different individuals.
1.4(b)	The Managing Director (MD) and/or Chief Executive Officer (CEO) of a listed Company shall not hold the same position in another listed Company;	✓		
1.4(c)	The Chairperson of the Board shall be elected from among the non-executive directors of the Company;	✓		
1.4(d)	The Board shall clearly define respective roles and responsibilities of the Chairperson and the Managing Director and /or Chief Executive Officer;	✓		
1.4(e)	In the absence of the Chairperson of the Board, the remaining members may elect one of themselves from non-executive directors as Chairperson for that particular Boards meeting the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	✓		
1.5	The Directors' Report to Shareholders :			
1.5(i)	Industry outlook & possible future development in the industry:	✓		The Directors' Report complies with the guidelines.
1.5(ii)	Segment- wise or product- wise performance;	✓		Do
1.5(iii)	Risks and concerns including internal and external risk factors, threat to sustainability and negative impact on environment, if any;	✓		Do
1.5(iv)	A discussion on Cost of Goods sold, Gross Profit and Net Profit Margin and Net profit Margin, Where applicable;	✓		Do
1.5(v)	Discussion on continuity of any Extra-Ordinary activities and their implication (gain or loss);	✓		Do
1.5(vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	✓		Do
1.5(vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	N/A		N/A

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.5(viii)	An explanation if the financial results deteriorate after the Company goes for IPO, RPO, Rights offer, Direct listing etc;	N/A		N/A
1.5(ix)	An explanation on any significant variance that occurs between Quarterly Financial performances and Annual Financial Statements;	✓		The Directors' Report complies with the guidelines.
1.5(x)	A statement of Remuneration paid to directors including independent directors;	✓		Do
1.5(xi)	A statement that The financial statements present fairly its state of affairs, the result of its operations, cash flows and changes in equity;	✓		Do
1.5(xii)	Proper books of accounts have been maintained;	✓		Do
1.5(xiii)	A statement that appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment;	✓		Do
1.5(xiv)	IAS/IFRS, as applicable in Bangladesh, have been followed and adequate disclosure for any departure;	✓		Do
1.5(xv)	A statement that the system of internal control is sound in design and has been effectively implemented and monitored;	✓		Do
1.5(xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	✓		Do
1.5(xvii)	A statement that there is no significant doubt upon the issuer Company's ability to continue as a going concern, if the issuer Company is not considered to be a going concern, the fact along with reasons there of shall be disclosed;	✓		Do
1.5(xviii)	An explanation that significant deviations from the last year's operating results of the issuer Company shall be highlighted and the reasons thereof shall be explained;	✓		Do
1.5(xix)	A statement where key operating and financial data of at least preceding 5 (five) years shall be summarized;	✓		Do
1.5(xx)	An explanation on the reasons if the issuer Company has not declared dividend (cash or stock) for the year;	N/A		10% cash dividend has been recommended by the BOD.
1.5(xxi)	Board's statement to the effect that no bonus share or stock dividend has been or shall be declared as interim dividend;	N/A		N/A
1.5(xxii)	The total number of Board meetings held during the year and attendance by each director;	✓		7 (seven) meetings were held during the year.
1.5(xxiii)	Pattern of shareholding and name wise details (disclosing aggregate number of shares) :			
1.5(xxiii)(a)	Parent/Subsidiary/Associated Companies and other related parties (Name wise details);	✓		Annexure-D
1.5(xxiii)(b)	Directors, Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and their spouses and minor children (Name wise details);	✓		Do
1.5(xxiii)(c)	Executives;	✓		Do
1.5(xxiii)(d)	Shareholders holding ten percent (10%) or more voting interest in the Company (Name wise details).	✓		Mr. Mohammad Obaidul Karim, Chairman of the company holds 15.18% voting interest and ICB holds 12.83%.

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.5 (xxiv)	In case of appointment/re-appointment of a Director, disclose :			
1.5(xxiv)(a)	A brief resume of the Director;	✓		
1.5(xxiv)(b)	Nature of his /her expertise in specific functional areas;	✓		
1.5(xxiv)(c)	Name of companies in which the person also holds the directorship and the membership of committees of that Board.	✓		
1.5(xxv)	Management's Discussion and Analysis signed by CEO or MD presenting detailed analysis of the Company's position and operations along with a brief discussion of changes in the financial statements, among others, focusing on :			
1.5(xxv)(a)	Accounting policies and estimation for preparation of financial statements;	✓		
1.5(xxv)(b)	Changes in accounting policies and estimation, if any, clearly describing the effect on financial performance or results and financial position as well as cash flows in absolute figure for such changes;	✓		
1.5(xxv)(c)	Comparative analysis (including effects of inflation) of financial performance or results and financial position as well as cash flows for current financial year with immediate preceding five years explaining reasons thereof;	✓		
1.5(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario;	✓		
1.5(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe;	✓		
1.5(xxv)(f)	Risks and concerns issues related to the financial statements, explaining such risk and concerns mitigation plan of the Company;	✓		
1.5(xxv)(g)	Future plan or projection or forecast for Company's operation, performance and financial position, with justification thereof i.e., actual position shall be explained to the shareholders in the next AGM;	✓		
1.5(xxvi)	Declaration or certification by the CEO and the CFO to the Board as required under condition No. 3(3) shall be disclosed as per Annexure-A;	✓		
1.5(xxvii)	The report as well as certificate regarding compliance of conditions of this Code as required under condition No. 9 shall be disclosed as per Annexure-B and Annexure-C.	✓		
1.6	Meetings of the Board of Directors :			
	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any condition of this Code.	✓		
1.7	Code of Conduct for the Chairperson, other Board members and Chief Executive Officer :			
1.7(a)	The Board shall lay down a code of conduct, based on the recommendation of the Nomination and Remuneration Committee (NRC) at condition No. 6, for the Chairperson of the Board, other board members and Chief Executive Officer of the Company;	✓		

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
1.7(b)	The code of conduct as determined by the NRC shall be posted on the website of the Company including, among others, prudent conduct and behavior; confidentiality; conflict of interest; compliance with laws, rules and regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency.	✓		The Code of Conduct for the Chairperson of the Board, other Board members and Chief Executive Officer of the company has been published in the website of the company.
2. Governance of Board of Directors of Subsidiary Company :				
2(a)	Provisions relating to the composition of the Board of the holding Company shall be made applicable to the composition of the Board of the subsidiary Company;	✓		Orion Power Meghnaghat Limited & Dutch Bangla Power & Associates Limited are the 2 (two) subsidiary companies of OPL.
2(b)	At least 1 (one) independent director on the Board of the holding Company shall be a director on the Board of the subsidiary Company;	✓		In Practice
2(c)	The minutes of the Board meeting of the subsidiary Company shall be placed for review at the following Board meeting of the holding Company;	✓		In Practice
2(d)	The minutes of the respective Board meeting of the holding Company shall state that they have reviewed the affairs of the subsidiary Company also;	✓		In Practice
2(e)	The Audit Committee of the holding Company shall also review the financial statements, in particular the investments made by the subsidiary Company.	✓		In Practice
3. Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS):				
3.1 Appointment :				
3.1(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	✓		In Practice
3.1 (b)	The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	✓		In Practice
3.1 (c)	The MD or CEO, CS, CFO and HIAC of a listed Company shall not hold any executive position in any other Company at the same time;	✓		In progress
3.1 (d)	The Board shall clearly define respective roles, responsibilities and duties of the CFO, the HIAC and the CS;	✓		In Practice
3.1 (e)	The MD or CEO, CS, CFO and HIAC shall not be removed from their position without approval of the Board as well as immediate dissemination to the Commission and stock exchange(s).	✓		In Practice

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
3.2	Requirement to attend Board of Directors' Meetings :			
	The MD or CEO, CS, CFO, and HIAC of the company shall attend the meetings of the Board. Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	✓		In Practice
3.3	Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO) :			
3.3(a)	The MD or CEO and CFO shall certify to the Board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	✓		
3.3(a)(i)	These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;	✓		
3.3(a)(ii)	These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.	✓		
3.3 (b)	The MD or CEO and CFO shall also certify that there are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the Company's Board or its members;	✓		
3.3 (c)	The certification of the MD or CEO and CFO shall be disclosed in the Annual Report.	✓		
4.	Board of Directors' Committee :			
4 (i)	Audit Committee;	✓		In Practice
4 (ii)	Nomination and Remuneration Committee.	✓		In Practice
5.	Audit Committee :			
5.1	Responsibility to the Board of Directors :			
5.1(a)	The Company shall have an Audit Committee as a sub-committee of the Board of Directors;	✓		In Practice
5.1(b)	The Audit Committee shall assist the BOD in ensuring that the financial statements reflect true and fair view of the state of affairs of the Company and in ensuring a good monitoring system within the business;	✓		In Practice
5.1(c)	The Audit Committee shall responsible to the BOD. The duties of the Audit Committee shall be clearly set forth in writing.	✓		In Practice
5.2	Constitution of the Audit Committee :	✓		
5.2(a)	The Audit Committee shall be composed of at least 3 (three) members;	✓		The Audit Committee is composed with 3 (three) members where 1 (one) is Non-Executive Director and 2 (two) are Independent Directors.

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
5.2(b)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓		The members of the Audit Committee are appointed by the Board where 1 (one) is Non-Executive Director and 2 (two) are Independent Directors.
5.2(c)	All members of the audit committee should be "financially literate" and at least 1 (one) member shall have accounting or related financial management background and 10 (ten) years of such experience;	✓		
5.2(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 1 (one) month from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	N/A		No such situation occurred during the reporting financial year.
5.2(e)	The Company Secretary shall act as the Secretary of the Audit Committee;	✓		In Practice
5.2(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) independent director.	✓		In Practice
5.3	Chairperson of the Audit Committee :			
5.3(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	✓		Mr. Md. Shafiqur Rahman, Independent Director is the Chairman of the Audit Committee.
5.3(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	✓		No such situation occurred during the reporting financial year.
5.3(c)	Chairperson of the Audit Committee shall remain present in the Annual General Meeting (AGM).	✓		In Practice
5.4	Meeting of the Audit Committee :			
5.4(a)	The Audit Committee shall conduct at least its four meetings in a financial year;	✓		In Practice
5.4(b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two-third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	✓		In Practice
5.5	Role of Audit Committee :			
5.5(a)	Oversee the financial reporting process;	✓		In Practice
5.5(b)	Monitor choice of accounting policies and principles;	✓		In Practice
5.5(c)	Monitor Internal Control Risk management process;	✓		In Practice
5.5(d)	Oversee hiring and performance of external auditors;	✓		In Practice
5.5(e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	✓		In Practice

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
5.5(f)	Review along with the management, the annual financial statements before submission to the Board for approval;	✓		In Practice
5.5(g)	Review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	✓		In Practice
5.5(h)	Review the adequacy of internal audit function;	✓		In Practice
5.5(i)	Review the Management's Discussion and Analysis before disclosing in the Annual Report;	✓		In Practice
5.5(j)	Review statement of all related party transactions submitted by the management;	✓		In Practice
5.5(k)	Review Management Letters or Letter of Internal Control Weakness issued by statutory auditors;	✓		In Practice
5.5(L)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external auditors;	✓		In Practice
5.5(m)	Oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission.	N/A		N/A
5.6	Reporting of the Audit Committee :			
5.6(a)	Reporting to the Board of Directors :			
5.6(a)(i)	The Audit Committee shall report on its activities to the Board;	✓		The report of the committee has been submitted to the Board of Directors.
5.6(a)(i)	The Audit Committee shall immediately report to the Board on the following findings, if any:	✓		In Practice
5.6(a)(ii)(a)	Report on conflicts of interests;	✓		No such event occurred during the reporting year.
5.6(a)(ii)(b)	Suspected or presumed fraud or irregularity or material defect identified in the internal audit and compliance process or in the financial statements;	✓		Do
5.6(a)(ii)(c)	Suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations;	✓		Do
5.6(a)(ii)(d)	Any other matter which the Audit Committee deems necessary shall be disclosed to the Board immediately.	✓		In Practice
5.6(b)	Reporting to the Authorities :	✓		No such event occurred during the reporting year.
5.7	Reporting to the Shareholders and General Investors :	✓		In Practice
6.	Nomination and Remuneration Committee (NRC) :			
6.1	Responsibility to the Board of Directors :			
6.1(a)	The Company shall have a Nomination and Remuneration Committee (NRC) as a sub-committee of the Board;	✓		In Practice

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
6.1(b)	The NRC shall assist the Board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors and top level executive as well as a policy for formal process of considering remuneration of directors, top level executive;	✓		In Practice
6.1(b)	The Terms of Reference (TOR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	✓		In Practice
6.2	Constitution of the NRC :			
6.2(a)	The Committee shall comprise of at least three members including an independent director;	✓		The NRC is composed with 3 (three) members.
6.2(b)	All members of the Committee shall be non-executive directors;	✓		All members of the NRC are Non-Executive Directors.
6.2(c)	Members of the Committee shall be nominated and appointed by the Board;	✓		The members of the NRC are appointed by the Board.
6.2(d)	The Board shall have authority to remove and appoint any member of the Committee;	✓		In Practice
6.2(e)	In case of death, resignation, disqualification, or removal of any member of the Committee or in any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) days of occurring such vacancy in the Committee;	N/A		No such situation occurred during the reporting financial year.
6.2(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	✓		In Practice
6.2(g)	The Company Secretary shall act as the secretary of the Committee;	✓		In Practice
6.2(h)	The quorum of the NRC meeting shall not constitute without attendance of at least an independent director;	✓		No such situation occurred during the reporting financial year.
6.2(i)	No member of the NRC shall receive, either directly or indirectly, any remuneration for any advisory or consultancy role or otherwise, other than Director's fees or honorarium from the Company.	✓		Do
6.3	Chairperson of the NRC :			
6.3(a)	The Board shall select 1 (one) member of the NRC to be Chairperson of the Committee, who shall be an independent director;	✓		Mr. Md. Shafiqur Rahman, Independent Director is the Chairman of the Committee.
6.3(b)	In the absence of the Chairperson of the NRC, the remaining members may elect one of themselves as Chairperson for that particular meeting, the reason of absence of the regular Chairperson shall be duly recorded in the minutes;	✓		In Practice

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
6.3(c)	The Chairperson of the NRC shall attend the annual general meeting (AGM) to answer the queries of the shareholders.	✓		The Chairperson of the NRC shall attend the upcoming Annual General Meeting (AGM).
6.4	Meeting of the NRC :			
6.4(a)	The NRC shall conduct at least one meeting in a financial year;	✓		In Practice
6.4(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	N/A		No such situation occurred during the reporting financial year.
6.4(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	✓		In Practice
6.4(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	✓		In Practice
6.5	Role of the NRC :			
6.5(a)	NRC shall be independent and responsible or accountable to the Board and to the shareholders;	✓		In Practice
6.5(b)	NRC shall oversee, among others, the following matters and make report with recommendation to the Board :	✓		In Practice
6.5(b)(i)	Formulating the criteria for determining qualifications, positive attributes and independence of a director and recommend a policy to the Board, relating to the remuneration of the directors, top level executive, considering the following :	✓		In Practice
6.5(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the Company successfully;	✓		In Practice
6.5(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks;	✓		In Practice
6.5(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of the Company and its goals;	✓		In Practice
6.5(b)(ii)	Devising a policy on Board's diversity taking into consideration age, gender, experience, ethnicity, educational background and nationality;	✓		In Practice
6.5(b)(iii)	Identifying persons who are qualified to become directors and who may be appointed in top level executive position in accordance with the criteria laid down, and recommend their appointment and removal to the Board;	✓		In Practice
6.5(b)(iv)	Formulating the criteria for evaluation of performance of independent directors and the Board;	✓		In Practice
6.5(b)(v)	Identifying the Company's needs for employees at different levels and determine their selection, transfer or replacement and promotion criteria;	✓		In Practice
6.5(b)(vi)	Developing, recommending and reviewing annually the Company's human resources and training policies;	✓		In Practice
6.5(c)	The Company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	✓		In Practice

Condition No.	Title	Compliance Status (Put ✓ in the appropriate column)		Remarks (If any)
		Complied	Not complied	
7. External/Statutory Auditors :				
7.1	The issuer Company shall not engage its external or statutory auditors to perform the following services of the Company, namely :	✓		
7.1(i)	Appraisal or valuation services or fairness opinions;	✓		
7.1(ii)	Financial information systems design and implementation;	✓		
7.1(iii)	Book-keeping or other services related to the accounting records or financial statements;	✓		
7.1(iv)	Broker-dealer services;	✓		
7.1(v)	Actuarial services;	✓		
7.1(vi)	Internal audit services or special audit services;	✓		
7.1(vii)	Any service that the Audit Committee determines;	✓		
7.1(viii)	Audit or certification services on compliance of corporate governance as required under condition No. 9(1);	✓		
7.1(ix)	Any other service that creates conflict of interest;	✓		
7.2	No partner or employees of the external audit firms shall possess any share of the Company they audit at least during the tenure of their audit assignment of that Company; his or her family members also shall not hold any shares in the said Company: Provided that spouse, son, daughter, father, mother, brother, sister, son-in-law and daughter-in-law shall be considered as family members;	✓		
7.3	Representative of external or statutory auditors shall remain present in the Shareholders' Meeting (Annual General Meeting or Extraordinary General Meeting) to answer the queries of the shareholders.	✓		
8. Maintaining a website by the Company :				
8.1	The Company shall have an official website linked with the website of the stock exchange;	✓		www.orionpharmabd.com linked with DSE and CSE.
8.2	The Company shall keep the website functional from the date of listing;	✓		In Practice
8.3	The Company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s).	✓		In Practice
9. Reporting and Compliance of Corporate Governance :				
9.1	The Company shall obtain a certificate from a practicing Professional Accountant or Secretary (Chartered Accountant or Cost and Management Accountant or Chartered Secretary) other than its statutory auditors or audit firm on yearly basis regarding compliance of conditions of Corporate Governance Code of the Commission and shall such certificate shall be disclosed in the Annual Report;	✓		Certificate has been obtained from ARTISAN-Chartered Accountants for the financial year ended on June 30, 2020 which is published in Annual Report.
9.2	The professional who will provide the certificate on compliance of this Corporate Governance Code shall be appointed by the shareholders in the annual general meeting;	✓		In Practice
9.3	The directors of the Company shall state, in accordance with the Annexure-C attached, in the directors' report whether the Company has complied with these conditions or not.	✓		In Practice

Annexure D


The pattern of shareholding

as on June 30, 2020

Categories	Name	Status	No. of shares held	% of holding
(a) Parent or Subsidiary or Associated Companies and other related parties	Nil			
(b) Directors, Chief Executive Officer, Company Secretary, Chief Financial Officer, Head of Internal Audit and Compliance and their spouses and minor children	Mr. Mohammad Obaidul Karim	Chairman	35,514,000	15.18
	Mrs. Zareen Karim	Managing Director	6,413,040	2.74
	Mrs. Arzuda Karim	Director	8,805,600	3.76
	Mr. Salman Obaidul Karim	Director	9,708,960	4.15
	Mrs. Hasina Begum (Nominated by Panbo Bangla Mushroom Ltd.)	Nominated Director	14,400,000	6.15
	Lt. Col. Kamal Ahmed, PSC (Retd.)	Independent Director	Nil	Nil
	Mr. Md. Shafiqur Rahman	Independent Director	Nil	Nil
	Mrs. Zareen Karim	Managing Director	6,413,040	2.74
	Mr. Md. Ferdous Jaman	Company Secretary	Nil	Nil
	Mr. Samaresh Banik	Chief Financial officer	Nil	Nil
	Mr. Md. Ibrahim Khalil	Head of Internal Audit and Compliance	Nil	Nil
(c) Executives	Mr. Md. Ashfaquul Alam	VP, Corporate Affairs	Nil	Nil
	Mr. Mahbubur Rahman	VP, Sales	Nil	Nil
	Mr. Md. Abu Sayed Khondoker	VP, Plant	Nil	Nil
	Mr. Md. Zakir Hossain	VP, Production	Nil	Nil
	Mrs. Ayesha Akhter	VP, Commercial, TSD & PPIC	Nil	Nil
(d) Shareholders holding ten percent (10%) or more voting interest in the company	Mr. Mohammad Obaidul Karim	Chairman	35,514,000	15.18
	ICB	Shareholder	30,013,810	12.83

Shareholding composition

as on June 30, 2020



Types of shareholders	No. of shareholders	No. of shares held	% of shareholding
Sponsors	5	74,841,600	31.98
Foreign Investors	153	3,852,998	1.65
Financial Institutions	189	109,366,464	46.74
General Public	35,134	45,938,938	19.63
Total	35,481	234,000,000	100.00

Range of holding in number of Shares	No. of shareholders	No. of shares held	% of shareholding
Upto 500 Shares	28,404	3,207,721	1.37
501 to 5,000 Shares	5,219	10,358,814	4.43
5,001 to 10,000 Shares	944	6,836,575	2.92
10,001 to 20,000 Shares	510	7,147,643	3.05
20,001 to above	404	206,449,247	88.23
Total	35,481	234,000,000	100.00

Annexure E

Compliance report on IAS/IFRS

IAS No.	IAS Title	Remarks
01	Presentation of Financial Statements	Applied
02	Inventories	Applied
07	Statement of Cash Flows	Applied
08	Accounting Policies, Changes in Accounting Estimates and Errors	Applied
10	Events after the reporting period	Applied
12	Income Taxes	Applied
16	Property, Plant and Equipment	Applied
19	Employee Benefits	Applied
20	Accounting of Government Grants and Disclosure of Government Assistance	N/A
21	The Effects of Changes in Foreign Exchange Rates	Applied
23	Borrowing Costs	Applied
24	Related Party Disclosures	Applied
26	Accounting and Reporting by Retirement Benefit Plans	N/A
27	Separate Financial Statements	Applied
28	Investment in Associates and Joint Ventures	Applied
29	Financial Reporting in Hyperinflationary Economics	N/A
32	Financial Instruments: Presentation	Applied
33	Earnings per share	Applied
34	Interim Financial Reporting	Applied
36	Impairment of Assets	Applied
37	Provisions, Contingent Liabilities and Contingent Assets	Applied
38	Intangible Assets	Applied
39	Financial Instruments: Recognition and Measurement	N/A
40	Investment Property	N/A
41	Agriculture	N/A

IFRS No.	IFRS Title	Remarks
01	First-time Adoption of International Financial Reporting Standards	N/A
02	Share-based Payment	N/A
03	Business Combinations	N/A
04	Insurance Contracts	N/A
05	Non-current Assets Held for Sale and Discontinues Operations	N/A
06	Exploration for and Evaluation of Mineral Resources	N/A
07	Financial Instruments: Disclosures	Applied
08	Operating Segments	Applied
09	Financial Instruments	Applied
10	Consolidated Financial Statements	Applied
11	Joint Arrangements	N/A
12	Disclosure of Interests in Other Entities	Applied
13	Fair Value Measurement	Applied
14	Regulatory Deferral Accounts	N/A
15	Revenue from Contracts with Customers	Applied
16	Lease	Applied
17	Insurance Contracts	N/A



The main prospect that integrated reporting provides us is the opportunity to think in a different way and make decisions on the basis of financial criteria along with the consideration of the socio-economic impacts of the decisions taken. Orion Pharma Limited incorporates 6 (six) capitals as a part of its long term business strategy which are influenced by the company's business activities to create values and we illustrate these capitals as per the International Integrated Reporting Council (IIRC)'s 6 (six) capitals framework in this Integrated Annual Report.

Financial capital

Financial capital represents the funds being used to facilitate the process of building and strengthening our ability to develop and create value for our stakeholders. We aim on enhancing value of our stakeholders and ensure long term sustainable growth by astute management of financial capital.

Sources of financial capital

The main sources of financial capital are:

- equity;
- debt financing;
- earned surplus etc. which are raised through the financing, operating and investing activities; and
- internal control.

Approaches to maintenance of financial capital

The company plans the effective utilization and deployment of available financial capital and tries to maintain strict financial discipline and controls to mitigate exchange rate, interest rate, credit risks etc. However, the company is constantly focusing on its actions to sustain growth, develop operations and ensure the highest return for the shareholders and strengthen the financial position. The followings are some of the approaches to maintaining our financial capital:

- We are operating in a capital-intensive pharmaceutical industry and are now in the business expansion stage for which OPL tends to retain more of its earnings to reinvest it rather than paying them out to shareholders.
- Other than internal fund raising option i.e. retained earnings, we also focus on availing long as well as short term loan

facilities as we are expanding our business operation by increasing our product lines. We analyze various factors for the selection of fund providers particularly for loan facility, including project financing and working capital loan.

- Funds generated are being used for the maintenance of regular business operation, repayment of loan along with interest expenses, investing activities and dividend payment.
- Orion Pharma Limited also addresses the following key factors to boost up the company's financial health:
 - Analysis of product wise performance;
 - Adoption of product specific strategies;
 - Timely introduction of potential medicines in the market as well as exit from loss making or slow moving product lines;
 - Close monitoring of cost element as well as identification of opportunity to minimize cost; and
 - Increasing operational efficiency through benchmarking against best-in-industry practices.



The overall financial performance for the reporting financial year 2019-20 is available in section "Performance and financials".

OPL Annual Report 2019-20



Outcomes in 2019-20

BDT 76.77

consolidated net asset value including revaluation surplus

BDT 3.84

consolidated earning per share

BDT 8.04

consolidated net operating cash flows per share

BDT 517.31 million

contributed to national exchequer

35,481

no. of shareholders

10%


cash dividend recommended

5.13%

return on capital employed


KPI: Consolidated revenue from net sales

During the reporting financial year, consolidated net sales revenue decreased by 12.15% even though the pharma sales revenue has increased by 3.38%. This is mainly due to the decrease of revenue from power generation. We could not attain the expected CAGR yet and our revenue growth has mainly been affected by the delay in the commencement of production in our new plant. However, we are determined and positive about successful completion of all requirements of our new plant and our focus for upcoming years is on achieving a significant growth in sales portfolio for ensuring sustainable business operation.




KPI: Consolidated net profit after tax attributable to shareholders

Despite of 12.15% decline in consolidated net sales revenue, we attained a 1.26% positive gross margin in the financial year 2019-20 compared to previous year. However, due to 37.15% increase in consolidated financial expenses, the net profit after tax saw a 24.56% downward movement during the reporting financial year. We are working to attain a stable positive CAGR over the years which will ensures our sustainable business operations.




KPI: Consolidated cash outflow in CAPEX

In addition to the regular acquisition of property, plant and equipment, we have a huge investment in capital work in progress in expanding our manufacturing capacities and upgrade the facilities in respect of technology, safety, environment etc. This capital work in progress denotes our continuous capital expenditure undertaken during the reporting year in the new plant as the plant is still under construction.




KPI: Leverage ratio (Debt to equity)

Over the last 5 (five) years, the company's debt financing has increased due to the huge funding requirement for the capital expenditure undertaken for construction of our new plant as well as refinancing of subsidiaries. As a result of the increase in debt funding, our debt to equity ratio increased to 0.98 over the period of 5 (five) years from 0.64 of financial year 2015-16.




KPI: Profitability ratio (Return on equity)

The company has experienced a 24.56% decrease in net profit after tax and this has resulted in the 3.47% return on equity during the reporting financial year compare to 4.71% return on equity in previous year.




KPI: Profitability ratio (Gross profit margin)

Gross profit margin has increased by 15.29% in the reporting financial year. Due to controlled and proper maintenance of expenses over the years, we have been able to maintain a stable and upward gross profit margin since last 5 (five) years. During the year, the gross profit margin is 33.71% which was 29.24% in previous year.



KPI: Market prospect ratio (Dividend payout)

Over the last few years, the dividend per share remained the same and the dividend payout ratio showed a stable movement. However, due to a decrease in EPS in the reporting financial year, 10% cash dividend has been recommended for the shareholders. As the company has been continuously investing in its expansion project, it prefers to reinvest its earnings which will eventually yield more earnings and return to the company's long-term shareholders.



Manufactured capital

Investment in manufactured capital is vital in order to produce high quality medicines that would contribute to sustainable competitive advantage. Significant investment in our finished products, manufacturing facilities, operations, technologies, capacities and distribution is an ongoing phenomenon that aims to safeguard our ability to deliver the values, satisfy the customer needs and achieve the strategic intent of the business.

Sources of manufactured capital

The main sources of manufactured capital are:

- Good Manufacturing Practices (GMP);
- ISO 9001:2015;
- Plant architecture and infrastructure;
- Manufacturing facilities and process;
- Production capacity;
- Technology and equipment;
- Environment, health and safety provision; and
- Distribution network etc.





Outcomes in 2019-20

2.29%

increased production of medicines

BDT 1,543.45 million

invested in capital expenditure

Construction & installation of GPB-1

has been completed

GPB-2 and GPB-3

under construction

Particle size analyzer

of APIs procured to ensure highest quality

Impurity Profile checking

started to ensure quality of APIs

Audit trail

implemented for better quality



Orion Pharma Park

Orion Pharma Park- our new pharmaceutical manufacturing plant

Our new plant "Orion Pharma Park" uses the latest technology in compliance with the 'Current Good Manufacturing Practices' standards of international regulatory authorities like USFDA, UK MHRA, EU, TGA (Australia) WHO etc. The plant has a complete array of pharmaceutical facilities and solutions in one complex with automatic process control and supervision systems in order to produce quality medicine. The high capacity, sophisticated, GAMP 5, EU GMP, Annex 15, 21CFR part 11 FDA regulated compliant production machinery of the plant will help to achieve the targeted growth by enhancing the production capacity.

The total area of GPB-1 is about 44,000 square feet. The site houses other supplementary infrastructures including utility and admin building, ETP building, warehouse, gate house etc. Other production buildings of the Pharma Park - General Pharma Unit-2 (GPB-2) and General Pharma Unit-3 (Cephalosporin) are currently under construction. Moreover, Supplement and Oncology are currently under development stage.


The plant's utility infrastructure has been designed including water purifier facility, steam, boiler, compressor, generator etc. to ensure adequate supply of water, electricity and gas. Besides, we have a central ETP from Effwa. The production site follows the best practices for fire, water and air management systems and employee health and safety issues. In totality, the new Pharma Park does not only result in increased production capacity, but also has resulted compliance with more regulatory requirements, safeguarding the environment, safety and health protection of employees in the workplace and environment.

Orion Pharma Park at a glance

Location	Sumilpara Siddhirganj Narayanganj -1431 Bangladesh
Area	20.85 acre
Production facilities	<ul style="list-style-type: none"> • General formulation • Cephalosporin • Supplement • Oncology • Ophthalmic
Production lines	<ul style="list-style-type: none"> • Oral Solid: Tablet (Uncoated, coated, effervescent, bi-layered), Powder for suspension, Sachet, Soft gel capsule, Hard gel capsule • Oral Liquid: Syrup, Suspension, Drop • Semisolid: Cream, Ointment, Gel, Suppository • Injection: Ampoule, Vial (liquid, powder, lyophilized), Prefilled Syringe • Ophthalmic- Eye Drop (steroid and non-steroid), Eye ointment

Distribution network

Our distribution network connects patients with healthcare products across urban and rural area. We distribute our products all over the country using our own distribution channel. We have a large number of vehicles and sales depots to ensure coverage of the whole country. In accordance with the market requirements, the stocks are distributed countrywide by company-owned distribution network.



60
Customized vehicles

769
Distribution personnel

Manufacturing process



Input

- API, excipients and packing materials are received and inspected as per Standard Operating Procedure (SOP) and kept in 'quarantine area';
- Sample analysis is done by the Quality Control (QC) whereby QC performs identification, potency determination and necessary tests of materials;
- Following QC approval, pass labels are fixed on containers and materials are shifted from Quarantine to specific approved area for preservation;
- Retest schedule is given after certain interval for quality evaluation by QC;
- Material requisition is placed by Production Department along with batch manufacturing procedure of the product;
- Materials are collected as per bill of material and sent to Production for dispensing;
- Purity, temperature, humidity and other conditions of the materials are checked by Production and Quality Assurance (QA) ; and
- Materials are weighted and dispensed to Production as per requisition.



Process

- OPL has 7 (seven) dosage forms - tablet, capsule, dry syrup, oral liquid, cream and ointment, injection and hand rub. Manufacturing procedure of each dosage form is different and has a SOP;
- Rooms and machines are fully cleaned and prepared for production;
- Medicinal product is processed according to validated SOP. The production operator and officer follow the written SOP and keep record of all their activities;
- The in-process quality is checked by the QA at every step of the manufacturing and quality is ensured in every step;
- After completion of every sub process, sample analysis is performed by the QA and sent to QC for evaluation;
- Upon approval by QC, QA fixes the pass label on the container and gives approval for next steps; and
- The prerequisite environment and regulatory condition of the products are maintained and ensured by the QA and Production at every level.



Output

- After packaging of products, all documents are reviewed by the QA Head and approved for distribution and sales;
- Representative samples from every batch are kept by the QA up to the shelf-life of the product for monitoring;
- 'Real time stability study' up to the shelf life is performed by the QA for further development; and
- When launching new products, product development and 'accelerated and real time stability study' is performed by the R&D.

Ensuring quality

Our journey for maintaining better quality begins from raw material selection process. Selecting DMF grade material from European or Asian best source and performing Vendor Audit accurately aid us to ensure best quality raw material sourcing. Proper study, engagement and dedication of qualified personnel result in unique formulations that make the product incomparable regarding quality. This year we have taken the following measures to further ensure quality of our medicines:

Particle Size Analyzer of APIs

OPL's Quality Control Department has procured a sophisticated equipment - particle size analyzer, which measures particle size of Active Pharmaceutical Ingredients (APIs). It enhances the product quality through measurement of particle size of API and delivers the consistently accurate, robust, reliable data that informs critical decision-making throughout R&D and manufacturing processes. Such knowledge-driven decisions are fundamental to ensuring the quality and performance of a diverse range of raw materials, intermediates and final products.

Impurity Profile Checking of APIs

This year OPL has also already started the Impurity Profile Checking of APIs which will ensure the API quality precisely by

acquiring the data that establishes biological safety and efficacy. APIs present in the formulations contain some undesired impurity and impurity profiling describes the account or description of maximum possible types of identified or unidentified impurities present in any APIs. These impurities can be API related impurities, process related impurities or stability related impurities. Presence of these unwanted impurities may influence bioavailability, safety and efficacy of APIs. This new initiative of the company is in compliance with various regulatory authorities such as ICH, USFDA etc. that have specified various limits for impurities in APIs.

Audit Trail

Another initiative undertaken by OPL is the implementation of Audit Trail in compliance with WHO, USFDA, PICS etc. Audit Trail helps to improve the product quality by creating the ability to follow records back to data origin that provides numerous benefits including transparency and a defense of records for compliance, record integrity and accuracy, system protection from misuse or harm, and security of sensitive or vital information.

Other than these we undertake the following processes to ensure quality of our medicines:

Analytical method validation	Analytical method validation ensures the ability of testing method to identify & quantify the active ingredients accurately.	KPI: Our all analytical method for testing raw material and finished products are VALIDATED.
Cleaning validation	It assures that a cleaning process removes all residues of the active pharmaceutical ingredients from every contact parts of equipment used for manufacturing of the product.	KPI: Our all cleaning methods for equipment are VALIDATED. Therefore, there is no risk of cross contamination during product manufacturing.
Dissolution profile comparison	This test is performed in order to compare the dissolution profile of the product with innovator product.	KPI: During product development we compare our developed product with Patent / Brand product.
DMF preparation	DMF preparation is a part of Good Documentation Practice & regulatory requirement from DGDA. It contains confidential detailed information about facilities, processes, or materials used in the manufacturing, processing, packaging and storing.	KPI: We prepare DMF for all products.
Annual product review	The purpose of this review is to verify the consistency of the manufacturing process, assess trends, determine the needs for changes in specifications, production, manufacturing and/or control procedures and evaluate the needs for revalidation.	KPI: We prepare annual product review for all products.
Coating conversion from organic to aqueous	Aqueous coating assures avoidance of related health hazard problem as well as cost reduction.	KPI: We have identified 10 (ten) products subject for conversion from organic to aqueous.

Fire, water & air management system

Fire management system

OPL uses intelligent addressable fire detection system. Fire drills are done once in every six months and training is provided to the personnel who are the member of the fire team. Our actions in this context are:

- All the areas including production, QA, QC, R&D, warehouse, and utility areas are covered by smoke detectors and modern fire alarm system;
- The whole facility is equipped with adequate number of fire extinguishers and fire hoses with fire hydrant. We also have proper evacuation system, assembly point with dedicated rescue and first aid team;
- In addition to the use of smoke detectors, manual Pull Station has been installed in each zone along with annunciation. It is integrated with BMS so that in case of fire, respective area air handling system is automatically shut down in order to control the oxygen supply to the area; and
- High pressure fire pumps along with standby pump and jokey pumps are installed to fight against fire.

Water management system

OPL is committed and constantly working on improving the water management of the company and plant as conserving water will contribute to more sustainable water availability. Our actions in this context are:

- Our plant is fully validated from Europe; and
- We have the most modern pre-treatment & softened water plant.

Air management system

OPL has the right air management technology installed in all buildings as pharmaceutical manufacturing facilities require high quality of air because the products are ingested or placed in humans and animals. Our actions in this context are:

- Individual air handing system with HEPA filter;
- Precise temperature control system by software;
- Precise humidity control system by software;
- Precise pressure difference control system by software; and
- For critical product through Bag-In and Bag-Out system.

Environment, health & safety consideration

Environment consideration

OPL gives utmost importance to environmental protection and strictly avoid the activities which may have any adverse impact on the environment. We believe that environmental protection should be implemented due to climate changes and natural calamities which affect our country every year. We have therefore designed the production process in the most resource and energy-efficient way as possible. Our actions in this context are:

- We established an Effluent Treatment Plant (ETP) of Capacity 375,000 Liters/day to treat the effluent from the plant; and
- OPL has introduced an Incinerator whose incineration capacity is 100 kg/hr. An incinerator is generally defined as any furnace used in the process of burning solid waste for the purpose of reducing the volume of the waste by removing combustible materials.



Details on steps undertaken by OPL for environmental protection is disclosed on pages 196-202

OPL Annual Report 2019-20

Health & safety consideration

The plant has been designed following the modern concept of safety guidelines. Safety and security department coordinates and trains up manpower for precautions and measurements of hazardous condition. A Standard Operating Procedure (SOP) on safety guidelines is followed by each and every person in the plant. We make regular safety assessments and ensure compliance with all existing laws in the field of environmental protection, hygiene and safety at work. We also have adequate risk control measures which are maintained throughout our company. A special care and training is planned for the safe handling of Hazardous chemical.



Details on steps undertaken by OPL for employee safety is disclosed on pages 169 & 174-175

OPL Annual Report 2019-20

Intellectual capital

Focus on intellectual capital to derive at better outcomes for our customers by investing in the knowledge, skills, experiences, expertise and competencies nurtured by the human resources of the company is our topmost priority. We continually work to develop a wide range basket of high quality, safe and effective generic pharmaceutical medicines of different therapeutic classes that address the medical needs of the society.

Sources of intellectual capital

The main sources of intellectual capital are:

- Intellectual property rights including –
 - License from DGDA to operate pharmaceutical products' manufacturing facilities
 - trademarks and registered marks;
- In house software development;
- Research strategy and implementation;
- Product development;
- Portfolio of products; and
- International market specific sales, distribution and marketing strategies.



Outcomes in 2019-20

9

new products successfully launched

2

new international markets were realized – Yemen and Kosovo

42

brands were recognized as flagship brands

80

products in pipeline under various development stages

'0'

adverse events reported under pharmacovigilance ensuring
best quality of product

No 'high patient risk'

complaint was received from customers

14

software and application developed by in-house software
engineer team

Our product portfolio

Our product portfolio is selected and tailored considering the requirements of the target markets in which we operate. We also perform continuous assessment of existing product portfolio to analyze product wise performance in the market it serves. Our portfolios are:



Portfolio	Description	Our strength
Antibiotic	Antibiotics fight against infections caused by bacteria and are prescribed to recover from critical infections/life threatening conditions of patients. Antibiotic portfolio is one of the major portfolios of OPL, having diversified products from different therapeutic groups like Cephalosporins, Macrolides, Fluoroquinolones and Carbapenems with all necessary dosage forms to cover patients of all age group.	We are enriched in Oral Cephalosporins with brands like Truso, Co-axet, Axet, Cefditor, Torped, Sefin, Xclor, Pedicef etc. Our strong footprints in institutions and hospitals are covered by Cephalosporin and Carbapenem Injectables like Vertex, Magnova, Zidim, Meromax. We have strength in Macrolides, Tetracycline and Flouroquinolones as well with Azalid, Xindal, Oriodox, Maximox, Maprocin, Orlev and Xemi. Our antibiotics always maintain all the cGMP guidelines with world class raw materials from different renowned sources and are committed to bringing the excellence to serve the people with highest quality products.
Antiviral	Antiviral drugs are a class of medication used for treating viral infections. For most viral infections, treatments can only help with symptoms while we wait for our immune system to fight off the virus. Antibiotics do not work for viral infections. So only the viral drugs can help us to fight against viral infections like Dengue fever, Covid-19, SARS, Zika, HIV, Hepatitis, Polio, Ebola, Influenza, etc.	We have high quality antiviral products like Fravir which is a tablet preparation of Favipiravir. In 2014, Favipiravir was approved in Japan to treat cases of influenza that were unresponsive to conventional treatment. Given its efficacy at targeting several strains of influenza, it has been investigated in other countries to treat novel viruses including Ebola and most recently, Covid-19.

Portfolio	Description	Our strength
<p>Antiprotozoal</p>	<p>Protozoan infections are responsible for diseases that affect many different types of organisms, including plants, animals, and some marine life. Many of the most prevalent and deadly human diseases are caused by a protozoan infection, including African sleeping sickness, amoebic dysentery, and malaria. Diarrheal disease continues to be a major cause of childhood mortality and morbidity in developing countries. Regions of Southeast Asia, including Bangladesh, experienced the highest mortality rate among children with diarrhea. Antiprotozoal agents are a class of pharmaceuticals used in treatment of protozoan infection.</p>	<p>We strongly believe that we can make a difference in the health sector of Bangladesh with our pharmaceutical products from the finest manufacturing facility of OPL. So we ensure quality brands to fight against protozoan infections in every corner of the country. Our antiprotozoal portfolio includes several brands like Zoana, Nidazyl, Oxiquin etc. are the symbol of trust and satisfactions.</p>
<p>Anti-ulcerant</p>	<p>This class of drugs is used to treat ulcers in the stomach and the upper part of the small intestine. There are several types of anti-ulcerant drugs like the proton pump inhibitors which work by blocking the secretion of gastric acid of parietal cells of stomach; H2 receptor blockers stop the action of histamine on the gastric parietal cells which ultimately inhibits the secretion of gastric acid; non systemic antacids provide local acid neutralizing effect and anti-foaming agents are used to reduce bloating, discomfort or pain caused by formation of excessive gas in stomach.</p>	<p>We are strongly focusing on this area having one of the unique brands in Eesomeprazole market- Exor, which is serving people of Bangladesh with immense pride of quality. OPL also manufacturers several other strong anti-ulcerant brands like Procap, Novelta, Marvelta, Pedicon etc.</p>
<p>Laxative</p>	<p>Constipation is a condition which occurs when the movements of bowel become less frequent and stools become difficult to pass. It happens most often due to changes in diet or routine, or due to inadequate intake of fiber. Laxatives or purgatives are substances that loosen stools and increase bowel movements. They are used to treat and prevent constipation.</p>	<p>We have a wide variety of laxative drugs to treat and prevent constipation, OPL offers brands like Milk of Magnesia, Ezyllax etc. to the market with excellent laxative properties.</p>
<p>Antiemetic</p>	<p>Antiemetic drugs are effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anesthetics, and chemotherapy directed against cancer.</p>	<p>We have a wide variety of antiemetic products available in different pharmaceutical dosage forms suitable for patients with all ages. Our most prominent brands in this portfolio include Onasia, Palostar, Cosy (Prokinetic), Anvert etc.</p>

Portfolio	Description	Our strength
CVS	Cardiovascular disease occurs as a result of sedentary life style, unhealthy food habit, lack of physical activity or by heredity. Cardiovascular disease is considered as life threatening as it may lead to stroke, myocardial infarction and ischemia, if not appropriately treated.	We treat CVS through our cardiovascular portfolio which includes Frulac (Diuretics), Clognil, Clognil Plus (Anticoagulants), Losan, Olmesafe-20, Olmesafe-AM, Olmesafe-HT, Betacal, Bisoloc, CCB (Antihypertensive), Angimet, Angimet MR (Antianginal), Rovex, Lipex, Fenocap (Lipid Lowering Agents) etc.
Anti-fibrinolytic	Fibrinolysis is a process that prevents blood clots from growing and becoming problematic. Antifibrinolytics are medicines that promote blood clotting by preventing or slowing down a process called fibrinolysis, which is the breakdown of blood clots. Antifibrinolytic agents may be used to help prevent or treat serious bleeding in patients who have certain conditions, such as hemophilia, very heavy menstrual bleeding, or some types of vascular tumors.	We offer Oranex to treat haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis that may occur in conditions like Prostatectomy and bladder surgery, Menorrhagia, Epistaxis, Conisation of the cervix, Management of dental extraction in patients with coagulopathies, Ulcerative colitis, Haematuria, Gastrointestinal haemorrhage.
Antidiabetic	Diabetes is a disease in which the blood glucose, or blood sugar, levels are too high. Diabetes can lead to several disabling and life-threatening complications, including stroke, heart attack, chronic kidney diseases, neuropathy, visual impairment and amputations. In recent years, the burden of diabetes has increased worldwide with disproportionately high morbidity and mortality in developing countries. Bangladesh is one of the countries with the highest number of people with diabetes worldwide.	We have different class of antidiabetic drugs trusted by the top diabetologists in the country. Our antidiabetic portfolio includes Linastar, Linastar M, Oclazid, Oclazid MR, Ormin, Stimulin etc.
Anticancer	Cancer is a group of disease complications which are commonly characterized by the uncontrolled growth and proliferation of cells, resulting in death. Cancer is a growing concern for the healthcare system in the world. It is the second leading cause of death globally and in Bangladesh, there are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newly diagnosed with cancer each year. So, with the growth of cancer patients in Bangladesh, the demand of oncology products is also growing rapidly.	We offer Enliven which is very effective against leukemia, myelodysplastic or myeloproliferative diseases, metastatic dermatofibrosarcoma, metastatic malignant gastrointestinal stromal tumors and many more. We are also planning expand our anticancer portfolio with a total of 52 products of different dosage forms which includes tablet, capsule, vial, pre-filled syringe and lyophilized powder.

Portfolio	Description	Our strength
CNS	Central Nervous System consists of the brain and spinal cord which is responsible for processing and controlling most of our body functions. Different types of medicines are used to treat dysfunction of CNS, including Anticonvulsants (used in the treatment of epileptic seizures), Anxiolytics (used to treat anxiety and panic disorder), antidepressants (treat depression e.g. SSRIs, SNRIs, atypical antidepressants, tricyclic antidepressants) etc.	We have presence in different segments of CNS related medicines carrying strong image among Neurologists and Psychiatrist having successful brands like Rivo, Timex, U4, Xil, Nervex, Nugesic, Bromazep etc. We are going to expand our presence in other areas of CNS like Antiparkinson etc. in near future.
Respiratory	Respiratory diseases are chronic problems and one of the major factors affecting health sector of Bangladesh. Antihistamines are drugs mainly used for treating allergies related to airways. Histamine attaches to specific receptors of body cells which results in symptoms such as runny nose, watery eyes, itching, redness, coughing and wheezing.	We have the flagship pioneer brand Deslor (Desloratadine) which is leading the market since its inception in Bangladesh from 2002. To reduce these symptoms there are other strong antihistamine brands include Rupenta, Nosedex, Riz, Broket, Cloramin, Orsal etc. We also offer Ambronil (Cough expectorants) and Deconil (Cough suppressant) to fight against cough (productive and non-productive) and common cold. We also have Axofyl to treat Asthma and COPD and Arovent to treat both Asthma and Allergic Rhinitis and we are supporting Respiratory Medicine Doctors with highest quality products for their patients.
Vitamin - Minerals and Hematinic	Vitamin-Minerals are considered as essential nutrients which perform hundreds of roles in the body. They help in the growth of the body, shore up bones, heal wounds and boosts immune system of the body. Also, they convert food into energy and repairs cellular damage. Major source of Vitamin-Minerals are fruits and vegetables. But in a country like Bangladesh, daily food habit of many people fails to maintain the daily requirement of Vitamin-Minerals for the body and is causing an ultimate need of Vitamin-Mineral supplemental medicines. Hematinics are nutrient required for the formation of blood cells in the process of hematopoiesis. The main Hematinics are Iron, B12 and folate. Deficiency in Hematinics can lead to anemia.	We have a basket full of different Vitamin-Minerals and Hematinic preparations like Calcium, Iron sucrose, Zinc, Iron, Folic acid etc. Our focus is mainly on nutritional deficiency during different age group and during pregnancy. This portfolio includes some of Orion's most well-known brands like Pep, Maxical, Ferrolin, Feroven, ESP, EC-Plus, Orioplex, Gold Kid, Goldage, Silvage, Newage, Combivit etc.
Pain management	Pain is a distressed feeling often caused by intense or damaging stimuli and one of the most common reasons for consulting physician in Bangladesh. Pain is complex, can interfere with a	We support patients with a broad range of treatment options that are indicated for the relief and maintenance of different types of pain like for mild pain and headache. We have Fevac

Portfolio	Description	Our strength
Pain management (Contd.)	person's quality of life and general functioning. This class of medicine is used for relief and maintenance of pain.	and Hedex, for moderate to severe postoperative pain management we have Ketorin and Novodol, for arthritic pain management we have Tendonil, Tenorix, Noak, Novoxen, Eroflam and Orfenac. For Muscle relaxants we have Baclon and Eprel and for Spasmodic pain relievers we have Onium and Alve etc.
Dermatological	Medicines used to treat skin conditions include topical and oral drugs for the treatment of a wide variety of diseases of the skin, hair and nails. This market is progressing with high potential and skin diseases account for a higher proportion of outpatient department in developing countries including Bangladesh. Infective skin diseases mostly bacterial and parasitic is predominant in Bangladesh though it is less frequent in developed countries.	We have image carrying products like Avison, Miki-H which are used to treat different types of skin infections effectively. There are other products like Xzema and Xenocort, used in managing critical skin diseases like Eczema and Psoriasis. With high potency and quality, these products are providing excellent results to patients and customers.
Antifungal	Antifungal medications or antimycotic medications are pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis (thrush), serious systemic infections such as cryptococcal meningitis, and others. Over one billion people in Bangladesh are believed to suffer from a fungal infection annually. These increasing number of fungal infected patients contributing a distinguishable progression on antifungal drug market in Bangladesh.	We have a separate manufacturing area only focusing on the preparation of antiviral products to fulfil the market demands. We have wide range of both topical and oral products for the treatment of fungal infections. Our oral antifungal brands like Conaz, Terbiderm, etc. have always been the reliable options for doctors while treating patients with fungal infections.
Antimicrobial	Antimicrobial products kill or slow the spread of microorganisms. Microorganisms include bacteria, viruses, protozoans, and fungi such as mold and mildew. Disinfectants are chemical agents designed to inactivate or destroy microorganisms. Sanitizers are substances that simultaneously clean and disinfect. In recent pandemic situation, Centers for Disease Control and Prevention (CDC) recommends consumers use an alcohol-based hand sanitizer that contains at least 60% alcohol to avoid microbial contamination.	We have brought into the market Hexion which is preparation of 0.5% Chlorhexidine Gluconate in 70% Isopropyl alcohol. Hexion is a brand of trust and quality available for everyone with a very affordable price in all over the country.

Portfolio	Description	Our strength
Other	<p>There are so many drugs we have outside of above-mentioned portfolios. Muscle relaxants are drugs that affect skeletal muscle function and decrease the muscle tone. They may be used to alleviate symptoms such as muscle spasms, pain, and hyperreflexia. Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. Osteoporosis is a bone disease that occurs when the body loses too much bone, makes too little bone, or both. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps. Around the world, 1 in 3 women and 1 in 5 men aged fifty years and over are at risk of an osteoporotic fracture. In fact, an osteoporotic fracture is estimated to occur every 3 seconds. The most common fractures associated with osteoporosis occur at the hip, spine and wrist.</p>	<p>We offer Tamlosin which is a brand of Tamsulosin HCL and is indicated for the treatment of the signs and symptoms of Benign Prostatic Hyperplasia (BPH). It is an antagonist of α1A-adrenoreceptors in the prostate. It binds selectively and competitively to postsynaptic α1A-adrenoreceptors, which convey smooth muscle contraction, thereby relaxing prostatic and urethral smooth muscle. Boncare is brand of Ibandronic Acid is used in the treatment and prevention of osteoporosis in men and women. It inhibits osteoclast activity and reduces bone resorption and turnover leading to a progressive gain in bone mass. We are also continuously adding new products to our portfolios and reaching the uncovered therapeutic areas. Also we are developing and introducing our existing brands to the latest available technologies to maintain highest product quality and ensuring the customer satisfactions by providing quality products and services.</p>

New products launched

In November 2019, OPL introduced a new product in antifungal portfolio to fight against recurrent fungal infection, under brand name Terbiderm. It belongs to the Terbinafine Group. There is 1 (one) product in the Terbiderm family:

Terbiderm
Terbinafine 250 mg



In June 2020, OPL introduced a new product in antidiabetic drugs portfolio to treat Type 2 diabetes mellitus, under the brand name Linastar. It belongs to the Linagliptin Group. There are 3 (three) products in the Linastar family:

Linastar-S
Linagliptin INN 5 mg

Linastar-M 2.5/500
Linagliptin INN 2.5 mg &
Metformin HCl BP 500 mg

Linastar-M 2.5/850
Linagliptin INN 2.5 mg &
Metformin HCl BP 850 mg



New Products launched in the face of Covid-19 pandemic

In March 2020, OPL introduced a new ethanol-based hand sanitizer inactivating the corona virus or removing it from the skin surface in Hand Rub Preparations portfolio, under brand name Hexion. It is a combination of Chlorhexidine Gluconate and Isopropyl alcohol. There are 2 (two) products in the Hexion family:

Hexion Hand Rub

Hexion 50 ml & 250 ml



In April 2020, OPL introduced a new product in Anti-malarial Drugs portfolio under brand name Oxiquin, to fight against corona virus as it showed evidences of safety and effectivity against Covid-19. It belongs to the Hydroxychloroquine Group. There are 2 (two) products in the Oxiquin family:

Oxiquin 200 Hydroxychloroquine Sulfate USP 200 mg

Oxiquin 400 Hydroxychloroquine Sulfate USP 400 mg



In April 2020, OPL introduced a new product in Anti-viral Drugs portfolio under brand name Fravir, to fight against corona virus as it showed evidences of safety and effectivity against Covid-19. It belongs to the Favipiravir Group. There is 1 (one) product in the Fravir family:

Fravir Favipiravir INN 200 mg




2 (two) new international markets – Kosovo & Yemen

During the reporting year, OPL started exporting to 2 (two) new countries - Yemen and Kosovo. Since August 2019 medicines of the CNS and Vitamin - Minerals and Hematinic portfolio are being exported to Kosovo. Moreover, since May 2020 medicines of the Antibiotic, Cardiovascular and Vitamin - Minerals and Hematinic portfolio are being exported to Yemen.

Flagship products

Another category of measuring the key performance of our intellectual capital is the number of flagship products. This shows our competitive advantage through our product strategy. As on June 30, 2020, we have recognized 42 brands among 104 brands as our flagship brands. These brands are the most advanced products in the line that OPL offers the people of Bangladesh.



Development of products

Research and Development (R&D) Department is one of the vital parts of a pharmaceutical plant. R&D is a key of innovation and is situated at the front end of the innovation life cycle. Research and development of products under different therapeutic areas are supported by the current portfolio, medical need, plant capabilities and product viabilities.

We have built up a sophisticated R&D center equipped with state-of-the-art equipment and facilities in the Orion Pharma Park at Siddhirganj, Narayanganj. In our R&D center, we also have a separate galenical and analytical laboratory. Our galenical laboratory is equipped with all the necessary machinery and equipment of GMP standard in small scale to develop products.

Our R&D team is fully dedicated to improving the existing product quality by applying research in the area of pharmaceutical product development. In its essence, developing new products are the ongoing jobs of this department. Their adequate knowledge and the concept of implementation helps to design future development and span the development of differentiated products, such as lyophilized injections, nasal sprays, oncology, hormone and ophthalmic products.

The strategies of R&D team for the development of new products focus on:

- Providing the best formulation ensuring with the maximum product stability;

- **1st time manufactured in Bangladesh**
 8 (eight) brands under their generics are the first-to-market products of OPL which are first time manufactured in Bangladesh.
 Pep Alve Frulac Tendonil Deslor Cefditor EC Plus Novelta
- **1st time manufactured by a local company in Bangladesh**
 2 (two) brands under their generics are the first-to-market products of OPL which are first time manufactured by a local company in Bangladesh.
 Nervex Onium
- **Products under pipeline**
 Currently, the company's pipeline contains over 50 (fifty) products in various stages of development. More than 30 (thirty) products have already been developed.

- Delivering an improved formulation with greater patient acceptability;
- Minimizing the product cost ;
- Designing eco-friendly formulation;
- Maximizing the productivity; and
- Facilitating the manufacturing process.

OUR CAPITALS > Intellectual capital

Over the years, we have developed expertise; gathered experience in chemistry, analytical techniques, and dosage forms and our research strategy and implementation are well supported by these expertise and experiences. The proof behind this is that there are various products we developed for the 1st time in Bangladesh and quite a few that are for the 1st time by any local medicine manufacturer.

Developed and registered products in the pipeline are the intellectual property of the company. The company continues to invest in its pipeline of generic products. Given the prospective future of medicinal needs and emerging diseases profiles, our product pipeline mainly represents the opportunities related to product line extension and new brand launching within and across targeted markets. The pipeline is continuously being monitored and analyzed for technical feasibility, to ensure only commercially feasible products are included and to make it aligned with the company's strategic objectives with a stronger focus on some products that offer significant return in value.

Patient safety ensured by reporting of '0' adverse effects

Pharmacovigilance (PV) activities are related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. The main goal is to ensure and promote public health through continuous monitoring of the safety data of all medicines that are marketed, ensuring the patient's right for safe, qualitative and effective medicines. To monitor & manage PV activity and to inform the regulatory authority (DGDA), every pharmaceutical company should have a key person who will be responsible for collecting the data of any type of adverse events and the concerned person should have contact number so that physicians/other healthcare professionals/patients /field forces may contact at any time to inform about adverse events.

Orion Pharma Limited always works for patient safety and is satisfactorily managing PV activities for all types of medicines. The pharmacovigilance team of OPL is responsible for monitoring and managing the safety of all medicines of the company. Head of Quality Assurance is responsible to check the product quality if any Adverse Event is reported and provides technical supports, Adverse Event report to regulatory department for submission to DGDA. During collection of information regarding suspected adverse events, the data are collected very carefully and information must be authentic and reliable. It is a basic need to prepare the report

by following the WHO Good Manufacturing Guidelines and DGDA Guidelines which ultimately ensures rational and safe use of medicines.

As a part of our product management process throughout its life cycle and adoption of best practices, we provide all comprehensive up-to-date safety information through the required channels to ensure our product safety information is available to the end customer or consumer. All clinical trials are under close monitoring for compliance to enhance and support our product safety information. During the reporting period, patient safety was ensured by reporting of '0' adverse effects.




Product safety, performance & quality

Patient safety is of utmost priority at OPL and we ensure that a zero-defect approach in respect of delivering quality products is adopted here. It is very crucial to understand product's safety profile including its quality and performance. We admit that responsible manufacturing and supply of medicines in accordance with the applicable regulations, and guidelines is our commitment and within the scope of our accountability towards the patients population through improving their quality of health. Stringent compliance processes are being applied and ensured throughout the supply chain management systems. We procure raw materials and packaging materials from the qualified and authorized suppliers who meet the necessary quality, regulatory as well as company's requirement.

We manufacture medicines at our own plant which is in compliance with good manufacturing practices (GMP). The quality assurance and quality control departments are responsible to ensure that only quality products which meet

the standards are released and get clearance to sale in the market. The products are constantly under monitoring throughout their self-life to confirm their quality and efficacy.

Only 1 (one) product complaint was received during the reporting year. It did not pose a high patient risk and was managed as per our standard operating procedure (SOP) on customer complaints.



Orion Pharma's popular hand sanitizer brand **Hexion** has met the WHO quality requirement. Recently, Bangladesh Council of Scientific and Industrial Research (BCSIR) has conducted a study where they have found 70% alcohol in **Hexion**.

Use **Hexion** to clean your hands and keep them COVID free.



Harmful
Methanol
Free

Hexion
Hand Rub

EP & BP Grade
Certified Disinfectant

অন্যথার্থে:



In Search of Excellence


*European Pharmacopoeia (EP)

*British Pharmacopoeia (BP)



*tbnnews.net

14 in-house software & application developed

Our IT department has developed software and applications along with updating the existing ones to simplify the day to day official tasks and strengthen the technological base of the company. OPL's highly skilled internal software engineers have developed many effective and useful software, applications with the objectives to ease carrying out, monitoring and reporting the day to day operational activities. Apart from purchasing software from vendors, as on the reporting date, there are 14 (fourteen) software developed by our in-house software engineering team as per the operational requirements of different departments.



Orion Online Solutions

 <p>MIS System Online Management Information Solution</p>	 <p>Fund Requisition Online Fund Management System</p>	 <p>e-Bill Process Online Bill Process System</p>	 <p>Empress HR Payroll</p>	 <p>Orion PMH (Web) Prescription from Mind to Heart</p>	 <p>Orion Gas Online Sales and Distribution System</p>
 <p>Steps ERP Material Management System</p>	 <p>Vehicle System Online vehicle management system</p>	 <p>4P & Self Target Orion Pharma Sell Target & Sales Monitor</p>	 <p>Orion SCM Orion Supply Chain Management</p>	 <p>Orion Scholar Medical Student Scholarship Program</p>	 <p>Steps ERP Material Management System (Outside)</p>

Human capital

Our employees are the foundation of our success. We are committed to providing an open, safe, diverse and inclusive work environment for each of our employees and offering competitive rewards to boost their productivity and job satisfaction.

Sources of human capital

Human capital is the employees' competencies, capabilities, skills and experiences and their motivations to innovate that the company utilizes to further its goals. The underlying principles which are the values and the code of conducts of the company are the fundamentals to foster this capital. The main sources of human capital are:

- Employee knowledge, expertise, skill and integrity;
- Training and skill development program;
- Employee engagement;
- Employee relations;
- Talent management; and
- Succession planning.

Ensuring an overall positive work environment through Employee Value Proposition (EVP)

We recognize that the employees are entitled to a good environment to work in and this is the most crucial factor in employee satisfaction. By encouraging and promoting a healthy and supportive work environment aligned to our organizational culture, we can improve productivity, business performance, employee morale and engagement.

All the activities we carry out, benefits we offer to our employees are by taking into consideration of the labor law and other relevant laws of the land. We strive to make our workplace environment and condition more conducive to optimizing employee potential, and to improving our long-term goals. The adoption of human resources strategy is underpinned by the theme of Employee Value Proposition (EVP).

Objectives of EVP



Valuing equality and diversity



Attracting people and developing talent



Providing rewards and recognition



Confirming employee engagement



Ensuring employee health and safety



Respecting human rights



Handling employee grievance



Supporting employee wellbeing



Improving employee relation



Managing succession planning



Outcomes in 2019-20

368

employees received training

6

deceased employees' families have been benefited under the scheme "Donation on Death"

646

employees purchased the medicines at a discounted price

157

employees got promotion in January 2020

100%

of OPL's workforce received regular yearly performance appraisal

Tours and picnic

arranged for employees

Employee wellness programs

COVID-19 test facility, medicine corner and doctor's chamber for employees






Employee diversity and equal opportunity

OPL strives to build an organization which reflects the diverse talents of a wide range of employees with different characteristics and also to establish equal employee opportunity for its valued employees. OPL has an equal and diverse workplace free from gender, age or race discrimination, hostility, and any kind of harassment with respect to religion, sexual orientation or minority.

The attraction, retention and development of employees remains equal for all qualified persons regardless of their religion, race or gender. The promotion is also based on the performance of the employee. Nepotism and lobbying both are strictly prohibited in case of choosing or promoting employees. Therefore, career development is equally open for all employees and OPL values and rewards the positive contribution of the employees' regardless the gender, position or designation.


Embracing diversity and inclusion in workplace and incorporating it into overall corporate culture helps stimulate in different ways of thinking and accumulate different knowledge together which expands scope of innovation and results in opportunities. Different people from different culture, background, gender and age are working under the same roof. So the outcome from their work is more vivid and accurate as the work is stimulated from different angle.

We believe that gender equality means the access and enjoyment of the same rewards, resources and opportunities regardless of gender. We also focus on creating an inclusive culture and workplace ensuring that all the employees including the female employees are given the best opportunity to succeed. In case of female participation in Board, 43% members are female. However female employees compared to the total number of employees are very low, but we are working towards bringing a positive change in female workforce participation through prioritization of female employee recruitment and development.






Board diversity: Gender



Diversity: Religion



Employee turnover



New employees



Intern



Building better employment process


Good human resources are one of the key indicators to success and hence the company assures maintaining the standard in hiring whatever the position is. Fair employment practices play a pivotal role and is the key to build a better future through strengthening our ability to identify and attract the right person with the right educational requirement, experience, skill and cultural fit.

A thorough routine process is performed in the selection and interview stages to make sure that the prospective candidates are as close a match as possible to the job requirements and are aligned with the company's mission, vision and values. Our employment policy is set to assure a clear and comprehensive

procedure in the steps involved in employment that ensure transparent and improved internal controls.

During the year, we continued redesigning the company's as well as the departmental organogram, designing policy to set a central reference of matters that would regulate and govern the hiring procedures. All these will form the base of our new policies to ensure a standard approach to offer equal or more favorable employment condition for our employees.

Employment procedures



Training & leadership development

Developing our employees and giving them opportunities to grow are the key focus areas for us. The basis of development of employees is to understand their true needs. All employee trainings and development programs are aligned with the company's strategic and operational needs. We invest continuously in our employees to help them thrive through ongoing learning and development to improve professional and leadership skills. We require employees to be adaptable, self-motivated, result-driven, decisive and responsive. We ensure that all employees are provided with equal opportunities for career advancement and development.

All the departmental and / or divisional heads are responsible to identify each employee's skill development needs through Training Need Assessment (TNA) and for the implementation of effective training program to address those needs with the support of human resources department. Our human resources development strategies evolve with the plans and progresses for individual employee development focusing on the sustainable growth as a whole for the organization.

Training and development schemes across the organization have included internal training programs, management and leadership development programs and job specific training programs. In total 368 employees (In 2018-19: 897 employees) were exposed to various trainings during the reporting financial year.

Orion Pharma Limited has training department which is assigned with the responsibilities of arranging in-house trainings including sales people training, induction and orientation to focus on developing and enhancing the functional capacity of our employees to do their work better.

In-house training

In-house training programs are led by the company itself and are being organized for facilitation of learning for employees. The senior management employees, expert / professional employees conduct such training program under the direct supervision of training department. During the reporting financial year, 368 employees (In 2018-19: 728 employees) attended various in-house training and skill development programs. These programs included-

- Induction and orientation; and
- Field force training.

External training / workshop

In order to enhance the particular skills and abilities of the employees, external training is provided by external consultants, specialists or organizations at different institutes or locations.

During the year, one of the work areas that most adversely affected is employee learning and development due to the outset of the Covid-19 pandemic. Our office was closed for almost 3 (three) months and even after resuming the office, our primary and major concern was to ensure the safety of employees. Therefore, both the number of training programs undertaken and the number of employees trained is significantly low in the reporting financial year.



The Managing Director speaking in a training session



Remuneration & benefits

As we emphasize on sustainability, the remuneration system focuses on attracting and retaining employees. The remuneration system is designed and reviewed from time to time so that it stands a motivating factor for them as well as it supports the performance-based thrust of the human resources. We ensure each and every employee's right to get paid the right amount at the right time.

Our remuneration structure for salaried employees (including the Executive Directors) contains fixed or guaranteed remuneration and incentive remuneration. Moreover, different types of benefits, not a part of remuneration policy, are provided to employees with a view to fostering positive work culture at OPL.

Remuneration- Fixed & incentive pay

The guaranteed or the fixed pay is the main part of employees' remuneration which is paid on monthly basis. The incentive pays include periodical or timed and long term incentives. These fixed or guaranteed pay and incentive pays are as follows:

- Regular guaranteed pay is the employee's monthly gross salary including the base salary plus different kinds of allowances.
- Periodical incentive pays include 2 (two) festival bonuses, 1 (one) performance bonus, annual increment and leave encashment or Leave Fare Assistance (LFA). The increment of employees solely depends on their performance. The review of remuneration is conducted on an annual basis and any resultant increase is effective from January of each year.
- Long term incentive pays are contributory provident fund, gratuity, workers' profit participation fund and term life insurance.

Because of the professional or legal requirements, some additional allowances are paid to the employees in addition to their regular guaranteed pay. These kinds of allowances (not limited to the following) are:

- Special allowance for workers of hazardous areas of plant;
- Retirement allowance;
- Night stay allowance;
- Overtime allowance;
- Field allowance;
- In-charge allowance;
- Risk allowance;
- City allowance;
- Laundry allowance; and
- Transfer allowance.

Work with benefits

(initiatives for enabling employees to display their abilities to the maximum possible extent)



Subsidized lunch facility

Promote a balanced and healthy diet ensuring convenient and nutritional intake.



Subsidized transportation facility

Provide transportation facility for easy and hassle-free commute to and from workplace.



Collaborative workplace

Create collaborative culture through designing an open-office layout.



Termed insurance facility

Offer termed insurance to provide immediate financial support to the insured employees and their families.



Learning & development

Encourage the employees pursuing higher studies to upgrade their qualification and extend co-operation by letting them attend their classes.

Opportunity to perform Holy Hajj & Umrah

Every year the company selects a few employees on lottery basis to send them for performing Holy Hajj and Umrah. Company considers this as social responsibility by making an opportunity for the employees to perform Holy Hajj and Umrah and willingly holds the responsibilities of the entire journey to ensure employees' convenience and satisfaction, fulfilling the purposes peripheral to holy tour. During the financial year 2019-20, we were not able to send any employee to perform Holy Hajj and Umrah as Saudi Arabia has banned international visitors from making the Islamic pilgrimage or Hajj this year in a bid to control coronavirus pandemic.

"Donation on death" benefit

As a part of social responsibility towards employees, the company makes a lump-sum payment as "Donation on death" to the legal heir/heirress or nominee of the deceased employees. In the financial year 2019-20, the company has donated to the families of 6 (six) deceased employees under this benefit scheme.

Medicines at discounted price

Another perk that we offer to our employees is that employees have the opportunity to purchase the company's medicines at a discounted price. Providing discounts on medicines helps employees get more for less. Employees can avail this discount for themselves as well as for their immediate family members. During the reporting financial year, 646 (six hundred forty six) employees purchased medicines at discounted prices.

Employee engagement

At Orion Pharma Limited, we believe that the more an employee feels part of the company, the more likely it is that they are engaged with what they do. Employee engagement is about understanding one's role in an organization, and making that role aligned with the organization's vision and objectives. An engaged employee acts as a member of the team and is very focused on the goals to be achieved.

OPL is always committed to providing a workplace where employees remain motivated and engaged because only engaged and motivated employees are capable of giving their full capability. We try to make our employees engaged so that

they actively participate in our long term goal attainment. It is our responsibility to make them understand about their role and how their involvement is crucial to us and the most vital thing for OPL is that they think of themselves as a part of the company.

The commitment that our people contribute to OPL is essential to our success. We focus on making our people feel strongly connected to the company because it motivates people to put in extra effort for their organization. In this regard, we conduct "Employee Engagement Survey" every year to obtain employee insights and in order to measure progress in creating a great workplace to work. We will continue to ensure that employee engagement and wellbeing are further enhanced in future years.



An employee of OPL receiving Rising Star Award for dedication and hard work

Employees' occupational health & safety


We recognize the importance of a safe and healthy working environment and we are committed to the safety and security of our employees. The prevention of work-related injuries including permanent disabling, occupational diseases, health and safety incident risks, improving productivity by reducing absenteeism etc. are the key focus areas, particularly for factory workers, head office employees and field force.

As we are operating in pharmaceutical industry where quality and compliance is must, control measures are in place throughout the chain to assure safe and compliant handling of all materials and products. Issue based risk assessment are conducted so that we can confirm the consideration and mitigation of all existing and emerging health and safety related risk.

Some of the initiatives (but not limited to) for employees' occupational health and safety are as follows:

Ear plugs / ear muffs	To protect ear from hazardous exposure to high levels of noise
Respirator mask	To protect the operator from very small airborne toxic particles or contaminants
Safety hoods	To protect both the worker and the environment from hazards of biological exposure
Safety helmet/ cap	To protect the head of the operator against hazards, mechanical, thermal and electrical shock
Safety shoe	To protect feet to prevent injuries in the workplace
Safety goggles	To protect eyes during chemical analysis and being contaminated by environmental hazards
Splashes or sprays	To be used for ensuring protection from particles and irritants
Surgical/ cotton and rubber hand gloves	To protect hands as well as products from contamination and cross contamination
Leather hand gloves	To be used during handling hot surface objects
Welding helmet	To protect eyes from spark light during welding of pipelines or any other materials
Face mask or disposable mask	To protect the environment by preventing large particles expelled by the operator to the environment
Emergency eye shower	To be taken during any eye accidental case with chemical in the lab
Emergency shower	To be taken during any body accidental case with chemical in the lab
Fume hood	To handle flammable solvents to remove the hazardous fume from the laboratory
Spillage kits	To be used for the control of spillage of corrosive chemicals in the lab
First aids	To be used in case of emergency treatment of injury (cut, burn etc.)

<p> Work related injuries</p> <p>2019-20 No. of injuries: 18 Lost days due to injuries: 89</p> <p>2018-19 No. of injuries: 3 Lost days due to injuries: 23</p>	<p> Fatalities</p> <p>2019-20 No. of fatalities: 6 Reasons: Health Issue</p> <p>2018-19 No. of fatalities: 4</p>	<p> Productivity</p> <p>2019-20 million pcs per employee</p> <p>2018-19 0.19 million pcs per employee</p>
--	--	---



Glimpse of some safety measures taken inside our manufacturing plant

Employee relation

We are always concerned about the rights and representation of our employees. Our aim is to support our employees to lead a quality of life for themselves and their families and to offer opportunities to make themselves developed for career advancement.

We are trying to entrench a uniform culture and instil company's values throughout the organization and its employees. OPL opts to shift from the cubicle dwelling and goes for a more open-space office, as it fosters a friendlier, more efficient and generally more humane workplace. This shift towards a more open office has promoted a sense of unity and facilitated collaboration between everyone at the

company. Employees now have better understanding among themselves and it also cultivates a sense of community by breaking barriers. As information is distributed evenly throughout a team, this new seating arrangement has also helped to enhance the efficiency of employees.

Our ongoing and interactive monthly management coordination meeting is an internal communication process and is also a management and employee information sharing and engagement platform. These meetings have created a doorway for the management to know about the opinions of the mid-level management and work for their concerns.



Glimpse of active involvement of the Managing Director in various motivational initiatives

Respect for human rights & ethical stance in human resources

We are committed to upholding the human rights, including freedom of opinion and expression. Our code of conduct entrenches the rights of all employees to be treated fairly and with equality and respect. No discrimination of employees on the basis of age, gender, ethnicity etc exist in the workplace. All labor, industrial and legal compliance issues are strictly complied with to uphold employee rights. We stand against child labor and forced labor. There is no child labor working in the company and the company ensures that no child is being hired. All our employees are aged 18 years and above. Moreover, we maintain a work environment where all our staffs and employees work willingly. We engage people with motivation instead of force which gives more productivity and success.

In line with our ethical HR practices, our human resource department always works with the responsibility of adding value to our success and without ethical HR practice the success is not achievable in true sense. The basic human and civil rights are strictly followed in OPL so that no employee deprives of his/her rights. We provide them with proper healthy work place, foods, working hour as per law and prayer time. HR strictly follows the privacy code for the employees. As employees provide their personal information when they are recruited, we keep them private, confidential and safe. Their other information like salary and appraisal is also kept confidential and secured. Our human resource practice is carried out with due respect, fairness and honesty. OPL respects its employees' belief and culture and our relation is based on trust and transparency.

Employee grievance handling

We recognize the failure of an employee not to perform to the best of their ability is mainly caused by the feeling of being treated unfairly or by feeling aggrieved. Therefore, we endeavor to ensure that formal grievance procedures are in place and employees have access to processes for the resolution of genuine grievances related to the workplace. Employees, who feel any kind of dissatisfaction or discontentment arising out of factors related to their job or workplace or even another employee, can raise their concerns directly to the human resources department tasked to look into the resolution of the complaint.

Succession management

It is imperative to adapt to new challenges and objectives and to face stiff competition for talent in order to remain effective. Therefore, effective succession management is a tool that plays a significant role to give the company a competitive edge. Our succession plan is aligned with the company's vision and strategic objectives to ensure the successors get adequate time to make themselves prepared for the next senior roles and responsibilities. Moreover, all the training and development programs is directly linked to develop the leadership standards and professional competencies of the potential successors. 157 number of employees got promotion in January 2020 as a reward of their performance in 2019. Because of all positive responses from employees, OPL is always eager to increase the investment as the outcomes are positive.

Succession of the existing employees is such an aspect where OPL has been investing more and more. The financial and non-financial benefits those are provided to the employees are the part of succession of employees.

OPL's succession planning aims to develop and train its employees with all sorts of skills necessary to enhance the employees capabilities and knowledge so that they are able to implement those in absence of department heads or senior officials especially when they resign/ retire from the company. The leaders are willingly working on grooming their junior colleagues through regular task assignments, corporate trainings and providing them with the opportunities to utilize their skills and learning in various ways.

To make the succession planning more effective, our company conducts performance appraisal on monthly basis for the employees to demonstrate their learning progress and assessing their area of development so that they can be provided with necessary training to develop themselves further. In this way, OPL is able to create a pool of efficient and reliable employees who will serve the company in near future.

Employee wellness

We believe that taking care of the wellness of employees can increase the productivity. We yearn to be a healthy and peaceful organization for the employees. We are always careful that all the health and safety criteria are fulfilled and employees are provided with different aspects of wellness.

Physical wellness

We have adopted the appropriate health and safety compliances so that the employees perform their and give the maximum output. We have a medical team comprising doctors and staffs in the office to provide emergency medical service at any time.

Social wellness

We are concerned for the employees' social wellness, value and status and try our utmost to provide them with such financial and non-financial benefits to cope up with the prevailing social trends.

Spiritual wellness

We are respectful to spiritual value of our employees, their beliefs, religions and religious practices. We provide them with well-furnished prayer place. Our lunch is also maintained by their religious belief and food is prepared keeping that in mind.

Environmental wellness

We understand that neat and clean working environment is a pre-condition for our employees. To maintain healthy and clean working environment all the time, a significant number of cleaners are working to keep the environment healthy and clean.

Occupational wellness

We ensure that our employees are satisfied with their job. We provide them with proper work rest, vacation, reward and promotion so that they feel valued here. We want to retain our employees and give them career wellness accordingly.

Intellectual wellness

We believe that the intellectual employees are the key factor for OPL's growth and success. We maintain flexible work environment where our employees can utilize their talent. Our talent management is caring of employees' intellectual development.

Psychological wellness

We value psychological wellness as it can make both positive and negative vive in employees. Our management takes various initiatives to keep them motivated. We implement different initiatives that positively impact the psychological health and safety of employees.

Financial wellness

We provide the financial benefits keeping the current competitive market in mind. Loans, advances and other benefits are also provided when required. Moreover, the employees' performance is evaluated monthly and financial appraisal is done yearly on the basis of performances.

Initiatives taken for employees during the Covid-19 pandemic

The coronavirus pandemic is a global health crisis and this pandemic has been spreading day by day. As an employer, it is our prime responsibility to protect our employees and take measures to ensure a safe workplace for them. We know that Covid-19 spreads primarily through respiratory droplets or contact with contaminated surfaces. Exposure can occur at the workplace, while travelling to work, during work-related travel to an area with local community transmission, as well as on the way to and from the workplace. We have carried out rapid risk assessments to determine the possibility of exposure risk in order to put in place preventive measures to protect our employees against Covid-19 after resuming our operational activities.

Ensuring hygienic work environment

With a view to keeping all employees safe and secured from Covid-19 during this pandemic situation, the management of OPL takes various initiatives including following the health guidelines of the Department of Health of Bangladesh Government. Some of the activities are as follows:



Providing pick and drop transport facility for all employees to avoid public transport.



Introducing disinfection tunnel or chamber at entrance point of the office and plant to sanitize employees.



Screening temperatures of the employees and ensuring wearing of masks before entering the workplace.




Placing sanitizing hand rub dispensers in prominent places around the workplace and ensuring that these dispensers are regularly refilled.




Scheduling different time slots for lunch and prayer in order to maintain social distance at the workplace.




Disinfection tunnel




Temperature screening



Turning off the air conditioner for 3 (three) hours every day and opening all the windows/ventilators during those 3 (three) hours for fresh air circulation.



Conducting Covid-19 test of the suspected employees from Institute of Epidemiology, Diseases Control and Research (IEDCR) and suggesting health tips to the affected employees.



Arranging in house isolation facility for the affected employees and ensuring proper supports (treatment guideline, medicine, food) to them.

Awareness campaign

A group of volunteers worked on creating awareness regarding Covid-19 after the office resumed to its daily work pattern. The volunteers conducted appropriate awareness campaign in the workplace on symptoms and signs associated with Covid-19 exposure, how the employees can pre-emptively protect themselves, what measures should be taken if they have been exposed to Covid-19 infection and many more related to this pandemic. Banners on protecting oneself from coronavirus were placed in different levels of the corporate office. There were also demonstrations of ideal hand-washing practices, use of basic hygiene kits (like soap and mask) and medical advices by a doctor to all workers staffs and employees.

Practice of social distancing

The Government of Bangladesh announced lockdowns throughout the country from March 2020 in order to promote social distancing, which basically directs the public to maintain distance both socially and physically. The management of Orion Pharma Ltd. honored the time demanded decision and declared work from home for the employees of corporate office. When general holiday declared by the government ended, to maintain social distancing, the employees attended office on roster basis. After start of full-fledged activities, the management ensured that social distancing is being strictly maintained.

Medicine corner & doctor's chamber

To help the employees to get quick access to doctor and medicine during this pandemic, Orion Pharma Ltd. opened a medicine corner in corporate office for all employees. All the employees can purchase medicine instantly from medicine corner for themselves and their family members in 30% discount. Furthermore, a doctor's chamber was opened for medical advices for the wellbeing's of employees and their family members.



Sanitizing



Awareness campaign



Medicine corner



Doctor's chamber

Social & relationship capital

Engaging with our key stakeholders and sharing values with them is fundamental to sustainable growth. We, as a responsible corporate citizen, carry out business activities with transparency, integrity that enables us to invest in various socio-economic development activities for improving the well-being of our country.

Sources of social & relationship capital

Social & relationship capital represents the relationships with communities, stakeholders, and the ability to share value with them for mutual benefit. The main sources of social & relationship capital are:

- Social care and wellbeing;
- Improving quality of life;
- Community welfare; and
- Environmental consideration.

Social capital: Contributing to sustainable growth of the nation

Orion Pharma Limited always gives utmost importance to its social capital. We believe that being a socially responsible business organization not only provides sustainable business models, but also has improved marketing, human resource, employee satisfaction, customer loyalty and brand perception.

Concentrating on social capital through various Corporate Social Responsibilities (CSR) simultaneously helps to satisfy the demand of potential stakeholders accordingly. CSR allows us to do our bit for the society, environment, customers and other relevant stakeholders. Our CSR model takes the following factors into consideration:

- Socio-economic scenario of Bangladesh and its journey towards attaining SDGs;
- Pressing national matters under humanitarian grounds;
- Value system of employees and management;
- Sense of duty and responsibility of the company towards the employees, customers, communities and environment;
- Sustainable development and enhanced accountability towards all the stakeholders;
- CSR initiatives of OPL and its subsidiaries; and
- CSR initiatives of Orion as a Group.



Outcomes in 2019-20

29

medical students are receiving scholarship

27

Chronic Myeloid Leukemia patients are getting Enliven capsule at a discounted price

30,000

packets of relief were distributed to underprivileged in Covid-19 pandemic

3,000

iftar packets were distributed to the distressed people of the society

2,000


copies of Orion Medical Journal were circulated

Health checkup program

for employees was arranged on World Diabetes Day

Awareness campaigns & programs

have been undertaken in print and social media



CSR in operational activities

We are committed to building a company that is sustainable, not only financially, but also socially and environmentally. Our CSR initiatives drive our long-term performance and operational efficiency. OPL goes the extra mile to ensure safety and quality of medicines.

Anti-counterfeit activities

OPL is very serious about product quality, safety and efficacy. To prevent counterfeit of medicines, we actively monitor and fight against any counterfeit activity. To prevent such incidence the following additional activities are practiced at OPL:

<p>Printed cap</p> <p>We use printed cap having "Orion Logo".</p>	<p>Hologram sticker</p> <p>We use hologram sticker having "Orion Logo" to seal the packets of finished products.</p>	<p>Barcode/QR code system</p> <p>We have implemented barcode/QR code system on the carton to prevent counterfeit of our export-products.</p>	<p>Product code verification system</p> <p>We have also started using of product code verification system where customers can SMS to DGDA approved specific number to confirm the authenticity of products.</p>
--	---	---	--

Pharmacovigilance (PV) activities

Our pharmacovigilance team is actively carrying out pharmacovigilance activities for all types of medicines. They are responsible for monitoring and managing the safety of all medicines of the company. They are strictly monitoring overall activities of pharmacovigilance including the inspection of the product quality if any adverse event is reported and providing

technical supports and Adverse Event (AE) report to regulatory department for submission to DGDA.



Details on pharmacovigilance can be found under "Patient safety" on page 156

OPL Annual Report 2019-20

CSR for employees

At OPL we believe that we have an obligation towards all our employees in keeping them motivated and also showing them the importance of good practice of social responsibility. This will also help the employees to realize the essence of being responsible to the society. Out of the benefits that are provided to all our employees which are mentioned in our 'Human Capital', we have mentioned below the extra initiatives adopted by the OPL for employees.

Donation on death

When a regular employee of OPL dies irrespective of death during working hours or later, the family members of deceased employee are provided some financial assistance as instant support. In many cases, the company also takes up the responsibility of education of the children of the deceased employee as an acknowledgement of their loyalty and attachment with the company. In this reporting year, family members of 6 (six) deceased employees were provided with the support of BDT 2 Lacs each under this benefit program.



Handing over the cheque of "Donation on death" to the family members of a deceased employee

Setting up medicine corner & doctor's chamber

During this Covid-19 pandemic, a medicine corner booth has been set up so that employees can purchase medicine instantly from medicine corner for themselves and their family members at 30% discount. Furthermore, a doctor's chamber has been opened for medical advices for the wellbeing's of employees and their family members as an effort to provide employees with more convenient means of addressing urgent health needs during Covid-19 pandemic.

Sponsoring Holy Hajj & Umrah

Every year OPL provides the opportunity to a few employees to perform Holy Hajj and Umrah. The company carries out all formalities and bears all the expenses such as airfare, accommodation and the relevant Hajj/Umrah expenses. This benefit is appreciated wholeheartedly by all our employees. However, in this reporting year employees were not sent to perform Hajj and Umrah due to the Covid-19 pandemic situation.

CSR for society

OPL focuses on long-term value of giving back to the society by providing educational facilities and sustaining health in various communities which can raise the standard of living. We concentrate on improving livelihood of the underprivileged in the society as a way of helping the mankind by considering the value of human-life.

Scholarship for medical students

One of the CSRs that OPL undertakes focuses on the education of the medical students. Mrs. Arzuda Karim, Director of OPL is personally involved in these activities and always tries to help the future medical service providers through financial and other motivational means. Every year we organize a ceremony and invites the top medical students from different government medical colleges all over Bangladesh to reward them with scholarships. Till the reporting date, a total of 29 (twenty nine) students are receiving scholarship. However, we could not organize this scholarship program during the reporting year due to the Covid-19 pandemic situation.



Enliven Patients Assistance Program (EPAP)

Orion Pharma Limited has been successfully running the Enliven Patients Assistance Program (EPAP) since 2004 to help the society. This program is an endeavor to provide Enliven at subsidized price or in some cases at free of cost for the underprivileged blood cancer patients with Chronic Myelogenous Leukemia (CML) in Bangladesh. Enliven is used to treat certain types of leukemia (blood cancer), bone marrow disorders, skin cancer or certain tumors of the stomach and digestive system. Under the EPAP program, the patients can get their Enliven drugs at complimentary prices and many of

CML patients are benefited throughout Bangladesh. This particular program is also easing the access to all financially deprived patients in purchasing the drug at an affordable price. Under this program, we provide an average discount of BDT 80 per capsule which equivalents to 60% of the medicine's actual price. This discount reduces the price of the Enliven capsules which is a small step on behalf of the company to help cancer patients. Since beginning we at OPL have served more than 200 (two hundred) Chronic Myeloid Leukemia patients under this program with a vow of maintaining this event in the future. In the financial year 2019-20, the company has enlisted 2 (two) new patients and renewed 25 (twenty five) patients under this program.

New clothes to orphan children

Orion Pharma Limited considers helping orphanages to be one of the most benevolent activities because betterment of livelihood of socially and economically deprived people is of utmost importance for the economy as a whole. Every year during the month of Ramadan, Orion provides new clothes and shoes to orphan children belonged to orphanages located in Jatrabari, Uttara and Hatirjheel. It is a pleasure for Orion to be able to stand beside these orphans and is always willing to help the underprivileged in fulfilling their rightful needs as much as possible. As a part of our philanthropic activities, Orion will continue to contribute the disadvantaged and deprived group in the society to ensure their improvement in the living standards.

Iftar to the underprivileged

Ramadan facilitates the path to paradise and keeping this notion in mind everyday in this holy month, a total of 3,000 iftar packets were distributed to the underprivileged people of the society. This is an effort undertaken by OPL to help out the needy people and make them happy by providing them with delicious iftar packets. Undoubtedly Orion will continue this endeavor in the future.



Underprivileged people receiving iftar in Ramadan

CSR initiatives undertaken during the Covid-19 pandemic

Relief program for distressed people

The socio-economic crisis caused by Covid-19 has hit Bangladesh's economy hard and jeopardized the country's achievements in poverty reduction. Low-income groups including day laborers and garment workers are badly affected groups as they instantaneously have become jobless and food assistance and financial supports were urgently required for them. During the reporting year, Orion has taken initiatives and distributed 30,000 packets of grocery items to the underprivileged both inside and outside Dhaka.



Relief program inside and outside Dhaka during Covid-19 pandemic

CSR for environment

OPL believes that going beyond environmental compliances makes good business sense and can help improve long term success. The company is always involved in activities undertaken for protecting and preserving the environment and makes more efforts at building a more sustainable and green future for the next generation and continue doing our bit for the environment.



Use of natural daylight

OPL has adopted a building design emphasizing access to daylight and enjoy benefits from natural light into building. Maximizing the usage of daylight is one of the cost-effective means of reducing the consumption of energy.



Upgraded lighting system

We have installed LED lighting fixtures in our corporate office as well as in manufacturing plant. By investing in the LED lighting, we have adopted one of the energy efficient substitutes and reduced energy consumed in lighting the facility.



Initiative for a paperless office

With the intention of going paperless and saving trees, we have started discouraging excessive printing. OPL's new office layout has been done by setting up central printers for each floor and promoting the idea of using both sides of papers. We always encourage using electronic channels and e-mailing for all types of communication and have also adopted computer based examination in place of traditional paper-and-pen examination for our recruitment and promotion exam.



Conservative use of water & natural gas

OPL ensures efficient use of water required in the medicine manufacturing process, in cleaning the machineries, for employee hygiene and for maintaining other environmental conditions. In addition through the efficient use of natural gas, we are also committed to assuring that all critical energy including natural gas are being used for all activities in a conservative way.



Reducing carbon emission

OPL is committed to minimizing the impact of carbon released from our plants and vehicles. Most of our machineries run in electricity or natural gas rather than diesel. This ensure less carbon emission. In case of vehicles, we ensure fuel quality which is an important element in reducing greenhouse gas emissions from transport and regularly carry out servicing of our vehicles.



Details on our ecofriendly initiatives can be found in "Natural capital" chapter on pages 196-202

OPL Annual Report 2019-20

Relationship capital: Connecting with our stakeholders

Relationship capital is an intangible capital involving sharing information solving problems and creating brand among our stakeholders who have interest an impact on our company activities.

Internal relationship

Our internal relationship represents how we take care of our employees to make sure that they are motivated, rewarded and acting as valued ambassadors of the company.

Employee rejuvenation through picnic

Every year we arrange picnics for our employees and workers, reciprocating to all the hard works they do dedicatedly throughout the year. On March 05, 2020 OPL arranged a special refreshment program in Meghbari Resort, Kaliganj, Gazipur. Employees and workers of different departments of the company including production, QA, QC, R&D, factory admin attended the program and all of them enjoyed the event.



Workers and employees attended picnic in 2020 in Meghbari Resort, Kaliganj, Gazipur

Annual sales & marketing conference

The Annual Sales and Marketing Conference 2019 was held at Orion Pharma Park, Siddhirganj, Narayanganj on January 19, 2020 with the overarching theme “Quality sales by generating quality Rx”. The event was attended by all the sales and marketing personnel of Orion Pharma Limited. The event was made further special with the presence of the Managing Director, Mrs. Zareen Karim. Mr. Mohammad Obaidul Karim, Chairman, Mr. Salman Obaidul Karim, Director and Mrs. Arzuda Karim, Director also joined the event. The Senior Management Personnel of other functional departments and members of sales and marketing team of Orion Pharma Ltd. along with field force were present in this colorful event. All of them boosted the confidence and determination of sales staff to perform better. The best performing Area Sales Managers and Regional Sales Managers shared their experiences. The best achievers amongst the sales team of different regions were recognized and rewarded. There was a raffle draw and the session ended with cultural event and gala dinner.



Annual Sales and Marketing Conference 2019 held at Orion Pharma Park, Siddhirganj, Narayanganj

Health checkup on World Diabetes Day

Orion Pharma Ltd. observed World Diabetes Day on November 14, 2019 by launching a diabetes screening campaign at the corporate office of the company. The day long campaign followed random diabetes test, blood pressure monitoring, BMI categorization and lifestyle consultation to all employees. They took service in the program through courteous care from the personnel of Product Management Department and Medical Services Department. The program was a symbol of care towards the employees of company. The diabetes program focused on the theme "Diabetes: Protect your Family". The campaign saw immense success and appreciation from all spheres of employees.



Employees participated in health checkup programs on World Diabetes Day observed by OPL

Fun & celebration

Our employees regularly participate in various events along with performing their job responsibilities, so that they have a refreshed mind and soul and proper mental balance at work. Orion Pharma Limited is a culturally diversified organization practicing culture with value. We believe that culture integrates us with our people, community and society. We celebrate the key religious, cultural, traditional and international occasions with our people by which our bonding gets stronger.

Our employees welcome "Pohela Falgun" and "Pohela Boishakh" with a great pleasure and enthusiasm by wearing traditional outfits. In addition to that the company also arranges gift hampers/boxes, sweet boxes with company logo on them and distributes those to employees as well as to different corporate houses, financial institutions, customers, suppliers and associates as greeting for the festival and as a symbol of bondage. The same trend is also followed on the beginning of the English New Year. Delicious cuisines are also served as lunch during those occasions for the employees to make the occasions more enjoyable and delightful with co-workers/colleagues.



Employees celebrating International Women's Day, one dish party and new year

Motivational tours

Offering employees rewards and recognition through organizing motivational tours is a great way to motivate employees to deliver their best for the company each and every day. OPL believes in recognizing successful completion of jobs with the view to boost the productivity of the employees and company as a whole. Our company often organizes yearly tours for employees who have accomplished their tasks fruitfully and performed with utmost sincerity. They can enjoy the trip to its fullest by visiting beautiful and renowned sights, therefore, creating glorious memories with their coworkers.



Motivational tour to Dubai

Management coordination meeting

OPL conducts management coordination meeting on a monthly basis comprising of Mid-Level and Top-Level Management with a view to developing future leaders of the company. In these meetings the importance of leadership development, change management, team building, development of human resources and topics on current socio-economic condition is highly emphasized upon and discussed extensively. The senior management also motivates the participants about instilling values of equal treatment and the practice of recognition of all junior colleagues' work. The participants present in the meetings later convey the meeting discussions and decisions to their junior colleagues for better coordination.



Employees attending & expressing their views in management coordination meeting

External relationship

Our external relationship says about how we deal with external stakeholders like customers, shareholders, community etc. who significantly impact how business will function in the market.

Customer complaint form

OPL has a Standard Operating Procedure (SOP) on management of customer complain. We deal with all complains as per our SOP. Our customers can provide their feedback or complaints, if any, by filling up a "Customer Complaint Form" available to each depot. Customers can collect the form from the respective areas field force and after writing the problems they have faced and seek solutions, they can give back it to them. Then the field forces send it to their respective depots and subsequently our PMD and Sales Department receive the same from depots.

After that, the Quality Assurance Department, which is mainly responsible to deal with this matter works on it to solve the problems and ensures no repetition of same problem in the future. During the financial year 2019-20, only 1 (one) complaint was received from customers and our Quality Assurance Department was able to solve it successfully .



Further details on this can be found in 'Intellectual capital' under 'Product safety, performance & quality.'

OPL Annual Report 2019-20



Different motivational tours arranged by OPL

Response to shareholders queries

Orion Pharma Limited has a dedicated Share Department to carry out all share related activities and provide services to its shareholders. Our share department is devoted to handling inquiries from shareholders and investors, as well as others who might be interested in a company's stock or financial stability. Also the department prepares quarterly result publications in company's website in a timely manner. Some of the important services provided to shareholders are:


- Transfer of shares;
- Transmission of shares;
- Appointment of nominees;
- Registration of powers of attorneys;
- Changing name;
- Updating change in addresses of shareholders;
- Issue of replacement /split/ consolidation of shares certificates;
- Payment of dividend, revalidation and issue of duplicate warrants;
- Copies of the annual report;
- Registration of bank mandates (Bank name, Account no., Bank address, Bank MICR number) in case of shares held in physical form;
- Issuance of income tax certificate deducted at source on cash dividend;
- Demat paper shares into electronic shares; and
- Keeping shareholders informed of developments and events that may influence the share price, in a transparent manner through PSI.

We also encourage shareholders to express their views and opinions in AGM and the Board of Directors note their suggestions with utmost seriousness.

Orion Medical Journal

OPL publishes the Orion Medical Journal on a quarterly basis. The journal was founded in September 1998 and recently it celebrated 20 years of trust and service to the medical professionals. The main purpose of the journal is to approach our fraternity in medical profession with the latest developments in the fields of medical practice and research. OPL is proud to state that several distinguished medical professionals comprise of the Advisory & review board of the

journal. During the reporting year 3,000 copies of the journal were published and circulated to healthcare professionals on quarterly basis.



Activities undertaken to update medical professionals

OPL aims at sharing with medical professionals useful information on various subjects of medical interest, organizing and sponsoring clinical meeting from time to time, arranging video shows on acute medical emergencies and so forth.

The Medical Services Department carried out many programs in the financial year 2019-20 which included organizing scientific seminars, round table meetings, rural promotional campaigns, intern doctors reception programs and many more. Scientific seminar is a continuous medical education program, where individual departments or host institutions present a particular research based case study with medical professionals and learners. Round table meeting is a gathering of a small group of doctors of an individual department or section of host institution or a medical college. Rural promotional campaigns are conducted among Diploma in medical faculty doctors, who work as a community based health service provider. Such campaigns help to increase the involvement of rural level medical professionals with the company. Other than these, OPL also conducted intern doctors reception programs where many interns and doctors participated to acknowledge and celebrate the internship of interns.



Different programs organized by OPL with healthcare professionals

Glimpse of our social awareness campaigns in the Daily Star

HEARTBURN DURING PREGNANCY

Heartburn in pregnancy may occur because of changing hormone levels, which can affect the muscles of the digestive tract and how different foods are tolerated. Pregnancy hormones can cause the lower esophageal sphincter (the muscle that holds stomach contents in place) to relax, allowing stomach acids to splash back up into the esophagus. In addition, the enlarged uterus can crowd the abdomen, pushing stomach acids upward. Although it's rare, gallstones can also cause heartburn during pregnancy.

Prevention and Treatment of Heartburn During Pregnancy

To reduce heartburn during pregnancy without hurting your baby, you should try the following:

- Eat several small meals each day instead of three large ones.
- Eat slowly.
- Avoid foods, pills or pills (stress) foods or any foods that seem to cause reflux of the lower esophageal sphincter and increase the risk of heartburn.
- Drink less while eating. Drinking large amounts while eating may increase the risk of acid reflux and heartburn.
- Don't lie down directly after eating.
- Elevate the head of your bed higher than the foot of your bed or place pillows under your shoulders to help prevent stomach acids from rising into your chest.
- Ask your doctor about using over-the-counter medications which are generally safe to use during pregnancy. You may find that liquid heartburn reducers are more effective in treating heartburn, because they cover the esophagus.
- Wear loose-fitting clothing. Tight-fitting clothes can increase the pressure on your stomach and abdomen.
- Avoid constipation.

If your heartburn persists, see your doctor. He or she may prescribe medications that are safe to take during pregnancy. Heartburn usually disappears following childbirth.

(WOMAD Medical Reference)

August 18, 2019

International Infection Prevention Week
October 13-19, 2019

VACCINES
are everybody's business

ORION Pharma Ltd.
In Search of Excellence

October 13, 2019

KEEP YOUR HEART HEALTHY

Be physically active
Regular, moderate physical activity is great for your heart health. It's never too late to start and get the benefits. It's also important to get fit during your day and break up your sitting time. Balance and maintain a healthy weight.

Maintaining a healthy weight can reduce the risk of heart disease and other problems. It can help to lower your body mass index and waist measurements and also lower stress.

Enjoy a variety of nutritious foods
Eating a variety of healthy foods can help with your weight, blood pressure and cholesterol. Look after your mental health.

We know that there can be a greater risk of heart disease for people who have depression, are socially isolated or do not have good social support. Having a great social life with family and friends can help. Depression is more than feeling sad or low. If you feel depressed for more than two weeks, talk to your doctor, a family member or someone you know well.

Be smoke-free
Being smoke-free is one of the best things you can do to protect your heart.

Simple Ways to Keep Your Heart Healthy
A healthy heart and a healthier you starts today with these quick tips.

Manage your blood cholesterol
Cholesterol is a fatty substance carried in your blood. Your body needs cholesterol to be healthy, but an imbalance of cholesterol in your blood can lead to a heart attack or stroke.

Manage your blood pressure
Blood pressure isn't usually something you can feel. If it's too high, it needs to be treated.

Manage diabetes
It's important to manage your diabetes to help prevent a heart attack or stroke. For information on managing diabetes.

ORION Pharma Ltd.
In Search of Excellence

October 22, 2019

ANTIBIOTIC AWARENESS WEEK
18-24 NOVEMBER 2019
Antibiotic Abuse with Care

World Antibiotic Awareness Week aims to increase awareness of global antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance.

ORION Pharma Ltd.
In Search of Excellence

November 17, 2019

WORLD AIDS DAY 2019
DECEMBER 1

AIDS (acquired immunodeficiency syndrome) is a syndrome caused by a virus called HIV (human immunodeficiency virus). The disease starts the immune system, making people much more vulnerable to infections and diseases. The susceptibility system of the syndrome progresses.

How is HIV transmitted?

- Sexual transmission
- Blood transfusion
- Blood transfusion

HIV and AIDS myths and facts
There are many misconceptions about HIV and AIDS. The virus CANNOT be transmitted from:

- Sharing toilets
- Using the same toilet
- Sharing towels
- Casual kissing
- Sharing cutlery
- Sneezing
- Mouth-to-mouth resuscitation
- Touching unbroken skin
- Or other forms of "casual contact"

Myth: HIV always leads to AIDS
HIV is the infection that causes AIDS. But this doesn't mean all HIV-positive individuals will develop AIDS. AIDS is a syndrome of immune system deficiency that is the result of HIV attacking the immune system over time and is associated with weakened immune response and opportunistic infections. AIDS is prevented by early treatment of HIV infection.

With current therapies, levels of HIV infection can be controlled and kept low, maintaining a healthy immune system for a long time and therefore preventing opportunistic infections and a diagnosis of AIDS,* explains Dr. Richard Joveros, professor of public health at Western University.

ORION Pharma Ltd.
In Search of Excellence

December 01, 2019

SORE THROAT

Sore throat symptoms include pain, burning or scratching sensations at the back of throat, pain when swallowing, and tenderness in the neck.

Signs & Symptoms:

- difficulty breathing
- an earache
- bloody mucus
- fever over 101 degrees F
- difficulty swallowing
- joint pain
- a rash
- a lump in the throat

ORION Pharma Ltd.
In Search of Excellence

December 15, 2019

What is diabetic eye disease?

Diabetic eye disease can affect many parts of the eye, including the retina, macula, lens and the optic nerve.

Diabetic eye disease is a group of eye conditions that can affect people with diabetes.

- Diabetic retinopathy affects blood vessels in the light-sensitive tissue called the retina that lines the back of the eye - it is the most common cause of vision loss among people with diabetes and the leading cause of vision treatment and blindness among working-age adults.
- Diabetic macular edema (DME), a consequence of diabetic retinopathy, DME is swelling in an area of the retina called the macula.

Diabetic eye disease also includes cataracts and glaucoma. All forms of diabetic eye disease have the potential to cause severe vision loss and blindness.

How can people with diabetes protect their vision?

Vision lost to diabetic retinopathy is sometimes irreversible. However, early detection and treatment can reduce the risk of blindness by 95 percent. Because diabetic retinopathy often has early symptoms, people with diabetes should get a comprehensive dilated eye exam at least once a year. People with diabetic retinopathy may need eye exams more frequently. Women with diabetes who become pregnant should have a comprehensive dilated eye exam as soon as possible. Additional exams during pregnancy may be needed.

Studies such as the Diabetic Control and Complications Trial (DCCT) have shown that controlling diabetes slows the onset and severity of diabetic retinopathy. DCCT study participants who kept their blood glucose level as close to normal as possible were significantly less likely than those without optimal glucose control to develop diabetic retinopathy, as well as kidney and nerve disorders. Other trials have shown that controlling elevated blood pressure and cholesterol can reduce the risk of vision loss among people with diabetes.

Treatment for diabetic retinopathy is often delayed until it starts to progress to PDR, or when DME occurs. Comprehensive dilated eye exams are needed more frequently as diabetic retinopathy becomes more severe. People with severe nonproliferative diabetic retinopathy have a high risk of developing PDR and may need a comprehensive dilated eye exam on average every 2 to 4 months.

ORION Pharma Ltd.
In Search of Excellence

December 22, 2019

What About Kid's Fracture Risk With Inhaled Steroids for Asthma?

Most pediatricians are aware of concerns that inhaled corticosteroids (ICS) can produce adverse skeletal effects, despite the fact that they are also very effective at asthma symptom control. Clinical trials demonstrate that prolonged use of ICS (Inhaled Corticosteroids) can lead to decreased bone mineral density, but whether this leads to increased fracture risk in children with asthma treated with ICS is unclear. A recent study by Grey and colleagues assessed a large population over time to determine whether ICS (Inhaled Corticosteroids) use was associated with fractures.

Regardless, these data should provide reassurance for both parents and providers with respect to the potential fracture risk associated with the use of ICS.*

What other important information should you know about corticosteroids?

- Keep a list of all medications your child is on and show the list to the doctor.
- Do not share your child's asthma with others and do not give anyone else's medicine to your child.
- Keep corticosteroids at room temperature in a cool, dry place away from sunlight.
- Do not use in the bathroom or kitchen.
- Check with your pharmacist how to store corticosteroid liquid.
- Storage will depend on the type of corticosteroid your child is taking.
- Do not keep any medicines that are out of date.
- Keep corticosteroids out of your child's sight, reach and locked up in a safe place.

ORION Pharma Ltd.
In Search of Excellence

December 29, 2019

Common signs and symptom of heart attack include -

- Chest pain or discomfort (angina) which can feel like pressure, squeezing, fullness, or pain in the center of the chest
- Discomfort in the upper body including the arms, neck, back, jaw, or stomach
- Nausea and vomiting
- Lightheadedness or fainting
- Shortness of breath, which can occur with or without chest pain
- Women (and some men) may have atypical symptoms such as abdominal distress, nausea, and fatigue, without chest pain

If having a heart attack,
Call emergency right away & chew an adult-size (325 mg) non-coated aspirin.

Angioplasty, also called percutaneous coronary intervention (PCI), is a procedure that should be performed within 90 minutes of a full thickness (STEMI) heart attack.

Fibrinolytic ("clot-busting") therapy should be given within 30 minutes of a heart attack if PCI is not available.

Acute coronary syndrome (ACS) refers to a group of conditions due to decreased blood flow in the coronary arteries such that part of the heart muscle is unable to function properly or dies.

ORION Pharma Ltd. In Search of Excellence

January 05, 2020

6 tips to get relief from joint pain in WINTER

DRESS WARMLY
It's cold outside, keep aching joints warm with gloves, and add extra layers over knees & hips.

HYDRATE
Even mild dehydration might make you more sensitive to pain, according to study results published in the September 2015.

LOSE WEIGHT
A 2012 article in the Journal of the American Medical Association (JAMA) highlighted the significant improvement people with knee arthritis can get from weight loss, from diet, & exercise.

ADD FISH OIL
The Arthritis Foundation recommends up to 2.6 grams of fish oil capsules taken a day. Make sure to let your doctor know if you try omega-3s, as they can increase the risk for bruising or bleeding.

GET A MASSAGE
Getting an hourly long massage once a week for at least eight weeks was shown to reduce pain, according to research in the June 2015.

LET WARM WATER COMFORT YOU
Swimming in a heated pool is a great exercise & walking to joints. You can also get relief from warm baths, according to the Arthritis Foundation.

ORION Pharma Ltd. In Search of Excellence

January 12, 2020

Dry Skins: Causes & Remedy

WINTER WEATHER
When the temperature drops, the humidity level plummets. Dry air sucks skin particles out of humectant at home.

STEAMY SHOWERS
Setting the shower too steamy dries your skin, but it doesn't do any good to skin. Cut down the shower temperature to lukewarm, and keep showers short.

THE RUB-DOWN
Fretter erode the skin and erasme the dries. Use hands or a soft washcloth instead.

AGING
As hormonal levels change over the years, skin becomes thin and parched. Keep a bottle of lotion near to bed so it's the first and last thing you use each day.

IRRITANTS
Lots of everyday fabrics and products can irritate skin from dryer sheets to perfume. Keep a bottle of lotion near to bed so it's the first and last thing you use each day.

YOUR HEALTH
If your skin is especially itchy & red, it could be a skin condition, like eczema, dermatitis or psoriasis. It can also be a symptom of diabetes such as diabetes or an endocrine thyroid gland. Visit your dermatologist immediately.

ORION Pharma Ltd. In Search of Excellence

January 19, 2020

Reasons You May Have Brain Fog

What is it?
"Brain fog" isn't a medical condition. It's a term used for certain symptoms that can affect your ability to think. You may feel confused or disorganized or find it hard to focus or put your thoughts into words.

Chemo-Brain
Many women find it harder to remember things during pregnancy. Carrying a fetus can change your body in lots of ways and hormones released to protect and nourish your baby may bring on memory problems.

Multitasking (MT)
This disease affects your central nervous system and can change the way your brain "talks" to the rest of your body. About half the people who have MT have memory with memory, attention, planning, or language. Learning and memory exercises can help with MT. Therapy can give you new ways to handle the tasks you have trouble with.

Medication
Some doses of drugs - over-the-counter and prescription - can cause brain fog. If you take medicine and notice that your thinking isn't as clear as it should be or you suddenly can't remember things, call your doctor. Be sure to let him know all the medicines you take.

Cancer Treatment
Chemotherapy - a treatment for cancer that uses strong drugs can lead to what's sometimes called "chemo brain." You may have trouble remembering details like names or dates, have a hard time multi-tasking or take longer to finish things. It usually goes away fairly quickly, but some people can be affected for a long time after treatment.

Depression
You may not remember things well or be able to think through problems easily. It's hard to know if this is linked to the loss of memory, attention, planning, or language. Learning and memory exercises can help with MT. Therapy can give you new ways to handle the tasks you have trouble with.

Sleep
You need sleep to help your brain work the way it should. But too much can make you feel foggy, too. Aim for 7 to 9 hours. To get good rest at bedtime, you may want to avoid coffee and alcohol after lunch and leave the computer and smartphone out of your bedroom. It also can help to get to bed and wake up at the same time every day.

ORION Pharma Ltd. In Search of Excellence

January 26, 2020

Corona Virus, Aware to Care

Can Kill 63 Million Lives. Death toll in China is 259 with confirmed cases of 11,791 (up to 1 Feb). Let's aware ourselves to protect ourselves.

How it spreads?
Mainly through air droplets in the air

- Through sneezing and cough
- Touching the victimized person
- Touching your mouth or nose after in contact with any object that has presence of virus
- Unhygienic toilet/washroom.

Prevention

- Frequently wash your hands with soap or hand sanitizer
- Do not touch your nose or mouth with uncleaned hands
- Cover your nose or mouth while sneezing or coughing
- Avoid close contact with people suffering from cold or flu
- Properly cook meats and eggs
- Avoid contact with pets or animals with naked hands
- May use mask at outdoors

Symptoms

- Cold
- Cough
- Fever
- Sinusitis
- Throat ache
- Headache
- Breathing Difficulty (barring of sense in severe case)

 People with weak immune system (Children, Senior citizens) may face pneumonia and bronchitis.

When to Wear Your Mask

- After sneezing or coughing
- After attending to a patient suffering from cold or flu
- Before and after preparing food
- After coming from washroom or toilet
- Whenever your hand feels dirty
- After in contact with feral pets or animals

Upon reveal of symptoms, drink lots of water and fluids, take adequate rest and seek advice from your nearest doctor.

ORION Pharma Ltd. In Search of Excellence

February 02, 2020

How the order you eat your food affects your health!

Recent Research Reveals

- Starting a meal by eating vegetables and protein and finishing it with carbohydrates, keeps us fuller than if we ate some foods in reverse order.
- Protein slows down release of sugar from carbohydrates into the blood stream.
- When diabetics ate vegetables and proteins first, their blood sugar levels were 20% lower 30 minutes later compared to when they ate the carbohydrates first.

"Starting your meal with vegetables and protein and finishing with carbohydrates could help maintain body weight"

ORION Pharma Ltd. In Search of Excellence

February 16, 2020

SIBLING BULLYING MAKES PSYCHOTIC DISORDERS THREE TIMES MORE LIKELY

People who were bullied by siblings during childhood are up to three times more likely to develop psychotic disorders such as schizophrenia in early adulthood, according to new research by the University of Warwick.

The researchers found that the more frequently children are involved in sibling bullying either as bully, victim or both the more likely they are to develop a psychotic disorder. Children who are victimized both at home and in school peers are even worse off being four times more likely to develop psychotic disorders than those not involved in bullying at all.

The researchers conclude that parents and health professionals should be made aware of the long-term mental health consequences that sibling bullying may have and that interventions must be developed in order to reduce and even prevent this form of aggression within families.

Psychotic disorders such as schizophrenia or bipolar disorder cause abnormal thoughts, perceptions and often involve hallucinations or delusions. Sufferers often experience severe distress and changes in behavior and mood and have a much increased risk of suicide and health problems.

ORION Pharma Ltd. In Search of Excellence

February 23, 2020

Hypercholesterolemia or widely known as HIGH CHOLESTEROL

What is Cholesterol
Cholesterol is a fatty substance that occurs naturally in the body. It performs several vital functions. It is needed to make the walls surrounding the body's cells and is the basic material that is converted to certain hormones. Your body makes all the cholesterol you need. You need only a small amount of fat in your diet to make enough cholesterol to stay healthy.

Symptoms
Most people with high cholesterol don't have any symptoms and cholesterol-related abnormalities cause significant narrowing of the arteries leading to their hearts or brains. The result can be heart-related chest pain (angina) or other symptoms of coronary artery disease, as well as symptoms of decreased blood supply to the brain (transient ischemic attacks or stroke).

Prevention
You may help to prevent high cholesterol by staying on a healthy diet and exercising daily. Avoid processed foods, especially those that contain saturated fats. Instead eat more from fruits and vegetables, whole-grain breads and cereals, and low-fat dairy products.

Blockage In Right Coronary Artery

ORION Pharma Ltd. In Search of Excellence

March 01, 2020

Social activities under taken during the Covid-19 pandemic

After the outbreak of Covid-19, the Government of Bangladesh adopted aggressive strategy immediately to stop spreading of the virus throughout the nation. Even after several months of battling, no vaccine is yet to get an approval to prevent this disease and so non-therapeutic measures have been proven as the next most effective solution to contain the spread of this deadly virus. A lower-middle-income country like Bangladesh has also followed the thumb rules of fighting against Covid-19 like staying at home to lessen the chances of transmitting the virus, maintaining social distancing, shutting down all academic institutions, avoiding public gatherings in critical areas etc.


Orion Pharma Ltd. being one of the leading members of pharmaceutical industry in Bangladesh, has been contributing to the society's emergency situation by raising social

awareness through running online campaigns, creating flyers and arranging interactive sessions with prominent doctors. OPL has started taking live webinar sessions (Orion Shastho Barta) with specialists of different diseases in its Facebook page, one of the most popular online platform, discussing on how to fight against other diseases in this pandemic era. People can take suggestions from the specialist and place their queries live on these sessions as well. Besides, Orion Pharma Ltd. has also opened up a hotline where anybody can take prescriptions from specialist doctors over the phone. During the pandemic situation, there is no better alternative to take telemedicine services to remain safe and sound and OPL has acted proactively to ensure that service.


Our Covid-19 awareness campaign in the Daily Star in April, May & June 2020

HOW TO HOME QUARANTINE


The home quarantined person should:




Stay in a well-ventilated single-room preferably with an attached toilet




Needs to stay away from elderly people, pregnant women, children




Restrict his/her movement within the house




Under no circumstances attend any social/religious gathering




Wash hand frequently with soap and water or with alcohol-based sanitizer




Avoid sharing household items like dishes, glasses, cups, utensils, towels, bedding



Wear a surgical mask at all the time. The mask should be changed every 6-8 hours





Dispose off used mask in a closed bin and bin should also be handled responsibly



If symptoms appear, he/she should immediately inform the nearest health centre

COVID-19 OUTBREAK

In Search of Excellence

Our Covid-19 awareness campaigns in social media

কোভিড-১৯ চিকিৎসায়
প্রাজমা খেরাপি প্রসঙ্গে সচেতনতা

ORION
In Search of Excellence

কে বা কারা প্রাজমা দিতে পারবে?

- যে ব্যক্তি COVID-19 টেস্ট Positive হবে, চিকিৎসা দিতে দুই হাফ, পরবর্তী ১৪ দিনে করোনার কোন লক্ষণ থাকবে না, এবং বর্তমানে COVID-19 টেস্ট Negative হবে।
- প্রাজমা দারা এবং মসীতা রোগীর হস্তে রূপ অবশ্যই মিলি বাস্তব হবে। প্রাজমা সন্ম করার পর, তা অন্যান্য সংক্রমক রোগের জন্য টেস্ট করতে হবে। সেন্সি. HIV.
- একজন প্রাজমা দারা এক থেকে তিনজন পর্যন্ত রোগীর চিকিৎসার জন্য পর্যায় প্রাজমা উৎসাহিত করতে পারেন।

প্রাজমা দাতার কোন স্বাস্থ্য ঝুঁকি আছে কি?

- প্রাজমা দেয়ার অল্প পাতার রোগ প্রতিরোধ ক্ষমতা দুর্বল হতে না বা দারা তাইরাসে পুনরায় আক্রান্ত হওয়ার অসম্ভাব্য থাকে না।

Ref: Health Health Publishing by National Health Action

জ্বর অথবা গলা ব্যথা হলোই করোনা নয়,

নিউমোনিয়া, টিনসিলাইটিস ও অন্যান্য ব্যাকটেরিয়ার সংক্রমণ হলেও জ্বর এবং গলা ব্যথা হতে পারে।

ক্রম লক্ষণ দেখা মিলে সেরিটাইটে চিকিৎসার পরামর্শ অনুযায়ী ঔষধ সেবন করুন।

আতঙ্ক নয়, সচেতন থাকুন

জনস্বাস্থ্য:

কোভিড-১৯ সচেতনতা

করোনা ভাইরাস দারা আক্রান্ত রোগীদের করোনা রোগের লক্ষণগুলো প্রকাশের ২-৩ দিন আগে থেকেই তাঁর আপোষপে মামুল করোনা ভাইরাস দারা সংক্রমিত হয়। সুতরাং কোন মানুষের করোনা রোগ সনাক্ত হলে উক্ত ২-৩ দিনের মধ্যে তাঁর সংস্পর্শে আসা মানুষদের কোয়ারেন্টিন নিশ্চিত করা এই মহামারী নিয়ন্ত্রণের অন্যতম পন্থা।

আতঙ্ক নয়, সচেতনতায় হবে জয়

জনস্বাস্থ্য:

Some initiatives taken after the reporting period (in July 2020)

Live webinar

Live Webinar On
Management of Mental Health during COVID-19 Pandemic

Date: 18th July, 2020 Time: 07:30PM

Speaker

Dr. Md. Raisul Islam Parag
MBBS, MD (Psychiatry), Bangladesh Department of Psychiatry, Dhaka Medical College Hospital

Moderator

Kazi Shamim
Deputy Manager, Sales Training Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Live Webinar On
Management of ENT Problem during COVID-19 Pandemic & Rainy Season

Date: 07th July, 2020 Time: 05:30PM

Speaker

Dr. Mohammad Farid Uddin Milky
MBBS, D.O Consultant (ENT), Bangladesh Medical College Hospital

Moderator

Kazi Shamim
Deputy Manager, Sales Training Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Live Webinar On
Current Situation of COVID-19 Pandemic in Bangladesh

Date: 09th July, 2020 Time: 09:00PM

Speaker

Prof. Dr. M. Alamgir Chowdhury
MBBS, DLO, MS, FRCS (Otolaryngology), Head, ENT-HNS Department, Anwer Khan Modern Medical College & Hospital

Moderator

Kazi Shamim
Deputy Manager, Sales Training Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Live Webinar On
Management of patients suffering from Obs & Gynae problems during COVID-19 Pandemic

Date: 14th July, 2020 (Tuesday) Time: 08:00PM

Speaker

Dr. Mala Banik
MBBS, FCPS, MD (Obs & Gynae), Assistant Professor, Sir Baidyanath Medical College & Hospital

Moderator

Dr. Nusrat Binte Rabban
Assistant Manager, Product Management Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Live Webinar On
Yoga for Peace and Healthy Life

Date: 19th July, 2020 Time: 07:30PM

Speaker

Ahmed Shariff
Chief Yoga Instructor, Quantum Foundation, Internationally Certified Yoga Trainer, Competitive Yoga Instructor, Iyengar (VIC), S-VYASA Yoga University, Bangalore, India

Moderator

Kazi Shamim
Deputy Manager, Sales Training Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Live Webinar On
What Every Women Need to Know About Pregnancy During Covid-19 Pandemic

Date: 23rd July, 2020 (Thursday) Time: 08:00PM

Speaker

Prof. Dr. Parul Jahan
MBBS, MCh, DNB, FCPS, MCh (Gynae), Obst & Gynec Specialist & Consultant, Senior Lecturer in Obstetrics & Gynaecology, Professor & Head, Obst & Gynec Department, Medical College For Women and Hospital, Uttara, Dhaka

Moderator

Dr. Nusrat Binte Rabban
Assistant Manager, Product Management Department, Orion Pharma Ltd.

For any query please call: +8809612-221100

Awareness campaigns



গুজব বা ভুল ধারণা উদঘাটন

COVID-19 আক্রমণ বেশিরভাগ রোগী কেন সুস্থ হয়ে উঠে?

- বেশিরভাগ যেকোন COVID-19 আক্রমণ আসনের হালকা বা মাঝারি উপসর্গ থাকে এবং Supportive Care নিতে তারা সুস্থ হয়ে উঠতে পারেন।
- আপনার যদি কাশি, জ্বর এবং শ্বাস নিতে সমস্যা হয় তবে কাঙ্ক্ষারূপে চিকিৎসা ও যত্ন নেওয়ার চেষ্টা করুন- প্রথমে টেলিমেডিসিনে যাওয়া সেবা নিতে কল করুন। আপনার যদি জ্বর হয় এবং ম্যালেরিয়া বা ডেঙ্গুর প্রকোপ আছে এমন কোনও এলাকায় অবস্থান করলে তবে অবিলম্বে চিকিৎসা নিন।
- নিজের সুস্থতা নিশ্চিত করতে আপনার হাত পরিষ্কার রাখুন এবং চোখ, মুখ ও নাক স্পর্শ করা থেকে বিরত থাকুন।



Hexion

Hand Rub
EP & BP Grade
Certified Disinfectant



গুজব বা ভুল ধারণা উদঘাটন

জগিং, ব্যায়াম বা অনুশীলনের সময় কি মাস্ক পরতে হবে?

- ব্যায়াম করার সময় মাস্ক পরা উচিত নয় কারণ তা শ্বাসকোশ শ্বাস নেওয়ার ক্ষমতা হ্রাস করতে পারে।
- ঘরে মাস্ককে আরও প্রাকৃতিকভাবে নিতে পারে বা শ্বাস নিতে অসুবিধা সৃষ্টি করে এবং জীবনায়ু দৃষ্টিকে সাহযোগিতা করে।
- অনুশীলনের সময় ওকাল্পনিক প্রতিযোগিতার ব্যবস্থাটি হলো অন্যদের থেকে কমপক্ষে ১ মিটার বা ৩ ফিট দৈর্ঘিক দূরত্ব বজায় রাখা।



Hexion

Hand Rub
EP & BP Grade
Certified Disinfectant



গুজব বা ভুল ধারণা উদঘাটন

পরম এবং অর্ধ আবেহাওয়া সম্পন্ন অঞ্চলে কি COVID-19 অধিক সংক্রমণ হতে পারে?

- পরম এবং অর্ধ আবেহাওয়া সহ অঞ্চলগুলি সবই কোনও জলবায়ুতে COVID-19 ভাইরাস সংক্রমণ হতে পারে।
- COVID-19 এর থেকে নিজেদের রক্ষার সর্বোত্তম উপায় হল কমপক্ষে ১ মিটার বা ৩ ফুট দৈর্ঘিক দূরত্ব বজায় রাখা এবং ঘন ঘন আপনার হাত পরিষ্কার করা।
- এটি করার মাধ্যমে আপনি আপনার হাতের জাইরাস নির্মূল করতে পারেন এবং তার ফলে আপনার চোখ, মুখ এবং শ্বাসকোশ জাইরাসের সংক্রমণ এড়াতে পারেন।



Hexion

Hand Rub
EP & BP Grade
Certified Disinfectant



গুজব বা ভুল ধারণা উদঘাটন


শীতল আবহাওয়া করোনা ভাইরাসকে ধ্বংস করতে পারে কি?

- শীতল আবহাওয়া মনুস করোনা ভাইরাসকে ধ্বংস করতে পারে না।
- শীতল আবহাওয়া মনুস করোনা ভাইরাস বা অন্যান্য রোগকে মেরে ফেলতে পারে বলে বিশ্বাস করারও কোন কারণ নেই।
- আমাদের মাস্কপেত্রের বাস্তবিক আশঙ্কায় বাহিরে আমাদের বা আবহাওয়া নির্বিশেষে ৩০.৫ ডিগ্রি এবং ৩৭ ডিগ্রি সেলসিয়াসের তাপমাত্রা থাকে, তা শীতকাল থেকে বা গ্রীষ্ম। সুতরাং আবহাওয়ার কোন প্রকোপ শীতের করোনা ভাইরাসের উপর প্রকোপ ফেলতে পারে না।
- করোনাভাইরাস থেকে নিজেকে রক্ষা করার সর্বোত্তম উপায় হলো হ্যান্ডস্যানিটাইজিং হ্যান্ড রাইব নিতে ঘন ঘন পরিষ্কার করা।



Hexion


Hand Rub
EP & BP Grade
Certified Disinfectant



গুজব বা ভুল ধারণা উদঘাটন


নিজেকে সূর্যের সরাসরি নিচে রেখে বা ২৫° সে. এর চেয়ে বেশি তাপমাত্রায় থেকে COVID-19 কে প্রতিরোধ করা কি সম্ভব?

- নিজেকে সূর্যের সরাসরি নিচে রেখে বা উচ্চ তাপমাত্রায় থেকে COVID-19 কে প্রতিরোধ বা প্রতিরোধ করা সম্ভব নয়।
- আবহাওয়া যতাই বৈচিত্র্য বা পরিমিত না কেন, আপনি COVID-19 এ আক্রমণ হতে পারেন। পরম আবহাওয়া সম্পন্ন দেশ সমূহ রেকর্ড সংখ্যক COVID-19 কেস রিপোর্ট করেছে।
- নিজের সুস্থতা নিশ্চিত করতে আপনি আপনার হাত ভালভাবে ও ঘন ঘন পরিষ্কার করুন এবং আপনার চোখ, মুখ ও নাক স্পর্শ করা থেকে বিরত থাকুন।



Hexion


Hand Rub
EP & BP Grade
Certified Disinfectant



গুজব বা ভুল ধারণা উদঘাটন

করোনা ভাইরাস মশার কামড়ের মাধ্যমে সংক্রমণ হতে পারে কি?


- করোনা ভাইরাস মশার কামড়ের মাধ্যমে সংক্রমণ হতে পারে না।
- আঙ্গু পর্যন্ত কোন মধ্য পোচা যায় নি বা প্রমাণ করে যে করোনা ভাইরাস মশার মাধ্যমে সংক্রমণ হতে পারে।
- করোনা ভাইরাস একটি স্বনকল্পের ভাইরাস যা প্রাথমিকভাবে সংক্রমিত ব্যক্তির হাঁচি, কাশি বা নাক থেকে লাগা বা পানির মাধ্যমে উৎপন্ন ত্রুণপদার্থের মাধ্যমে ছড়ায়।
- নিজেকে সুরক্ষিত রাখতে, আপনাকে প্রতিক্রিয়া স্যানিটাইজার নিতে আপনার হাত ঘন ঘন পরিষ্কার করুন অথবা সাবিনে ও পানি দিয়ে ধুয়ে ফেলুন।
- এছাড়াও, হাঁচি বা কাশি হয় এমন কারও সাথে খনিষ্ঠ যোগাযোগ এড়িয়ে চলুন।




Hexion

Hand Rub
EP & BP Grade
Certified Disinfectant


Orion Shashtho Barta




ওরিয়ন
স্বাস্থ্য
বার্তা




ওরিয়ন স্বাস্থ্যবার্তা





Dr. Nusrat Rabbani



Prof. Parul Jahan

ওরিয়ন ফার্মা লি. আয়োজিত স্বাস্থ্য বার্তায় আজকের আলোচ্য বিষয়
"What Every Women Need to Know About Pregnancy During Covid-19 Pandemic"

Powered by
ExOr Onium ESP

PS, MS (Gynae and Obs), Obs and Gynae Specialist & Laparoscopic Surgeon. বিশেষজ্ঞের পরামর্শের উপস্থিতিতে সন্ধানিত অতিথি হিসেবে উপস্থিত আছেন Prof. Dr. Parul Jahan

Natural capital

Integrating green practices in our operational activities is a part of our values. Our approach to using natural resources in a conservative way and taking initiatives to reduce any adverse impact of our business operations to the environment portrays our contribution towards a greener environment and sustainable value creation.

Sources of natural capital

Natural capital represents a group of all renewable and non-renewable environmental resources and processes used to manufacture products which eventually support the prosperity of the organization. The main sources of natural capital are:

- Efficient utilization of natural resources including water and energy;
- Ecological balance by green landscaping;
- Managing carbon emission;
- Pharmaceutical waste and effluent management;
- Installation of solar PV panels;
- Air pollution / dust emission; and
- Daylight inclusion at workplace etc.



Outcomes in 2019-20

Structural layout of building

facilitates maximum utilization of natural light

21.48%

decrease in annual paper consumption

3.83%

decrease in annual natural gas usage

5.05%

decrease in annual water usage

Installation of ETP

with capacity of 375,000 litre/day

Installation of Incinerator

of 100 kg/hr

Installation of 3,077 LED lights

results in energy savings



Ecological plan

Appropriate landscaping is done so that no water can accumulate in case of heavy rain. Also many plants and grass are grown in the open space so that no dust can be generated from the bare land. The drainage system is designed in such a way that generation of dust is controlled. An appropriate ecological balance is done by implementing planned greeneries.

Environmental management & stewardship

We believe that the sustainability of business is directly related to sustainability of environment. Therefore, we always focus on endeavors to minimize any negative impact that we might have on the environment through our business operation. Keeping environment safe and pollution free remains our utmost priority. Failure to ensure the eco-friendly use of machines and materials leads to risk of cancellation of our legal license to operate. Both the corporate office and the production plant ensures the highest level of environmentally safe operation and compliance with environmental regulatory requirements. Our initiatives further guarantee our efforts to improve our energy efficiency and minimize adverse impact on environment.

Control of air pollution or dust emission

Maintaining an effective air pollution or dust collection system is crucial particularly in production areas. Our production block is maintained by HVAC system of class 100000 area using HEPA filters which filter the air through removing at least

99.97% of airborne particles and minimize the risk of the release of harmful substances into the atmosphere.

Automation by Building Management System (BMS)

BMS is a fully automation system which is able to control, monitor and ensure proper clean environment inside the production area as well as control temperature, humidity and pressure differential. All the utility systems are connected to BMS for automatic central control. Our fire detection system is also integrated with BMS.

Biodiversity

Our business activities are not creating any adverse impact on the environment as we have adopted all kinds of initiatives including the solid and liquid waste management system. On top of that none of the business units are located in any conservation area or area of high biodiversity.



Utilization of natural daylight

With the aim of ensuring sustainability benefits in terms of energy savings, we have adopted a building design emphasizing access to daylight and enjoy benefit from bringing natural light into the building. Maximizing the usage of daylight is one of the cost-effective means of reducing the consumption of energy.



Solar PV panels

OPL has installed solar PV panels in its new plant to provide electricity for production and industrial operations. The main objective of setting up solar panels is to reduce dependency on natural grid for power supply. Our company is looking forward to strive towards a pollution free environment with a better future for our country and this is a step in that direction.

Responsible management of waste & effluent

As part of pharmaceutical industry, all the industrial waste and effluent are properly processed, managed and disposed before discharging to the environment. The solid waste are comprised of the following:

- Raw materials container like carton, poly bag, paper bag etc.;
- Packaging materials like film foil, lid foil, carton, label, insert, glass and PET bottle, spoon, torn papers, polythene etc.;
- Rejected tablets, capsules, powders, blisters, ampoules, vials etc. from daily manufacturing;
- Laboratory area chemical containers ; and
- Used and rejected filters coming from HVAC system, process machines, laboratories etc.

The liquid waste or effluent are generated from the following activities:

- Equipment washing in general washing area;

- All machines' product contact parts washing through automatic washing system; and
- Laboratory area chemical washing after use.

Effluent Treatment Plant (ETP)

We have an ETP with neutralizing capacity of 3,75,000 litre/day. Liquid waste or effluent are collected through industrial drainage system network spread below each production floor. Production rooms and central washing area have industrial hygiene type floor trap installed and through UPVC piping network all the waste are collected to underground PIT outside of production building which is directly connected to ETP through pipeline and wastage will be passed through Effluent Treatment Plant (ETP) for treatment and making it safe for the environment. After final treatment of effluent with the help of ETP, the water is used for gardening purpose of the factory premises or it is discharged to the local central drainage network. Everyday routine test is carried out in the laboratory to ensure the compliance with the regulations.



Incinerator

We have recently installed an incinerator with incineration capacity of 100 kg/hr. An incinerator is generally defined as any furnace used in the process of burning solid waste for the purpose of reducing the volume of the waste by removing combustible materials. The incinerator is used for disposal of waste materials of rejected tablets, capsules, powders, blisters, ampoules, vials etc. from daily manufacturing. During formulation of medicine, wastage or process loss is 2-3% which is not recoverable. This type of wastage is also incinerated by passing through incinerator.

Upgraded lighting system

In order to improve energy efficiency and lower carbon emissions, LED lighting fixtures have been installed in our corporate office as well as in manufacturing plant. By investing in the installation of LED lighting, we have adopted one of the energy efficient substitutes and assure the savings of energy consumed in lighting the facility. The installation of 3,077 LED lights during the reporting year (total 4,727 LED lights) results in energy savings per year.

Use of rabbits for toxicity test

New medicines require testing because manufacturer must measure both the beneficial and harmful effects of a compound on a whole organism. A medicine is initially tested on a suitable animal model before clinical trials on human being. The animal test provides data on efficacy and safety of medicinal products. Our microbiologists use rabbits for conducting adverse toxicity effect of first time launched parenteral products and market complaints.

Rabbit is not a carrier of any health hazard potential pathogen. Our rabbit house is located on the top floor of the factory building where a total of 9 (nine) rabbits are available. We have 2 (two) workers in 2 (two) shifts to look after our animals.

Converting to a paperless office

The initiatives to make a digital switch to paperless office is another approach to do our part to ensure that we are committed to preserving the environment. We admit that we feel comfortable in doing our works using papers as we are habituated to this traditional way of working. Nonetheless, we are working on changing the culture to accept paperless as the new way of working. At the same time we also agree that paper retention will be necessary in some cases and our motive is to reduce the use of papers, not to eliminate it altogether. With this in mind, we are selecting technologies and adopting strategies that promote reduction in paper usage in the workplace.



Incinerator in our plant



Candidates attending computer based recruitment exam

As a small step to encourage going paperless in our office, we have started by discouraging excessive printing. For this OPL's office layout has been done by setting up central printers for each floor and promoting the idea of using both sides of papers.

We always encourage using electronic channels and e-mailing for all types of communication, which reduces the consumption of paper thereby results in decrease in deforestation. In case of working with coworkers and employees and sharing information, we use our own mail server, File Transfer Protocol (FTP) server, Google Drive, Dropbox etc. to share documents, files and more, and can easily collaborate and work together.

OUR CAPITALS > Natural capital

We now use finger punching attendance machine for better employee attendance management. We have also adopted computer based register system instead of paper based register book. Replacement of paper based works by digital system causes less use of paper.

Along with this, implementation of technologies such as scanning, duplex printer are some other attempts to replace paper-based processes with electronic or digital forms. Another initiative to go paperless and save trees is that we have adopted computer based examination in place of traditional paper-and-pen examination for our recruitment and promotion exam.

Parameters	2019-20	2018-19	2017-18
Paper used (in quires)	99,560	126,800	130,080

The annual paper consumption has decreased by 21.48% (27,240 quires) in comparison to the prior year.

Managing carbon emission

We are committed to bringing an improvement in our environmental performance by reducing the carbon emission from our business activities. We pursue investment in energy efficient machineries and maximum usage electricity of national grid and natural gas as utilities, which are less carbon intensive, in production process.

We are operating in pharmaceutical industry where the field force is highly dependent on the frequent use of motorcycles for carrying out their job responsibilities. Also the distribution of medicines is done through the delivery van across the country. But we are aware of the fact that vehicles contribute significantly to total emissions of carbon dioxide (CO₂), the main greenhouse gas. Since we cannot avoid the use of vehicles because of the nature of our business activities, we are committed to minimize the impact of carbon released from our vehicles. We have adopted the following strategies in this respect:

- Ensure fuel quality which is an important element in reducing greenhouse gas emissions from transport;
- Regularly servicing vehicle can save its fuel use, increase its performance and fuel efficiency which in turn reduce carbon emission from vehicle; and
- Follow fuel management efficiently.

We encourage the use of teleconferencing and video conferencing, when possible, for long distance meetings. This system is also helping us reduce carbon emission as we can avoid use of vehicles.

Conservative use of natural resources

Water

We recognize that fresh usable water has been identified as one of the scarce resources in Bangladesh as Bangladesh has one of the highest population densities in the world. Therefore, we are very much aware of efficient use of water everywhere. As a manufacturing company, the extensive use of water is required in the medicine manufacturing process, in cleaning the machineries, for employee hygiene and for maintaining other environmental conditions. Deep tube well water is the main source of water at Orion Pharma Park, manufacturing site at Siddhirganj, Narayanganj. Monitoring facilities are available to ensure minimum wastage of water.

Parameters	2019-20	2018-19	2017-18
Water used (m ³)	81,041	85,350	93,107

The annual water usage has decreased by 5.05% (4,309 m³) in comparison to the prior year.

Natural gas

Gas is another limited natural resource in Bangladesh. We are facing severe gas shortage problem. Gas crisis is an ongoing issue and therefore, we mostly depend on electricity for our operational activities. However, through the efficient use of natural gas, we are committed to assuring that all critical energy including natural gas are being used for all activities in a conservative way.

Parameters	2019-20	2018-19	2017-18
Gas used (m ³)	809,571	841,999	933,304

The annual natural gas usage has decreased by 3.83% (32,248 m³) in comparison to the prior year.



Operating context analysis

Porter's five forces model

Industry analysis is a vital part of the decision-making process in business. In this case Michael Porter's model is a widely used tool for industry analysis which identifies 5 (five) core competitive forces and by gaining knowledge about these forces and how they impact on the business, we can make better decisions and plan better.



Threats of entry posed by new or potential competitors

Impact on our business **Low**

- Economies of scale achieved by the established businesses;
- Huge capital intensive business;
- Access to the distribution channel is difficult;
- Stringent government rules and regulations, particularly regulatory permission from the drug authority; and
- Customers brand loyalty.



Degree of rivalry among existing companies

Impact on our business **High**

- High rivalry exists among the companies in the industry as same generics under different brand names are available;
- Industry is benefited from the strong demand of the consumers; and
- In the long run companies require low fixed cost and high working capital.



Bargaining power of buyers

Impact on our business **Low**

- As medicine is one of the basic needs, price sensitivity is low. Also government strictly maintains the retail price of lifesaving medicines, so consumers don't worry about pricing; and
- If any drug is prescribed by medical practitioners or physicians, the end user prefers to buy that without thinking about any alternative



Bargaining power of suppliers

Impact on our business **Medium**

- Pharmaceutical companies of Bangladesh procure raw materials largely through importing from various countries. In case of inappropriate bargaining from suppliers, pharmaceutical companies can switch but switching costs are high.



Threat of substitute products

Impact on our business **Medium**

- Generic drug companies do not spend in research and development of new drugs. So they can sell their medicines at cheaper rate. Hence threat exists in generic competition; and
- If any medicine is prescribed by medical practitioners then end user usually buys that medicine. However, customers can switch to another brand due to the unavailability of suggested brand as there are many substitutes of a generic.

SWOT analysis

This SWOT (strengths, weaknesses, opportunities and threats) analysis is a process where the management team identifies the internal and external factors that will affect OPL's performance. The company's strengths and weaknesses are the internal factors whereas opportunities and threats deal with factors external to the company. This helps the overall corporate planning process in which financial and operational goals are set for the upcoming year and strategies are created to accomplish these goals.



Strengths

What we do well

- OPL has overseas marketing network in 15 countries, products of OPL already have been registered in 7 countries and in the process of registering products in more than 12 countries;
- Strong corporate and company brand image;
- Strong, transparent and professional management;
- Strong demand for our cardiovascular drugs;
- World leading generics are available in our product line;
- Construction is in process to build the biggest Pharma Park in the country with huge production capacity including capacity of hi-tech products;
- Strong and country wide distribution network ensures supply of products up to retail level;
- High quality products with extensive product lines;
- Active participation in CSR activities;
- Front runner of some generics for the 1st time launched in Bangladesh; and
- Existence of competitive advantages.

- Limited presence in international market;
- Substandard position in a few areas of HR indicators;
- Lagging behind in starting full-fledged production in new production plant; and
- Grappling with introduction of new potential generic medicines in the market.



Weaknesses

Where we need to improve

What we can achieve

Opportunities



- Emerging new international markets;
- High annual growth rate of pharmaceutical industry in Bangladesh with lot of potential;
- Increasing demand for quality healthcare products due to the increase in consciousness among people;
- Grant for the least developed countries, including Bangladesh, an exemption from obligations to implement patents and data protection for pharmaceutical products until 2033 as per trade related intellectual property rights (TRIPS); and
- Chronic diseases continue to be the major factors for mortality worldwide, with developing nations suffering from high levels of public health problems related to chronic diseases.

- Increase in competition both in local and overseas pharmaceutical market;
- Change in rules and regulations from Bangladesh Food & Drugs Authority can make products out of the market;
- Exposed to foreign currency fluctuations in case of importing raw materials and exporting products;
- Interest rate fluctuations can have an adverse effect on the business sustainability;
- Political instability and turbulence and disruption by the law enforcement agencies may disrupt supply chain, production and hamper cost competitiveness; and
- Impact on supply chain, operation and distribution if Covid-19 pandemic situation worsens or persists to stay for a long time.

What obstacles we face

Threats



PESTLE analysis











This PESTLE (political, economical, social, technological, legal and environmental) analysis of pharmaceutical industry sector investigates the important aspects of various external factors that are affecting the industry as well as the company and is used for business and strategic planning, marketing, planning, organizational change, business and product development and research reports.

 Political	 Economical	 Social
<p>Factors</p> <ul style="list-style-type: none"> • Political instability e.g. hartal, strikes; • Export, import policy; • Government rules and regulations; and • Increase of government pressure on healthcare. <p>Our response</p> <ul style="list-style-type: none"> • The political condition of Bangladesh has been quite stable during the last few financial year; and • We neither faced any big troubles while carrying out our regular business activities nor any government rules and regulations were against us. 	<p>Factors</p> <ul style="list-style-type: none"> • Exchange rate and interest rate fluctuations; • Global economic crisis; • Intense competition in pharma industry; • Annual growth rate of pharmaceutical industry in Bangladesh; and • Fluctuation in GDP growth rate due to pandemic situation. <p>Our response</p> <ul style="list-style-type: none"> • As we are facing strong competition in local market for which we have taken effective marketing strategies to retain our position in the market and achieve the marketing objectives set; • In order to sustain in this highly competitive industry, we are focusing more on medicines required to cure chronic diseases; and • Due to uncertain economic condition in the face of Covid-19, we have been adopting alternate strategies to mitigate the negative effects of pandemic. 	<p>Factors</p> <ul style="list-style-type: none"> • Creation of job opportunities; • Increase in health conscious consumers; • Increase in population and diseases like obesity, diabetes and associated health risks; • Increase in demand of high quality healthcare products; • Betterment of the society; • Active participation in social networking with healthcare professionals; and • Change in lifestyle. <p>Our response</p> <ul style="list-style-type: none"> • We are continuously focusing on identifying the medicinal needs of the society and the shift in disease pattern so that we can capture the market before our competitors by delivering the right products at the right time; and • We actively participate in various social and philanthropic activities to share values with the society and to achieve economic growth, environmental protection and social welfare.

 Technological	 Legal	 Environmental
<p>Factors</p> <ul style="list-style-type: none"> • Advancement in technologies and machineries; • Customized treatment; • Development in ICT sector in Bangladesh; and • New technology development and obsolescence. <p>Our response</p> <ul style="list-style-type: none"> • World class machinery and equipment are available at our new manufacturing plant; and • Various updated and customized software mostly developed by our own IT team, when required, are being used for the operation and maintenance of operational activities. 	<p>Factors</p> <ul style="list-style-type: none"> • Increased litigation; • Change in rules and regulations from Bangladesh Food & Drugs Authority; • Strict advertising law; • Strict price control policy of the government; • Health and safety regulations; and • Compliance with World Health Organization (WHO) on Good Manufacturing Practice (GMP). <p>Our response</p> <ul style="list-style-type: none"> • There is no legal or regulatory issue against our company as we are always concerned to adhere to all legal and regulatory matters applicable for us; and • The concerned departments are responsible to renew all legal documents, licenses, certificates and to adapt any change in laws, rules and regulations on timely basis without making any violation. 	<p>Factors</p> <ul style="list-style-type: none"> • Increase in environmental agenda about climate change; and • Increase in community awareness about environmental issues; <p>Our response</p> <ul style="list-style-type: none"> • We are doing our business by adopting ecofriendly technology and operation process which preserve the environment through energy efficiency, maximum usage of daylight, making our office paperless and effective waste management.

Business model for value creation

Our business model revolves around our promise “Healthier life, our commitment” and the model enables us to deliver value for our stakeholders in a sustainable manner. As a pharmaceutical company, we operate in a competitive, highly regulated industry and calibrate 6 (six) capitals as well as our value drivers to provide high quality medicines across the markets. All our business activities have impact on potential stakeholders and on the resources used in the process, including land, water and energy.

Drivers	Sources of value creation	Value creation process
<p>Aspiration</p> <p>Vision, Mission & Values</p> <p>Good corporate citizenship practices</p> <p>Governance framework & code of conduct</p>	<p> Financial capital</p> <ul style="list-style-type: none"> • Equity funding • Debt funding • Cash generation abilities 	<p> Development of broad & differentiated portfolios of generic products</p> <p>Identification of medicinal needs</p> <p>▼</p> <p>Product development & registration</p>
<p>Strategic management</p> <p>Operating context</p> <p>Strategic approaches</p> <p>Key stakeholders inclusiveness</p>	<p> Manufactured capital</p> <ul style="list-style-type: none"> • Plant infrastructure • Production capacity • Health and safety guidelines • Manufacturing facilities • Machineries, equipment & technologies • Distribution network 	<p> Manufacture of medicines and maintenance of highest quality standards</p> <p>Raw materials & packing materials procurement</p> <p>▼</p> <p>Production of generic drugs</p>
<p>Risk & opportunity management</p> <p>Opportunities & risks</p> <p>Future outlook</p>	<p> Intellectual capital</p> <ul style="list-style-type: none"> • Licence from DGDA to operate pharmaceutical products manufacturing facilities • Product development • Research strategy & implementation • Product portfolio • Presence in emerging markets 	<p> Sales and distribution management across geographies through experienced sales and marketing team</p> <p>Promote, sale & distribute products in both domestic & international markets</p> <p>▼</p> <p>Healthcare professional engagement & support</p> <p>▼</p> <p>Patient / consumer use of medicines</p>
	<p> Human capital</p> <ul style="list-style-type: none"> • 2,696 number of employees • Employees' knowledge, expertise & performance • Remuneration & benefits • Training & development • Succession planning • Innovative culture 	<p> Incorporation of environmental management plans for all business activities</p> <p>Minimizing the impact on environment through carrying out environmental stewardship responsibilities</p>
	<p> Social & Relationship capital</p> <ul style="list-style-type: none"> • Corporate social responsibility • Strong stakeholder relationship & corporate reputation • Regulatory compliance 	
	<p> Natural capital</p> <ul style="list-style-type: none"> • Focus on environmental protection • Green activities 	

Contributing to achieving the Sustainable Development Goals



For more details see page 6
OPL Annual Report 2019-20

Strategic allocation of resources	Outputs of process	The values we created
<ul style="list-style-type: none"> We allocate and utilize financial capital in a proper way for enhanced shareholder returns We invest in a product portfolio that presents opportunities for sustainable revenue growth We build a strong supply chain management to strengthen our ability to serve customers by delivering products faster We practice health, safety and environment issues on our regular operations to ensure our sustainable business We act responsibly in financial statements as well as report and communicate effectively with stakeholders We identify legitimate interest of potential stakeholders and engage with them accordingly to maintain corporate reputation and stakeholders trust We provide proper training facilities to our employees to make them developed and improve their skills to perform more in their roles We have a strong sales force in 33 regions and distribute products through 19 depots and 69 customized vehicles We give high priority to have or share a positive employee relationship that results in high employee engagement, productivity and morale We ensure product quality at various steps from materials to final packaged product and also provide quick response on product specific customer queries We perform environment friendly operation, manage waste and efficient use of natural resources We have a dedicated R&D team working on development and improvement of new and existing products respectively We are involved in serving society by participating in various philanthropic activities 	<p>No. of brands 104</p> <p>No. of presentations 203</p> <p>No. of therapeutic areas 36</p> <p>No. of generics 112</p>	<p>Financial capital</p> <ul style="list-style-type: none"> Profit after tax - BDT 665.69 million EBITDA - BDT 2,459.68 million Earning per share - BDT 2.84 Net cash generated from operation - BDT 1,882.33 million <p>Manufactured capital</p> <ul style="list-style-type: none"> Capital expenditure - BDT 1,543.45 million Production increased by 2.29% <p>Intellectual capital</p> <ul style="list-style-type: none"> No. of flagship products - 42 No. of first to market products - 10 No. of overseas markets - 15 <p>Human capital</p> <ul style="list-style-type: none"> No. of employees received trainings - 368 No. of employees received promotions - 157 Employee wellness programs in the eve of Covid-19 <p>Social & Relationship capital</p> <ul style="list-style-type: none"> Lives impacted through CSR activities - 35,056 Payment to government - BDT 517.31 million Payment to shareholders as dividend - BDT 1.00 per share <p>Natural capital</p> <ul style="list-style-type: none"> Proper treatment of waste through ETP and incinerator Dust free air emission from factory Conservative use of natural & other resources Maximum usage of daylight Reduced water consumption Reduced paper consumption

Value chain model

We portray Porter's Value Chain Analysis to explore all business activities, the way in which value chain activities are performed, to see how they are connected and how these activities are affecting costs and profits.

All 5 (five) primary business activities are essential to create value and competitive advantages.



Inbound logistics	Operation	Outbound logistics	Sales & marketing	Service
<ul style="list-style-type: none"> • Strong relationship with suppliers and vendors • Sourcing supplies of high quality materials • Efficient warehouse facilities • Logistics and stock management 	<ul style="list-style-type: none"> • Identifying, developing and delivering medicines • Automated manufacturing processes • Compliance in the production process • Quality control and inspection. 	<ul style="list-style-type: none"> • On time delivery through depots and own customized vehicles • Inventory management • Efficient dispatch and delivery system • Emergency supply 	<ul style="list-style-type: none"> • Efficient sales force • Regular training of the sales team • Effective customer management system • Entering emerging markets • Sales and market analysis • Branding and promotion 	<ul style="list-style-type: none"> • Product complaint form • Customer survey and seeking feedback • Better responses to changing consumer needs • Expired product management



<p>Providing opportunity to our talented workforce to build up long and rewarding careers</p> <p>Employees</p> <p>368 employees received trainings</p> <p>157 employees got promotion</p>	<p>Paying dividends to shareholders as well as reinvestment of returns for future growth</p> <p>Shareholders</p> <p>10% cash dividend proposed for shareholders</p>
--	---

All 4 (four) support business activities are integral to the effectiveness of primary activities.

Firm infrastructure	Human resource management	Technology development	Procurement
<ul style="list-style-type: none"> • Prevalence of good governance and code of business conduct • Structured departments and hierarchical system • Better accounting and financial management practices • Infrastructural layout ensuring minimum use of natural resources 	<ul style="list-style-type: none"> • Strong HR department to recruit, train and motivate employees • Excellent corporate culture for team work and leadership development • Competitive salary package and compensation benefits • Ensuring healthy working environment 	<ul style="list-style-type: none"> • Installation of machinery and equipment with advanced technologies • Automated Central Distribution Centre, distribution channels and depots • Real time access to sales records from all depots • Development of in-house customized software 	<ul style="list-style-type: none"> • Direct contact with vendors and suppliers • Good cross border relationship • IT based procurement planning and inventory management system • Practice of strong code of business conduct



Delivering high quality, affordable pharmaceutical products in areas where medical needs are high

Patients

203
number of medicines under
36 therapeutic areas


Undertaking various CSR activities and participating in national development through contributing to national exchequer

Society

BDT 517.31
million paid to
government

BDT 3.63
million invested in CSR
activities

Our strategic objectives



Patient health & safety

Capital linkage

- Manufactured
- Intellectual
- Social and relationship

Stakeholder linkage

- Patients
- Doctors and Pharmacies
- Government and Regulators
- Suppliers
- Shareholders and investors

Section linkage

On pages 156-157, 178-179 & 188

Focus area with strategic plan

Maintain quality products

We understand that quality is critical to satisfying customers and retaining their loyalty. The Research and Development Department over here works very hard to improve the quality of the products by using the best raw materials and latest technology. Also the Quality Assurance and Quality Control Departments are accountable to maintain the quality throughout the process.

Respond to customers within a reasonable time

Customers expect to be responded to within a short span of time with appropriate service. OPL always responds back to customers regarding any queries or services, within the shortest span of interval. We treat each customer complaint with compassion and respond to them in such a way that shows them care.

Pharmacovigilance

The Pharma-covigilance team of OPL is responsible for monitoring and managing the safety of all medicines of the company. All comprehensive information is provided through the required channels to ensure our product safety. Every procedure is conducted under close monitoring for compliance to enhance and support our product safety information.

Related risk

- Product quality
- Market demand and completion
- Stakeholder relationship
- Compliance issues
- Financial issues
- Corporate reputation

Related opportunity & outlook

- Highest quality management standards in manufacturing plant
- Post sale product quality assurance

Operational excellence



Capital linkage

- Manufactured
- Financial
- Social and relationship

Stakeholder linkage

- Shareholders and investors
- Society
- Competitors

Section linkage

On pages 105-107, 134-137, 180-181, 188-195 & 240-243

Focus area with strategic plan

Improved productivity

OPL uses the best technology that helps to maintain the quality of the medicines and enables the management to attain the most effective and efficient production process. OPL works to have the most output at the lowest cost possible. We also carry out reviews of operation process in a continuous basis, to find out bottlenecks, upgrade where necessary and remove unnecessary processes to save both time and cost.

Strict cost control & management

OPL exercises strict cost supervision as cost control is critical and an enterprise cannot afford to underestimate the budget on an important project. We are proactive and continually focus on cost control methods, so that we can avoid the need to react suddenly to changing circumstances. Strict cost control is important because it improves company's ability to operate from a position of strength.

Sustained financial performance

OPL utilizes a combination of funding sources which helps to create more growth, opportunities and overall potential. We employ a balanced mix of debt and equity funding to maximize the return on capital employed. We manage our cash flow and achieve our short term goals taking into account both the historical analysis and future targets.

Community engagement


OPL believes that corporate houses have a sense of responsibility towards the society that must be fulfilled because the success of each has a huge impact on the other. We review the CSR Program and its budget allocation on a quarterly basis, as we believe that CSR provides us long term growth and success by building a warm image of the entity, which is a reflection of the mind-set of the owners of the company.

Related risk

- Supply disruption
- Stakeholder relationship
- IT failure
- Credit risk
- Liquidity crisis
- Financial sector scenario
- Interest rate risk
- Exchange rate risk

Related opportunity & outlook

- State of art technology
- Green initiatives



The graphic features a yellow shield-like shape at the top with a grid of dots and a lightbulb icon containing a caduceus. Below this, on a teal background, are three sections: 'Capital linkage', 'Stakeholder linkage', and 'Section linkage'.

Product specific strategy

Capital linkage

- Intellectual
- Financial

Stakeholder linkage

- Patients
- Doctors and Pharmacies
- Competitors
- Shareholders and investors

Section linkage

On pages 146-159

Focus area with strategic plan

Strong brand image

OPL is continuously engaged in increasing brand awareness and promotion. With a view to establishing strong brands in the market, we select brands on a quarterly basis to promote them further. We also attend different doctor conferences and trade fairs overseas to inform about the quality of our medicines.

Strong research & development

Product research and development is very crucial in the pharmaceutical industry. OPL takes every initiative to strengthen the research and development team, because they ultimately bring improvements in product lines.

New product development assessment

OPL believes that adding a new product or entering a new market segment offers the opportunity for exponential growth. Before deciding to develop new products, OPL assesses both the opportunity and risk of new product development.

Related risk

- Product pipeline and development
- Market demand and competition

Related opportunity & outlook

- Enhance specialized segments

Ethical behavior & governance



Capital linkage

- Financial
- Human
- Social and relationship

Stakeholder linkage

- Shareholders and investors
- Government and regulators
- Society

Section linkage

On pages 48-132

Focus area with strategic plan

Corporate governance

The Board at OPL develops policies in relation to the overall governance of the organization which plays significant role in the formulation and adoption of the organization's strategic direction. The Board has an appropriate balance between Directors with experience and knowledge of the organization and specialist expertise.

Business ethics & code of conduct

OPL has a Code of Conduct for all its employees which is a collection of rules and regulations that includes what is and is not acceptable in terms of ethics and values. In addition, OPL has formulated a special Code intended to serve as a source of guiding principles for the Board and the CEO.

Compliance


OPL conducts its operation and business in compliance with all the relevant laws, rules, regulations and standards applicable to the company. We follow compliance in every aspect of customer health, employee safety, financial reporting, quality of product, production and plant, international business and so on.

Related risk

- Corporate reputation
- Compliance issues

Related opportunity & outlook

- Adoption of good governance



Market presence

Capital linkage

- Financial
- Intellectual
- Human

Stakeholder linkage

- Patients
- Employees

Section linkage
On pages 24, 142 & 148-153

Focus area with strategic plan

Broader market with strong foundation

OPL is working to redefine the market by increasing the number of territories. We plan to go for further capital expenditure in order to broaden and strengthen its distribution coverage from our warehouse to remote areas of the country for delivering quality medicines timely to the consumers. OPL also takes measures so that the distribution centers including the CDC strictly monitor cash and credit sales especially in case of bulk sales orders to prevent product migration and unethical sales, which will ultimately enhance our foundation through sustainable business operations.

Knowledge based professional team

OPL always works towards making a knowledge based professional team. Taking this into our core consideration, we pursue to provide both on-job training of field forces by supervisors along with training on detailing skill & product discussion during field visit.

Global footprint expansion


OPL carries out an extensive 'due diligence' before expanding to international borders. Emerging markets offer an attractive growth prospect, as several of these countries see rapidly rising incomes, better-informed patients, and expanding access to healthcare. Winning strategies are formulated so that we can enter there. We also have the plan to enter regulated markets for which we are trying to attain required certifications and consolidations.

Related risk

- Market demand and competition
- Supply disruption
- People and talent

Related opportunity & outlook

- Entry in new emerging markets



Employee wellbeing and engagement



Capital linkage

- Human
- Financial

Stakeholder linkage

- Employees
- Government and Regulators

Section linkage

On pages 160-175

Focus area with strategic plan

Talent management through training & education

Training and development is a continuous process in OPL throughout the year so that the continuous improvement of employees is ensured. As a diverse working place, we conduct training for ethical, cultural and social interactions along with job oriented trainings.

Employee engagement

OPL is always committed to provide a workplace where employees remain motivated and engaged. We focus on making our people feel strongly connected to the company because it motivates people to put in extra effort for the organization.

Occupational health & safety

OPL always ensures that employees can and are able to do their work effectively. Compliance with significant regulations in workplace is maintained always. Health and safety is the key factor for us to promote the wellness of the employees.

Monthly appraisal


At OPL performance appraisal is carried out on a monthly basis to demonstrate their learning progress and assess their area of improvement. This is done with the motive of a succession planning so that OPL is able to create a pool of efficient and reliable employees.

Related risk

- People and talent
- Health and safety
- Corporate reputation

Related opportunity & outlook

- Opportunities for employee growth

A vertical graphic on the left side of the page. The top half is orange with a grid of white dots and a white leaf icon. The bottom half is teal. The text 'Eco-friendly environment practices' is centered in the orange section. Below it, in the teal section, are three sub-sections: 'Capital linkage', 'Stakeholder linkage', and 'Section linkage', each with a bulleted list of items.

Eco-friendly environment practices



Capital linkage

- Natural
- Social and relation
- Financial

Stakeholder linkage

- Society
- Government and regulators
- Shareholders and investors

Section linkage

On pages 145, 182 & 196-202

Focus area with strategic plan

Eco-friendly staff practices

OPL implements sustainable business practices and also encourages employees to live a sustainable and eco-conscious life. The idea of reducing both waste and consumption is highly supported in the office premises. The company supports and follows the concepts of recycling, reusing, carpooling etc.

Environment friendly production plan

OPL uses clean technology in its production process. The company's Environmental Management System (EMS) guarantees that it is operating without making the environment polluted. The company implements strategies in areas especially concentrating on air pollution and dust emission.

Efficient waste management

We have effective waste management systems in practice. Liquid waste or effluent are treated through ETP and then is used for washing machines or gardening at our plant. Solid waste are collected and disposed off in an eco-friendly way through incinerator.

Conservative use of natural resources

At OPL we ensure conservative use of natural resources. We always try to efficiently use natural gas, water and electricity. Details of these initiatives can be further seen in our "Natural capital". We have a day light saving lay-out and also use energy-saving bulbs. Many initiatives are undertaken inspired by the concept of paperless office.

Safe expired product destruction

We have effective expired products management systems in practice carried out through our ETP. The expired medicines are dissolved and treated through the ETP. The packaging materials are either sold to the third party or disposed off in an eco-friendly way.

Related risk

- Environmental consideration

Related opportunity & outlook

- Green initiatives

Opportunities & outlook

Propelled by the change in healthcare and disease patterns, increase in per capita income, easier access to medicine and health care professional, the demand, use or requirement of medicine will be increasing day by day, bringing new opportunities for growth in coming years.

Orion Pharma Limited continues to ensure that the system, process, and technology are aligned to the changing business environment and help us achieve strategic objectives. Along with strengthening our core business and our position in both existing and emerging markets through a differentiated portfolio, we are also poised to explore opportunities related to all other supporting business activities including incorporation of more sustainable and environmentally conscious policies into our operation.



01 State of art technology

Our first phase manufacturing block has the capability with optimum capacity of producing oral tablets, capsules, syrups, suspensions, pediatrics drops and other dosage forms with fully equipped independent Research & Development, Quality Control and Quality Assurance departments.

The upcoming multi production line will produce sterile injectable products which encompass critical to curative care medications in particular antibiotics, cardiovascular, neurological, gastroenterological, anesthesia, gynecological, nephrological, hematology etc. It will also have dedicated and separated steroid and non-steroidal topical cream & ointment facility with highly advanced-to-date manufacturing technology to pacify the wide range of skin related problems along with another two fully automation guided additional production lines: softgel capsule and powder for suspension (PFS).

The upcoming oncology facility will emerge as the innovation of engineering with updated medical science capable of producing world class medications to rejuvenate the hope for cancer patients. This devoted and high-containment manufacturing processing will ensure 100% isolations and guaranteed zero discharge technology for all possible dosage forms.

In accordance with the global standard, Orion's Cephalosporin block is going to gain the highest degree of scientific innovation-to-date for the anti-infective market. The prime directive focus is to manufacture cephalosporin products for all possible dosage form in separate and dedicated self-contained areas with auto prevention of all sorts of cross-contamination by in-built design.

02 Highest quality management standards in manufacturing plant

All the manufacturing blocks particularly the Oncology Manufacturing Block is the strategic facility of the Orion Pharma as its action will be on a global standard in satisfying company's export and local demand having strict accordance with highest quality management standards like US FDA and UK MHRA cGMP specifications.

03 Enhance specialized segment

OPL is working on developing branded generic drugs in specialty segments specifically in cephalosporin, ophthalmology, dietary supplement dermatology, and oncology, to address clinically unmet needs of the patients.

04 Post-sale product quality assurance

OPL already has Customer Complaint Form to respond to customers regarding any queries or services. We have also introduced pharmacovigilance to monitor and manage the safety of all medicines of the company. Till now no Adverse Effect (AE) has been reported and we target to achieve 0-AE report every month and are working towards maintaining it.



05 Entry in new emerging markets

OPL has a lot of potential in the international scenario as it is working to enter countries like Albania, Uzbekistan, Cameroon, Vietnam and Costa Rica, Nigeria, Brunei Darussalam, Ivory Coast, Egypt, Botswana, Namibia, Zambia, Zimbabwe, Uganda, Venezuela, China and Azerbaijan.

06 Adoption of good governance

OPL always abide by the law and conform to all regulatory bindings. Good governance holds that many perspectives combine to result in the best possible decision-making. We believe that there is no end to improvement in this sector and we still have more aspects where we have room for improvement.

07 Opportunities for employee growth

OPL focuses on employee engagement and inclusion to motivate and create room for employee growth. We believe that employees who are invested in their roles are more productive and the key to them being more involved is creating an inclusive culture. Our company is planning to do more in the future, especially for minorities and female employees so that they feel more engaged, as it is most essential to retain employees. The company also has a monthly appraisal system for employees where room for their development is identified and accordingly they are provided with various training facilities so that there is more scope of career growth of employees.

08 Green initiatives






During the last couple of years, OPL has adopted many initiatives that are environment friendly such as use of natural daylight, upgraded lighting system, conversion to a paperless office, conservative use of water & natural gas, reduced carbon emission. Liquid waste are treated through ETP and solid waste are disposed off through incinerator. We hope to make more efforts at building a more sustainable and green future.

Stakeholder engagement strategy

Stakeholder analysis is critical for our success and we are aware that our actions and how we run our business affect more and more people with the expansion of business. The positive response from these people helps us to grow our business. On the contrary, their negative feedback can block our way to expand and grow bigger.

Hence we have carefully identified and prioritized our stakeholders, their interest and concern through conducting impact analysis and developed best engagement mechanism as the way to respond to those identified interests and concerns. We believe that effective stakeholder management also means communicating with your stakeholders and understanding their needs by establishing a sound relationship, and make them feel trusted and relevant, successfully meeting project objectives.

Stakeholders	Why they are important	What matters to them	How we engage with them
 Patients	<ul style="list-style-type: none"> • Ultimate users • Final revenue source • Main source of sustainability of the business 	<ul style="list-style-type: none"> • Product quality • Availability of medicines • After sales service 	<ul style="list-style-type: none"> • Pharmacovigilance • Launching new products • Website • Product complaint form • Telemedicine • Orion Shastho Barta
 Employees	<ul style="list-style-type: none"> • Competent employees to attain objectives • Our image holder and contributor to profit 	<ul style="list-style-type: none"> • Job security • Transparent recruitment process • Periodic salary review in view of adjusting the cost of living • Healthy working environment • Training & development • Career growth 	<ul style="list-style-type: none"> • Adjusted salary package • Training and other facilities • Monthly performance reviews and appraisal • In-house awareness campaign • Medicine corner and doctor's chamber
 Shareholders & Investors	<ul style="list-style-type: none"> • Invest for the betterment and growth of the company • Accountable to them as they seek return on their investment 	<ul style="list-style-type: none"> • Return on investment • Sustainability and going concern issues • Effective corporate governance • Strategic objectives • Social and environmental contribution 	<ul style="list-style-type: none"> • Annual General Meeting • Integrated Annual Report • Regular repayment of debt and declaration of dividend • Financial statements quarterly, half yearly and yearly • Declaration of (PSI) • Website • Regular communication

Stakeholders	Why they are important	What matters to them	How we engage with them
 Government & Regulators	<ul style="list-style-type: none"> Control and develop policy Provide license and certificates Control export and import 	<ul style="list-style-type: none"> Legislative compliance Corporate governance Environmental and social credentials Timely reporting and VAT, tax payment Pricing Product quality 	<ul style="list-style-type: none"> Discussion, seminar and dialogue Contribution to national exchequer Conform to relevant laws and regulations and reporting to Government and regulatory bodies Regular communication Factory visit
 Suppliers	<ul style="list-style-type: none"> Supply production materials and operational facilities On time delivery Quality of supplied products After sales service facility 	<ul style="list-style-type: none"> Fair and smooth transaction Sustainable growth of the company Fair payment 	<ul style="list-style-type: none"> Regular interaction Supplier visit and audit Timely payment to vendors
 Society	<ul style="list-style-type: none"> Sustainable business operation Social and environmental contribution 	<ul style="list-style-type: none"> Ethical stance Social value creation Creation of employment opportunity Environmental preservation Health and safety measures 	<ul style="list-style-type: none"> CSR initiatives Website Social awareness campaign Integrated Annual Report Social media
 Doctors & Pharmacies	<ul style="list-style-type: none"> Influence prescription of our medicines Directly impact our business Information provider 	<ul style="list-style-type: none"> Certification Product quality Availability of medicines Diversified product portfolio After sales service 	<ul style="list-style-type: none"> Seminars, webinar, meetings and workshops Orion Medical Journal Regular ongoing visit by field force
 Competitors	<ul style="list-style-type: none"> Influence strategic decisions and planning Directly impact the ability to succeed 	<ul style="list-style-type: none"> Financial performance Business trends Value creation for long run Competitive advantage 	<ul style="list-style-type: none"> Social media Website Integrated Annual Report

Competitive edge with our value proposition

Strong foot step in cardiovascular drugs

Orion Pharma Ltd. started its professional journey with stronger footstep in the cardiovascular segment. Amongst the leading cardiovascular drugs "FRULAC", "CLOGNIL & CLOGNIL PLUS", "LOSAN & LOSAN-Plus" and "ROVEX" are remarkable. For the 1st time in Bangladesh we launched "FRULAC" in 2002. Since then with the reliability from leading cardiologists, "FRULAC" has been leading the in the cardiovascular market not only in Bangladesh but also in Myanmar market.

World leading generics in the product lines

Orion Pharma Ltd. has launched Rosuvastatin and Esomeprazole under the brand name "ROVEX" and "EXOR" respectively. Considering the brand potentiality and value, Orion Pharma Ltd. has kept these brands as highest promotional priority as flagship products. During the reporting year, the company launched Olmesartan & its combinations with brand name "OLMESAFE".

Front runner – 1st time in Bangladesh

Orion Pharma Ltd. is always keen to launch new and innovative product in Bangladesh. In Bangladesh Orion Pharma Ltd. have a good number of brands launched 1st time. "PEP", "EC-PLUS", "FRULAC", "ONIUM", "ALVE", "CEFDITOR", "MAROMAX", "NOVELTA", "DESLOR" and so on. Moreover Orion Pharma Ltd. has launched "TENDONIL" which is one and only in Bangladesh.

High quality API from world's renowned suppliers

As far as quality is concerned, we are always in search of excellence. Therefore whenever we think of launching any new molecule, we search for the highest quality API. The quality of APIs has a significant effect on the efficacy and safety of medication. Poorly manufactured or compromised APIs have been connected to serious issues, such as illnesses and even death. Hence, Orion Pharma has been importing APIs from well recognized companies of Italy, USA, Denmark, Germany, Spain and so on. Not only that we have also introduced US DMF (Drug Master File) Grade raw material for few of our products which ensure proof of purity and complete documentation. At the same time we also use DC (Direct Compression) Grade raw materials having increased dissolution rate to ensure rapid onset of action and product of higher stability.



Performance & Financials 2019-20

- Auditors' report and audited statements
- Five years' highlights
- Horizontal & vertical analysis
- Graphical presentation
- Value added statement

Five years' highlights

consolidated

Particulars	2019-20	2018-19	2017-18	2016-17	2015-16*
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME DATA					
Net sales revenue	7,647.70	8,705.17	10,423.10	9,534.35	14,799.74
Gross profit	2,577.84	2,545.68	2,376.20	2,419.25	3,861.26
Operating profit	835.31	1,041.78	965.18	968.87	1,608.70
Profit before tax	795.53	1,028.31	953.63	959.58	1,593.86
Net profit after tax	665.69	882.35	801.76	794.50	1,323.07
Earnings before interest, tax & depreciation (EBITDA)	2,459.68	2,347.49	2,343.97	2,377.60	3,763.93
STATEMENT OF FINANCIAL POSITION DATA					
Authorized capital	5,000.00	5,000.00	5,000.00	5,000.00	5,000.00
Paid up capital	2,340.00	2,340.00	2,340.00	2,340.00	2,340.00
Shareholders' equity	17,963.72	17,594.35	17,054.21	16,602.52	16,377.82
Non-controlling interest	1,225.99	1,154.63	1,065.40	962.62	838.31
Total equity	19,189.71	18,748.98	18,119.61	17,565.13	17,216.13
Total non-current liabilities	13,255.94	8,150.48	7,081.93	5,175.15	5,935.32
Total current liabilities	4,395.45	4,090.96	5,513.16	5,422.50	3,738.46
Total non-current assets	19,094.53	18,714.58	18,413.93	18,199.06	18,286.61
Property, plant & equipment	14,930.94	12,937.53	13,144.23	13,555.93	14,058.34
Total current assets	17,746.58	12,275.84	12,300.76	9,963.73	8,603.29
Total assets	36,841.11	30,990.42	30,714.70	28,162.79	26,889.91
Net current assets/(liabilities)	13,351.13	8,184.88	6,787.61	4,514.23	4,864.84
FINANCIAL RATIOS					
Gross profit ratio (%)	33.71	29.24	22.80	25.37	26.09
Current ratio (times)	4.04	3.00	2.23	1.83	2.30
Debt equity ratio (times)	0.98	0.71	0.70	0.66	0.61
Return on equity (%)	3.47	4.71	4.42	4.52	7.69
Return on capital employed (%)	5.13	5.86	6.55	6.67	11.78
Price earnings ratio –DSE (times)	14.79	8.81	12.07	14.94	6.51
Price earnings ratio –CSE (times)	14.75	8.75	12.27	14.88	6.55
ORDINARY SHARES INFORMATION					
Face value per share (BDT)	10.00	10.00	10.00	10.00	10.00
Quoted price per share-DSE (BDT)	42.00	33.20	41.40	50.80	36.80
Quoted price per share-CSE (BDT)	41.90	33.00	42.10	50.60	37.00
Number of shares outstanding	234,000,000	234,000,000	234,000,000	234,000,000	234,000,000
Cash Dividend (%)	10.00**	15.00	15.00	15.00	15.00
Net asset value per share (BDT) (including revaluation surplus)	76.77	75.19	72.88	70.95	69.99
Net asset value per share (BDT) (excluding revaluation surplus)	68.69	66.98	64.55	62.48	61.34
Net operating cash flow per share (BDT)	8.04	6.19	9.38	9.62	16.62
Earnings per share (BDT)	2.84	3.77	3.43	3.40	5.65
Number of shareholders	35,481	30,171	34,515	48,863	63,949
OTHER INFORMATION					
Number of employees	2,696	2,743	2,527	2,287	2,223

* Figures mentioned for FY 2015-16 are for 18 (eighteen) months

** Proposed

Horizontal & vertical analysis

consolidated










Horizontal	2019-20	2018-19	2017-18	2016-17	2015-16
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME DATA					
Net sales revenue	52%	59%	70%	64%	100%
Gross profit	67%	66%	62%	63%	100%
Operating profit	52%	65%	60%	60%	100%
Profit before tax	50%	65%	60%	60%	100%
Net Profit after tax	50%	67%	61%	60%	100%
Earnings before interest, tax & depreciation	65%	62%	62%	63%	100%
Earnings per share*	50%	67%	61%	60%	100%
STATEMENT OF FINANCIAL POSITION DATA					
Paid up capital	100%	100%	100%	100%	100%
Shareholders' equity	110%	107%	104%	101%	100%
Non-controlling interest	146%	138%	127%	115%	100%
Total equity	111%	109%	105%	102%	100%
Total non-current liabilities	223%	137%	119%	87%	100%
Total current liabilities	118%	109%	147%	145%	100%
Total non-current assets	104%	102%	101%	100%	100%
Property, plant & equipment	106%	92%	93%	96%	100%
Total current assets	206%	143%	143%	116%	100%
Total assets	137%	115%	114%	105%	100%
Net current assets/(liabilities)	274%	168%	140%	93%	100%

Vertical	2019-20	2018-19	2017-18	2016-17	2015-16
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME DATA					
Net sales revenue	100.00%	100.00%	100.00%	100.00%	100.00%
Gross profit	33.71%	29.24%	22.80%	25.37%	26.09%
Operating profit	10.92%	11.97%	9.26%	10.16%	10.87%
Profit before tax	10.40%	11.81%	9.15%	10.06%	10.77%
Net Profit after tax	8.70%	10.14%	7.69%	8.33%	8.94%
Earnings before interest, tax & depreciation	32.16%	26.97%	22.49%	24.94%	25.43%
Earnings per share*	28.40%	37.70%	34.30%	34.00%	56.50%
STATEMENT OF FINANCIAL POSITION DATA					
Paid up capital	6.35%	7.55%	7.62%	8.31%	8.70%
Shareholders' equity	48.76%	56.77%	55.52%	58.95%	60.91%
Non-controlling interest	3.33%	3.73%	3.47%	3.42%	3.12%
Total equity	52.09%	60.50%	58.99%	62.37%	64.02%
Total non-current liabilities	35.98%	26.30%	23.06%	18.38%	22.07%
Total current liabilities	11.93%	13.20%	17.95%	19.25%	13.90%
Total non-current assets	51.83%	60.39%	59.95%	64.62%	68.01%
Property, plant & equipment	40.53%	41.75%	42.79%	48.13%	52.28%
Total current assets	48.17%	39.61%	40.05%	35.38%	31.99%
Total assets	100.00%	100.00%	100.00%	100.00%	100.00%
Net current assets/(liabilities)	36.24%	26.41%	22.10%	16.12%	18.09%










* Earning per share has been shown as a percentage of book value per share

Graphical presentation

consolidated



Figures mentioned for FY 2015-16 are for 18 (eighteen) months




Contribution to national exchequer

The contribution to the National Exchequer of the company was BDT 517.31 million in FY 2019-20, of which BDT 349.96 million was made on local stage and BDT 167.35 million was made on import stage. We will continue to support the Government through our contribution to National Exchequer in the upcoming years, in order to help establish a sustainable level of tax contribution.


Year-wise contribution to exchequer in terms of criteria

Amount in BDT million
As of June 30, 2020



Year-wise contribution to exchequer against sales


Amount in BDT million
As of June 30, 2020



Stage-wise contribution to exchequer


Amount in BDT million
As of June 30, 2020

Import stage



In import stage we paid advance tax, advance VAT, supplementary duty and other duties.

Local stage



In local stage we paid income tax, advance income tax, tax deducted at source, VAT, advance VAT and VAT deducted at source.

Human resource accounting

OPL informs stakeholders regarding the changes occurring overtime with regards to the human resources of the business, and of the cost and value they create for the organization. Our company uses the Lev and Schwartz model to assess the value of human resource. As per this model, human resource of a company is the summation of value of all the net present value (NPV) of expenditure on employees. The total value of human capital has been ascertained BDT 784.18 million for the financial year 2019-20 and BDT 763.78 million for the financial year 2018-19. The total value added to human capital is BDT 281.34 million for the financial year 2019-20 and BDT 274.02 million for the financial year 2018-19.

H.R Value Accounting: Lev & Schwartz model

Amount in BDT million
As of June 30, 2020

Year	2019-20	2018-19
Number of employees	2,696	2,743
Net revenue	2,297.74	2,222.54
Value of human resources*	784.18	763.78
Value added	281.34	274.02
Ratio of:		
Net revenue/ value of human resources	2.93	2.91
Value added/ value of human resources	0.36	0.36



*Value of human resources	2019-20	2018-19
Salaries, wages & other allowances	739.47	716.92
Fooding expenses	23.75	24.87
Training, overseas travel & conference	8.31	8.52
Workers profit participation fund	12.64	13.47
Total	784.18	763.78

Value added statement consolidated

Amount in BDT million

VALUE ADDED	2019-20	2018-19
Value added by operating activities	2,653.85	2,737.28
Net revenue	7,647.70	8,705.17
Less: Cost of goods and services provided	(4,993.86)	(5,967.90)
Value added by investing activities	47.56	30.97
Interest and other income	41.09	22.25
Share of profit from associates	6.47	8.72
Wealth created	2,701.41	2,768.25

VALUE DISTRIBUTED	2019-20	%	2018-19	%
Distributed to employees	962.59	35.63	909.15	32.84
Salaries, wages, allowances and bonus	962.59	35.63	909.15	32.84
Distributed to Government	17.78	0.66	44.24	1.60
Income tax	17.78	0.66	44.24	1.60
Distributed to providers of capital	234.00	8.66	351.00	12.68
Dividend	234.00	8.66	351.00	12.68
Value reinvested	983.99	36.42	843.27	30.46
Depreciation and amortization	936.82	34.68	822.06	29.70
Deferred tax	47.17	1.75	21.21	0.77
Value retained	503.05	18.62	620.58	22.42
Retained profit	431.69	15.98	531.35	19.19
Non-controlling interest	71.36	2.64	89.23	3.22
Wealth created	2,701.41	100.00	2,768.25	100.00




Share performance

Particulars	DSE	CSE
Stock symbol	ORIONPHARM	ORIONPHARM
Business segment	Pharmaceuticals & chemicals	Pharma & chemicals
Company ID	18486	13027
Listing year	2013	2013
Market category	A	A
Electronic share	Yes	Yes
Total number of outstanding securities	234,000,000	234,000,000

Particulars	June 2020	June 2019
Market capitalization – DSE (BDT million)	9,828.00	7,768.80
Market capitalization – CSE (BDT million)	9,804.60	7,722.00
EPS (BDT)	2.48	3.77
DPS (BDT)	1.00	1.50
Payout ratio (%)	35.21	39.74
Share price – DSE (BDT)	42.00	33.20
Share price – CSE (BDT)	41.90	33.00
Weighted average number of shares outstanding	234,000,000	234,000,000


MONTH END SHARE PRICE (DSE)

From July 2019 to June 2020




MONTH END SHARE PRICE (CSE)

From July 2019 to June 2020




MARKET CAPITALIZATION (DSE)

Amount in BDT Million



MARKET CAPITALIZATION (CSE)

Amount in BDT Million



Orion Pharma Limited

Auditor's Report and Consolidated Financial Statements For the year ended 30 June 2020

 **S.F. AHMED & CO.**
Chartered Accountants ...since 1958
Member Firm of HLB International

Dhaka Office:

House - 51 (2nd & 3rd Floor), Road - 9, Block - F,
Banani, Dhaka - 1213, Bangladesh
Phones: (880-2) 9870957, 01707079855,
01707079856
Fax: (880-2) 55042314
E-mail: sfaco@dhaka.net; sfaco@sfahmedco.com

Chittagong Office:

Ispahani Building (2nd Floor)
Agrabad C/A, Chittagong, Bangladesh
Phone: (880) 31-716184
Fax: (880) 31-713683
Email: sfaco@bbts.net

S. F. AHMED & CO.

Chartered Accountants | since 1958

House # 51 (2nd & 3rd Floors)
Road # 09, Block F,
Banani, Dhaka 1213,
Bangladesh
Website: www.sfahmedco.com

Telephone : (88-02) 9872584, 9870957
Mobile (88) 01707 079855, 01707 079856
Fax (88-02) 55042314
E-mail sfaco@sfahmedco.com
sfaco@dhaka.net

INDEPENDENT AUDITOR'S REPORT TO THE SHAREHOLDERS of Orion Pharma Limited Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Orion Pharma Limited and its subsidiaries (the Group), which comprise the consolidated statement of financial position as at 30 June 2020 and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity, consolidated statement of cash flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of the Company as at 30 June 2020 and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the consolidated financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole and in forming our opinion thereon and we do not provide a separate opinion on these matters.

Key audit matter description	How the scope of our audit responded to the key audit matter
<p>Revenue</p> <p>ISAs require that, as part of our overall response to the risk of fraud, when identifying and assessing the risks of material misstatement due to fraud, we evaluate which types of revenue or revenue transactions might give rise to potential fraud risks.</p> <p>The Group sells different kinds of pharmaceutical products, animal health products, oncology-based products, agro-based products and power generation across a number of geographical areas in home and abroad. We have specifically focused this key audit matter to cut-off and occurrence for revenue recorded within 30 June 2020. Pressures to meet stakeholders' expectations could provide incentives to record revenues where controls of the goods have not passed.</p>	<p>Audit procedures performed</p> <p>We performed walkthroughs of the revenue cycle at significant components to gain an understanding of when the revenue should be recognized, to map out the relevant controls end to end and the processes in place.</p> <p>We assessed the design and implementation of these controls. We tested a sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents. We performed analytical reviews to identify any unusual or one-off material revenue transactions.</p>



Key audit matter description	How the scope of our audit responded to the key audit matter
<p>The associated disclosure is included within Note 27. For specific detail on the Group's accounting policy, please see Note 3.1.</p>	<p>We identified and considered the impact of any credit notes or inventory returns occurring after year-end, including evaluating the impact of any material overdue debts from customers.</p> <p>With regard to the implementation of IFRS 15 "Revenue from Contract with Customers", we verified management's conclusion from assessing different types of contracts and the accuracy of the revised accounting policies in light of the industry specific circumstances and our understanding of the business. We tested the appropriateness of the accounting treatment on a sample basis. In addition, we verified the accuracy of IFRS 15 related disclosures.</p> <p>Key observations communicated to the Audit Committee</p> <p>We were satisfied that the revenue recognition policies have been applied appropriately. Based on the work performed, we concluded that revenue has been recorded appropriately.</p>
<p>Inventory</p>	
<p>At the reporting date, the carrying value of inventory amounted to Taka 1,277,620,688 which is 3.47% of total assets. Inventories were considered as a key audit matter due to the size of the balance and because inventory valuation involves management judgement.</p> <p>Inventory valuation and existence was an audit focus area because of the number of locations/stores that inventory was held at, and the judgement applied in the valuation of inventory to incorporate inventory shrinkage.</p> <p>According to the Group's accounting policy, inventories are measured at the lower of cost or net realizable value. The Group has specific procedures for identifying risk for obsolete items and measuring inventories at the lower of cost and net realizable value.</p> <p>The associated disclosure is included within Note 11. For specific detail on the Group's accounting policy, please see Note 3.5.</p>	<p>Audit procedures performed</p> <ul style="list-style-type: none"> Assessing the compliance of Group's accounting policies over inventory with applicable accounting standards. Assessing the inventory valuation process and practices. On major locations, we tested the effectiveness of the key controls. Assessing the analyses made by management with respect to slow moving and obsolete stock. Attending inventory count on 30 June 2020 and reconciling the count results to the inventory listings to test the completeness of data. Comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories. Reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year. Evaluating the correctness of the valuation of raw materials and packing material as per FIFO method. Reviewing the calculation of standard labor hours and their regular comparison with actual labor hours of production; and reviewing the process of valuing work-in-progress. <p>Key observations communicated to the Audit Committee</p> <p>We were satisfied that the inventory recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that inventories have been recorded appropriately.</p>

Key audit matter description	How the scope of our audit responded to the key audit matter
Property, plant and equipment and capital work in progress	
<p>At the reporting date, the carrying value of the Group's property, plant and equipment and construction work in progress amounted to Taka 14,930,942,237 and 1,651,460,156 respectively. The valuation of property, plant, and equipment was identified as a key audit matter due to the significance of this balance to the financial statements, as well as the significance of management's judgements in determining its valuation.</p> <p>In considering the valuation of property, plant, and equipment, we focused on the assessment of the followings:</p> <ul style="list-style-type: none"> • Inherent risks associated with property, plant and equipment. • Potential misstatements in property, plant, and equipment on account of frauds and errors. • Valuation of capital work in progress to PPE. • Assessment of useful lives of assets. • Assessment of impairment of assets. <p><u>Inherent risks associated with property, plant and equipment</u></p> <ul style="list-style-type: none"> • Property, plant and equipment may include assets that should have been derecognised following sale, other transfer of rights or abandonment. • Expenditure that should have been recognised as property, plant and equipment but has not been so recognised, including capitalised finance costs. • Depreciation may have been incorrectly calculated. <p><u>Potential misstatements in property, plant and equipment on account of frauds and errors</u></p> <ul style="list-style-type: none"> • Purchase of an asset at an inflated price especially from a related party. • Wrong write-off of the asset as scrap, obsolescence, missing, donated, or destroyed. • Expenditures for repairs and maintenance recorded as property, plant and equipment or vice versa. • Capitalization of expenditure which are not normally attributable to the cost of the property, plant and equipment. • Recording of an asset purchased, which in effect has not actually been received by the entity at all. <p><u>Valuation of capital work in progress to PPE</u></p> <p>Management needs to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work in progress. An appropriate system needs to put in place to capture all directly identifiable costs, which can be capitalised, to be so</p>	<p><u>Audit procedures performed</u></p> <ul style="list-style-type: none"> • We obtained an understanding of the client and its environment to consider inherent risk related to property, plant, and equipment. Our understanding includes: <ul style="list-style-type: none"> ◆ Obtaining an understanding of the internal control over property, plant, and equipment. ◆ Assessing the risks of material misstatement and designing tests of controls and substantive procedures that cover the following aspects: <ul style="list-style-type: none"> ✓ Substantiate the existence of property, plant, and equipment. ✓ Establish the completeness of recorded property, plant, and equipment. ✓ Verify the cut-off of transactions affecting property, plant, and equipment. ✓ Establish the proper valuation or allocation of property, plant, and equipment and the accuracy of transactions affecting property, plant, and equipment. ✓ Determine the correctness and appropriateness of classification of property, plant and equipment. • We obtained an understanding of the potential misstatements in property, plant, and equipment on account of frauds and errors. • We evaluated the assumptions made by management in the determination of useful lives to ensure that these are consistent with the principles of IAS 16 "Property, Plant and Equipment". • We compared the useful lives of each class of asset in the current year to the prior year to determine whether there were any significant changes in the useful lives of assets, and considered the reasonableness of changes based on our knowledge of the business and the industry. • We verified records e.g. contractor bills, work orders and certification of work performed by the specialized personnel to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work in progress. • We also verified the date on which the assets are moved from the capital work in progress account to the property, plant and equipment (the date on which the asset is ready for intended use), so that the depreciation on property, plant and equipment may be computed correctly.

Key audit matter description	How the scope of our audit responded to the key audit matter
<p>accumulated to capital work in progress whilst expenses which are not eligible for being capitalised are identified and charged to revenue in the normal course.</p> <p>Assessment of useful lives of assets</p> <p>Management applies estimates and judgements in its determination of useful lives of assets and reviews the useful lives of assets at each financial year end and adjusts for changes, where appropriate.</p> <p>Impairment of assessment</p> <p>At the end of each reporting period, management assesses whether there is any indication that an asset may be impaired. If any such indication exists, management estimates the recoverable amount of the asset. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount.</p> <p>The associated disclosure is included within Note 5 & 7. For specific detail on the Group's accounting policy, please see Note 3.2.</p>	<ul style="list-style-type: none"> • We reconciled the movement of capital work in progress from opening to closing, specifically verifying additions during the year, capital assets completed during the year and impairment of any opening capital work in progress items. • We assessed whether there are circumstances that indicate a possible impairment of property, plant and equipment and if such circumstances exist, how the same have been dealt with by the entity. <p>Key observations communicated to the Audit Committee</p> <p>We were satisfied that the property, plant and equipment recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that property, plant and equipment have been recorded appropriately.</p>

Reporting on Other Information

Management is responsible for the other information. The other information comprises the information included in the Annual Report, other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If we identify such material inconsistencies or apparent material misstatement, we are required to determine whether there is a material misstatement in the consolidated financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. **We have nothing to report in respect of these matters.**

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Group so far as it appeared from our examination of these books;
- c) the consolidated statement of financial position and consolidated statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts; and
- d) the expenditure incurred was for the purposes of the Group's business.

The engagement partner on the audit resulting in this independent auditor's report is Md. Enamul H. Choudhury.

Dated, Dhaka;
08 November 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Consolidated Statement of Financial Position
As at 30 June 2020

	Notes	Amount in Taka	
		30 June 2020	30 June 2019
Assets			
Non-current assets		19,094,525,507	18,714,576,518
Property, plant and equipment	5	14,930,942,237	12,937,529,084
Right of use Assets	6	50,347,853	-
Construction work-in-progress	7	1,651,460,156	3,369,075,037
Investment in associate	9	319,403,000	254,282,000
Other investments	10	2,142,372,262	2,153,690,397
Current assets		17,746,581,258	12,275,841,589
Inventories	11	1,277,620,688	918,051,609
Trade and other receivables	12	11,648,659,127	10,108,011,586
Advances, deposits and prepayments	13	3,766,540,017	1,145,562,629
Fixed deposit with banks	14	19,583,098	12,028,336
Cash and cash equivalents	15	1,034,178,328	92,187,429
Total assets		36,841,106,765	30,990,418,107
Shareholder's equity and liabilities			
Shareholder's equity		17,963,721,397	17,594,351,998
Share capital	16	2,340,000,000	2,340,000,000
Share premium		8,016,892,026	8,016,892,026
Reserves	17	1,936,593,119	1,908,891,010
Retained earnings	18	5,670,236,252	5,328,568,962
Non - controlling interest	19	1,225,990,411	1,154,626,813
Total equity		19,189,711,809	18,748,978,811
Non-current liabilities		13,255,941,300	8,150,475,040
Redeemable preference shares	Annexure-F	-	500,000,000
Provision for decommissioning of assets	Annexure-G	143,405,563	143,405,563
Long term loan	20	12,871,151,380	7,356,383,000
Lease obligation	21	46,909,046	26,573,217
Employee benefits payable	22	51,864,239	25,886,783
Deferred tax liability	23	142,611,072	98,226,477
Current liabilities		4,395,453,657	4,090,964,256
Current portion of long term loan	20.3	201,882,832	256,375,584
Current portion of lease obligation	21.1	38,345,934	15,417,560
Short term loans	24	565,995,722	565,283,464
Trade and other payables	25	3,185,123,864	2,590,499,077
Accrued expenses	26	404,105,305	663,388,571
Total equity and liabilities		36,841,106,765	30,990,418,107
Number of shares used to compute NAV		234,000,000	234,000,000
Net asset value (NAV) including revaluation surplus		76.77	75.19
Net asset value (NAV) excluding revaluation surplus		68.69	66.98

The annexed notes form an integral part of these financial statements.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
08 November 2020

Sd/-
S F Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED
Statement of Financial Position
As at 30 June 2020

	Notes	Amount in Taka	
		30 June 2020	30 June 2019
Assets			
Non-current assets		13,041,155,930	12,040,783,721
Property, plant and equipment	5a	7,860,572,660	5,246,736,287
Right of use Assets	6	50,347,853	-
Construction work-in-progress	7	1,651,460,156	3,369,075,037
Investment in subsidiaries	8	1,017,000,000	1,017,000,000
Investment in associate	9	319,403,000	254,282,000
Other investments	10	2,142,372,262	2,153,690,397
Current assets		8,207,699,634	7,242,106,413
Inventories	11a	345,170,358	270,587,251
Trade and other receivables	12a	5,920,737,952	6,020,796,815
Advances, deposits and prepayments	13a	1,291,850,015	907,965,205
Fixed deposit with banks	14	19,583,098	12,028,336
Cash and cash equivalents	15a	630,358,211	30,728,806
Total assets		21,248,855,564	19,282,890,134
Shareholder's equity and liabilities			
Shareholder's equity		12,367,122,098	12,469,096,711
Share capital	16	2,340,000,000	2,340,000,000
Share premium		8,016,892,026	8,016,892,026
Reserves	17a	1,552,679,134	1,509,109,947
Retained earnings	18a	457,550,939	603,094,738
Non-current liabilities		7,201,719,921	5,091,407,432
Long term loan	20a	6,987,470,945	4,940,720,955
Lease obligation	21	46,909,046	26,573,217
Employee benefits payable	22.a	24,728,858	25,886,783
Deferred tax liability	23	142,611,072	98,226,477
Current liabilities		1,680,013,544	1,722,385,991
Current portion long term loan	20.a.1	201,882,832	256,375,584
Current portion of lease obligation	21.1	38,345,934	15,417,560
Short term loans	24	565,995,722	565,283,464
Trade and other payables	25.a	603,503,932	623,062,003
Accrued expenses	26.a	270,285,125	262,247,380
Total shareholder's equity and liabilities		21,248,855,564	19,282,890,134
Number of shares used to compute NAV		234,000,000	234,000,000
Net asset value (NAV) including revaluation surplus		52.85	53.29
Net asset value (NAV) excluding revaluation surplus		46.92	47.31

The annexed notes form an integral part of these financial statements.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
08 November 2020

Sd/-
S F Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2020

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue from net sales	27	7,647,703,031	8,705,172,867
Cost of goods sold	28	(1,016,645,021)	(986,119,636)
Cost of power generation	29	(4,053,220,067)	(5,173,369,794)
Gross profit		2,577,837,943	2,545,683,437
Operating expenses		(991,394,391)	(948,530,229)
General and administrative expenses	30	(390,695,212)	(362,879,890)
Selling and distribution expenses	31	(600,699,179)	(585,650,340)
Profit from operation		1,586,443,551	1,597,153,207
Financial expenses	32	(792,229,161)	(577,625,205)
Interest and other income	33	41,092,252	22,249,730
Net profit from operation		835,306,643	1,041,777,733
Workers profit participation fund		(39,776,507)	(13,466,976)
Net profit before tax		795,530,136	1,028,310,756
Income tax		(64,948,176)	(65,450,396)
Current tax expenses	34	(17,777,911)	(44,244,820)
Deferred tax income/(expense)	23.1	(47,170,266)	(21,205,576)
Net profit after tax		730,581,960	962,860,360
Share of profit from associate	9	6,467,800	8,722,411
Net profit after tax		737,049,760	971,582,771
Less: Non controlling interest	19	(71,363,599)	(89,227,797)
Net profit attributable to ordinary shareholders		665,686,161	882,354,974
Other comprehensive income		54,635,251	(14,264,018)
Fair value gain/(loss) on marketable securities		(11,233,620)	(7,958,757)
Fair value gain/(loss) on investment in associates		63,331,730	(8,301,920)
Share of other comprehensive income of associate		(248,530)	22,510
Deferred tax income/(expenses) on revaluation surplus of PPE & fair value changes in marketable securities		2,785,671	1,974,149
Total comprehensive income attributable to ordinary shareholders		720,321,411	868,090,956
Earnings per share (EPS)	35	2.84	3.77

The annexed notes form an integral part of these financial statements.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
08 November 2020

Sd/-
S F Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2020

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue from net sales	27a	2,297,740,301	2,222,541,814
Cost of goods sold	28	(1,016,645,021)	(986,119,636)
Gross profit		1,281,095,280	1,236,422,177
Operating expenses		(902,584,790)	(858,597,090)
General and administrative expenses	30a	(301,885,611)	(272,946,751)
Selling and distribution expenses	31	(600,699,179)	(585,650,340)
Profit from operation		378,510,491	377,825,087
Financial expenses	32a	(154,139,090)	(117,268,314)
Interest and other income	33	41,092,252	22,249,730
Net profit from operation		265,463,653	282,806,504
Workers profit participation fund		(12,641,126)	(13,466,976)
Net profit before tax		252,822,527	269,339,528
Income tax		(64,948,176)	(65,450,396)
Current tax expenses	34	(17,777,911)	(44,244,820)
Deferred tax income/(expense)	23.1	(47,170,266)	(21,205,576)
Net profit after tax		187,874,350	203,889,131
Share of profit from associate	9	6,467,800	8,722,411
Net profit after tax		194,342,150	212,611,542
Other comprehensive income		54,635,251	(14,264,019)
Fair value gain/(loss) of marketable securities		(11,233,620)	(7,958,757)
Fair value gain/(loss) on investment in associates		63,331,730	(8,301,921)
Share of other comprehensive income of associate		(248,530)	22,510
Deferred tax income/(expenses) on revaluation surplus of PPE & fair value changes of marketable securities		2,785,671	1,974,149
Total comprehensive income attributable to ordinary shareholders		248,977,400	198,347,523
Earnings per share (EPS)	35a	0.83	0.91

The annexed notes form an integral part of these financial statements.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
08 November 2020

Sd/-
S F Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Consolidated Statement of Changes in Equity
For the year ended 30 June 2020

Particulars	Amount in Taka						
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Sub Total	Non-Controlling Interest	Total
Balance as at 01 July 2019	2,340,000,000	8,016,892,026	1,908,891,010	5,328,568,962	17,594,351,999	1,154,626,813	18,748,978,811
Net profit after Tax	-	-	-	665,686,161	665,686,161	71,363,599	737,049,760
Fair value gain/(loss) on investment in associates	-	-	63,331,730	-	63,331,730	-	63,331,730
Dividend for the year 2018-2019	-	-	-	(351,000,000)	(351,000,000)	-	(351,000,000)
Adjustment for sale of marketable securities	-	-	47,987	-	47,987	-	47,987
Fair value gain/(loss) on marketable securities	-	-	(11,233,620)	-	(11,233,620)	-	(11,233,620)
Share of other comprehensive income of associate	-	-	(248,530)	-	(248,530)	-	(248,530)
Adjustment for deferred tax on revaluation surplus	-	-	2,785,671	-	2,785,671	-	2,785,671
Depreciation on revaluation surplus	-	-	(26,981,129)	26,981,129	-	-	-
Balance as at 30 June 2020	2,340,000,000	8,016,892,026	1,936,593,119	5,670,236,252	17,963,721,397	1,225,990,411	19,189,711,809

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Consolidated Statement of Changes in Equity
For the year ended 30 June 2019

Particulars	Amount in Taka						
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Sub Total	Non-Controlling Interest	Total
Balance as at 01 July 2018	2,340,000,000	8,016,892,026	1,944,512,924	4,752,806,311	17,054,211,261	1,065,399,016	18,119,610,277
Prior year adjustment	-	-	-	15,956,766	15,956,766	-	15,956,766
Net profit after tax	-	-	-	882,354,974	882,354,974	89,227,797	971,582,771
Fair value gain/(loss) on investment in associates	-	-	(8,301,921)	-	(8,301,921)	-	(8,301,921)
Dividend for the year 2017-2018	-	-	-	(351,000,000)	(351,000,000)	-	(351,000,000)
Adjustment for sale of marketable securities	-	-	7,093,015	-	7,093,015	-	7,093,015
Fair value gain/(loss) on marketable securities	-	-	(7,958,757)	-	(7,958,757)	-	(7,958,757)
Share of other comprehensive income	-	-	22,510	-	22,510	-	22,510
Adjustment for deferred tax on revaluation surplus	-	-	1,974,149	-	1,974,149	-	1,974,149
Adjustment for depreciation on revaluation surplus	-	-	(28,450,911)	28,450,911	-	-	-
Balance as at 30 June 2019	2,340,000,000	8,016,892,026	1,908,891,010	5,328,568,962	17,594,351,998	1,154,626,813	18,748,978,811

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Dated, Dhaka;
 08 November 2020

Sd/-
S F Ahmed & Co.
 Chartered Accountants

ORION PHARMA LIMITED
Statement of Changes in Equity
For the year ended 30 June 2020

Particulars	Amount in Taka				
	Ordinary Share Capital	Share Premium	Reserve	Retained Earnings	Total
Balance as at 01 July 2019	2,340,000,000	8,016,892,026	1,509,109,947	603,094,738	12,469,096,711
Net profit after tax	-	-	-	194,342,150	194,342,150
Dividend for the period 2018- 2019	-	-	-	(351,000,000)	(351,000,000)
Fair value gain/(loss) on investment in associates	-	-	63,331,730	-	63,331,730
Share of other comprehensive income of associate	-	-	(248,530)	-	(248,530)
Adjustment for sale of marketable securities	-	-	47,987	-	47,987
Fair value gain/(loss) on marketable securities	-	-	(11,233,620)	-	(11,233,620)
Adjustment for deferred tax on revaluation surplus	-	-	2,785,671	-	2,785,671
Adjustment for depreciation on revaluation surplus	-	-	(11,114,051)	11,114,051	-
Balance as at 30 June 2020	2,340,000,000	8,016,892,026	1,552,679,134	457,550,939	12,367,122,098

ORION PHARMA LIMITED
Statement of Changes in Equity
For the year ended 30 June 2019

Particulars	Amount in Taka				
	Ordinary Share Capital	Share Premium	Reserve	Retained Earnings	Total
Balance at 01 July 2018	2,340,000,000	8,016,892,026	1,528,864,782	712,942,598	12,598,699,407
Prior year adjustment	-	-	-	15,956,766	15,956,766
Net profit after tax	-	-	-	212,611,542	212,611,542
Dividend for the period 2017- 2018	-	-	-	(351,000,000)	(351,000,000)
Fair value gain/(loss) on investment in associates	-	-	(8,301,921)	-	(8,301,921)
Share of other comprehensive income of associates	-	-	22,510	-	22,510
Adjustment for sale of marketable securities	-	-	7,093,015	-	7,093,015
Fair value gain/(loss) on marketable securities	-	-	(7,958,757)	-	(7,958,757)
Adjustment for deferred tax on revaluation surplus	-	-	1,974,149	-	1,974,149
Adjustment for depreciation on revaluation surplus	-	-	(12,583,832)	12,583,832	-
Balance as at 30 June 2019	2,340,000,000	8,016,892,026	1,509,109,947	603,094,738	12,469,096,711

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

Dated, Dhaka,
08 November 2020

Sd/-
S F Ahmed & Co.
Chartered Accountants

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Consolidated Statement of Cash Flows
For the year ended 30 June 2020

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
A. Cash flows from operating activities			
Cash received from customers and others		6,686,325,836	9,692,190,702
Cash paid to suppliers and others		(3,951,502,857)	(7,394,162,508)
Cash payment for operating expenses		(816,026,026)	(801,728,472)
Cash generated from operations		1,918,796,953	1,496,299,722
Income taxes paid		(36,465,342)	(47,752,252)
Net cash (used in)/ provided by operating activities	36	1,882,331,611	1,448,547,470
B. Cash flows from investing activities			
Acquisition of property, plant & equipment		(646,393,821)	(815,813,155)
Proceeds from sale of PPE		5,795,000	1,350,000
Capital work-in-progress		(897,060,499)	(532,643,067)
Investment in securities and others		132,503	18,677,590
Investment in subsidiaries, associate and others		89,970,348	(461,351,605)
Investment in FDR		(7,554,761)	(4,463,074)
Interest, dividend & other income		36,396,540	21,999,242
Net cash (used in)/ provided by investing activities		(1,418,714,691)	(1,772,244,069)
C. Cash flows from financing activities			
Proceed from/(repayment of) long term loan		4,960,275,628	926,249,112
Proceed from/(repayment of) short term loan		(3,008,814,249)	(78,693,428)
Payment of lease obligation		(34,542,816)	(7,582,425)
Interest paid		(1,065,485,018)	(594,953,758)
Dividend paid		(373,059,566)	(336,185,883)
Net cash (used in)/ provided by financing activities		478,373,979	(91,166,381)
Net cash increase/(decrease) during the year (A+B+C)		941,990,899	(414,862,980)
Cash & cash equivalents at the beginning of the year		92,187,429	507,050,409
Cash & cash equivalents at the end of the year		1,034,178,328	92,187,429
Net operating cash flows per share (NOCFPS)	36.1	8.04	6.19

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED
Statement of Cash Flows
For the year ended 30 June 2020

	Notes	Amount in Taka	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
A. Cash flows from operating activities			
Cash received from customers and others		2,312,676,543	2,194,277,763
Cash paid to suppliers and others		(874,143,337)	(761,305,773)
Cash payment for operating expenses		(816,026,026)	(801,728,472)
Cash generated from operations		622,507,180	631,243,518
Income taxes paid		(36,465,342)	(47,752,252)
Net cash (used in)/ provided by operating activities	36.a	586,041,838	583,491,267
B. Cash flows from investing activities			
Acquisition of property, plant & equipment		(645,319,587)	(809,807,368)
Proceeds from sale of PPE		5,795,000	1,350,000
Capital work-in-progress		(897,060,499)	(532,643,067)
Investment in securities and others		132,503	18,677,590
Investment in subsidiaries, associate and others		89,970,348	(461,351,605)
Investment in FDR		(7,554,761)	(4,463,074)
Interest, dividend & other income		36,396,540	21,999,242
Net cash (used in)/ provided by investing activities		(1,417,640,457)	(1,766,238,282)
C. Cash flows from financing activities			
Proceed from/(repayment of) long term loan		1,992,257,238	1,358,925,234
Proceed from/(repayment of) short term loan		712,258	(17,067,801)
Payment of lease obligation		(34,542,816)	(7,582,425)
Interest paid		(154,139,091)	(117,268,315)
Dividend paid		(373,059,566)	(336,185,883)
Net cash (used in)/ provided by financing activities		1,431,228,024	880,820,810
Net cash increase/(decrease) during the year (A+B+C)		599,629,405	(301,926,204)
Cash & cash equivalents at the beginning of the year		30,728,806	332,655,011
Cash & cash equivalents at the end of the year		630,358,211	30,728,806
Net operating cash flows per share (NOCFPS)	36.a.1	2.50	2.49

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Notes, Comprising a Summary of Significant Accounting Policies and
Other Explanatory Information
For the year ended 30 June 2020

1. Reporting entity

1.1 Background of the entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company "Orion House" is situated at 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh.

The company was listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.1.2 Nature of business

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

1.2 Subsidiary companies

1.2.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. (IEL Consortium and Associate Ltd.) was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO power-based plant on quick rental basis in Meghnaghat, Dhaka with machineries and equipment supplied by Wartsila OY, Finland. The generated output of 105 MW electricity is being regularly supplied to national grid. Orion Pharma Ltd. Holds 95% of equity share of this company directly.

1.2.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Limited was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO power plant on quick rental basis in Siddhirganj, Narayanganj with machineries and equipment supplied by Wartsila OY, Finland. The generated output of 105 MW electricity is being regularly supplied to national grid. Orion Pharma Ltd. Holds 67% of equity share of this company.

1.2 Associate company

Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. Holds 21.76 % of equity share of this company directly.

2. Basis of preparation and presentation of financial statements

2.1 Statement of compliance

The financial statements have been prepared in accordance with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, Securities and Exchange Rules 1987 and other relevant local laws as applicable.

2.2 Components of the financial statements

According to IAS-1 "Presentation of Financial Statements", the complete set of financial statements includes the following components-

- i. Statement of Financial Position as at 30 June 2020,
- ii. Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2020,
- iii. Statement of Changes in Equity for the year ended 30 June 2020,
- iv. Statement of Cash Flows for the year ended 30 June 2020, and
- v. Notes, comprising a summary of significant accounting policies and other explanatory information for the year ended 30 June 2020.

2.3 Basis of measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value as explained in the accompanying notes.

2.4 Functional and presentation currency

The financial statements are prepared and presented in Bangladesh Taka/Tk./BDT, which is the company's functional currency. The Company earns its major revenues in BDT and all other incomes/expenses and transactions are in BDT. Further, the entire funds from financing activities are presented in BDT.

2.5 Comparative information

Comparative information has been disclosed in respect of year 01 July 2018 to 30 June 2019 for all numerical information in the financial statements and also the narrative, descriptive and rearrange of information where it is relevant for understanding of the current year's financial statements.

2.6 Reporting period

The financial year of the parent and subsidiary companies cover one year from 1 July 2019 to 30 June 2020.

2.7 Use of estimates and judgments

The preparation of financial statements in conformity with International Financial Reporting Standards (IFRS) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are recognized in the period in which the estimate is revised and in any future periods affected as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

2.8 Materiality, aggregation and off setting

Each material item as considered by management significant has been displayed separately in the financial statements. No amount has been set off unless the company has legal right to set off the amounts and intends to settle on net basis. Income and expenses are presented on a net basis only when permitted by the relevant accounting standards. The values of any asset or liability as shown in the statement of financial position are not off-set by way of deduction from another liability or asset unless there exist a legal right therefore.

2.9 Going concern review

As per IAS-1, a company is required to make assessment at the end of each year to make assessment of its capability to continue as going concern. Management of the company makes such assessment each year. The company has adequate resources to continue its operation for the foreseeable future and has wide coverage of its liabilities. For this reason, the directors continue to adopt going concern assumption while preparing the financial statements.

2.10 Date of authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on 08 November 2020.

PERFORMANCE & FINANCIALS > Notes to the financial statements

2.11 Corporate accounting standards practiced

The following IASs are applicable to the financial statements for the year under review:

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant and Equipment
IAS 19	Employee Benefits
IAS 21	The Effects of Changes in Foreign Exchange Rates
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 27	Separate financial statements
IAS 28	Investments in Associates and Joint Ventures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IAS 38	Intangible Assets

The following IFRSs are applicable to the financial statements for the year under review:

IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 10	Consolidated Financial Statements
IFRS 12	Disclosure of Interests in other Entities
IFRS 13	Fair Value Measurement
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases

3. Significant accounting policies

The accounting policies set out below are consistent with those used in the previous year. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Orion Pharma Limited.

Changes in accounting policies

The Group changes its accounting policy only if the change is required by an IFRS or results in the financial statements providing reliable and more relevant information about the effects of transactions, other events or conditions on the Group's financial position, financial performance or cash flows. Changes in accounting policies is to be made through retrospective application by adjusting opening balance of each affected components of equity i.e. as if new policy has always been applied.

Implementation of IFRS 16 'Leases'

The Group has applied IFRS 16 'Leases' with effect from 1 July 2019. IFRS 16 provides for the recognition, measurement, presentation and disclosure of leases. On transition to IFRS 16, As Right of use assets was equivalent to the lease liabilities at the date of initial application, no cumulative effect was necessary in retained earnings at the date of initial application.

Changes in accounting estimates

Estimates arise because of uncertainties inherent within them, judgment is required but this does not undermine reliability. Effect of changes of accounting estimates is included in profit or loss statement.

Correction of error in prior period financial statements

The Group corrects material prior period errors retrospectively by restating the comparative amounts for the prior period(s) presented in which the error occurred; or if the error occurred before the earliest prior period presented, restating the opening balances of assets, liabilities and equity for the earliest prior period presented.

3.1 Revenue

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be measured reliably, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment and excluding taxes or duties. The specific recognition criteria described below must also be met before revenue is recognized.

Sale of goods

Revenue from the sale of goods is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually on delivery of the goods.

Interest income

For all financial instruments measured at amortized cost and interest-bearing financial assets classified as available-for-sale, interest income is recorded using the Effective Interest Rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the net carrying amount of the financial asset or liability. Interest income is included in other income in the Statement of Profit or Loss and other Comprehensive Income.

Dividends

Revenue is recognized when the company's right to receive the payment is established, which is generally when shareholders approve the dividend.

Other income

Other Income recognized on accrual basis as per frame-work of International Financial Reporting Standards (IFRSs).

3.2 Property, plant and equipment

Recognition and measurement

An item shall be recognized as property, plant and equipment if and only if it is probable that future economic benefits associated with the item will flow to the entity and the cost of the item can be measured reliably in accordance with the provisions of IAS 16: Property, Plant and Equipment.

Property, plant and equipment are initially recognized at cost and subsequently land, buildings & civil constructions and plant & machineries are stated at fair value. The property, plant and equipment are presented at cost/fair value, net of accumulated depreciation and/or accumulated impairment losses, if any. The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for long-term debt availed for the construction/implementation of the PPE, if the recognition criteria are met.

Subsequent costs

The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of an item if it is probable that the future economic benefits embodied within the part will flow to the company and its cost can be measured reliably. The costs of the day-to-day servicing of property, plant and equipment are recognized in the profit and loss account as 'Repair & Maintenance' when it is incurred.

Depreciation on property, plant & equipment

Depreciation of an assets begins when it is available for use under reducing balance method. Depreciation is charged on all PPE except land and land developments at the following rates:

Particulars of Assets	Rate of Depreciation
Factory & office building	10%
Plant & machinery	15%
Furniture and fixtures	15%
Vehicles	20%
Office equipment	15%
Laboratory equipment	15%
Road & road development	2%

Revaluation of property, plant and equipment

Land, buildings & civil constructions and plant & machineries are subsequently measured at fair value. Valuations are performed at specific intervals to ensure that the fair value of a revalued asset does not differ materially from its carrying amount.

On 31 December 2008 & 31 December 2011 the company has made revaluation of the Company's Land and Land developments, Factory and Office Building and Plant and Machinery to reflect fair value thereof in terms depreciated current cost thereof. Details of revaluation as on 31 December 2011 are as follows:

Particulars of the assets	Name of the Valuer	Qualification of the Valuer	Date of Revaluation	The carrying amount of Assets	Value of Assets after revaluation	Revaluation Surplus
1. Land and Land development	Syful Shamsul Alam & Co. (Statutory auditor at that year S.F. Ahmed & Co.)	Chartered Accountants	31 December 2011	1,167,752,249	2,340,699,850	1,172,947,601
2. Factory and Office Building				144,440,015	198,198,786	53,758,771
3. Plant & Machinery				130,512,146	177,645,275	47,133,129
Total				1,442,704,410	2,716,543,911	1,273,839,501

The increase in the carrying amount of revalued assets is recognized in the separate component of equity under the head "Revaluation Surplus".

Other fixed assets were kept outside the scope of the revaluation works. These are expected to be realizable at written down value (WDV) thereof mentioned in The Statement of Financial Position of the company.

Impairment

The carrying amounts of property, plant and equipment are reviewed at each Statement of Financial Position date to determine whether there is any indication of impairment loss as per IAS 36: Impairment of Assets. If any such indication exists, recoverable amount is estimated in order to determine the extent of the impairment loss, if any. Impairment loss is recorded on judgmental basis, for which provision may differ in the future years based on the actual experience.

Disposal of property, plant and equipment

An item of property, plant and equipment is removed from The Statement of Financial Position when it is disposed of or when no future economic benefit is expected from its use or disposal. The gain or loss on the disposal of an item of property, plant and equipment is included in The Statement of Profit or Loss and Other Comprehensive Income of the year in which de-recognition occurs.

Property, plant and equipment under construction/acquisition have been accounted for as capital work-in-progress until construction/acquisition is completed and measured at cost.

3.3 Leases

The Group identifying a contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is conveyed where the customer has both the right to direct the identified asset's use and to obtain substantially all the economic benefits from that use.

The right of use asset is initially measured at the amount of the lease liability plus any initial direct costs incurred by the lessee. Adjustments may also be required for lease incentives, payments at or prior to commencement and restoration obligations or similar.

Depreciation have charged on right to use assets on straight line basis over the lease period.

The lease liability is initially measured at the present value of the lease payments payable over the lease term, discounted at the rate implicit in the lease if that can be readily determined. If that rate cannot be readily determined, the lessee shall use their incremental borrowing rate.

3.4 Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds.

3.5 Inventories

Inventories are included in the financial statements at the lower of cost (including raw materials, direct labor, other direct costs and related production overheads) and net realizable value. Cost is generally determined on a first in, first out basis.

3.6 Investment in associates

An entity in which an investor has significant influence but which is neither a subsidiary nor an interest in a joint venture is classified as investment in associates. Equity Method has been followed in accordance with IAS 28 "Investments in Associates and Joint Ventures".

3.7 Consolidated financial statements

A parent prepares consolidated financial statements when it controls one or more other entities using uniform accounting policies like transactions and other events in similar circumstances as per IFRS 10 "Consolidated Financial Statements".

Consolidated financial statements:

- Combine like items of assets, liabilities, equity, income, expenses and cash flows of the parent with those of its subsidiaries.
- Offset (eliminate) the carrying amount of the parent's investment in each subsidiary and the parent's portion of equity of each subsidiary.
- Eliminate in full intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between entities of the group (profits or losses resulting from intragroup transactions that are recognized in assets, such as inventory and fixed assets, are eliminated in full).

3.8 Earnings per share (EPS)

The company calculates Earning Per Share (EPS) in accordance with IAS 33 "Earnings Per Share" which has been shown on the face of The Statement of Profit or Loss and Other Comprehensive Income and the computation of EPS is stated in Note - 35 of the financial statements.

Basic earnings

This represents earnings for the period attributable to the ordinary shareholders. As there no preference dividend, minority interest or extra ordinary items, the net profit for the year has been considered as fully attributable to ordinary shareholders. Basic earnings per has been calculated by dividing the net profit or loss by the number of ordinary share outstanding during the year.

Diluted earnings per share (DEPS)

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and weighted average number of ordinary shares outstanding, for the effect of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there were no potential ordinary shares during the relevant period.

3.9 Foreign currency transactions

Foreign currency transactions are recorded, on initial recognition in the functional currency at the spot exchange rate ruling at the transaction date.

At the end of each reporting period in compliance with the provision of IAS 21: The Effects of Changes in Foreign Exchange Rates.

- (a) Foreign currency monetary items are translated using the closing rate.
- (b) Non-monetary items that are measured in terms of historical costs in a foreign currency are translated using the exchange rate at the date of the transaction.
- (c) Non-monetary items that are measured at fair value in a foreign currency is translated using the exchange rate at the date when the fair value is determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rate different from those at which they were translated on initial recognition during the period or in previous financial statements is recognized in Statement of Profit or Loss and Other Comprehensive Income in the period in which they arise.

3.10 Employee benefits provision

Recognized provident fund (RPF)

Permanent employees of the company are entitled to get provident fund where both the employee's and employer's contribution is respectively 10% which is recognized.

Workers' profit participation fund (WPPF)

WPPF charged @ 5% of net profit before tax as per labour Act 2006 (Amended in 2018), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".

3.11 Provisions, accrued expenses and other payables

Provisions are recognized when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in The Statement of Profit or Loss and Other Comprehensive Income net of any reimbursement.

Other payables are not interest bearing and are stated at their nominal value.

3.12 Financial Instruments

3.12.1 Financial assets

Investment in shares

The Group has elected to designate equity investments as measured at Fair Value through Other Comprehensive Income (FVTOCI). They are initially recorded at fair value plus transaction costs and then remeasured at subsequent reporting dates to fair value. Unrealized gains and losses are recognized in other comprehensive income.

Dividends on equity investments and distributions from funds are recognized in the statement of profit or loss and other comprehensive income when the Group's right to receive payment is established.

Investment in fixed deposit receipt

Fixed deposit, comprising funds held with banks and other financial institutions, are initially measured at fair value, plus direct transaction costs, and are subsequently measured at amortized cost using the effective interest method at each reporting date. Changes in carrying value are recognized in profit.

Trade receivables

Trade receivables are measured in accordance with the business model under which each portfolio of trade receivable is held. The Group has a portfolio of trade receivables that is being managed within a business model whose objective is to collect contractual cash flows, and are measured at amortized cost. Trade receivables measured at amortized cost are carried at the original invoice amount less allowance for expected credit losses.

Expected credit losses are calculated in accordance with the simplified approach permitted by IFRS 9, using a provision matrix applying lifetime historical credit loss experience to the trade receivables. The expected credit loss rate varies depending on whether and the extent to which settlement of the trade receivables is overdue and it is also adjusted as appropriate to reflect current economic conditions and estimates of future conditions. For the purpose of determining credit loss rates, customers are classified into groupings that have similar loss patterns. The key drivers of the loss rate are the nature of the business unit and the location and type of customer.

When a trade receivable is determined to have no reasonable expectation of recovery it is written off, firstly against any expected credit loss allowance available and then to the income statement. Subsequent recoveries of amounts previously provided for or written off are credited to the income statement.

Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, balances with banks and financial institutions, and highly liquid investments with maturities of three months or less when acquired. They are readily convertible into known amounts of cash and are held at amortized cost under the hold to collect classification, where they meet the hold to collect "solely payments of principals and interests" test criteria under IFRS 9. Those not meeting these criteria are held at fair value through profit and loss.

3.12.2 Financial liabilities

Borrowings

All borrowings are initially recorded at the amount of proceeds received, net of transaction costs. Borrowings are subsequently carried at amortized cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognized as a charge to the statement of profit or loss and other comprehensive income over the period of the relevant borrowing.

Trade payables

Trade payables are recognized initially at fair value. Subsequent to initial recognition they are measured at amortized cost using the effective interest method.

3.12.3 Impairment of financial assets

IFRS 9 requires an expected credit loss (ECL) model to be applied to financial assets rather than the incurred credit loss model required under IAS 39. The expected credit loss model requires the Group to account for expected losses as a result of credit risk on initial recognition of financial assets and to recognize changes in those expected credit losses at each reporting date. The Group recognizes a loss allowance on trade receivables based on lifetime expected credit losses.

3.13 Operating segments

No geographical segment reporting is applicable for the company as required by IFRS 8: "Operating Segments", as the company operates in a single geographical area.

3.14 Statement of cash flows

The Statement of Cash Flows has been prepared in accordance with the requirements of IAS-7: Statement of Cash Flows. The cash generating from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS-7 whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed.

3.15 Related party disclosures

As per IAS-24 'Related Party Disclosures', parties are considered to be related if one of the parties has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. The company carried out transactions in the ordinary course of business on an arm's length basis at commercial rates with its related parties. Related party disclosures have been given in note-38 in financial statements.

3.16 Income tax

Income tax expense comprises current and deferred tax. Income tax expense is recognized in the income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity.

3.16.1 Current tax

Current tax expense has been recognized on the basis of the Finance Act 2020 and Income Tax Ordinance 1984.

3.16.2 Deferred tax

Deferred tax is calculated using the carrying amount and tax base of assets and liabilities. Deferred tax arises due to temporary difference deductible or taxable for the events or transactions recognized in The Statement of Profit or Loss and Other Comprehensive Income. A temporary difference is the difference between the tax base of an asset or liability and its carrying amount / reported amount in the statement of financial position. Deferred tax asset or liability is the amount of income tax recoverable or payable in future periods recognized in the current period. The deferred tax asset / income or liability / expense do not create a legal recoverability / liability to and from the income tax authority. Deferred tax also arises due to revaluation of property, plant and equipment. The resulting impact of deferred tax assets / liabilities on revaluation surplus is included in The Statement of Profit or Loss and Other Comprehensive Income.

3.17 Contingent assets and liabilities

3.17.1 Contingent assets

A Contingent asset is disclosed when it is a probable asset that arises from the past events and whose existence will be confirmed only by the occurrence or non- occurrence of one or more uncertain future events not wholly within the control of the entity.

3.17.2 Contingent liabilities

A contingent liability is disclosed when it is a possible obligation that arises from the past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity.

The company has no contingent assets or liabilities which require disclosures under IAS-37. Contingent assets and contingent liabilities are not recognized in the financial statements.

3.18 Events after the reporting period

As per IAS-10: 'Events After the Reporting Period', events after the reporting period that provide additional information about the company's position at the balance sheet date or those that indicate the going concern assumption is not appropriate are reflected in the financial statements. Events after the reporting period have been given in note- 41 in the financial statements.

4 Risk exposure

4.1 Interest rate risk

Interest rate risk is the risk that Company faces due to unfavorable movements in the interest rates. Changes in the government's monetary policy, along with increased demand for loans/ investments tend to increase the interest rates. Such rises in interest rates mostly affect companies having floating rate loans or companies investing in debt securities.

Management perception

The company maintains low debt/ equity ratio; and accordingly, adverse impact of interest rate fluctuation is insignificant.

4.2 Exchange rate risk

Exchange rate risk occurs due to changes in exchange rates. As the company imports materials and equipment from abroad and also earns revenue in foreign currency, unfavorable volatility or currency fluctuation may affect the profitability of the company. If exchange rate increases against local currency, opportunity arises for generating more profit.

Management perception

The products of the company are sold mostly in local currency. Therefore, volatility of exchange rate will have no impact on profitability of the company.

4.3 Industry risk

Industry risk refers to the risk of increased competition from foreign and domestic sources leading to lower prices, revenues, profit margin, and market share which could have an adverse impact on the business, financial condition and results of operation.

Management perception

Management is optimistic about growth opportunity in pharmaceutical sector in Bangladesh. Furthermore, there is untapped international market.

4.4 Market risk

Market risk refers to the risk of adverse market conditions affecting the sales and profitability of the company. Mostly, the risk arises from falling demand for the product or service which would harm the performance of the company. On the other hand, strong marketing and brand management would help the company increase their customer base.

Management perception

Management is fully aware of the market risk, and act accordingly. Market for pharmaceuticals, drugs and medicines in Bangladesh is growing at an exponential rate. Moreover, the company has a strong marketing and brand management to increase the customer base and customer loyalty.

4.5 Operational risk

Non-availabilities of materials/equipment/services may affect the smooth operational activities of the company. On the other hand, the equipment may face operational and mechanical failures due to natural disasters, terrorist attacks, unforeseen events, lack of supervision and negligence, leading to severe accidents and losses.

Management perception

The company perceives that allocation of its resources properly can reduce this risk factor to great extent. The company hedges such risks in costs and prices and also takes preventive measures therefore.

4.6 Liquidity risk

Liquidity risk is defined as the risk that the company will not be able to its obligations on time or at a reasonable price.

Management perception

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/ fund to make the expected payment within due date.

		Amount in Taka			
		30 June 2020	30 June 2019		
5. Property, plant and equipment					
Opening balance		12,937,529,084	13,144,226,580		
Add: Addition during the year		2,904,286,804	616,465,384		
Less: Sale /disposal during the year		(1,517,015)	(1,099,512)		
		15,840,298,873	13,759,592,453		
Less: Depreciation charged during the year		(909,356,636)	(822,063,368)		
Written down value		14,930,942,237	12,937,529,084		
Details have been presented in Annexure - A.1					
5a. Property, plant and equipment					
Opening balance		5,246,736,287	4,809,521,233		
Add: Addition during the year		2,903,212,570	610,459,597		
Less: Sale /disposal during the year		(1,517,015)	(1,099,512)		
		8,148,431,842	5,418,881,318		
Less: Depreciation charged during the year		(287,859,182)	(172,145,031)		
Written down value		7,860,572,660	5,246,736,287		
Details have been presented in Annexure - A.2					
6. Right of use Assets					
Opening balance		-	-		
Add: Addition during the year		77,807,019	-		
		77,807,019	-		
Less: Depreciation charged during the year		(27,459,166)	-		
Details have been shown in Annexure - B		50,347,853	-		
7. Construction work in progress					
Opening balance		3,369,075,037	2,836,431,969		
Add: Addition during the year		897,060,499	532,643,067		
Less: Transferred to PPE		(2,614,675,380)	-		
Closing balance		1,651,460,156	3,369,075,037		
A state of the art factory is being constructed at Siddirgonj, Narayangonj to increase the overall production capacity of the company. In relation to that purpose substantial amount has been transferred to PPE from CWIP.					
8. Investment in subsidiaries					
		Share holding (%)		Amount in Taka	
Name of the subsidiary company	Number of shares	30 June 2020	30 June 2019	30 June 2020	30 June 2019
Orion Power Meghnaghat Ltd.	95,000,000	95.00	95.00	950,000,000	950,000,000
Dutch Bangla Power & Associates Ltd.	6,700,000	67.00	67.00	67,000,000	67,000,000
Total				1,017,000,000	1,017,000,000
Investment in subsidiaries are stated at cost.					
9. Investment in associates					
Orion Infusion Limited					
Opening balance		254,282,000	260,041,000		
Add: Share of profit during the year		6,467,800	8,722,411		
Less: Dividend during the year		(4,430,000)	(6,202,000)		
Add: Share of other comprehensive income		(248,530)	22,510		
Add: Fair value adjustment		63,331,730	(8,301,921)		
		319,403,000	254,282,000		
10. Other investment					
Investment in marketable securities (Note 10.1)		23,916,586	35,234,721		
Investment in non-Quoted Shares (Note 10.2)		2,118,455,676	2,118,455,676		
		2,142,372,262	2,153,690,397		
10.1 Investment on marketable securities					
AB Investment Limited		13,946,191	19,849,892		
Bank Asia Securities Limited		3,772,363	6,018,329		
LankaBangla Securities Limited		6,198,032	9,366,500		
		23,916,586	35,234,721		
Details have been presented in Annexure - C					
10.2 Investment in non-quoted shares					
Orion Power Khulna Limited		500,000	500,000		
Orion Power Dhaka Limited		500,000	500,000		
ICB Islami Bank Limited		246,000	246,000		
Orion Infrastructure Limited		2,117,209,676	2,117,209,676		
		2,118,455,676	2,118,455,676		

		Amount in Taka	
		30 June 2020	30 June 2019
11.	Inventories		
	Raw materials	145,426,337	126,896,948
	Packing materials	68,227,685	42,072,240
	Work-in-process	17,129,910	13,817,389
	Finished goods	75,769,179	44,674,750
	Printing Stationeries	2,826,678	2,700,130
	Promotional materials	6,114,954	4,775,586
	Goods in transit	434,800,503	136,980,104
	Mobil & Chemical	-	66,152,627
	Spare parts	340,123,417	399,272,958
	Inventory HFO & LFO	187,202,025	80,708,877
		1,277,620,688	918,051,609
11.a	Inventories		
	Raw materials	145,426,337	126,896,948
	Packing materials	68,227,685	42,072,240
	Work-in-process	17,129,910	13,817,389
	Finished goods	75,769,179	44,674,750
	Printing Stationeries	2,826,678	2,700,130
	Promotional materials	6,114,954	4,775,586
	Goods in transit	29,675,615	35,650,208
		345,170,358	270,587,251
12.	Trade & other receivables		
	Trade receivables	2,661,828,822	1,700,033,898
	Other receivables (Note-12.1)	8,986,830,305	8,407,977,688
		11,648,659,127	10,108,011,586

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	2,661,828,822	1,700,033,898
Above 180 days	-	-
	2,661,828,822	1,700,033,898

SL. No.	Particulars	Amount in Taka	
		30 June 2020	30 June 2019
I	Trade receivables considered good in respect of which the company is fully secured	2,661,828,822	1,700,033,898
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	Total	2,661,828,822	1,700,033,898

As on 30 June 2020 the company did not make any provision on the trade receivable as was no indication of impairment.

12.1	Other receivables		
	Claim receivables, insurance & others	3,064,643	2,158,262
	Divided receivable	4,430,000	6,202,000
	Interest on FDR	165,532	260,876
	Other receivables	209,566,675	179,159,898
	Current account with other related companies (Note. 12.1.1)	8,769,603,456	8,220,196,653
		8,986,830,305	8,407,977,688

12.1.1 Current account with other related companies

Noakhali Gold Foods Limited	33,129,928	24,974,785
Orion Properties Limited	33,871,089	33,871,089
Orion Gas Limited	49,200,000	49,200,000
Orion Power Khulna Limited	1,029,967,694	1,029,967,694
Orion Power Dhaka Limited	2,431,298,916	2,412,647,852
Jafflong Tea Company Limited	2,408,371	2,408,371
Orion Agro Products Limited	240,118,758	235,180,820
Interior Accom Consortium Limited	155,495,459	155,495,459
Digital Power & Associate Limited	444,684,971	327,635,887

PERFORMANCE & FINANCIALS > Notes to the financial statements

	Amount in Taka	
	30 June 2020	30 June 2019
Orion Footwear Limited	107,775,395	91,600,000
Orion Oil & Shipping Limited	215,230,919	151,412,851
Panbo Bangla Mushroom Limited	115,006,570	108,235,190
Orion Power Unit-2 Dhaka Limited	2,178,093,169	2,590,024,972
Orion Home Appliance Limited	47,848,000	7,848,000
Orion Knit Textiles Limited	220,544,115	219,000,000
Orion Hospitals Limited	16,500,000	4,400,000
Orion Power Rupsha Limited	305,033,401	245,563,731
Orion Power Sonargaon Limited	1,001,896,701	529,229,951
Energon Renewable (BD) Limited	1,500,000	1,500,000
Orion Quaderia Textiles Limited	130,000,000	-
Horizon Media & Publications Limited	10,000,000	-
	8,769,603,456	8,220,196,653
12.a Trade & other receivables		
Trade receivables	155,652,117	170,170,631
Other receivables (Note - 12.a.1)	5,765,085,835	5,850,626,184
	5,920,737,952	6,020,796,815

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	155,652,117	170,170,631
Above 180 days	-	-
	155,652,117	170,170,631

SL. No.	Particulars	Amount in Taka	
		30 June 2020	30 June 2019
I	Trade receivables considered good in respect of which the company is fully secured	155,652,117	170,170,631
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	Total	155,652,117	170,170,631

As on 30 June 2020 the company did not make any provision on the trade receivable as was no indication of impairment.

12.a.1 Other receivables

Claim receivables, insurance & others	3,064,643	2,158,262
Divided receivable	4,430,000	6,202,000
Interest on FDR	165,532	260,876
Other receivables	209,566,675	179,159,898
Current account with subsidiaries (12.a.1.1)	369,399,764	370,748,526
Current account with other related companies (12.a.1.2)	5,178,459,222	5,292,096,622
	5,765,085,835	5,850,626,184

12.a.1.1 Current account with subsidiaries

Dutch Bangla Power & Associates Limited	369,399,764	370,748,526
	369,399,764	370,748,526

12.a.1.2 Current account with other related companies

Orion Properties Limited	20,331,532	20,331,532
Orion Power Khulna Limited	986,021,913	986,021,913
Orion Power Dhaka Limited	2,176,293,707	2,176,293,707
Interior Accom Consortium Limited	107,995,459	107,995,459
Orion Agro Product Limited	232,265,920	232,265,920
Orion Power Unit -2 Dhaka Limited	1,358,708,776	1,483,046,176
Orion Power Rupsha Limited	186,800,000	186,800,000
Digital Power & Associates Limited	97,341,915	97,341,915
Orion Hospitals Limited	12,700,000	2,000,000
	5,178,459,222	5,292,096,622

	Amount in Taka	
	30 June 2020	30 June 2019
13. Advances, deposits and prepayments		
Advances:		
Advance income tax (Note-13.1)	133,033,784	104,849,701
Advance imprest money	43,000	114,000
Advance motor cycle	14,630,196	17,589,968
Advance - car loan	2,976,934	2,216,569
Collection advance	5,455,130	6,237,861
Advance to C&F agents	1,382,576	2,271,727
Advance to Supplier	225,604,358	203,211,611
Advance against land purchase	325,000,000	325,000,000
Advance against material loan	2,381,414	1,084,773
Advance office rent	6,898,673	5,277,769
Advance to employee	3,867,815	8,481,024
Other advance	2,037,716,920	125,132,500
Advance to depot	-	2,862,079
Advance for Impoted machinery	640,756,566	198,365,774
	3,399,747,367	1,002,695,356
Deposits:		
Earnest money	455,000	1,311,770
Security deposit	45,422,826	44,953,056
Bank guarantee	69,712,449	68,853,576
L/C margin	191,656,453	11,661,282
VAT current account	-	2,087
Lease deposit	15,021,334	11,917,725
	322,268,062	138,699,495
Prepayments:		
Insurance premium	953,003	321,119
Bank guarante, commission & charge	43,571,585	2,829,138
Deferred expenses	-	1,017,520
	44,524,588	4,167,777
	3,766,540,017	1,145,562,629
13.1 Advance income tax		
Opening balance	104,849,700	63,999,535
Add: Addition during the year	28,184,084	24,893,400
	133,033,784	88,892,935
Less: Adjustment for previous years assessment	-	15,956,766
	133,033,784	104,849,701
13.a Advances, deposits & prepayments		
Advances:		
Advance income tax (Note -13.a.1)	131,716,484	103,789,126
Advance imprest money	43,000	114,000
Motor cycle advance	14,630,196	17,589,968
Advance - car loan	2,976,934	2,216,569
Collection advance	5,455,130	6,237,861
Advance to C&F agents	1,382,576	2,271,727
Advance against material loan	2,381,414	1,084,773
Advance office rent	6,898,673	5,277,769
Advance against land purchase	325,000,000	325,000,000
Machinery & equipment	75,093,648	177,470,072
Electrical equipment	359,486	656,915
Construction	31,008,033	13,942,575
Advance for Impoted machinery	640,756,566	198,365,774
Advance to depot	-	2,862,079
	1,237,702,141	856,879,207
Deposits		
Earnest money	455,000	1,311,770
Security deposit	34,911,306	34,953,056
Bank guarantee	4,217,634	3,358,761
VAT current account	-	2,087
Lease deposit	14,563,934	11,460,324
	54,147,874	51,085,998
	1,291,850,015	907,965,205
All advances, deposits and prepayments are considered regular and recoverable in the normal course of business.		
13.a.1 Advance income tax		
Opening balance	103,789,126	63,118,101
Addition during the year	27,927,358	24,714,260
Less: Adjustment for previous years' assessment	-	15,956,766
	131,716,484	103,789,126

PERFORMANCE & FINANCIALS > Notes to the financial statements

	Amount in Taka	
	30 June 2020	30 June 2019
14. Fixed deposit with banks		
Social Islami Bank Limited, Principal Branch, Dhaka.	8,512,435	8,028,336
Agrani Bank Limited	11,070,663	4,000,000
Details have been presented in Annexure -D	19,583,098	12,028,336
15. Cash & cash equivalents		
Cash in hand (Note -15.1)	10,613,804	9,995,563
Cash at B/O account (Note -15.2)	93,022	7,830
Balance with banks on account	10,706,826	10,003,393
Current account	420,797,288	66,357,659
Short term deposit account	602,674,214	15,826,377
	1,023,471,502	82,184,036
	1,034,178,328	92,187,429
15.1 Cash in hand		
Head office	4,972,534	6,334,646
Depot office	5,641,270	3,660,917
	10,613,804	9,995,563
15.2 Cash at B/O account		
Bank Asia Securities Limited	89,350	4,493
Jahan Securities Limited	2,874	3,324
LankaBangla Securities Limited	798	14
	93,022	7,830
15.a Cash and cash equivalents		
Cash in hand (Note -15.a.1)	8,445,688	8,967,393
Cash at B/O account (Note -15.a.2)	93,022	7,830
	8,538,710	8,975,223
Cash at Bank:		
Current account	19,145,287	15,826,377
Short term deposit account	602,674,214	5,927,206
Details have been presented in Annexure-E	621,819,501	21,753,583
	630,358,211	30,728,806
15.a.1 Cash in hand		
Head office - central cash & main cash	2,804,418	5,306,476
Depot office - petty cash	5,641,270	3,660,917
	8,445,688	8,967,393
15.a.2 Cash at B/O account		
Bank Asia Securities Limited	89,350	4,493
Jahan Securities Limited	2,874	3,324
LankaBangla Securities Limited	798	14
	93,022	7,830
16. Share capital		
Authorized capital		
500,000,000 ordinary shares of Tk. 10 each	5,000,000,000	5,000,000,000
Issued, subscribed and paid-up capital		
234,000,000 ordinary shares of Tk. 10 each	2,340,000,000	2,340,000,000

Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of Holding	
			30 June 2020	30 June 2019
Up to 500 Shares	28,404	3,207,721	1.37	0.76
501 to 5,000 Shares	5,219	10,358,814	4.43	3.08
5001 to 10,000 Shares	944	6,836,575	2.92	2.30
10,001 to 20,000 Shares	510	7,147,643	3.05	2.61
20,001 to above	404	206,449,247	88.23	91.24
Total	35,481	234,000,000	100.00	100.00

Amount in Taka

30 June 2020

30 June 2019

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			30 June 2020	30 June 2019
Sponsors	5	74,841,600	31.98	31.98
Foreign Investor	153	3,852,998	1.65	2.59
Financial institutions	189	109,366,464	46.74	48.12
General public	35,134	45,938,938	19.63	17.31
Total	35,481	234,000,000	100.00	100.00

Orion Power Meghnaghat Limited	Number of Shares	30 June 2020		30 June 2019	
		Face Value	% of holding	Face Value	Total
Orion Pharma Limited	95,000,000	950,000,000	95.00%	950,000,000	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	30,000,000	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	5,000,000	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	5,000,000	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	6,000,000	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	3,500,000	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	500,000	0.05%
Total	100,000,000	1,000,000,000	100%	1,000,000,000	100%

Dutch Bangla Power & Associates Limited	Number of Shares	30 June 2020		30 June 2019	
		Face Value	% of holding	Face Value	% of holding
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67,000,000	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	500,000	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1,000,000	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30,875,000	30.88%
Orion Tea Company Limited	50,000	500,000	0.50%	500,000	0.50%
Jafflong Tea Co. Limited	2,500	25,000	0.03%	25,000	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	100,000	0.10%
Total	10,000,000	100,000,000	100%	100,000,000	100%

17. Reserves

Fair value gain/(loss) on investment in associates (Note -17.1)
 Fair value gain/(loss) on marketable securities (Note -17.2)
 Share of other comprehensive income of associate (Note - 17.3)
 Revaluation surplus on property, plant and equipment (Note -17.4)

237,175,941	173,844,211
(22,090,059)	(12,022,989)
5,748,129	5,996,659
1,715,759,107	1,741,073,129
1,936,593,119	1,908,891,010

17.1 Fair value gain on investment in associates

Opening balance
 Fair value gain/ (loss) during the year

173,844,211	182,146,131
63,331,730	(8,301,920)
237,175,941	173,844,211

17.2 Fair value gain/(loss) on marketable securities

Opening balance
 Adjustment of sale of marketable securities
 Fair value gain/(loss) on marketable securities (Note - 17.2.1)
 Transferred to deferred tax assets/(liabilities)

(12,022,989)	(11,243,821)
47,987	7,093,015
(11,233,620)	(7,958,757)
1,118,563	86,574
(22,090,059)	(12,022,989)

17.2.1 Fair value gain/(loss) on marketable securities during the year

Unrealized gain/(loss) position (closing)
 Unrealized gain/(loss) position (opening)
Total change during the year
 Fair value adjustment for sale of securities (realized loss)
Unrealized gain/(loss) during the year

(24,544,509)	(13,358,875)
(13,358,875)	(12,493,134)
(11,185,633)	(865,742)
(47,987)	(7,093,015)
(11,233,620)	(7,958,757)

17.3 Share of other comprehensive income

Opening balance
 Add: Addition during the year

5,996,659	5,974,149
(248,530)	22,510
5,748,129	5,996,659

PERFORMANCE & FINANCIALS > Notes to the financial statements

		Amount in Taka	
		30 June 2020	30 June 2019
17.4	Revaluation surplus on property, plant & equipment		
	Opening balance	1,741,073,129	1,767,636,465
	Adjustment during the year to retained earnings for depreciation	(26,981,129)	(28,450,911)
	Adjustment of deferred tax on revaluation surplus	1,667,108	1,887,575
		1,715,759,107	1,741,073,129
17.a	Reserve		
	Fair value gain on investment in associates (Note - 17.a.1)	237,175,941	173,844,211
	Fair value gain/(loss) on marketable securities (Note - 17.a.2)	(22,090,058)	(12,022,988)
	Share of other comprehensive income (Note - 17.a.3)	5,748,128	5,996,659
	Revaluation surplus on property, plant & equipment (Note - 17.a.4)	1,331,845,122	1,341,292,066
		1,552,679,134	1,509,109,947
17.a.1	Fair value gain on investment in associates		
	Opening balance	173,844,211	182,146,132
	Fair value gain/(loss) during the year	63,331,730	(8,301,921)
		237,175,941	173,844,211
17.a.2	Fair value gain/(loss) on marketable securities		
	Opening balance	(12,022,988)	(11,243,821)
	Adjustment of sale of marketable securities	47,987	7,093,015
	Fair value gain/(loss) on marketable securities (Note - 17.a.2.1)	(11,233,620)	(7,958,757)
	Transferred to deferred tax assets/(liabilities)	1,118,563	86,574
		(22,090,058)	(12,022,988)
17.a.2.1	Fair value gain/(loss) on marketable securities during the year		
	Unrealized gain/(loss) position (closing)	(24,544,509)	(13,358,875)
	Unrealized gain/(loss) position (opening)	(13,358,875)	(12,493,134)
	Fair value adjustment for sale of securities realized gain/(loss)	(47,987)	(7,093,015)
	Unrealized gain/(loss) during the year	(11,233,620)	(7,958,757)
17.a.3	Share of other comprehensive income		
	Opening balance	5,996,659	5,974,148
	Add: Addition during the year	(248,530)	22,510
		5,748,128	5,996,659
17.a.4	Revaluation surplus on property, plant & equipment		
	Opening balance	1,341,292,066	1,351,988,323
	Adjustment during the year to retained earnings for depreciation	(11,114,051)	(12,583,832)
	Adjustment of deferred tax on revaluation surplus	1,667,108	1,887,575
		1,331,845,122	1,341,292,066
18.	Retained earnings		
	Opening balance	5,328,568,962	4,752,806,311
	Prior year adjustment	-	15,956,766
		5,328,568,962	4,768,763,077
	Net profit after tax	665,686,161	882,354,974
	Dividend for the year	(351,000,000)	(351,000,000)
	Adjustment for depreciation on revaluation surplus	26,981,129	28,450,911
		5,670,236,252	5,328,568,962
18.a	Retained Earnings		
	Opening balance	603,094,738	712,942,599
	Adjustment for previous years tax assessment	-	15,956,766
	Net profit after tax	194,342,150	212,611,542
	Dividend for the year	(351,000,000)	(351,000,000)
	Adjustment for depreciation on revaluation surplus	11,114,051	12,583,832
		457,550,939	603,094,738
19.	Non-controlling interest		
	Opening balance	1,154,626,813	1,065,399,016
	Share of operating profit	71,363,599	89,227,797
	Closing balance	1,225,990,411	1,154,626,813
20.	Long term loan		
	Syndicated loan and other long term loans (Note 20.1)	13,073,034,212	7,607,068,438
	Working capital loan (Note 20.2)	-	5,690,146
		13,073,034,212	7,612,758,584
	Less: Current portion of long term loan (Note 20.3)	(201,882,832)	(256,375,584)
		12,871,151,380	7,356,383,000

	Amount in Taka	
	30 June 2020	30 June 2019
20.1 Syndicated loan and other long term loans		
Agrani Bank Limited, Principal. Br.	-	61,776,943
Janata Bank Limited	-	58,786,665
Term Loan - AB Bank Limited	-	317,837,274
Term Loan -Agrani Bank Limited	-	222,372,922
Term Loan-Premier Bank Limited	-	488,400,000
Phoenix Finance & Investment Limited	188,353,872	224,410,610
Bangladesh Finance and and Investment Limited	-	24,852,600
Mashreq bank PSC	5,883,680,435	-
Mercantile Bank Limited	-	750,000,000
International leasing and financial services Limited	-	157,664,496
Meridian finance & Investment Limited	13,356,974	22,697,487
Agrani Bank Limited, (BMRE)	3,078,758,648	2,284,532,768
Term Loan-IPDC	-	510,798,096
Social Islami Bank Limited	938,069,748	845,565,953
AL-Arafa Islami Bank Limited	1,776,578,444	1,596,609,845
ODDO BHF AG Finance	576,109,548	40,762,780
Rupali Bank Limited	618,126,543	-
	13,073,034,212	7,607,068,438
Details have been presented in annexure- H		
20.2 Working capital loan		
Agrani Bank Limited, (CC Hypo)	-	5,690,146
	-	5,690,146
20.3 Current portion of long term loan		
International leasing and Financial Services Limited	-	157,664,496
Meridian Finance & Investment Limited	12,119,184	12,119,184
Phoenix Finance & Investment Limited	61,739,304	61,739,304
Bangladesh Finance and and Investment Limited	-	24,852,600
ODDO BHF AG Finance	128,024,344	-
	201,882,832	256,375,584
20.a Long term loan		
International leasing and Financial Services Limited	-	157,664,496
Meridian Finance & Investment Limited	13,356,974	22,697,487
Phoenix Finance & Investment Limited	188,353,872	224,410,610
Bangladesh Finance and and Investment Limited	-	24,852,600
Agrani Bank Ltd. -BMRE	3,078,758,648	2,284,532,768
Social Islami Bank Limited	938,069,748	845,565,953
AL-Arafa Islami Bank Limited	1,776,578,444	1,596,609,845
ODDO BHF AG Finance	576,109,548	40,762,780
Rupali Bank Limited	618,126,543	-
	7,189,353,777	5,197,096,539
Less: Current portion of long term loan (Note 20.a.1)	(201,882,832)	(256,375,584)
	6,987,470,945	4,940,720,955
20.a.1 Current portion long term loan		
International leasing and Financial Services Limited	-	157,664,496
Meridian Finance & Investment Limited	12,119,184	12,119,184
Phoenix Finance & Investment Limited	61,739,304	61,739,304
Bangladesh Finance and Investment Limited	-	24,852,600
ODDO BHF AG Finance	128,024,344	-
	201,882,832	256,375,584
21 Lease obligation		
Phoenix Finance & Investment Limited	33,270,557	41,990,777
Lease obligation (Office rent)	51,984,423	-
	85,254,980	41,990,777
Less: Current portion of lease obligation (Note 21.1)	(38,345,934)	(15,417,560)
	46,909,046	26,573,217
21.1 Current portion of lease obligation		
Phoenix Finance & Investment Limited	15,457,560	15,417,560
Lease obligation (Office rent)	22,888,374	-
	38,345,934	15,417,560

PERFORMANCE & FINANCIALS > Notes to the financial statements

	Amount in Taka	
	30 June 2020	30 June 2019
22 Employee benefits		
Employee welfare fund (Note -22.1)	6,567,966	3,970,221
Bangladesh workers welfare foundation (Note -22.2)	8,892,117	4,914,467
Workers profit participation fund (Note -22.3)	36,404,155	17,002,094
	51,864,239	25,886,783
22.1 Employee welfare fund		
Opening balance	3,970,221	4,373,458
Add: Addition for the year	3,977,650	1,346,698
Less: Payment during the year	(1,379,905)	(1,749,934)
	6,567,966	3,970,221
22.2 Bangladesh workers welfare foundation		
Opening balance	4,914,467	3,567,769
Add: Addition for the year	3,977,650	1,346,698
	8,892,117	4,914,467
22.3 Workers profit participation fund		
Opening balance	17,002,095	21,977,919
Add: Addition for the year	31,821,206	10,773,581
Less: Payment during the year	(12,419,146)	(15,749,406)
	36,404,155	17,002,094
22.a Employee benefits		
Employee welfare fund (Note -22.a.1)	3,854,428	3,970,221
Bangladesh workers welfare foundation (Note -22.a.2)	6,178,579	4,914,467
Workers profit participation fund (Note -22.a.3)	14,695,850	17,002,094
	24,728,858	25,886,783
22.a.1 Employee welfare fund		
Opening balance	3,970,221	4,373,458
Add: Addition for the year	1,264,113	1,346,698
Less: Payment during the year	(1,379,905)	(1,749,934)
	3,854,428	3,970,221
22.a.2 Bangladesh workers welfare foundation		
Opening balance	4,914,467	3,567,769
Add: Addition for the year	1,264,113	1,346,698
	6,178,579	4,914,467
22.a.3 Workers profit participation fund		
Opening balance	17,002,094	21,977,919
Add: Addition for the year	10,112,901	10,773,581
Less: Payment during the year	(12,419,146)	(15,749,406)
	14,695,850	17,002,094
23 Deferred tax liability		
Opening balance	98,226,477	78,995,050
Adjustment for deferred tax expenses /(income) (Note-23.1)	47,170,266	21,205,576
Adjustment for deferred tax on revaluation surplus (Note-23.2)	(2,785,671)	(1,974,149)
	142,611,072	98,226,477
23.1 Adjustment during the year on deferred tax on PPE		
Deferred tax liability on PPE (closing)	92,896,578	45,726,312
Deferred tax liability on PPE (opening)	45,726,312	24,520,736
Deferred tax expenses/(income)	47,170,266	21,205,576

WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2018), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".

Particular	WDV as at 30 June 2020		Amount in Taka	
	Tax base	Accounting Base	Deferred tax liability as on 30.06.2020	Deferred tax liability as on 30.06.2019
Written down value of property, plant and equipment	3,504,988,302	3,876,574,612	(92,896,578)	(45,726,312)

Amount in Taka

30 June 2020

30 June 2019

23.2 Adjustment of deferred tax on revaluation Surplus

Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)

Deferred tax liability on revaluation surplus (Opening)

Deferred tax expenses/(income)

49,714,494

52,500,165

(2,785,671)

52,500,165

54,474,314

(1,974,149)**23.2.1 Adjustment of deferred tax on revaluation surplus**

Particulars	WDV as at 30 June 2020		Amount in Taka	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.06.2020	Deferred Tax Liability as on 30.06.2019
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	67,682,516	(10,152,377)	(11,280,419)
Revaluation reserved plant & machinery	-	20,364,702	(3,054,705)	(3,593,771)
Revaluation reserve on marketable securities	-	(24,544,509)	2,454,451	1,335,888
Total		1,362,231,438	(49,714,494)	(52,500,165)

24. Shot term loans

Cash credit (Hypo), Agrani Bank Limited, WASA Corp. Branch

LTR Agrani Bank Limited, WASA Corporate Branch

Loan against marketable securities

357,913,873

142,200,919

65,880,930

565,995,722

357,815,415

141,075,571

66,392,478

565,283,464**25 Trade and other payables**

Goods suppliers & manufacturer

Other payable

Current account with inter companies (Note -25.1)

2,618,526,029

456,809,503

109,788,332

3,185,123,864

2,007,663,158

401,601,631

181,234,288

2,590,499,077**25.1 Current account with inter companies**

Interior Accom Consortium Limited

Orion Capital Limited

Digital Power & Associates Limited

Orion Power Rupsha Limited

33,157,000

18,420,000

-

58,211,332

109,788,332

33,157,000

18,420,000

54,095,379

75,561,909

181,234,288**25.a Trade and other payables**

Goods suppliers & manufacturer

Other payables

270,338,394

333,165,538

603,503,932

274,202,851

348,859,152

623,062,003**26. Accrued expenses**

Salary and wages payable

Director remuneration payable

Depot expenses payable

Telephone & mobile bill payable

Payable for final settlement of employee

Utilities payable

Provision for income tax (Note 26.1)

Corporate governance audit fees

Statutory Audit fees

Interest on preference share

Retention money

Retirement benefit- P.F.

Provision for gratuity

Interest payable on Phonix Finance and Investment Limited

Interest payable on Mashreq Dubai

Interest payable on term loan

Withholding VAT

Withholding tax

81,647,029

10,649,877

300,000

1,042,140

7,507,047

2,172,517

197,862,877

57,500

1,265,000

-

3,618,657

34,048,932

21,622,489

2,279,198

5,396,631

5,692,894

16,810,471

12,132,046

404,105,305

85,781,615

8,925,000

-

1,190,355

7,694,942

2,164,166

188,622,950

57,500

1,265,000

155,243,639

3,618,657

32,506,296

16,997,422

3,746,272

-

129,101,742

15,722,265

10,750,750

663,388,571

PERFORMANCE & FINANCIALS > Notes to the financial statements

	Amount in Taka	
	30 June 2020	30 June 2019
26.1 Provision for income tax		
Opening balance	188,622,950	167,416,122
Add: Addition during the year	17,777,911	44,244,820
	206,400,861	211,660,942
Less: Payment/AIT adjustment during the year	(8,537,984)	(23,037,992)
	197,862,877	188,622,950
26.a Accrued expenses		
Salary and wages payable	59,924,626	61,642,468
Depot expenses payable	843,418	-
Director remuneration payable	300,000	300,000
Telephone & mobile bill payable	1,042,140	1,190,355
Payable for final settlement of employee	7,507,047	7,694,942
Utilities payable	2,172,517	2,164,166
Provision for income tax (Note - 26.a.1)	197,862,877	188,622,950
Corporate governance audit fees	57,500	57,500
Statutory Audit fees	575,000	575,000
	270,285,125	262,247,380
These are unsecured & is payable within one year.		
26a.1 Provision for income tax		
Opening balance	188,622,950	167,416,122
Add: Addition during the year	17,777,911	44,244,820
	206,400,861	211,660,942
Less: Payment/AIT adjustment during the year	(8,537,984)	(23,037,992)
Closing balance	197,862,877	188,622,950
	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
27. Revenue from net sales		
Local sales	2,144,549,213	2,048,430,562
Export sales	153,191,088	172,918,054
Gain/(loss) in exchange rate fluctuation	-	1,193,198
Revenue from power generation (Note-27.1)	5,349,962,730	6,482,631,053
	7,647,703,031	8,705,172,867
27.1 Revenue from power generation		
Reference rental price	2,645,760,000	2,617,280,770
Reference energy price (variable - O&M)	124,948,190	126,309,511
HFO received from OOSL	2,591,605,481	3,792,452,629
Foreign exchange gain /(loss)	(12,350,941)	(53,411,857)
	5,349,962,730	6,482,631,053
27.a Revenue from net sales		
Local sales	2,144,549,213	2,048,430,562
Export sales	153,191,088	172,918,054
Gain/(loss) on foreign exchange transaction	-	1,193,198
	2,297,740,301	2,222,541,814
28. Cost of goods sold		
Raw materials consumed (Note - 28.1)	440,014,412	423,581,407
Packing materials consumed (Note - 28.2)	192,825,828	222,552,717
Work in process - opening	13,817,389	15,292,500
Work in process - closing	(17,129,910)	(13,817,389)
Total consumption	629,527,720	647,609,236
Factory overhead (Note - 28.3)	431,014,446	314,316,780
Cost of goods manufactured	1,060,542,166	961,926,016
Add: Opening stock of finished goods	44,674,750	81,299,632
Cost of goods available for sale	1,105,216,916	1,043,225,648
Less: Closing stock of finished goods	(75,769,179)	(44,674,750)
Less: Cost of physician sample	(12,802,715)	(12,431,262)
Cost of goods sold	1,016,645,021	986,119,636

	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
28.1 Raw materials consumed		
Opening stock	126,896,948	98,045,864
Add: Purchase during the year	458,543,800	452,432,491
Goods Available for use	585,440,748	550,478,355
Less: Closing stock	(145,426,337)	(126,896,948)
Consumed during the year	440,014,412	423,581,407
28.2 Packing materials consumed		
Opening stock	42,072,240	52,195,944
Add: Purchase during the year	218,981,273	212,429,013
Goods available for use	261,053,513	264,624,957
Less: Closing stock	(68,227,685)	(42,072,240)
Consumed during the year	192,825,828	222,552,717
28.3 Factory overhead		
Salaries, wages & other allowances	125,311,043	121,556,543
Travelling & conveyance	4,872,888	4,557,430
Entertainment	2,147,607	2,463,240
Worker's food expenses	15,282,708	15,697,794
Uniform, liveries & others	270,600	139,663
Godown rent	-	4,885,684
Utilities	33,176,712	17,470,605
Cleaning & washing	374,229	142,105
Carrying inward	601,648	633,814
Postage, telephone & others	466,816	524,808
Fuel & lubricants	4,954,266	4,211,017
Fees & taxes	1,305,658	721,022
Books & periodicals	9,766	11,122
Printing & stationeries	5,553,745	5,154,464
Insurance premium	1,542,832	1,258,835
Repair & maintenance	8,486,255	8,286,711
Depreciation (Annexure-A & B)	214,583,297	121,612,835
Lease rent	185,896	557,688
Research & development	751,419	1,150,636
Spare parts	10,709,854	2,952,326
Security services	427,208	328,438
	431,014,446	314,316,780
29. Cost of power generation		
Opening balance	146,861,504	488,614,358
Add: Purchase during the year (Note- 29.1)	2,913,764,434	3,686,042,366
	3,060,625,938	4,174,656,724
Less: Closing Balance	(187,202,025)	(146,861,504)
	2,873,423,913	4,027,795,220
Add : Plant Overhead (Note- 29.2)	1,179,796,154	1,145,574,574
	4,053,220,067	5,173,369,794
29.1 Purchase of raw materials		
Mobil & chemical	67,877,520	72,650,059
HFO - OOSL	2,845,886,914	3,613,392,307
	2,913,764,434	3,686,042,366
29.2 Plant overhead		
O & M service	139,617,639	138,137,379
Salaries & allowances	162,945,537	158,365,296
Repair & maintenance	195,611,948	133,041,018
Travelling & conveyance	7,979,688	5,645,309
Insurance, taxes & duties	-	534,078
Depreciation	621,497,454	649,918,337
Miscellaneous expenses	44,920,447	33,176,245
Foreign exchange gain/(loss)	-	20,226,454
Land rent	6,912,684	6,530,458
Insurance	310,756	-
	1,179,796,154	1,145,574,574

	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
30. General and administrative expenses		
Salaries, allowance & bonus	153,195,444	151,093,194
Directors' remuneration	20,400,000	20,400,000
Meeting attendance fees	660,000	420,000
Fuel & lubricants	4,214,239	3,442,341
Traveling & conveyance	3,219,825	5,821,134
Entertainment	3,806,802	4,826,888
Office rent	-	9,527,186
Cleaning & washing	4,962,427	4,734,006
Utilities	19,539,843	12,639,931
Postages, telephone & others	6,706,716	8,673,170
Bank charges & commission	2,006,800	1,112,083
Fees & taxes	21,138,920	10,724,285
Fooding & expenses	19,214,541	24,694,558
Software consultancy & other fees	12,364,860	4,567,015
Books & periodicals	99,501	103,730
Printing & stationeries	4,954,313	4,211,821
Repairs & maintenance	4,143,211	3,728,729
Depreciation (Annexure-A & B)	70,697,807	37,305,787
Lease rent	1,960,548	4,053,660
Statutory audit fees	1,265,000	1,265,000
Corporate governance audit fees	57,500	57,500
Annual listing & other fees	1,200,000	1,200,000
Overseas travel & training expenses	2,013,182	2,121,346
Insurance premium	1,765,119	2,230,948
Miscellaneous expenses	165,237	217,981
AGM expenses	1,731,250	1,599,307
Donation & Subscription	-	2,472,466
Security guard expenses	13,566,936	16,010,221
Advertisement and publicity	12,015,191	16,278,041
Corporate social responsibility (CSR)	3,630,000	7,347,563
	390,695,212	362,879,890
30.a General and administrative expenses		
Salaries, allowances & bonus	153,195,444	151,093,194
Directors' remuneration	3,600,000	3,600,000
Meeting attendance fees	660,000	420,000
Fuel & lubricants	4,214,239	3,442,341
Travelling & conveyance	3,219,825	2,803,044
Entertainment	2,042,845	2,343,082
Office rent	-	9,527,186
Cleaning & washing	4,962,427	4,734,006
Utilities	18,236,512	11,562,846
Postage, telephone & others	4,636,213	4,532,801
Bank charges & commission	2,006,800	1,112,083
Fees & taxes	3,401,503	4,296,118
Fooding expenses	7,172,233	7,674,241
Software consultancy & others	2,970,800	3,546,535
Books & periodicals	99,501	103,730
Printing & stationeries	2,769,536	2,839,364
Repair & maintenance	4,143,211	3,728,729
Depreciation (Annexure-A & B)	70,697,807	37,305,787
Lease rent	1,960,548	4,053,660
Statutory audit fees	575,000	575,000
Corporate governance audit fees	57,500	57,500
Annual listing & other fees	1,200,000	1,200,000
Overseas travel & training expenses	2,013,182	2,121,346
Insurance premium	1,765,119	2,230,948
Miscellaneous expenses	165,237	217,981
AGM expenses	1,731,250	1,599,307
Donation & subscription	-	2,472,466
Security services	1,425,657	1,169,858
Advertisement & Publicity	761,222	511,036
Corporate social responsibility (CSR)	2,202,000	2,072,563
	301,885,611	272,946,751

	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
31. Selling and distribution expenses		
Salaries, allowances & bonus	460,965,547	444,271,030
Field force TA/DA	10,029,607	11,623,138
Printing & stationeries	8,031,732	8,145,528
Postage, telephone & others	8,545,196	8,427,040
Fooding expenses	1,298,230	1,497,410
Product renewal & development	2,352,513	2,242,654
Software consultancy & others	4,077,727	5,071,500
Training & conference	5,329,855	5,738,564
Office rent (Depot)	-	10,872,417
Repair & maintenance	950,626	820,425
Travelling & conveyance	1,388,899	1,239,154
Bank charges & commission	1,787,025	2,215,289
Carrying & distribution expenses	20,382,423	19,561,236
Entertainment	1,047,613	1,201,581
Promotional materials	14,187,914	15,164,175
Sample expenses	12,802,715	12,431,262
Export expenses	1,836,333	2,071,509
Depreciation (Annexure-A & B)	30,037,244	13,226,408
Lease rent	5,709,504	6,756,624
Fuel & lubricants	2,167,511	2,124,311
Fees & taxes	355,192	606,136
Overseas traveling & training	965,815	661,535
Security services	1,901,771	1,864,331
Utilities	1,210,961	1,265,677
Insurance premium	3,117,824	4,307,397
Books & periodicals	10,451	9,836
Advertisement & publicity	208,950	2,234,173
	600,699,179	585,650,340
32. Financial expense		
Agrani Bank Limited. Cash Credit (H) - 48	31,880,971	31,715,956
Agrani Bank Limited, LTR	7,796,266	11,869,943
Phoenix Finance & Investments Limited	35,532,879	28,936,193
International Leasing and Financial Services Limited	4,766,919	37,416,767
Bangladesh Finance and Investment Limited	18,403,237	3,763,579
Meridian Finance & Investment Limited	2,788,424	4,081,633
Agrani Bank Limited	49,107,236	-
Finance cost on lease obligation (Office rent)	4,222,401	-
Interest on Long Term Borrowing	403,228,036	295,498,828
Interest on redeemable Preference Share	159,286,324	121,725,998
Interest Expense - Mashreq PSC	-	26,502,555
Loan Processing fees	22,708,750	2,505,000
Bank Charge, commission & Fees	52,507,719	13,608,753
	792,229,161	577,625,205
32.a Financial expenses		
Agrani Bank Limited. Cash credit (H) - 48	31,880,971	31,715,956
Agrani Bank Limited, LTR	7,796,266	11,869,943
Phoenix Finance & Investments Limited	35,173,637	28,420,436
International Leasing and Financial Services Limited	4,766,919	37,416,767
Bangladesh Finance and Investment Limited	18,403,237	3,763,579
Meridian Finance & Investment Limited	2,788,424	4,081,633
Agrani Bank Limited	49,107,236	-
Finance cost on lease obligation (Office rent)	4,222,401	-
	154,139,090	117,268,314
33. Interest & other income		
Interest on FDR	1,076,613	724,053
Interest income	31,702,573	25,521,918
Dividend income	1,012,648	954,250
Insurance claim received	199,286	568,289
Sale of scrap & others	5,441,357	1,574,235
Gain/(loss) on sale of marketable securities (Note 33.1)	(47,987)	(7,093,015)
Gain / (loss) on foreign exchange fluctuations	1,707,763	-
	41,092,252	22,249,730
33.1 Income on sale of marketable securities		
Gain/(loss) on sale of marketable securities	(46,137)	527,646
Interest on portfolio credit and others	(1,850)	(7,620,662)
	(47,987)	(7,093,015)

	Amount in Taka	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
34. Current tax		
Profit before tax	252,822,527	269,339,528
Add: accounting depreciation	315,318,348	172,145,031
Less: Tax depreciation	494,402,374	257,130,779
Taxable income	73,738,501	184,353,779

Income tax provision

Particulars	Taxable income	Amount in Taka	
		30 June 2020	30 June 2019
25% income tax on taxable profit	67,877,197	16,969,299	42,258,058
Half of 25% Income tax on export net profit	4,848,656	606,082	1,795,912
20% income tax on dividend received	1,012,648	202,530	190,850
Total	73,738,501	17,777,911	44,244,820

Minimum tax

Calculation of gross receipt

Revenue from net sales	2,297,740,301	2,222,541,814
Other income		
Interest on FDR	1,076,613	724,053
Interest Income	31,702,573	25,521,918
Dividend income	1,012,648	954,250
Insurance claim received	199,286	568,289
Sale of scrap & others	5,441,357	1,574,235
Total Gross Receipts	2,337,172,778	2,251,884,559
Minimum Tax (.60% On Total Gross Receipts)	14,023,037	13,511,307
Tax provision whichever is higher	17,777,911	44,244,820

Income tax provision is higher between tax at regular rate on income and minimum tax on gross receipts U/S 82C, 2 (b) of Income Tax Ordinance 1984. Hence tax at regular rate is accounted for as it is higher than the minimum tax.

35. Earnings per share (EPS)

The computation is given below:

Net profit after tax	665,686,161	882,354,974
Ordinary shares outstanding during the year	234,000,000	234,000,000
Earning per share	2.84	3.77

35.a Earnings per share

The computation is given below:

Net profit after tax	194,342,150	212,611,542
Ordinary shares outstanding during the year	234,000,000	234,000,000
Earnings per share	0.83	0.91

During the reporting year the company did not issue any share. Hence there is no requirement to calculate weighted average ordinary share.

36. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:

Particulars	30 June 2020	30 June 2019
Net profit before tax	795,530,136	1,028,310,759
Workers profit participation fund	12,641,126	13,466,976
Interest & other income	(41,092,253)	(22,249,730)
Financial expenses	792,229,161	577,625,205
Depreciation	936,815,801	822,063,368
Increase/(Decrease) in inventory	(359,569,078)	270,460,857
Increase/(Decrease) in receivables	(978,163,862)	200,335,402
Increase/(Decrease) in advance, deposit & prepayments	(340,650,714)	(31,588,748)
Increase/(Decrease) in employee benefit	13,336,330	(17,499,340)
Increase/(Decrease) in payable	1,010,201,355	(1,389,674,380)
Increase/(Decrease) in accrued expenses	77,101,224	24,822,898
Income taxes paid	(36,465,342)	(47,752,252)
Foreign exchange gain/(loss)	417,728	20,226,454
Net cash flow from operating Activities	1,882,331,611	1,448,547,470
36.1 Net operating cash flow per share	8.04	6.19

Amount in Taka	
01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019

36.a Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method:

Particulars	30-Jun-20	30-Jun-19
Net profit before tax	252,822,527	269,339,528
Workers profit participation fund	12,641,126	13,466,976
Interest & other income	(41,092,253)	(22,249,730)
Financial expenses	154,139,090	117,268,314
Depreciation	315,318,348	172,145,031
Increase/(Decrease) in inventory	(74,583,107)	1,337,938
Increase/(Decrease) in receivables	14,518,514	(28,264,050)
Increase/(Decrease) in advance, deposit & prepayments	824,947	14,696,665
Increase/(Decrease) in employee benefit	(13,799,051)	(17,499,340)
Increase/(Decrease) in payable	2,501,495	101,863,089
Increase/(Decrease) in accrued expenses	(1,202,183)	9,139,098
Income taxes paid	(36,465,342)	(47,752,252)
Foreign Exchange Gain/(Loss)	417,728	-
Net cash flow from operating activities	586,041,838	583,491,267
36.a.1 Net operating cash flow per share	2.50	2.49

37. Segmental information

The Group's operational segments are pharmaceuticals, power, and investments. The operational segments results are as follows:

Particulars	Pharmaceuticals	Power	Totals
Revenue from sales	2,297,740,301	5,349,962,730	7,647,703,031
Expenses	(1,919,229,811)	(4,142,029,668)	(6,061,259,480)
Segment result	378,510,490	1,207,933,062	1,586,443,551
Capital expenditure			
Additions to property, plant & equipment	2,903,212,570	1,074,234	2,904,286,804
Other segment information			
Interest & other income	41,092,252	-	41,092,252
Financial Expenses	(154,139,090)	(638,090,071)	(792,229,161)
Provision for income tax	(17,777,911)	-	(17,777,911)
Share of profit from associate	6,467,800	-	6,467,800
Depreciation expenses	(315,318,348)	(621,497,454)	(936,815,802)
Segment assets	19,862,455,800	16,978,650,965	36,841,106,765
Segment liabilities	8,881,733,465	8,769,661,491	17,651,394,956

38. Related party transactions

38.1 The Company has entered into transactions with other entities that fall within the definition of related party as contained in IAS-24 "Related Party Disclosures". The Company opines that terms of related party transactions do not significantly differ from those that could have been obtained from third parties. Total transactions of the significant related parties as at 30 June 2020 are as follows:

Name of Related Party	Relationship	Nature of Transaction	Opening Balance as on 01.07.2019	Addition during the year	Adjustment during the year	Closing Balance as on 30.06.2020
Orion Power Meghnaghat Limited (95,000,000 Ordinary Shares @ TK 10 Each)	Subsidiary	Investment in Shares	950,000,000	-	-	950,000,000
Dutch Bangla Power & Associates Limited (6,700,000 Ordinary Shares @ Tk. 10 Each)	Subsidiary	Investment in Shares	67,000,000	-	-	67,000,000
Orion Infusion Limited (44,30,000 Ordinary Shares @ TK. 10 each)	Associate	Investment in Shares	44,300,000	-	-	44,300,000
Orion Power Khulna Limited (50,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	500,000	-	-	500,000
Orion Power Dhaka Limited (50,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	500,000	-	-	500,000
Orion Infrastructure Limited (200,000,000 Ordinary Shares @ TK. 10 each)	Trade Investment	Investment in Shares	2,117,209,676	-	-	2,117,209,676
Orion Infusion Limited	Associate	Receivable/(Payable)	(63,728,273)	-	-	(63,728,273)
Dutch Bangla Power & Associate Limited	Subsidiary	Inter Company Current A/C	370,748,526		(1,348,762)	369,399,764
Orion Properties Limited	Common Director/ Shareholders	Inter Company Current A/C	20,331,532	-	-	20,331,532
Orion Power Khulna Limited	Trade Investment	Inter Company Current A/C	986,021,913	-	-	986,021,913
Orion Power Dhaka Limited	Trade Investment	Inter Company Current A/C	2,176,293,707	-	-	2,176,293,707
Orion Agro Product Limited	Common Director/ Shareholders	Inter Company Current A/C	232,265,920	-	-	232,265,920
Interior Accom Consortium Limited	Common Director/ Shareholders	Inter Company Current A/C	107,995,459	-	-	107,995,459
Orion Power Unit -2 Dhaka Limited	Common Director/ Shareholders	Inter Company Current A/C	1,483,046,176	-	(124,337,400)	1,358,708,776
Orion Power Rupsha Limited	Inter Company	Inter Company Current A/C	186,800,000	-	-	186,800,000
Digital Power & Associates Limited	Inter Company	Inter Company Current A/C	97,341,915	-	-	97,341,915
Orion Hospitals Limited	Inter Company	Inter Company Current A/C	2,000,000	10,700,000	-	12,700,000
Kohinoor Chemical Co. (BD) Limited	Inter Company	Trading Goods	(3,224,963)	894,825	(2,302,096)	(4,632,234)
Total:			8,775,401,588	11,594,825	(127,988,258)	8,659,008,155

* All related party transaction have complied with the BSEC (notification no. BSEC/CMRRCD/ 2009-193/Admin / 103 dated February 5, 2020) during the financial year.

38.2 Payments/ Perquisites to Key Management Personnel

Payments and perquisites given to the Company Secretary, Chief Financial Officer, Head of Internal Audit, Vice Presidents, Assistant Vice Presidents during the year are disclosed below:

Particulars	Amount in Taka	
	30 June 2020	30 June 2019
Basic salary	14,877,228	13,120,568
House rent	7,488,632	6,561,757
Medical allowance	1,254,000	857,467
Conveyance	1,071,000	748,033
Other allowance	2,917,563	3,225,034
Bonus	1,441,363	1,654,744
Profit participation fund	1,155,344	645,300
Contribution to provident fund (employer)	1,319,058	912,774
LFA	-	455,886
	31,524,188	28,181,563

39. Production capacity

Item	Unit	Production Capacity		Yearly Production		Capacity Utilization	
		2020	2019	2020	2019	2020	2019
Tablet & capsule	Million Pcs	694.26	694.26	523.20	508.57	75.36%	73.25%
Oral liquid, injection, powder for suspension, cream & ointment	Million Pcs	23.68	23.68	17.27	15.49	72.93%	65.42%

40. General**40.1 Capital expenditure commitment**

There was capital expenditure contracted but not incurred or provided as on 30 June 2020 and material capital expenditure authorized by the board.

40.2 Claims not acknowledged

There is no claim against the company not acknowledged as debt as on 30 June 2020.

40.3 Credit facilities not availed

There is no credit facilities available to the company as on 30 June 2020 under any contract, other than trade credit available in the ordinary course of business.

40.4 Director's responsibility statements

The Board of Directors take the responsibility for the preparation and presentation of these financial statements.

40.5 Commission, brokerage or discount agents sales:

No commission, brokerage or discount was incurred or paid by the company against sales during the period from 1 July 2019 to 30 June 2020.

40.6 Employee details

- i) During the year, there were 2,244 employees employed for the full year and 452 employees less than the full year at a remuneration of Taka 3,000 per month and above.
- ii) At the end of the period, there were 2,696 employees in the Company.

40.7 Rounding off

Amounts appearing in these financial statements have been rounded off to the nearest Taka and, wherever considered necessary.

41 Events after the reporting period

41.1 The Board of Directors meeting held on 08 November 2020 had recommended 10% cash dividend for the year ended 30 June 2020 for placement before the Shareholder's for approval at 55th AGM of the company. There is no material events after the reporting date that are not adjusting events came to management attention which may be needful for the stakeholders.

41.2 Except the facts above, there was no material event after the reporting date that is adjusting/ non adjusting event came to management attention which may be needful to be disclosed for the stakeholders.

Sd/-
Managing Director

Sd/-
Director

Sd/-
Chief Financial Officer

Sd/-
Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Schedule of property, plant and equipment
As at 30 June 2020

Particulars	Annexure-A. 1						
	Written down value as at 01.07.2019	Additions during the year	Sale /Disposal During the year	Total as on 30.06.2020	Rate of Dep. (%)	Depreciation charged during the year	Written down value as at 30.06.2020
Land & land development	2,721,799,335	127,957,031	-	2,849,756,366	-	-	2,849,756,366
Factory & office building	484,657,538	1,899,698,457	-	2,384,355,995	10%	114,185,704	2,270,170,292
Plant & machinery	7,499,276,746	249,755,124	-	7,749,031,870	15%	708,653,084	7,040,378,787
Furniture & fixtures	75,008,991	9,910,291	-	84,919,282	15%	12,201,730	72,717,552
Office equipment	102,220,557	16,115,555	-	118,336,112	15%	17,826,737	100,509,375
Vehicles	21,091,188	12,619,453	(1,517,015)	32,193,626	20%	4,585,846	27,607,780
Laboratory equipment	51,305,515	-	-	51,305,515	15%	7,695,828	43,609,687
Road & Road Development	-	588,230,892	-	588,230,892	2%	2,941,154	585,289,738
Sub-total:	10,955,359,870	2,904,286,804	(1,517,015)	13,858,129,659		868,090,083	12,990,039,576
At Revaluation							
Land & land development	1,599,675,401	-	-	1,599,675,401	-	-	1,599,675,401
Factory & office building	90,163,874	-	-	90,163,874	10%	8,719,646	81,444,228
Plant & machinery	230,138,177	-	-	230,138,177	15%	20,108,556	210,029,621
Sub-total:	1,919,977,451	-	-	1,919,977,452		28,828,201	1,891,149,250
Leased Assets							
Vehicle	62,191,763	-	-	62,191,763	20%	12,438,353	49,753,410
Sub-total:	62,191,763	-	-	62,191,763	-	12,438,353	49,753,410
Total 2019-2020	12,937,529,084	2,904,286,804	(1,517,015)	15,840,298,874	-	909,356,636	14,930,942,237
Total 2018-2019	13,144,226,580	616,465,384	(1,099,512)	13,759,592,452	-	822,063,368	12,937,529,084

ORION PHARMA LIMITED
Schedule of property, plant and equipment
As at 30 June 2020

								Annexure-A.2
								Amount in Taka
SL. No.	Particulars	Written down value as at 01.07.2019	Addition during the year	Disposal/sale during the year	Balance as on 30.06.2020	Rate of Dep. (%)	Depreciation charged during the year	Written down value as at 30.06.2020
1	Land & land development	2,469,265,069	127,957,031	-	2,597,222,100	-	-	2,597,222,100
2	Factory & office Building	150,344,478	1,899,698,457	-	2,050,042,935	10%	62,526,909	1,987,516,026
3	Plant & machinery	927,667,521	249,755,124	-	1,177,422,646	15%	159,499,913	1,017,922,733
4	Furniture & fixtures	75,008,992	9,910,291	-	84,919,283	15%	12,201,731	72,717,552
5	Office equipment	97,920,020	15,041,321	-	112,961,341	15%	15,844,936	97,116,405
6	Vehicles	15,142,934	12,619,453	(1,517,015)	26,245,372	20%	3,596,308	22,649,064
7	Laboratory equipment	51,305,514	-	-	51,305,514	15%	7,695,827	43,609,687
8	Road & Road Development	-	588,230,892	-	588,230,892	2%	2,941,154	585,289,738
	A. Sub-Total	3,786,654,527	2,903,212,570	(1,517,015)	6,688,350,082		264,306,779	6,424,043,303
At revaluation								
1	Land & land development	1,298,728,729	-	-	1,298,728,729	-	-	1,298,728,729
2	Factory & office building	75,202,796	-	-	75,202,796	10%	7,520,280	67,682,516
3	Plant & machinery	23,958,473	-	-	23,958,473	15%	3,593,771	20,364,702
	B. Sub-Total	1,397,889,997	-	-	1,397,889,997		11,114,051	1,386,775,947
Leased asset								
1	Vehicles	62,191,762	-	-	62,191,762	20%	12,438,352	49,753,409
	Sub-total:	62,191,762	-	-	62,191,762		12,438,352	49,753,409
	TOTAL (A+B+C)-2019-2020	5,246,736,287	2,903,212,570	(1,517,015)	8,148,431,841	-	287,859,182	7,860,572,660
	TOTAL - 2018-2019	4,809,521,233	610,459,597	(1,099,512)	5,418,881,318	-	172,145,031	5,246,736,287

Allocation of depreciation charge for the year has been made in the accounts as follows:

SL. No.	Particulars	Factory overhead	General and admin expense	Selling & distribution expense	Total
1	Factory & office Building	28,018,876	35,023,594	7,004,719	70,047,189
2	Plant & machinery	163,093,684	-	-	163,093,684
3	Furniture & fixtures	2,440,346	4,880,692	4,880,692	12,201,731
4	Office equipment	3,168,987	8,714,715	3,961,234	15,844,936
5	Vehicles	359,631	2,517,416	719,262	3,596,308
6	Lease-vehicle	-	9,950,682	2,487,670	12,438,352
7	Laboratory equipment	7,695,827	-	-	7,695,827
8	Road & Road Development	2,941,154	-	-	2,941,154
	Total	207,718,505	61,087,099	19,053,577	287,859,182

ORION PHARMA LIMITED
Schedule of Right of Use Assets
As at 30 June 2020

		Annexure-B					
		Amount in Taka					
SL. No.	Particulars	Written down value as at 01.07.2019	Addition during the year	Balance as on 30.06.2020	Rate of Depreciation	Depreciation charged during the year	Written down value as at 30.06.2020
1	Right of use Assets	-	77,807,019	77,807,019	-	27,459,166	50,347,853
	Total	-	77,807,019	77,807,019	-	27,459,166	50,347,853

Allocation of depreciation charge for the year has been made in the accounts as follows:

Particulars	Factory overhead	General & administration expense	Selling & distribution expense	Total
1 Right of use Assets	6,864,792	9,610,708	10,983,666	27,459,166
Total	6,864,792	9,610,708	10,983,666	27,459,166

ORION PHARMA LIMITED
Investment in Marketable Securities
For the year ended 30 June 2020

Annexure-C

Amount in Taka

Particulars	30-Jun-20		30-Jun-19	
	Market Value	Cost Price	Market Value	Cost Price
AB Investment Ltd.				
Alif Industries Limited	1,262,063	4,554,183	2,768,669	4,554,183
Apex Footwear Limited	10,862,368	18,755,421	14,656,519	18,755,421
Central Pharmaceuticals Limited	79,933	161,317	75,726	161,317
Islami Bank Bangladesh Limited	1,741,828	3,484,013	2,348,979	3,484,013
Sub- total	13,946,191	26,954,934	19,849,892	26,954,934
Bank Asia Securities Ltd				
Intech Online Limited	1,007,303	2,778,306	1,665,133	2,778,306
Islami Bank Bangladesh Limited	525,000	1,334,853	708,000	1,334,853
Summit Alliance Port Limited	690,560	2,074,176	956,000	2,074,000
Golden Harvest Agro Industries Limited	-	-	103,796	130,407
Agni Systems Limited	738,675	1,364,895	1,113,525	1,364,895
National Housing Finance & Investment Limited	270,600	622,270	468,600	622,270
Premier Leasing & Finance Limited	540,225	1,891,890	1,003,275	1,891,890
Sub- total	3,772,363	10,066,390	6,018,329	10,196,621
LankaBangla Securities Ltd.				
Intech Online Limited	588,000	1,193,140	972,000	1,193,140
Legacy Footwear Limited	817,700	1,733,821	1,732,900	1,733,821
National Housing Limited	1,623,600	2,836,434	2,811,600	2,836,434
The ACME Laboratories Limited	3,168,732	5,676,375	3,850,000	5,678,647
Sub- total	6,198,032	11,439,770	9,366,500	11,442,042
Grand Total	23,916,586	48,461,094	35,234,721	48,593,597

Fair value adjustments	2019-2020	2018-2019
Cost Price	48,461,094	48,593,597
Market Price	23,916,586	35,234,721
Unrealized gain / (Loss)	(24,544,509)	(13,358,876)

ORION PHARMA LIMITED
Fixed deposit with banks
As at 30 June 2020

Annexure-D

Sl. No.	Name of Bank	Instrument no.	Opening balance 01.07.2019	Re-Invested amount	Interest income				Closing balance 30.06.2020	
					Accrued during the year	Accrued previous year	Realized during the year	Income during the year		Tax at source
1	Social Islami Bank Ltd.-MTDR	0025311263757	1,725,015	1,832,217	5,191	5,463	119,114	118,843	11,911	1,832,217
2	Social Islami Bank Ltd.-MTDR	0025311260179	2,660,608	2,819,694	16,448	17,294	176,762	175,916	17,676	2,819,694
3	Social Islami Bank Ltd.-MTDR	0025311255512	3,642,713	3,860,524	46,326	43,105	242,012	245,233	24,201	3,860,524
	Sub total		8,028,336	8,512,435	67,966	65,862	537,888	539,992	53,789	8,512,435
4	Agrani Bank Ltd. - FDR	0200012681578	1,500,000	1,622,173	14,769	59,250	135,748	91,266	13,575	1,622,173
5	Agrani Bank Ltd. - FDR	0200012311958	2,500,000	2,732,754	28,808	135,764	258,615	151,659	25,862	2,732,754
6	Agrani Bank Ltd. - FDR	0200014640505	-	3,078,127	9,833	-	86,808	96,641	8,681	3,078,127
7	Agrani Bank Ltd. - FDR	0200013746245	-	3,637,609	44,157	-	152,899	197,055	15,290	3,637,609
	Sub total		4,000,000	11,070,663	97,566	195,014	634,070	536,621	63,407	11,070,663
	Total		12,028,336	19,583,098	165,532	260,876	1,171,958	1,076,613	117,196	19,583,098

Amount in Taka

ORION PHARMA LIMITED
Balance with Banks on Account
As at 30 June 2020

Annexure - E

Amount in Taka

Sl. No.	Name of Bank	Name of Branch	Account Number	30 June 2020	30 June 2019
Current Accounts (Main)					
1	Pubali Bank Ltd.	Tejgaon Branch, Dhaka	1256	425	1,575
2	Sonali Bank Ltd.	Tejgaon Branch, Dhaka	275/4	47,201	47,201
3	Agrani Bank Ltd.	Wasa Branch, Dhaka	797310	879,253	3,126,509
4	Rupali Bank Ltd.	TCB Branch, Dhaka	708	21,547	21,547
5	National Bank Ltd.	Mohakhali Branch	34017	76,178	2,775,435
6	ICB Islami Bank Ltd.	Principal Office, Dhaka	6417	2,896,062	2,898,792
7	The City Bank Ltd.	Principal Branch, Dhaka	110558491	5,000	5,000
8	The City Bank Ltd.	Gulshan Branch, Dhaka	11001	4,945	5,290
9	Social Islami Bank Ltd.	Principal Branch, Dhaka	55830	694,020	2,732,199
10	Bank Al-Falah Ltd.	Motijheel Branch, Dhaka	2965	8,500	8,500
11	Agrani Bank Ltd.	Principal Branch, Dhaka	3884	559,830	561,020
12	Sonali Bank Ltd.	Farmgate Branch	33010919	137,206	270,267
13	AB Bank Ltd	Principal Branch	4005-784715-000	792,513	33,434
14	The Premier Bank Ltd	Gulshan Branch	5448	93,780	94,470
15	Brac Bank Ltd	Gulshan Branch	250001	617,897	608,261
16	AL-Arafa Islami Bank Ltd.	Corporate Branch, Dhaka	50228	25,405	29,555
17	Agrani Bank Ltd.	Shiddirgonj Branch	5002	22,407	-
18	Rupali Bank Ltd.	Local office Branch	262	100,632	-
Sub Total (i)				6,982,801	13,219,055
Current Accounts (Collection)					
19	Agrani Bank Ltd.	Chattogram Branch,	363	15,979	15,979
20	Agrani Bank Ltd.	Bogura Branch, Bogura	1233	11,659	11,659
21	Agrani Bank Ltd.	Rupsha Stand Road, Khulna	6069	1,667,528	21,046
22	Agrani Bank Ltd.	Barishal Branch, Barishal	1804	318	318
23	Agrani Bank Ltd.	Sylhet Branch, Sylhet	1866/1314	7,303	7,303
24	Agrani Bank Ltd.	Court Road Br. Narayangong	6467	484,003	91,563
25	Agrani Bank Ltd.	Rangpur Branch, Rangpur	4405	68	68
26	Agrani Bank Ltd.	Monoharpur Br. Cumilla	5304	70	70
27	Agrani Bank Ltd.	Faridpur Branch, Faridpur	4008	95,004	2,344
28	National Bank Ltd.	Bogura Branch, Bogura	1565	89,488	9,263
29	National Bank Ltd.	Barishal Branch, Barishal	0382	667,824	644,308
30	National Bank Ltd.	Subid Bazar Branch, Sylhet	7190	493,424	315,754
31	National Bank Ltd.	Mymensingh Branch	2957	450,243	8,290
32	National Bank Ltd.	Rangpur Branch, Rangpur	6653	468,455	37,593
33	National Bank Ltd.	Babu Bazar Branch, Dhaka	2378	19,016	19,016
34	Sonali Bank Ltd.	Greter Road Br. Rajshahi	1432	749,065	5,758
35	Agrani Bank Ltd.	Chowmohani Branch	9074	846,307	118,863
36	ICB Islami Bank Ltd.	Chattogram Branch,	2978	13,744	13,744
37	National Bank Ltd.	Gonestala Road, Dinajpur	3678	726,755	401,913
38	National Bank Ltd.	Tangail	2605	500,140	23,891
39	National Bank Ltd.	Moulavibazar	7153	1,077,584	461,367
40	Agrani Bank Ltd.	New Market Br. Kustia	8152	31,270	155,118
41	National Bank Ltd.	Cox's Bazar	13962	8,518	3,021
42	Agrani Bank Ltd.	BSCIC Cumilla	6639	122	2,858
43	National Bank Ltd.	CDA, Chattogram	6171	830,311	207,000
44	National Bank Ltd.	Sikder Tower Branch Sylhet	9870	28,295	29,215
45	Agrani Bank Ltd.	Wasa Corp. Br	Fund Buildup	2,879,993	-
Sub Total (ii)				12,162,486	2,607,322
Sub Total (i+ii)				19,145,287	15,826,377
STD Accounts					
46	National Bank Ltd.	Mohakhali	2515	31,745	1,766,948
47	Bank Asia Ltd.	Mohakhali	00038	151,749	86,142
48	Agrani Bank Ltd.	WASA Branch	99023	598,360,488	3,736,958
49	Social Islami Bank Ltd.	Principal Branch	1464	407,666	5,566
50	AB Bank Ltd.	Principal Branch	784715-000	130,960	129,194
51	Bank Asia Ltd.	Mohakhali	000190	64,852	129,881
52	AB Bank Ltd.	Principal Branch	760188-430	103,056	72,517
53	Agrani Bank Ltd.	Wasa Corp. Br	200014863618	3,423,698	-
Sub Total (iii)				602,674,214	5,927,206
Total Balance in current & STD accounts (i+ii+iii)				621,819,501	21,753,583

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Redeemable Preference Share
As at 30 June 2020

Annexure - F

Amount in Taka	
30 June 2020	30 June 2019
Dutch Bangla Power & Associates Limited	500,000,000
-	500,000,000
-	500,000,000

The redeemable preference shares bearing interest @ 15% per annum were issued by Agrani Bank Limited. As per IFRS 7-"Financial Instrument: Disclosure" the substance of a financial instrument rather than its legal form governs its classification on the entity's financial statements. Accordingly, the redeemable preference shares which, in substance, meet the conditions of a financial liability, have been classified as liabilities in the financial statements.

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Provision for Decommissioning of Assets
As at 30 June 2020

Annexure - G

	Amount in Taka	
	30 June 2020	30 June 2019
Plant & machinery	59,922,594	59,922,594
Building	83,482,969	83,482,969
	143,405,563	143,405,563

Orion Power Megnaghat Ltd. has established its electricity generating plant on government land and assumed that after the contract period it may have to be removed from the land. The company has recognized a provision for decommission obligations associated the electricity generating facility. In determining the fair value of the provision, assumptions and estimates are made in relation to discount rates, the expected cost to dismantle and remove the plant from the site and the expected timing of those costs. The carrying amount of the provision as at 30 June 2020 was BDT 143,405,563.

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Term Loan
As at 30 June 2020

Annexure - H

	Amount in Taka	
	30 June 2020	30 June 2019
Orion Power Meghnaghat Limited		
Term loan -Mashreq bank-PSC Dubai	2,941,840,217	-
	2,941,840,217	-
Dutch Bangla Power and Associates Limited		
Syndication loan	-	2,409,971,899
Term loan -Mashreq bank-PSC Dubai	2,941,840,217	-
Working capital loan	-	5,690,146
	2,941,840,217	2,415,662,045
Syndication loan		
Long term borrowings		
Agrani Bank Limited - Principal Branch	-	61,776,943
Janata Bank Limited	-	58,786,665
Term Loan - AB Bank Limited	-	317,837,274
Term Loan - Agrani Bank Limited	-	222,372,922
Term Loan -Premier Bank Limited	-	488,400,000
Term Loan IPDC	-	510,798,096
Mercantile Bank Limited	-	750,000,000
	-	2,409,971,899

The loans from banks are secured first ranking fixed charge over land, buildings and civil constructions, plant & machineries of the company, a first ranking floating charge over the stocks, receivables, revenue/sale proceeds, proceeds of accounts, insurance proceeds in favour of the term loan lenders on pari passu and pro rata basis. The company has also assigned benefits under all insurance policies on pari passu basis to the lenders.

The loans are also secured by personal guarantee of all directors of the company and lien of initial paid up capital of the promoters of the company.

The sponsors have also given an undertaking to retain the majority share of the project during the tenor of the loan, to be in control of the management of the company and to inject necessary equity fund to finance any cost overrun of the project and to maintain all the covenants unless otherwise mutually agreed between the lenders and the company.

Working capital loan

Agrani Bank Limited- Principal Branch	-	5,690,146
	-	5,690,146

Working capital loan under syndication loan arrangement bearing interest @ 9.00% per annum are repayable in 23 equal monthly installments starting from 09 September 2018.



Directors' report and
audited financial statements
of the subsidiaries

**Orion Power Meghnaghat Ltd.
Dutch Bangla Power & Associates Ltd.**

Subsidiary 1

Orion Power Meghnaghat Limited



Directors' report

Reference to the provisions of Section 184 of the Companies Act 1994, and IAS/ IFRS codes, as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), it is a pleasure and privilege on the part of the Board of Directors to submit the Directors' report of Orion Power Meghnaghat Limited to the shareholders together with the audited financial statements containing Statement of Financial Position as at June 30, 2020, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows and Notes to the financial statements for the year ended June 30, 2020 at this Annual General Meeting.

Operations

Orion Power Meghnaghat Limited (OPML) is a power generation company and was incorporated on June 30, 2010 as "IEL Consortium and Associates Ltd.". The name of the company was changed the name to "Orion Power Meghnaghat Limited" on January 18, 2012. OPML completed implementation of a 100 MW HFO Power based plant on quick rental basis in Meghnaghat, Narayanganj, near the bank of the Meghna river and has been in commercial operation since May 08, 2011 for a period of 5 (five) years. Total area of this power plant is around 8 (eight) acre and it is connected with national grid, Sonargaon substation.

The company aims at delivering reliable and most affordable electricity across the country by using brand new European machineries and equipment. The term to supply electricity was expired in 2016 and has been extended for next 5 (five) years by executing an amendment to the contract for supply of power on rental basis by and between Bangladesh Power Development Board (BPDB) and the company dated December 28, 2016. OPML has been in profitable operations all over the years till date. There are 142 employees and stuffs and they are working round the clock in 3 (three) shifts. Orion Pharma Ltd. holds 95% of equity share of this company.

Appointment of Auditors

The Auditors, S. F. Ahmed & Co., Chartered Accountants, who were appointed as the statutory auditors of the company in the last Annual General Meeting, will retire in the ensuing AGM and have confirmed their eligibility and willingness to accept their office for the forthcoming financial year, if re-appointed.

Acknowledgement

The Board of Directors thankfully acknowledge the contribution made and support & co-operation given by the BPDB, employees, creditors, banks, insurance companies, utility providers, and the Government in particular and look forward to a bright future for all of us.

Sd/-

Mohammad Obaidul Karim
Chairman

Shareholding structure

The present shareholding pattern of the company is as follows:

Shareholders' name	No. of shares held	% of holding
Orion Pharma Limited	95,000,000	95.00
Integral Energy Limited	3,000,000	3.00
Jafflong Tea Company Limited	500,000	0.50
Mohammad Obaidul Karim	500,000	0.50
Salman Obaidul Karim	600,000	0.60
Arzuda Karim	350,000	0.35
Haarhuis Genertoren B.V.	50,000	0.05
Total	100,000,000	100.00

Board of Directors

The following persons are the members of the Board of the company:

Name	Position
Mr. Mohammad Obaidul Karim	Chairman
Mr. Salman Obaidul Karim	Managing Director
Mrs. Arzuda Karim	Director
Mr. Md. Shafiqur Rahman	Nominated Director

Financial reviews

The summary of the comparative analysis of results of 2019-20 and 2018-19 is as follows:

Particulars	Amount in BDT	
	2019-20	2018-19
Revenue	2,704,911,834	3,324,664,830
Gross profit	570,718,297	654,660,626
Profit from operation	524,004,484	610,457,168
Net Profit before tax	384,749,691	575,831,103
Net Profit after tax	384,749,691	575,831,103
Total assets	8,972,853,687	5,734,994,825
Shareholders' equity	4,860,979,261	4,476,229,570
Earnings per share	3.85	5.76
Net asset value per share	48.61	44.76

Orion Power Meghnaghat Ltd.

Auditors' Report & Financial Statements
As at and for the year ended 30 June 2020

 **S. F. AHMED & CO.**
Chartered Accountants

(Member Firm of HLB International)

House # 51 (2nd & 3rd Floors), Road # 09, Block # F, Banani, Dhaka-1213

AUDITORS' REPORT TO THE SHAREHOLDERS
 of
Orion Power Meghnaghat Ltd.

Opinion

We have audited the financial statements of Orion Power Meghnaghat Ltd. (the "Company"), which comprise the financial position as at 30 June 2020, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at 30 June 2020, and of its performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) as explained in note 2.1.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained in note 2, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

PERFORMANCE & FINANCIALS > Auditors' report

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books; and
- c) the statements of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts.

The engagement partner on the audit resulting in this independent auditor's report is Md. Enamul H. Choudhury.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Orion Power Meghnaghat Ltd.
Statement of Financial Position
As at 30 June 2020

	Notes	Amount in BDT	
		30 June 2020	30 June 2019
ASSETS			
Non-current assets			
Property, plant and equipment	4	3,090,185,151	3,407,463,900
		3,090,185,151	3,407,463,900
Current assets			
Inventories	5	417,117,512	362,361,806
Trade and other receivables	6	3,077,049,549	1,914,060,038
Advances, deposits and prepayments	7	2,087,501,766	44,061,834
Cash and cash equivalents	8	300,999,709	7,047,248
		5,882,668,536	2,327,530,924
TOTAL ASSETS		8,972,853,687	5,734,994,825
EQUITY AND LIABILITIES			
Equity			
Share capital	9	1,000,000,000	1,000,000,000
Revaluation surplus on property, plant and equipment		164,228,116	178,508,824
Retained earnings		3,696,751,145	3,297,720,746
		4,860,979,261	4,476,229,570
Non-current liabilities			
Long term borrowings	10	2,941,840,217	-
Provision for decommission of assets	11	143,405,563	143,405,563
Employee benefits payable	12	19,237,485	-
		3,104,483,265	143,405,563
Current liabilities			
Trade and other payables	13	901,457,334	1,018,422,507
Accrued expenses	14	105,933,827	96,937,185
		1,007,391,161	1,115,359,692
TOTAL EQUITY AND LIABILITIES		8,972,853,687	5,734,994,825

The annexed notes form an integral part of these statements.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Orion Power Meghnaghat Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2020

	Notes	Amount in BDT	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue	15	2,704,911,834	3,324,664,830
Cost of power generation	16	(2,134,193,537)	(2,670,004,203)
Gross profit		570,718,297	654,660,626
Operating expenses			
General and administrative expenses	17	(46,713,813)	(44,203,458)
Profit from operation		524,004,484	610,457,168
Finance cost	18	(120,017,308)	(34,626,065)
Net profit from operation		403,987,176	575,831,103
Worker's profit participation fund		(19,237,485)	
Net profit before tax		384,749,691	575,831,103
Income Tax Expenses		-	-
Net profit after tax		384,749,691	575,831,103
Other comprehensive income		-	-
Total comprehensive income for the year		384,749,691	575,831,103
Basic Earning Per Share (EPS)	19	3.85	5.76

The annexed notes form an integral part of these statements.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Orion Power Meghnaghat Ltd.
Statement of Changes in Equity
For the year ended 30 June 2020

	Amount in BDT			
	Share Capital	Revaluation Surplus on fixed assets	Retained Earnings	Total
Balance at 01 July 2018	1,000,000,000	192,789,532	2,707,608,934	3,900,398,466
Transfer of depreciation on revaluation surplus to retained earnings		(14,280,708)	14,280,708	-
Net profit after tax			575,831,103	575,831,103
Balance at 30 June 2019	1,000,000,000	178,508,824	3,297,720,746	4,476,229,570
Balance at 01 July 2019	1,000,000,000	178,508,824	3,297,720,746	4,476,229,570
Transfer of depreciation on revaluation surplus to retained earnings		(14,280,708)	14,280,708	-
Net profit after tax			384,749,691	384,749,691
Balance at 30 June 2020	1,000,000,000	164,228,116	3,696,751,145	4,860,979,261

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Dated, Dhaka;
24 September 2020

Orion Power Meghnaghat Ltd.
Statement of Cash Flows
For the year ended 30 June 2020

	Amount in BDT	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
A. Cash flows from operating activities		
Cash receipts from customers and others	2,654,364,836	3,638,140,604
Cash paid to suppliers, employees and other parties	(2,178,857,783)	(2,849,487,138)
Net cash provided by operating activities	475,507,053	788,653,466
B. Cash flows from investing activities		
Property, plant and equipment	(159,234)	(337,800)
Investment In Associates	-	-
Net cash used in investing activities	(159,234)	(337,800)
C. Cash flows from financing activities		
Proceed from/(Repayment of) long term borrowings	2,941,840,217	(855,370,000)
Repayment of short term borrowings/finance	(3,008,614,898)	(60,812,925)
Payment against finance cost	(114,620,677)	(38,191,378)
Net cash used in financing activities	(181,395,358)	(954,374,303)
Net changes in cash and cash equivalents (A+B+C)	293,952,461	(166,058,636)
Cash and cash equivalents at 01 July 2019	7,047,248	173,105,885
Cash and cash equivalents at 30 June 2020	300,999,709	7,047,248

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Dated, Dhaka;
24 September 2020

ORION POWER MEGHNAGHAT LTD.
Notes to the Financial Statements
As at and for the year ended 30 June 2020

1. Corporate information

Orion Power Meghnaghat Ltd., a public limited company in Bangladesh, was incorporated on June 30, 2010 as "IEL Consortium and Associates Ltd." and obtained the certificate of commencement of business on June 30, 2010. On January 18, 2012, the name of the company has been changed to Orion Power Meghnaghat Ltd. The registered office of the company is at Orion House, 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh.

1.1 Nature of business

The company has set up a 100 MW HFO Power Plant on quick rental basis in Meghnaghat, Sonargaon, Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from May 08, 2011. The contract has been extended for further five (5) years effective from May 09, 2016 vide memo no-27.00.0000.071.14.035.2013.535 dated 01 December 2016.

2. Basis of preparation of financial statements

2.1. Reporting framework and compliance thereof

The financial statements have been prepared in compliance with the requirements of the Companies Act 1994 and other relevant local laws and regulations, and in accordance with the International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs).

2.2 Measurement of the elements of financial statements

Measurement is the process of determining the monetary amounts at which the elements of the financial statements are to be recognized and carried in the statement of financial position and profit or loss and other comprehensive income. The measurement basis adopted by the company is historical cost except for buildings & civil constructions and plant & machinery which are stated at fair value. Under the historical cost, assets are recorded at the amount of cash or cash equivalents paid or the fair value of the consideration given to acquire them at the time of their acquisition. Liabilities are recorded at the amount of proceeds received in exchange for the obligation.

2.3 Functional and presentation currency

The functional and presentation currency of the company is Bangladeshi Taka (BDT). The company earns its revenues in United State Dollars (US\$), however, all other incomes/expenses and transactions are in Bangladesh Taka (BDT) and the competitive forces and regulations of Bangladesh determine the sale prices of its goods and services. Further, the entire funds from financing activities are generated in BDT and the receipts from operating activities are retained in BDT.

2.4 Going concern

When preparing financial statements, management shall make an assessment of an entity's ability to continue as a going concern. The company prepares its financial statements on a going concern basis as the company has adequate resources to continue its operation for the foreseeable future and management does not intend to liquidate the entity or to cease trading, or has no realistic alternative but to do so.

2.5 Accrual basis of accounting

The company prepares its financial statements, except for cash flow information, using the accrual basis of accounting. When the accrual basis of accounting is used, an entity recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the Framework.

2.6 Materiality and aggregation

The company presents separately each material class of similar items and items of a dissimilar nature or function unless they are immaterial. Financial statements result from processing large numbers of transactions or other events that are aggregated into classes according to their nature or function.

2.7 Offsetting

The company does not offset assets and liabilities or income and expenses, unless required or permitted by an IFRS.

2.8 Statement of cash flows

The Statement of Cash Flows has been prepared under 'Direct Method' in accordance with the requirements of IAS 7: Statement of Cash Flows.

2.9 Reporting period

The financial period of the company covers one year from 01 July 2019 to 30 June 2020.

2.10 Comparative information and rearrangement thereof

Comparative information has been disclosed in respect of the twelve months period from 01 July 2018 to 30 June 2019 for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

2.11 Use of estimates and judgments

The preparation of financial statements in conformity with International Accounting Standard (IASs) and International Financial Reporting Standards (IFRSs) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are given prospective effect in the financial statements as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

3. Significant accounting policies

The accounting policies set out below have been applied for the period presented in these financial statements.

3.1 Property, plant and equipment (PPE)

Recognition and measurement

An item shall be recognized as property, plant and equipment if, and only if it is probable that future economic benefits associated with the item will flow to the entity, and the cost of the item can be measured reliably.

Property, plant and equipment were initially stated at cost and subsequently buildings & civil constructions and plant & machineries were revalued and shown at fair value in 2011, since then the assets were depreciated from the revalued amount. All property, plant and equipment are presented, net of accumulated depreciation and/or accumulated impairment losses, if any. The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for long-term debt availed for the construction/implementation of the PPE, if the recognition criteria are met.

Subsequent costs

When significant parts of property, plant and equipment are required to be replaced at intervals, the company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repairs and maintenance costs are recognized in the income statement as incurred.

Revaluation

Valuations are performed at specific intervals to ensure that the fair value of a revalued asset does not differ materially from its carrying amount. On each reporting date, management assesses the fair value of the assets to ensure that fair value of revalued assets does not differ materially from its carrying amount. At 31 December 2011, the company made revaluation of its Building & Civil Constructions and Plant and Machineries by Syful Shamsul Alam & Co., Chartered Accountants to reflect fair value thereof in terms of depreciated current cost.

Any revaluation surplus on property, plant and equipment is recorded in other comprehensive income and hence, credited to the revaluation surplus on property, plant and equipment in equity, except to the extent that it reverses a revaluation decrease of the same asset previously recognized in the income statement, in which case, the increase is recognized in the income statement. A revaluation deficit is recognized in the income statement, except to the extent that it offsets an existing surplus on the same asset recognized in the asset revaluation reserve.

A transfer from the revaluation surplus on property, plant and equipment to retained earnings is made for the difference between depreciation based on the revalued carrying amount of the assets and depreciation based on the asset's original cost on each reporting date. Additionally, accumulated depreciation as at the revaluation date is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset. Upon disposal, any revaluation reserve relating to the particular asset being sold is transferred to the retained earnings.

Depreciation

Depreciation of an asset begins when it's get ready for use. Depreciation is charged on all property plant and equipment other than land and land developments, on a straight line basis over the expected economic lives as follows:

<u>Group of PPE</u>	<u>Expected economic life</u>
Building & civil construction	20 years
Vehicles	5 years
Office equipments	5 years
Furniture & fixtures	6 to 7 years
Plant & machineries	2 to 20 years

Impairment

At each year end, the company assesses whether there is any indication that the carrying amount of an asset exceeds its recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs to sell and its value in use. An impairment loss is recognized as an expense in the statement of profit or loss and other comprehensive income in accordance with the provision of International Accounting Standards (IAS) 36 unless the asset is revalued in accordance with IAS 16; in this case, the impairment is also recognized in other comprehensive income up to the amount of any previous revaluation. No such assets have been impaired during the year and for this reason no provision has been made for impairment of assets.

An assessment is made at each reporting date whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the company estimates the assets or CGUs recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. Such reversal is recognized in the statement of profit or loss and other comprehensive income unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Retirements and disposals

An asset is derecognized upon disposal or when no future economic benefits are expected from its use and subsequent disposal. Gains or losses arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized as gain or loss from disposal of asset under other income in the statement of profit or loss and other comprehensive income.

3.2 Foreign currency transactions

Transactions in foreign currencies are initially recorded by the company at the functional currency spot rates on the date on which the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. All differences arising on settlement or translation of monetary items are taken to the statement of profit or loss and other comprehensive income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

3.3 Inventories

Inventories stated at lower of cost and net realizable value as per International Accounting Standard (IAS) 2: Inventories. Costs incurred in bringing each product to its present location and conditions are accounted for on a First in First out (FIFO) basis. Costs comprise of expenditure incurred in the normal course of business in bringing out such inventories to its location and conditions.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

3.4 Provisions, accrued expenses and other payables

Provisions and accrued expenses are recognized in the financial statements in line with the International Accounting Standard (IAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when

- the company has a legal or constructive obligation as a result of past event.
- it is probable that an outflow of economic benefit will be required to settle the obligation.
- a reliable estimate can be made of the amount of the obligation.

Other payables are not interest bearing and are stated at their nominal value.

3.5 Provision for decommissioning costs

Orion Power Meghnaghat Ltd. has established its electricity generating plant in government land and assumed that after the contract period it may have to remove the plant from the land. The company has recognized a provision for decommission obligations associated the electricity generating facility. In determine the fair value of the provision, assumptions and estimates are made in relation to discount rates, the expected cost to dismantle and remove the plant from the site and the expected timing of those costs. The carrying amount of the provision as at June 30, 2020 was BDT 143,405,563.

3.6 Revenue recognition

Revenue is recognized in the statement of profit or loss and other comprehensive income upon supply of electricity, quantum of which is determined by survey of meter reading. Revenue is measured at fair value of consideration received or receivable. Revenue under Power Purchase Agreement (PPA) comprises capacity payments and energy payments. Capacity payments are recognized according to the terms set out in the PPA. Energy payments are calculated based on electricity delivered to BPDB.

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment.

3.7 Taxation

Current tax

As per sec. 52N of Income Tax Ordinance 1984, 6% tax is payable at the time of rental received as TDS. Bangladesh Power Development Board (BPDB) shall be responsible for payment of income taxes, VAT, duties, levies, all other charges imposed or incurred inside Bangladesh on any payment made by BPDB to Orion Power Meghnaghat Ltd. or the importation (on a re exportable basis) of any plant /equipment (excluding consumable) and /or spare parts before commercial operation date and /or replacement equipment and spare parts for operation throughout the contract period as per contract No.09756 article-17. As 6% TDS is directly paid by BPDB on the invoice amount. So tax amount is not recognized either as income or expenses in the statement of profit or loss and other comprehensive income.

3.8 Borrowing cost

In compliance with the requirement of IAS 23 (borrowing cost), borrowing cost that are directly attributable to the acquisition, construction or production of a qualifying asset form part of the cost of the asset and, therefore capitalized. Other borrowing costs are recognized in the statement of profit or loss and other comprehensive income as finance cost.

3.9 Finance cost

Finance costs comprise interest on long term borrowings, interest on redeemable preference shares and bank charges. All finance costs are recognized in the statement of profit or loss and other comprehensive income except to the extent that are capitalized as per IAS 23.

3.10 Financial instrument

The company classifies non-derivative financial assets into the following categories: financial assets at fair value through profit or loss, financial assets at fair value through other comprehensive income and amortized cost.

The company classifies non-derivative financial liabilities into the other financial liabilities category.

(i) Non-derivative financial assets and financial liabilities – recognition and derecognition

The company initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date.

The company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the company is recognized as a separate asset or liability.

The company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire.

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

(ii) Non-derivative financial assets – measurement

Financial assets at fair value through profit or loss

A financial asset is classified as at fair value through profit or loss if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognized in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value and changes therein, including any interest or dividend income, are recognized in profit or loss.

Financial assets at fair value through other comprehensive income

These assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at fair value and changes therein, other than impairment losses and foreign currency differences on debt instruments are recognized in other comprehensive income (OCI) and accumulated in the fair value reserve. When these assets are derecognized, the gain or loss accumulated in equity is reclassified to profit or loss.

Amortized cost

These assets are initially recognized at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortized cost using the effective interest method.

(iii) Non-derivative financial liabilities – measurement

Non-derivative financial liabilities are initially recognized at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortized cost using the effective interest method.

A financial instrument is any contract that gives rise to financial assets and a financial liability or equity instrument of another entity.

Impairment of financial instruments

Financial assets

The company considers evidence of impairment for financial assets at both a specific asset and collective asset level at each reporting date. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor will enter bankruptcy, etc. accordingly, 100% provision is made over the amount outstanding.

Non-financial assets

The carrying amounts of the company's non-financial assets (tangible and intangible) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any).

Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

3.11 Segment reporting

No geographical and operational segment reporting is applicable for the company as required by IFRS 8 "Operating Segment", as the company operates in single operation in a single geographical area.

3.12 Earnings per share

Basic earnings per share amounts are calculated by dividing net profit for the period attributable to ordinary equity holders by the number of ordinary shares outstanding during the year (Note-19).

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there were no potential dilutive ordinary shares during the relevant periods.

3.13 Events after reporting date

There have not been any significant events since the reporting date to the date of issue of the financial statements, which could affect the figures stated in the financial statements.

3.14 Commitments and contingencies

Contingencies arising from claim, litigation assessment, fines, penalties etc. are recorded when it is probable that a liability has been incurred and the amount can reasonably be measured.

Capital commitments

The company has no commitment of capital expenditure as at June 30, 2020.

Guarantees

The company has given a bank guarantee of BDT 20,501,000 (BDT 20,501,000; 2019) to BPDB.

4 Property, plant and equipment

Sl. No.	Group of PPE	COST			Depreciation			Amount in BDT Written Down Value as at 30.06.2020
		Balance as at 01.07.2019	Addition during the year	Balance as at 30.06.2020	Balance as at 01.07.2019	Charged during the year	Balance as at 30.06.2020	
A. At historical cost								
	Building & civil construction	541,035,963	-	541,035,963	491,084,136	30,635,084	521,719,220	19,316,743
	Plant & machineries	5,337,605,102	-	5,337,605,102	2,160,784,656	271,750,385	2,432,535,041	2,905,070,061
	Vehicles	12,106,948	-	12,106,948	10,639,037	542,004	11,181,041	925,907
	Office equipments	14,992,715	159,234	15,151,949	14,277,824	229,802	14,507,626	644,323
	Furniture & fixtures	3,804,777	-	3,804,777	3,804,777	-	3,804,777	-
	Sub Total	5,909,545,505	159,234	5,909,704,739	2,680,590,430	303,157,275	2,983,747,705	2,925,957,034
B. Revaluation								
1	Building & civil construction	16,547,715	-	16,547,715	6,205,404	827,388	7,032,792	9,514,923
2	Plant & machineries	269,066,416	-	269,066,416	100,899,902	13,453,320	114,353,222	154,713,194
	Sub Total	285,614,131	-	285,614,131	107,105,306	14,280,708	121,386,014	164,228,117
	Total 30 June 2020 (A+B)	6,195,159,636	159,234	6,195,318,870	2,787,695,736	317,437,983	3,105,133,719	3,090,185,151
	Total 30 June 2019	6,194,821,836	337,800	6,195,159,636	2,441,581,426	346,114,310	2,787,695,736	3,407,463,900

		Amount in BDT	
		30 June 2020	30 June 2019
5 Inventories			
	Spare parts	226,572,147	265,978,652
	HFO , Mobil & Chemical	50,537,832	80,708,877
	Goods in transit	140,007,532	15,674,276
		417,117,512	362,361,806
6 Trade receivables			
	Receivables from BPDB	996,939,065	946,392,067
	Current account with other related companies (6.01)	2,080,110,483	967,667,970
		3,077,049,549	1,914,060,037
6.01 Current account with other related companies			
	Dutch Bangla Power and Associates Ltd.	771,270,509	305,503,260
	Panbo Bangla Mushroom Ltd.	58,558,976	52,537,596
	Orion Gas Ltd.	12,700,000	12,700,000
	Digital Power & Associates Ltd.	71,131,807	-
	Orion Footwear Ltd.	62,005,829	50,600,000
	Orion Oil & Shipping Ltd.	138,847,669	46,930,733
	Orion Power Unit - 2 Dhaka Ltd.	180,279,066	345,812,957
	Orion Power Dhaka Ltd.	85,652,077	68,301,013
	Noakhali Gold Foods Ltd.	10,859,928	3,974,785
	Orion Agro Products Ltd.	5,968,510	1,530,572
	Orion Home Appliances Ltd.	41,048,000	1,048,000
	Orion Power Rupsha Ltd.	118,233,401	58,763,731
	Energon Renewables (BD) Ltd.	1,500,000	1,500,000
	Orion Power Sonargaon Ltd.	377,485,156	15,095,766
	Orion Quaderia Textiles Ltd.	130,000,000	-
	Horizon Media & Publications Ltd.	10,000,000	-
	Orion Hospital Ltd.	2,800,000	1,600,000
	Orion Properties Ltd.	1,769,557	1,769,557
		2,080,110,483	967,667,970
7 Advances, deposits and prepayments			
	Advances (Note - 7.1)	1,959,271,107	5,394,194
	Deposits (Note - 7.2)	106,260,703	36,041,582
	Prepayments (Note - 7.3)	21,969,957	2,626,058
		2,087,501,766	44,061,833
7.1 Advances			
	Advance Employee	2,154,997	1,637,870
	TDR - Phoneix Finance	135,500	135,500
	Advance to supplier	18,235,030	2,815,605
	Advance income tax	1,028,660	805,219
	Other investment	1,895,616,920	-
	Other Receivables	42,100,000	-
		1,959,271,107	5,394,194
7.2 Deposits			
	Bank guarantee Margin - BPDB	20,501,000	20,501,000
	Bank guarantee Margin - Others	3,879,300	3,879,300
	L/C Margin account	81,880,403	11,661,282
		106,260,703	36,041,582

		Amount in BDT	
		30 June 2020	30 June 2019
7.3 Prepayments			
	Bank guarantee commission	21,211,483	1,414,569
	Insurance premium	758,474	193,969
	Defferd Exp. - Security Bill	-	1,017,520
		21,969,957	2,626,058
8 Cash and cash equivalents			
	Cash in hand	968,296	277,341
	Cash at bank (Note- 8.01)	300,031,413	6,769,907
		300,999,709	7,047,248
8.1 Cash at bank			
	Agrani Bank Limited Principal Branch A/C- 0200000121457	794,326	113,154
	Janata Bank Ltd, A/C No: 0100206811816	22,068,536	-
	Bank Asia Ltd. A/C-02836000112	27,369,432	5,255,328
	FSIBL A/C 1121110000572	11,411	15,131
	Social Islami Bank Limited, A/C No. 13300058029	733,089	736,279
	AB Bank Limited. A/c. 4005788335000	969,586	249,266
	Premier Bank, Motijheel - 10811100017352	271,636	277,996
	IBBL A/C No- 20501360100448316	45,710	46,975
	Janata Bank Limited. FC A/C No. 0100207160410	247,692,024	-
	Agrani Bank Limited, A/C No. 264033	75,663	75,778
		300,031,413	6,769,907
9 Share capital			
	Authorised capital		
	400,000,000 Ordinary shares of BDT 10/- each	4,000,000,000	4,000,000,000
		4,000,000,000	4,000,000,000
	Issued, subscribed, called - up & paid up capital		
	100,000,000 Ordinary Shares of BDT 10/- each	1,000,000,000	1,000,000,000
	The shareholding position of the company are as under:		
Shareholder	Number of share	30 June 2020	30 June 2019
Orion Pharma Ltd.	95,000,000	950,000,000	950,000,000
Integral Energy Ltd.	3,000,000	30,000,000	30,000,000
Jafflong Tea Company Ltd.	500,000	5,000,000	5,000,000
Mohammad Obaidul Karim	500,000	5,000,000	5,000,000
Salman Obaidul Karim	600,000	6,000,000	6,000,000
Arzuda Karim	350,000	3,500,000	3,500,000
Haarhuis Genertoren B.V.	50,000	500,000	500,000
	100,000,000	1,000,000,000	1,000,000,000
10 Long term borrowings			
	Mashreq Bank PSC ,Dubai	2,941,840,217	-
		2,941,840,217	-

	Amount in BDT	
	30 June 2020	30 June 2019
11 Provision for decommission of assets		
Plant & machinery	59,922,594	59,922,594
Building	83,482,969	83,482,969
	143,405,563	143,405,563
12 Employee benefits payable		
Employee welfare fund	1,923,748	-
Bangladesh workers welfare foundation	1,923,748	-
Worker's profit participation fund	15,389,988	-
	19,237,485	-
<p>WPPF is charged @ 5% of net profit before tax as per labor law act 2006 (Amended in 2008), whereas 80% is allocated to "Worker's profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".</p>		
13 Trade and other payables		
Accounts payable - suppliers	849,880,334	912,750,128
Current account with inter companies (note-13.1)	51,577,000	105,672,379
	901,457,334	1,018,422,507
13.1 Current account with inter companies		
Interior Accom Consortium Ltd.	33,157,000	33,157,000
Orion Capital Ltd.	18,420,000	18,420,000
Digital Power and Associates Ltd.	-	54,095,379
	51,577,000	105,672,379
14 Accrued expenses		
Salary and other allowance	8,635,207	10,799,758
Director's remuneration	5,076,667	4,500,000
Provident fund	19,996,474	18,814,150
Lease Finance	1,030,470	1,585,935
Interest Payable on long term borrowings	5,396,631	-
Retention money	2,089,606	2,089,606
Withholding VAT	12,061,561	11,241,041
Withholding tax	9,673,123	8,578,452
Audit fees	345,000	345,000
Provision for gratuity	11,308,478	9,551,850
Other payable	30,320,609	29,431,393
	105,933,827	96,937,185
15 Revenue		
Reference rental price	1,322,880,000	1,311,310,000
Reference energy price (Variable - O&M)	64,594,354	67,690,844
Sales Revenue - HFO OOSL	1,323,591,182	1,989,116,394
Foreign exchange gain /(Loss)	(6,153,702)	(43,452,408)
	2,704,911,834	3,324,664,830
16 Cost of power generation		
Opening Balance	80,708,877	246,522,908
Add: Purchase (16.1)	1,494,899,797	1,950,020,063
	1,575,608,674	2,196,542,971
Less: Closing Balance	50,537,832	80,708,877
	1,525,070,842	2,115,834,093
Add: Plant overhead (16.2)	609,122,695	554,170,110
	2,134,193,537	2,670,004,203

	Amount in BDT	
	30 June 2020	30 June 2019
16.1 Purchase of raw material		
Mobil & Chemical	34,063,120	33,792,154
HFO - OOSL	1,460,836,677	1,916,227,909
	1,494,899,797	1,950,020,063
16.2 Plant overhead		
O & M service	80,818,725	40,173,756
Repair & maintenance	91,110,989	35,803,358
Salaries & allowances	87,419,600	86,681,782
Tours & travel	4,807,215	2,249,549
Foreign exchange loss	-	20,226,454
Land rent	6,912,684	6,530,458
Depreciation	317,437,983	346,114,310
Insurance, taxes & duties	-	205,003
Miscellaneous expenses	20,615,499	16,185,439
	609,122,695	554,170,110
17 General and administrative expenses		
Director remuneration	8,400,000	8,400,000
Advertisement	6,634,786	8,756,348
Entertainment	1,763,957	2,483,806
Fooding expenses	5,474,786	6,667,937
Plant office transport	-	3,018,090
Plant office utilities	507,000	431,800
Plant office communication	1,573,096	3,526,132
Fees & taxes	8,445,142	870,659
Stationary, accessories & supplies	402,707	826,766
Security service	5,938,289	7,737,470
Consultancy fees	5,932,050	321,000
Fuel test fees	-	543,450
Audit fee	345,000	345,000
CSR	1,297,000	275,000
	46,713,813	44,203,458
18 Finance cost		
Interest on long term borrowings	63,993,581	26,502,555
Loan Processing fees	22,708,750	2,505,000
Interest Expenses- Lease Finance (Phoneix Finance)	151,599	209,207
Bank commission & VAT on Comm.	32,888,511	5,298,058
Bank charges	274,867	111,245
	120,017,308	34,626,065
19 Earning per share		
The computation is given below:		
Profit after tax	384,749,691	575,831,103
Number of ordinary shares outstanding during the period	100,000,000	100,000,000
Basic earning per share (EPS)	3.85	5.76

20 Financial risk management objectives and policies

The company's principal financial liabilities comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the company's operations. The company has trade receivables, and cash and bank balances that arrive directly from its operations.

Financial instruments give rise to cash flow interest rate risk, foreign currency risk, other price risk, credit risk, and liquidity risk. Information on how these risks arise is set out below, as are the objectives, policies and processes agreed by the board for their management and the methods used to measure each risk.

The company's senior management oversees the management of these risks. The senior management ensures that the financial risk-taking activities are governed by appropriate policies and procedures and those financial risks are identified, measured and managed in accordance with policies and risk appetite.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As a policy, the company has decided to obtain all its borrowings at fixed interest rates. Hence there is no exposure to the risk of changes in market interest rates.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The company's earnings and cash flows are significantly influenced by US dollars (USD) since USD is the currency in which the company's sales are denominated. The financial position and results of the company can be affected significantly by movements in the BDT / USD exchange rates. Presently, the company does not hedge any exposure on account of foreign currency risk.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The company is exposed to credit risk from its operating activities (primarily for trade receivables) and from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

Trade receivables

At present all output of the company is sold to a single customer and trade receivable as on the reporting dates represents amounts receivable from the said customer. The party is a government owned undertaking and the management does not foresee any risk relating to the credit quality of the customer.

Financial instruments and cash deposits

Credit risk from balances with banks is managed by the company's treasury department in accordance with the company's policy. Investments of surplus funds are made only with approved counterparties. Counterparty credit limits are reviewed by the company's Board of Directors on regular basis, and may be updated throughout the year subject to approval of the Board of Directors. The limits are set to minimize the concentration of risks and therefore mitigate financial loss through potential counterparty's failure.

Liquidity risk

Liquidity risk is defined as the risk that the company will not be able to settle or meet its obligations on time or at a reasonable price.

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

The table below summarizes the maturity profile of the financial liabilities based on contractual undiscounted payments.

As at June 30, 2019:

Particulars	Long term borrowings	Provision for Decommission of Assets	Trade payables	Accruals and other payables	Total
Amount repayable within 1 year	-	-	901,457,334	105,933,827	1,007,391,161
Amount repayable within 2 to 5 years	2,941,840,217	143,405,563	-	-	3,085,245,780

21 **Related party transactions**

The company has entered into transactions with other entities that fall within the definition of related party as contained in BAS-24 "Related Party Disclosures". Total transactions of the significant related party as at 30 June 2020 are as follows:

Name of related parties	Relationship	Nature of transaction	Opening balance as on 01. 07.2019	Addition	Adjustment	Closing balance as on 30. 06.2020
Orion Pharma Ltd.	Holding Company	Investment in Share Capital	(950,000,000)	-	-	(950,000,000)
Dutch Bangla Power & Associates Ltd.	Common director/ Share holding	Intercompany Current A/C	305,503,259	522,797,087	(57,029,837)	771,270,509
Panbo Bangla Mushroom Ltd.	Common director/ Share holding	Intercompany Current A/C	52,537,596	6,021,380	-	58,558,976
Interior Accom Consortium Ltd.	Common director/ Share holding	Intercompany Current A/C	(33,157,000)	-	-	(33,157,000)
Orion Gas Ltd	Common director/ Share holding	Intercompany Current A/C	12,700,000	-	-	12,700,000
Digital Power & Associates Ltd.	Common director/ Share holding	Intercompany Current A/C	(54,095,379)	125,227,185	-	71,131,807
Orion Power Dhaka Ltd.	Common director/ Share holding	Intercompany Current A/C	68,301,013	17,351,064	-	85,652,077
Orion Properties Ltd.	Common director/ Share holding	Intercompany Current A/C	1,769,557	-	-	1,769,557
Orion Capital Ltd.	Common director/ Share holding	Intercompany Current A/C	(18,420,000)	-	-	(18,420,000)
Orion Footwear Ltd.	Common director/ Share holding	Intercompany Current A/C	50,600,000	11,859,242	(453,413)	62,005,829
Orion Oil & Shipping Ltd.	Common director/ Share holding	Intercompany Current A/C	46,930,733	353,925,046	(262,008,110)	138,847,669
Noakhali Gold Foods Ltd.	Common director/ Share holding	Intercompany Current A/C	3,974,785	6,885,143	-	10,859,928
Orion Power Unit-2 Dhaka Ltd.	Common director/ Share holding	Intercompany Current A/C	345,812,958	440,906,780	(606,440,672)	180,279,066
Orion Agro Product Ltd.	Common director/ Share holding	Intercompany Current A/C	1,530,572	4,437,938	-	5,968,510
Orion Home Appliance Ltd.	Common director/ Share holding	Intercompany Current A/C	1,048,000	40,000,000	-	41,048,000
Orion Power Rupsha Ltd.	Common director/ Share holding	Intercompany Current A/C	58,763,731	64,806,500	(5,336,831)	118,233,401
Orion Power Sonargaon Ltd.	Common director/ Share holding	Intercompany Current A/C	15,095,766	372,193,470	(9,804,080)	377,485,156
Orion Quaderia Textiles Ltd.	Common director/ Share holding	Intercompany Current A/C	-	130,000,000	-	130,000,000
Horizon Media & Publications Ltd	Common director/ Share holding	Intercompany Current A/C	-	10,000,000	-	10,000,000
Energon Renewables (BD) Ltd.	Common director/ Share holding	Intercompany Current A/C	1,500,000	-	-	1,500,000
Orion Hospital Ltd.	Common director/ Share holding	Intercompany Current A/C	1,600,000	1,200,000	-	2,800,000

Particulars	Value in BDT
Managerial remuneration paid or payable during the period to the directors, including managing directors, a managing agent or manager	8,400,000
Expenses reimbursed to managing agent	-
Commission or remuneration payable separately to a managing agent or his associate	-
Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company	-
The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the period	-
Any other perquisite or benefits in cash or in kind stating approximate money value where applicable	-
Share Based payments	-
Other allowances and commission including guarantee commission	-
(i) Pensions	-
(ii) Gratuities	-
(iii) Payments from a provident funds, in excess of own subscription and interest thereon	-

22 Capacity utilization

Licensed capacity	Installed capacity	Plant factor 2019	Plant factor 2018
		(% on licensed capacity)	(% on licensed capacity)
100.00 MW	106.80 MW	Average 24.00% Max. 62.00%	Average 43.00% Max. 65.00%

23 Employee details

During the period, there were 142 employees employed for the full year and at the end of the period, there were 142 employees in the company with remuneration of BDT 8,976 per month and above.

24 Rounding off

Amounts appearing in these financial statements have been rounded off to the nearest BDT.

25 Authorisation of financial statements to issue

The financial statements were authorised for issue by the Board of Directors on 24 September 2020.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Subsidiary 2

Dutch Bangla Power & Associates Ltd.



Directors' report

Reference to the provisions of Section 184 of the Companies Act 1994, and IAS/ IFRS codes, as adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), it is a pleasure and privilege on the part of the Board of Directors to submit the Directors' report of Dutch Bangla Power & Associates Limited to the shareholders together with the audited financial statements containing Statement of Financial Position as at June 30, 2020, Statement of Profit or Loss and Other Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows and Notes to the financial statements for the year ended June 30, 2020 at this Annual General Meeting.

Operations

Dutch Bangla Power & Associates Limited (DBPAL) is a power generation company and was incorporated on July 1, 2010 as a public limited company in Bangladesh. The company has set up a 100 MW HFO power plant on quick rental basis in Siddhirganj, Narayanganj, near the bank of the Shitalakshya river and has been in commercial operation since July 21, 2011 for a period of 5 (five) years. It is connected with national grid through Siddhirganj substation.

The use of world class equipment and deployment of world class EPC contractor enabled us to finish this project in due time, the erection period of this project was only 9 (nine) months. The term to supply electricity was expired in 2016 and has been extended for next 5 (five) years by executing an amendment to the contract for supply of power on rental basis by and between Bangladesh Power Development Board (BPDB) and the company dated December 28, 2016. DBPAL has been in profitable operations all over the years till date. There are 135 employees and staffs and they are working round the clock in 3 (three) shifts. Orion Pharma Ltd. holds 67% of equity share of this company.

Appointment of Auditors

The Auditors, S. F. Ahmed & Co., Chartered Accountants, who were appointed as the statutory auditors of the company in the last Annual General Meeting, will retire in the ensuing AGM and have confirmed their eligibility and willingness to accept their office for the forthcoming financial year, if re-appointed.

Acknowledgement

The Board of Directors thankfully acknowledge the contribution made and support & co-operation given by the BPDB, employees, creditors, banks, insurance companies, utility providers, and the Government in particular and look forward to a bright future for all of us.

Sd/-

Mohammad Obaidul Karim

Chairman

Shareholding structure

The present shareholding pattern of the company is as follows:

Shareholders' name	No. of shares held	% of holding
Orion Pharma Limited	6,700,000	67.00
Mr. Mohammad Obaidul Karim	100,000	1.00
Mrs. Arzuda Karim	10,000	0.10
Mr. Salman Obaidul Karim	3,087,500	30.88
Shenzen Nanshan Power Co. Limited	50,000	0.50
Jafflong Tea Company Limited	2,500	0.02
Orion Tea Company Limited	50,000	0.50
Total	10,000,000	100.00

Board of Directors

The following persons are the members of the Board of the company:

Name	Position
Mr. Mohammad Obaidul Karim	Chairman
Mr. Salman Obaidul Karim	Managing Director
Mrs. Arzuda Karim	Director
Mr. Md. Shafiqur Rahman	Nominated Director

Financial reviews

The summary of the comparative analysis of results of 2019-20 and 2018-19 is as follows:

Particulars	Amount in BDT	
	2019-20	2018-19
Revenue	2,645,050,896	3,157,966,223
Gross profit	726,024,365	654,600,635
Profit from operation	683,928,576	608,870,954
Net profit before tax	157,957,918	183,140,128
Net profit after tax	157,957,918	183,140,128
Total assets	8,777,067,787	7,665,784,934
Shareholders' equity	2,978,610,449	2,820,652,531
Earnings per share	15.80	18.31
Net asset value per share	297.86	282.06

Dutch Bangla Power & Associates Ltd.

Auditors' Report & Financial Statements
As at and for the year ended 30 June 2020

 S. F. AHMED & CO.
Chartered Accountants

(Member Firm of HLB International)

House # 51 (2nd & 3rd Floors), Road # 09, Block # F, Banani, Dhaka-1213



Member Firm of HLB International

■ House 51 (2nd Floor)
Road 9, Block F,
Banani, Dhaka 1213,
Bangladesh

■ Telephone : (88-02) 9872584, 9870957
Mobile 880 1707079855, 01707079856
Fax (88-02) 55042314
E-mail sfaco@dhaka.net
sfali@sfahmedco.com
ahmeds@bol-online.com

AUDITORS' REPORT TO THE SHAREHOLDERS
of
DUTCH BANGLA POWER AND ASSOCIATES LTD.

Opinion

We have audited the financial statements of Dutch Bangla Power and Associates Ltd. (the "Company"), which comprise the financial position as at 30 June 2020, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion, the accompanying financial statements give true and fair view, in all material respects, of the financial position of the Company as at 30 June 2020, and of its performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs) as explained in note 2.1.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs as explained in note 2, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the Management to ensure effective internal audit, internal control and risk management functions of the Company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements

PERFORMANCE & FINANCIALS > Auditors' report

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it appeared from our examination of these books; and
- c) the statements of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts.

The engagement partner on the audit resulting in this independent auditor's report is Md. Enamul H. Choudhury.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Dutch Bangla Power and Associates Ltd.
Statement of Financial Position
As at 30 June 2020

	Notes	Amount in BDT	
		30 June 2020	30 June 2019
ASSETS			
Non-current assets			
Property, plant and equipment	4	3,980,184,427	4,283,328,898
		3,980,184,427	4,283,328,898
Current assets			
Inventories	5	515,332,818	285,102,553
Trade and other receivables	6	3,791,541,898	2,849,406,521
Advances, deposits and prepayments	7	387,188,236	193,535,588
Cash and cash equivalents	8	102,820,408	54,411,375
		4,796,883,360	3,382,456,037
TOTAL ASSETS		8,777,067,787	7,665,784,934
EQUITY AND LIABILITIES			
Equity			
Share capital	9	100,000,000	100,000,000
Revaluation surplus on property, plant and equipment		340,145,185	343,578,627
Retained earnings		2,538,465,264	2,377,073,904
		2,978,610,449	2,820,652,531
Non-current liabilities			
Long term borrowings	10	2,941,840,217	2,415,662,045
Preference share	11	-	500,000,000
Employee benefits payable	12	7,897,896	-
		2,949,738,113	2,915,662,045
Current liabilities			
Trade and other payables	13	2,697,188,906	1,572,523,874
Accrued expenses	14	151,530,319	356,946,484
		2,848,719,225	1,929,470,358
TOTAL EQUITY AND LIABILITIES		8,777,067,787	7,665,784,934

The annexed notes form an integral part of these statements.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Dutch Bangla Power and Associates Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2020

	Notes	Amount in BDT	
		01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
Revenue	15	2,645,050,896	3,157,966,223
Cost of power generation	16	(1,919,026,531)	(2,503,365,589)
Gross profit		726,024,365	654,600,635
Operating expenses			
General and administrative expenses	17	(42,095,788)	(45,729,681)
Profit from operation		683,928,576	608,870,954
Finance cost	18	(518,072,763)	(425,730,826)
Net profit from operation		165,855,814	183,140,128
Worker's profit participation fund		(7,897,896)	-
Net Profit before tax		157,957,918	183,140,128
Income tax expenses		-	-
Net Profit after tax		157,957,918	183,140,128
Other comprehensive income		-	-
Total comprehensive income for the year		157,957,918	183,140,128
Basic Earning Per Share (EPS)	19	15.80	18.31

The annexed notes form an integral part of these statements.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Signed in terms of our separate report of even date annexed.

Dated, Dhaka;
24 September 2020

Sd/-
S. F. Ahmed & Co.
Chartered Accountants

Dutch Bangla Power and Associates Ltd.
Statement of Changes in Equity
For the year ended 30 June 2020

	Amount in BDT			
	Share Capital	Retained Earnings	Revaluation Surplus	Total
Balance at 01 July 2018	100,000,000	2,190,500,334	347,012,069	2,637,512,403
Transfer of depreciation on revaluation surplus to retained earnings	-	3,433,442	(3,433,442)	-
Net profit after tax	-	183,140,128	-	183,140,128
Balance at 30 June 2019	100,000,000	2,377,073,904	343,578,627	2,820,652,531
Balance at 01 July 2019	100,000,000	2,377,073,904	343,578,627	2,820,652,531
Transfer of depreciation on revaluation surplus to retained earnings	-	3,433,442	(3,433,442)	-
Net profit after tax	-	157,957,918	-	157,957,918
Balance at 30 June 2020	100,000,000	2,538,465,264	340,145,185	2,978,610,449

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Dated, Dhaka;
24 September 2020

Dutch Bangla Power and Associates Ltd.
Statement of Cash Flows
For the year ended 30 June 2020

	Amount in BDT	
	01 July 2019 to 30 June 2020	01 July 2018 to 30 June 2019
A. Cash flows from operating activities		
Cash receipts from customers and others	1,719,284,457	3,859,772,334
Cash paid to suppliers, employees and other parties	(898,501,737)	(3,783,369,597)
Net cash provided by operating activities	820,782,720	76,402,737
B. Cash flows from investing activities		
Acquisition of property, plant and equipment	(915,000)	(5,667,987)
Net cash used in investing activities	(915,000)	(5,667,987)
C. Cash flows from financing activities		
(Repayment of)/Proceeds from long term borrowings	26,178,172	422,693,878
Payment against finance cost	(796,725,250)	(439,494,065)
(Repayment of)/Proceeds from short term borrowing	(911,609)	(812,702)
Net cash used in financing activities	(771,458,687)	(17,612,889)
Net changes in cash and cash equivalents (A+B+C)	48,409,034	53,121,862
Cash and cash equivalents at 01 July 2019	54,411,375	1,289,513
Cash and cash equivalents at 30 June 2020	102,820,409	54,411,375

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer

Dated, Dhaka;
24 September 2020

Dutch Bangla Power and Associates Ltd. Notes to the Financial Statements As at and for the year ended 30 June 2020

1. Corporate information

Dutch Bangla Power and Associates Ltd. was incorporated on 01 July 2010 as a public limited company in Bangladesh and obtained the certificate of commencement of business under the Companies Act 1994, on the same date. The registered office of the company is at Orion House, 153-154 Tejgaon Industrial Area, Dhaka-1208, Bangladesh.

1.1 Nature of business

The company has set up a 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj with machineries and equipments supplied by Wartsila Finland OY for generation and supply of electricity. The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from July 21, 2011. The contract has been extended for further five (5) years effective from July 22, 2016 vide memo no-27.00.0000.071.14.122.2010.534 dated 01 December 2016.

2. Basis of preparation of financial statements

2.1. Reporting framework and compliance thereof

The financial statements have been prepared in compliance with the requirements of the Companies Act 1994 and other relevant local laws and regulations, and in accordance with the International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs).

2.2 Measurement of the elements of financial statements

Measurement is the process of determining the monetary amounts at which the elements of the financial statements are to be recognized and carried in the statement of financial position and statement of profit or loss and other comprehensive income. The measurement basis adopted by the company is historical cost except for land, buildings & civil constructions and plant & machinery which are stated at fair value. Under the historical cost, assets are recorded at the amount of cash or cash equivalents paid or the fair value of the consideration given to acquire them at the time of their acquisition. Liabilities are recorded at the amount of proceeds received in exchange for the obligation.

2.3 Functional and presentation currency

The functional and presentation currency of the company is Bangladeshi Taka (BDT). The company earns its revenues in United State Dollars (US\$), however, all other incomes/expenses and transactions are in Bangladeshi Taka (BDT) and the competitive forces and regulations of Bangladesh determine the sale prices of its goods and services. Further, the entire funds from financing activities are generated in BDT and the receipts from operating activities are retained in BDT.

2.4 Going concern

When preparing financial statements, management shall make an assessment of an entity's ability to continue as a going concern. The company prepares its financial statements on a going concern basis as the company has adequate resources to continue its operation for the foreseeable future and management does not intend to liquidate the entity or to cease trading, or has no realistic alternative but to do so.

2.5 Accrual basis of accounting

The company prepares its financial statements, except for cash flow information, using the accrual basis of accounting. When the accrual basis of accounting is used, an entity recognizes items as assets, liabilities, equity, income and expenses (the elements of financial statements) when they satisfy the definitions and recognition criteria for those elements in the Framework.

2.6 Materiality and aggregation

The company presents separately each material class of similar items and items of a dissimilar nature or function unless they are immaterial. Financial statements result from processing large numbers of transactions or other events that are aggregated into classes according to their nature or function.

2.7 Offsetting

The company does not offset assets and liabilities or income and expenses, unless required or permitted by a IFRS.

2.8 Statement of cash flows

The Statement of Cash Flows has been prepared under 'Direct Method' in accordance with the requirements of IAS 7: Statement of Cash Flows.

2.9 Reporting period

The financial period of the company covers one year period from 01 July 2019 to 30 June 2020.

2.10 Comparative information and rearrangement thereof

Comparative information has been disclosed in respect of the twelve months period from 01 July 2018 to 30 June 2019 for all numeric information in the financial statements and also the narrative and descriptive information where it is relevant for understanding of the current year's financial statements.

2.11 Use of estimates and judgments

The preparation of financial statements in conformity with International Accounting Standards (IASs) and International Financial Reporting Standards (IFRSs) requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions of accounting estimates are given prospective effect in the financial statements as required by IAS 8: "Accounting Policies, Changes in Accounting Estimates and Errors".

3. Significant accounting policies

The accounting policies set out below have been applied for the period presented in these financial statements.

3.1 Property, plant and equipment (PPE)

Recognition and measurement

An item shall be recognized as property, plant and equipment if, and only if it is probable that future economic benefits associated with the item will flow to the entity, and the cost of the item can be measured reliably.

Property, plant and equipment were initially stated at cost and subsequently buildings & civil constructions and plant & machineries were revalued and shown at fair value in 2011, since then the assets were depreciated from the revalued amount.

The cost of an item of property, plant and equipment comprises its purchase price, import duties and non-refundable taxes, after deducting trade discount and rebates, and any costs directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the intended manner. The cost also includes the cost of replacing part of the property, plant and equipment and borrowing costs for long-term debt availed for the construction/implementation of the PPE, if the recognition criteria are met.

Subsequent costs

When significant parts of property, plant and equipment are required to be replaced at intervals, the company recognizes such parts as individual assets with specific useful lives and depreciates them accordingly. Likewise, when a major inspection is performed, its cost is recognized in the carrying amount of the plant and equipment as a replacement if the recognition criteria are satisfied. All other repair and maintenance costs are recognized in the income statement as incurred.

Revaluation

Land, buildings & civil constructions and plant & machineries are measured at fair value. Valuations are performed at specific intervals to ensure that the fair value of a revalued asset does not differ materially from its carrying amount. On each reporting date, management assess the fair value of the assets to ensure that fair value of revalued assets does not differ materially from its carrying amount. At 31 December 2011, the company made revaluation of its Land and Land developments, Buildings and Plant and Machinery by Syful Shamsul Alam & Co., Chartered Accountants to reflect fair value thereof in terms of Depreciated Current Cost.

Any revaluation surplus on property, plant and equipment is recorded in the statement of profit or loss and other comprehensive income and hence, credited to the revaluation surplus on property, plant and equipment in equity, except to the extent that it reverses a revaluation decrease of the same asset previously recognized in the income statement, in which case, the increase is recognized in the statement of profit or loss and other comprehensive income. A revaluation deficit is recognized in the statement of profit or loss and other comprehensive income, except to the extent that it offsets an existing surplus on the same asset recognized in the asset revaluation reserve.

A transfer from the revaluation surplus on property, plant and equipment to retained earnings is made for the difference between depreciation based on the revalued carrying amount of the assets and depreciation based on the asset's original cost on each reporting date. Additionally, accumulated depreciation as at the revaluation date is eliminated against the gross carrying amount of the asset and the net amount is restated to the revalued amount of the asset. Upon disposal, any revaluation reserve relating to the particular asset being sold is transferred to the retained earnings.

Depreciation

Depreciation of an asset begins when it's get ready for use. Depreciation is charged on all property plant and equipment other than land and land developments, on a straight line basis over the expected economic lives as follows:

<u>Group of PPE</u>	<u>Expected economic life</u>
Building & civil construction	20 years
Vehicles	5 years
Office equipments	5 years
Furniture & fixtures	6 to 7 years
Plant & machineries	2 to 20 years

Impairment

At each year end, the company assesses whether there is any indication that the carrying amount of an asset exceeds its recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating units (CGU) fair value less costs to sell and its value in use. An impairment loss is recognized as an expense in the statement of profit or loss and other comprehensive income in accordance with the provision of International Accounting Standards IAS 36 unless the asset is revalued in accordance with IAS 16, in this case, the impairment is also recognized in the statement of profit or loss and other comprehensive income up to the amount of any previous revaluation. No such assets have been impaired during the year and for this reason no provision has been made for impairment of assets.

An assessment is made at each reporting date whether there is any indication that previously recognized impairment losses may no longer exist or may have decreased. If such indication exists, the company estimates the assets or CGUs recoverable amount. A previously recognized impairment loss is reversed only if there has been a change in the assumptions used to determine the asset's recoverable amount since the last impairment loss was recognized. Such reversal is recognized in the statement of profit or loss and other comprehensive income unless the asset is carried at a revalued amount, in which case, the reversal is treated as a revaluation increase.

Retirements and disposals

An asset is derecognized upon disposal or when no future economic benefits are expected from its use and subsequent disposal. Gains or losses arising from the retirement or disposal of an asset is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized as gain or loss from disposal of asset under other income in the statement of profit or loss and other comprehensive income.

3.2 Foreign currency transactions

Transactions in foreign currencies are initially recorded by the company at the functional currency spot rates on the date on which the transaction first qualifies for recognition.

Monetary assets and liabilities denominated in foreign currencies are retranslated at the functional currency spot rate of exchange at the reporting date. All differences arising on settlement or translation of monetary items are taken to the statement of profit or loss and other comprehensive income.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates as at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined.

3.3 Inventories

Inventories stated at lower of cost and net realizable value as per IAS 2: Inventories. Costs incurred in bringing each product to its present location and conditions are accounted for on a First in First out (FIFO) basis. Costs comprise of expenditure incurred in the normal course of business in bringing out such inventories to its location and conditions.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

3.4 Provisions, accrued expenses and other payables

Provisions and accrued expenses are recognized in the financial statements in line with the International Accounting Standard (IAS) 37 "Provisions, Contingent Liabilities and Contingent Assets" when

- the company has a legal or constructive obligation as a result of past event.
- it is probable that an outflow of economic benefit will be required to settle the obligation.
- a reliable estimate can be made of the amount of the obligation.

Other Payables are not interest bearing and are stated at their nominal value.

3.5 Revenue recognition

Revenue is recognized in the statement of profit or loss and other comprehensive income upon supply of electricity, quantum of which is determined by survey of meter reading. Revenue is measured at fair value of consideration received or receivable. Revenue under Power Purchase Agreement (PPA) comprises capacity payments and energy payments. Capacity payments are recognized according to the terms set out in the PPA. Energy payments are calculated based on electricity delivered to BPDB.

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the company and the revenue can be reliably measured, regardless of when the payment is being made. Revenue is measured at the fair value of the consideration received or receivable, taking into account contractually defined terms of payment.

3.6 Taxation

Current tax

As per sec. 52N of Income Tax Ordinance 1984, 6% tax is payable at the time of rental received as TDS. Bangladesh Power Development Board (BPDB) shall be responsible for payment of income taxes, VAT, duties, levies, all other charges imposed or incurred inside Bangladesh on any payment made by BPDB to Dutch-Bangla Power and Associates Ltd. or the importation (on a re exportable basis) of any plant /equipment (excluding consumable) and /or spare parts before Commercial Operation Date and /or replacement equipment and spare parts for operation throughout the contract period as per contract No.09756 article-17. As 6% TDS is directly paid by BPDB on the invoice amount. So tax amount is not recognized either as income or expenses in the statement of profit or loss and other comprehensive income.

3.7 Borrowing cost

In compliance with the requirement of IAS 23 Borrowing Cost, borrowing cost that are directly attributable to the acquisition, construction or production of a qualifying asset form part of the cost of the asset and, therefore capitalized. Other borrowing costs are recognized in the statement of profit or loss and other comprehensive income as finance cost.

3.8 Finance cost

Finance costs comprise interest on long term borrowings, dividend on preference shares and bank charges. All finance costs are recognized in the statement of profit or loss and other comprehensive income except to the extent that are capitalized as per IAS 23.

3.9 Financial instrument

The company classifies non-derivative financial assets into the following categories: financial assets at fair value through profit or loss, financial assets at fair value through other comprehensive income and amortized cost.

The company classifies non-derivative financial liabilities into the other financial liabilities category.

(i) Non-derivative financial assets and financial liabilities – recognition and derecognition

The company initially recognizes loans and receivables and debt securities issued on the date when they are originated. All other financial assets and financial liabilities are initially recognized on the trade date.

The company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. Any interest in such derecognized financial assets that is created or retained by the company is recognized as a separate asset or liability.

The company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire.

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

(ii) Non-derivative financial assets – measurement

Financial assets at fair value through profit or loss

A financial asset is classified as at fair value through profit or loss if it is classified as held-for-trading or is designated as such on initial recognition. Directly attributable transaction costs are recognised in profit or loss as incurred. Financial assets at fair value through profit or loss are measured at fair value and changes therein, including any interest or dividend income, are recognised in profit or loss.

Financial assets at fair value through other comprehensive income

These assets are initially recognised at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at fair value and changes therein, other than impairment losses and foreign currency differences on debt instruments are recognised in other comprehensive income (OCI) and accumulated in the fair value reserve. When these assets are derecognised, the gain or loss accumulated in equity is reclassified to profit or loss.

Amortised cost

These assets are initially recognised at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, they are measured at amortised cost using the effective interest method.

(iii) Non-derivative financial liabilities – measurement

Non-derivative financial liabilities are initially recognised at fair value less any directly attributable transaction costs. Subsequent to initial recognition, these liabilities are measured at amortised cost using the effective interest method.

A financial instrument is any contract that gives rise to financial assets and a financial liability or equity instrument of another entity.

Impairment of financial instruments

Financial assets

The company considers evidence of impairment for financial assets at both a specific asset and collective asset level at each reporting date. Financial assets are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

Objective evidence that financial assets are impaired can include default or delinquency by a debtor, indications that a debtor will enter bankruptcy, etc. accordingly, 100% provision is made over the amount outstanding.

Non-financial assets

The carrying amounts of the company's non-financial assets (tangible and intangible) are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated in order to determine the extent of impairment loss (if any).

Impairment losses recognised in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortisation, if no impairment loss had been recognised.

3.10 Segment reporting

No geographical and operational segment reporting is applicable for the company as required by IFRS 8 "Operating Segment", as the company operates in single operation in a single geographical area.

3.11 Earnings per share

Basic earnings per share amounts are calculated by dividing net profit for the period attributable to ordinary equity holders by the number of ordinary shares outstanding during the year (Note-19).

Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive potential ordinary shares. However, dilution of EPS is not applicable for these financial statements as there were no potential dilutive ordinary shares during the relevant periods.

3.12 Events after reporting date

There have not been any significant events since the reporting date to the date of issue of the financial statements, which could affect the figures stated in the financial statements.

3.13 Commitments and contingencies

Contingencies arising from claim, litigation assessment, fines, penalties etc. are recorded when it is probable that a liability has been incurred and the amount can reasonably be measured.

Capital commitments

The company has no commitment of capital expenditure as at June 30, 2020.

Guarantees

The company has given a bank guarantee of BDT 20,501,000 (BDT 20,501,000; 2019) to BPDB.

4 Property, plant and equipment

Sl. No.	Group of PPE	COST			Amount in BDT		
		Balance as at 01.07.2019	Addition during the year	Balance as at 30.06.2020	Depreciation Charged during the year	Balance as at 30.06.2020	Written Down Value as at 30.06.2020
A. At historical cost							
1	Land & land development	252,534,266	-	252,534,266	-	-	252,534,266
2	Building & civil construction	440,050,552	-	440,050,552	21,023,711	176,713,029	263,337,523
3	Plant & machineries	5,545,469,998	-	5,545,469,998	277,402,785	2,428,084,005	3,117,385,993
4	Vehicles	9,139,557	-	9,139,557	1,439,797	6,099,009	3,040,548
5	Office equipments	22,701,133	915,000	23,616,133	759,736	19,875,222	3,740,911
6	Furniture & fixtures	2,768,718	-	2,768,718	-	2,768,718	-
Sub Total		6,272,664,224	915,000	6,273,579,224	300,626,029	2,633,539,983	3,640,039,241
B. Revaluation							
1	Land	300,946,672	-	300,946,672	-	-	300,946,672
2	Building & civil construction	7,439,607	-	7,439,607	371,978	3,192,818	4,246,789
3	Plant & machineries	61,229,292	-	61,229,292	3,061,464	26,277,568	34,951,724
Sub Total		369,615,571	-	369,615,571	3,433,442	29,470,386	340,145,185
Total 30 June 2020 (A+B)		6,642,279,795	915,000	6,643,194,795	304,059,471	2,663,010,369	3,980,184,427
Total 30 June 2019		6,636,611,808	5,667,987	6,642,279,795	303,804,027	2,358,950,898	4,283,328,898

	Amount in BDT	
	30 June 2020	30 June 2019
5 Inventories		
Goods in transit	265,117,356	85,655,620
HFO, Mobile & Chemical	136,664,192	66,152,627
Spare parts	113,551,270	133,294,306
	515,332,818	285,102,553
6 Trade and other receivables		
Receivables from BPDB	1,509,237,639	583,471,200
Current account with other related companies (Note-6.1)	2,282,304,259	2,265,935,321
	3,791,541,898	2,849,406,521
6.1 Current account with other related companies		
Digital Power and Associates Ltd.	276,211,250	230,293,972
Orion Gas Ltd.	36,500,000	36,500,000
Orion Footwear Ltd.	45,769,566	41,000,000
Panbo Bangla Mushroom Ltd.	56,447,594	55,697,594
Orion Power Unit -2 Dhaka Ltd.	639,105,327	761,165,839
Noakhali Gold Foods Ltd.	22,270,000	21,000,000
Interior Accom Consortium Ltd.	47,500,000	47,500,000
Orion Homes Appliances Ltd.	6,800,000	6,800,000
Jafflong Tea Company Ltd.	2,408,371	2,408,371
Orion Oil & Shipping Ltd.	76,383,250	104,482,118
Orion Power Dhaka Ltd.	169,353,132	168,053,132
Orion Agro Products Ltd.	1,884,328	1,384,328
Orion Power Sonargaon Ltd.	624,411,545	514,134,185
Orion Knit Textiles Ltd.	220,544,115	219,000,000
Orion Hospital Ltd.	1,000,000	800,000
Orion Power Khulna Ltd.	43,945,781	43,945,781
Orion Properties Ltd.	11,770,000	11,770,000
	2,282,304,259	2,265,935,321
7 Advances, deposits and prepayments		
Advances (Note 7.1)	203,231,520	140,879,354
Margin (Note 7.2)	160,890,565	51,114,515
Prepayments (Note 7.3)	23,066,151	1,541,719
	387,188,236	193,535,588
7.1 Advances		
Advance Employee	1,712,818	6,843,154
Advance to supplier	100,908,161	8,326,444
Advance income tax	288,641	255,356
TDR - Phoenix Finance	321,900	321,900
Others Receivables	100,000,000	125,132,500
	203,231,520	140,879,354

	Amount in BDT	
	30 June 2020	30 June 2019
7.2 Deposits		
Bank guarantee Margin-PDB	20,501,000	20,501,000
Bank guarantee Margin-Others	20,613,515	20,613,515
Security Deposit Loan	10,000,000	10,000,000
L/C Margin	109,776,050	-
	160,890,565	51,114,515
7.3 Prepayments		
Insurance premium	194,529	127,150
Bank guaranty charge	22,360,102	1,414,569
Security service	511,520	-
	23,066,151	1,541,719
8 Cash and cash equivalents		
Cash in hand	1,199,820	750,829
Cash at bank (Note-8.1)	101,620,588	53,660,546
	102,820,408	54,411,375
8.1 Cash at bank		
Agrani Bank Limited Pr. Branch-020000051380- (101506810)	1,831,420	21,153,229
Bank Asia Ltd. A/c no. 2836000111	309,937	266,813
AB Bank Ltd.A/c no. 4005788422000	1,530,594	28,963,251
SIBL - 9021330449659	207,478	210,668
UCBL A/c no. 0951101000009438	94,905	95,595
Premier Bank, Motijheel 10811100017351	75,932	1,244
Bank Asia Ltd. A/c no. 04933001013	90,907	91,597
National Bank Limited. 1067003055909	96,620	98,170
Mercantile Bank Limited 110111127382718	7,406	2,779,979
Agrani Bank Limied. FC A/C No. 0200014751805	97,375,390	-
	101,620,588	53,660,546
9 Share capital		
Authorised capital		
100,000,000 Ordinary shares of TK. 10/- each	1,000,000,000	1,000,000,000
	1,000,000,000	1,000,000,000
Issued, subscribed, called - up & paid up capital		
10,000,000 Ordinary Shares of Tk 10/- each	100,000,000	100,000,000
	100,000,000	100,000,000

The shareholding position of the company are as under:

Name	No. of Share	30 June 2020	30 June 2019
Orion Pharma Ltd.	6,700,000	67,000,000	67,000,000
Shenzhen Nanshan Power Company Ltd.	50,000	500,000	500,000
Mohammad Obaidul Karim	100,000	1,000,000	1,000,000
Salman Obaidul Karim	3,087,500	30,875,000	30,875,000
Jafflong Tea Company Ltd.	2,500	25,000	25,000
Orion Tea Company Ltd.	50,000	500,000	500,000
Arzuda Karim	10,000	100,000	100,000
	10,000,000	100,000,000	100,000,000

	Amount in BDT	
	30 June 2020	30 June 2019
10 Long term borrowings		
Agrani Bank Limited	-	61,776,942
Janata Bank Limited	-	58,786,665
Mashreq Bank PSC, Dubai	2,941,840,217	-
Agrani Bank Limited - (Working Capital)	-	5,690,147
Term Loan - AB Bank Ltd.	-	317,837,274
Term Loan - Agrani Bank Limited	-	222,372,922
Term Loan - IPDC	-	510,798,096
Marchentile Bank	-	750,000,000
Term Loan - Premier Bank Limited	-	488,400,000
	2,941,840,217	2,415,662,045
11 Preference share		
Agrani Bank Limited	-	500,000,000
	-	500,000,000
12 Employee benefits payable		
Employee welfare fund	789,790	-
Bangladesh worker's welfare foundation	789,790	-
Worker's profit participation fund	6,318,317	-
	7,897,896	-
13 Trade and other payables		
Accounts payable - suppliers	1,498,307,301	820,710,179
Current account with inter companies (note-13.1)	1,198,881,604	751,813,695
	2,697,188,906	1,572,523,874
13.1 Current account within inter companies		
Orion Pharma Ltd.	369,399,764	370,748,526
Orion Power Rupsha Ltd.	58,211,332	75,561,909
Orion Power Meghnaghat Ltd.	771,270,509	305,503,260
	1,198,881,604	751,813,695

WPPF is charged @ 5% of net profit before tax as per labor law act 2006 (Amended in 2008), whereas 80% is allocated to "Worker's profit participation fund" , 10% to "Employee welfare fund" and 10% to " Bangladesh workers welfare foundation".

	Amount in BDT	
	30 June 2020	30 June 2019
14 Accrued expenses		
Interest payable on long term borrowings	5,692,894	129,101,742
Salary & others allowances	13,087,196	13,339,389
Director's remuneration	4,729,792	4,125,000
Interest payable on preference share	-	155,243,639
Retention money	1,529,051	1,529,051
Withholding VAT	4,748,910	4,481,224
Withholding tax	2,458,923	2,172,298
Other payable	93,323,356	23,311,086
Audit fee	345,000	345,000
Lease finance	1,248,728	2,160,337
Provision for gratuity	10,314,011	7,445,572
Providend fund	14,052,458	13,692,146
	151,530,319	356,946,484
15 Revenue		
Reference rental price	1,322,880,000	1,305,970,770
Reference energy price (Variable-O&M)	60,353,836	58,618,667
Sales Revenue HFO - OOSL	1,268,014,299	1,803,336,235
Foreign exchange gain/(loss)	(6,197,239)	(9,959,449)
	2,645,050,896	3,157,966,223
16 Cost of power generation		
Opening Balance	66,152,627	242,091,450
Add: Purchase (16.1)	1,418,864,637	1,736,022,303
	1,485,017,264	1,978,113,753
Less: Closing Balance	136,664,192	66,152,627
	1,348,353,071	1,911,961,126
Add: Plant overhead (16.2)	570,673,459	591,404,463
	1,919,026,531	2,503,365,589
16.1 Purchase of raw material		
Mobil & Chemical	33,814,400	38,857,905
HFO - OOSL	1,385,050,237	1,697,164,398
	1,418,864,637	1,736,022,303

	Amount in BDT	
	30 June 2020	30 June 2019
16.2 Plant overhead		
O & M service	58,798,914	97,963,623
Repair & maintenance	104,500,959	97,237,660
Salaries & allowances	75,525,937	71,683,514
Travelling & conveyance	3,172,473	3,395,759
Insurance	310,756	329,075
Depreciation	304,059,471	303,804,027
Miscellaneous Exp.	24,304,948	16,990,806
	570,673,459	591,404,463
17 General and administrative expenses		
Director's remuneration	8,400,000	8,400,000
CSR	131,000	5,000,000
Advertisement	4,619,183	7,010,657
Fooding and Entertainment	6,567,522	10,352,380
Office utilities	796,331	645,285
Office communication	497,407	614,237
Fees & taxes	9,292,275	5,014,058
Stationary, accessories & supplies	1,782,070	545,691
Security service	6,202,990	7,102,893
Professional and consultancy fees	3,462,010	699,480
Audit fee	345,000	345,000
	42,095,788	45,729,681
18 Finance cost		
Interest on long term borrowings	339,234,455	295,498,828
Interest on redeemable preference share	159,286,324	121,725,998
Interest Expenses - Lease Finance	207,643	306,550
Bank charges, commission and fees	19,344,341	8,199,450
	518,072,763	425,730,826
19 Earning per share		
The computation is given below:		
Profit after tax	157,957,918	183,140,128
Weighted average number of ordinary shares outstanding during the period	10,000,000	10,000,000
Basic earning per share (EPS)	15.80	18.31

20 Financial risk management objectives and policies

The company's principal financial liabilities comprise loans and borrowings, trade and other payables. The main purpose of these financial liabilities is to finance the company's operations. The Company has trade receivables, and cash and bank balances that arrive directly from its operations.

Financial instruments give rise to cash flow interest rate risk, foreign currency risk, other price risk, credit risk, and liquidity risk. Information on how these risks arise is set out below, as are the objectives, policies and processes agreed by the board for their management and the methods used to measure each risk.

The company's senior management oversees the management of these risks. The senior management ensures that the financial risk-taking activities are governed by appropriate policies and procedures and those financial risks are identified, measured and managed in accordance with policies and risk appetite.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As a policy, the Company has decided to obtain all its borrowings at fixed interest rates. Hence there is no exposure to the risk of changes in market interest rates.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The company's earnings and cash flows are significantly influenced by US dollars (USD) since USD is the currency in which the company's sales are denominated. The financial position and results of the company can be affected significantly by movements in the BDT / USD exchange rates. Presently, the company does not hedge any exposure on account of foreign currency risk.

Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The company is exposed to credit risk from its operating activities (primarily for trade receivables) and from its financing activities, including deposits with banks, foreign exchange transactions and other financial instruments.

Trade receivables

At present all output of the company is sold to a single customer and trade receivable as on the reporting dates represents amounts receivable from the said customer. The party is a Government owned undertaking and the management does not foresee any risk relating to the credit quality of the customer.

The company evaluates the concentration of risk with respect to trade receivables as low irrespective of the fact that the company's trade receivables are related to a single customer. The above conclusion has been made since the entire receivable is from BPDB which is a Government of Bangladesh undertaking.

Financial instruments and cash deposits

Credit risk from balances with banks is managed by the company's treasury department in accordance with the Company's policy. Investments of surplus funds are made only with approved counterparties. Counterparty credit limits are reviewed by the company's Board of Directors on regular basis, and may be updated throughout the year subject to approval of the Board of Directors. The limits are set to minimize the concentration of risks and therefore mitigate financial loss through potential counterparty's failure.

Liquidity risk

Liquidity risk is defined as the risk that the company will not be able to settle or meet its obligations on time or at a reasonable price.

The company's approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, management ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including the servicing of financial obligation through preparation of the cash forecast, prepared based on time line of payment of the financial obligation and accordingly arrange for sufficient liquidity/fund to make the expected payment within due date.

The table below summarizes the maturity profile of the financial liabilities based on contractual undiscounted payments.

As at June 30, 2020:

Particulars	Long term borrowings	Redeemable preference share	Trade payables	Accruals and other payables	Total
Amount repayable within 1 year	-	-	2,697,188,906	151,530,319	2,848,719,225
Amount repayable within 2 to 5 years	2,941,840,217	-	-	-	2,941,840,217

21 Related party transactions

The company has entered into transactions with other entities that fall within the definition of related party as contained in BAS-24 "Related Party Disclosures". Total transactions of the significant related party as at 30 June 2020

Name of related party	Relationship	Nature of transaction	Opening balance as on 01.07.2019	Addition	Adjustment	Closing balance as on 30.06.2020
Orion Pharma Ltd.(Share Capital)	Holding Company	Investment in Share Capital	(67,000,000)	-	-	(67,000,000)
Orion Pharma Ltd.	Holding Company	Intercompany Current A/C	(370,748,526)	1,900,000	(551,238)	(369,399,764)
Orion Power Meghnaghat Ltd.	Common director/ Share holding	Intercompany Current A/C	(305,503,260)	53,850,751	(522,797,087)	(774,449,596)
Panbo Bangla Mushroom Ltd.	Common director/ Share holding	Intercompany Current A/C	55,697,594	750,000	-	56,447,594
Digital Power & Associates Ltd.	Common director/ Share holding	Intercompany Current A/C	230,293,973	46,161,613	(244,336)	276,211,250
Orion Gas Ltd.	Common director/ Share holding	Intercompany Current A/C	36,500,000	-	-	36,500,000
Orion Power Dhaka Ltd.	Common director/ Share holding	Intercompany Current A/C	168,053,132	1,300,000	-	169,353,132
Orion Power Khulna Ltd.	Common director/ Share holding	Intercompany Current A/C	43,945,781	-	-	43,945,781
Noakhali Gold Foods Ltd.	Common director/ Share holding	Intercompany Current A/C	21,000,000	1,270,000	-	22,270,000
Orion Properties Ltd.	Common director/ Share holding	Intercompany Current A/C	11,770,000	-	-	11,770,000
Orion Oil & Shipping Ltd.	Common director/ Share holding	Intercompany Current A/C	104,482,118	279,818,061	(307,916,929)	76,383,250
Orion Footwear Ltd.	Common director/ Share holding	Intercompany Current A/C	41,000,000	5,000,000	(230,434)	45,769,566
Orion Power Unit-2 Dhaka Ltd.	Common director/ Share holding	Intercompany Current A/C	761,165,839	98,830,676	(220,891,188)	639,105,327
Interior Accom Consortium Ltd.	Common director/ Share holding	Intercompany Current A/C	47,500,000	-	-	47,500,000
Orion Homes Appliance Ltd.	Common director/ Share holding	Intercompany Current A/C	6,800,000	-	-	6,800,000
Orion Power Rupsha Ltd.	Common director/ Share holding	Intercompany Current A/C	(75,561,909)	20,850,000	(3,499,422)	(58,211,331)
Jaffong Tea Company Ltd.	Common director/ Share holding	Intercompany Current A/C	2,408,371	-	-	2,408,371
Orion Agro Products Ltd.	Common director/ Share holding	Intercompany Current A/C	1,384,328	500,000	-	1,884,328
Cargo Maritime Ltd.	Common director/ Share holding	Intercompany Current A/C	-	-	-	-
Orion Power Sonargaon Ltd.	Common director/ Share holding	Intercompany Current A/C	514,134,185	115,080,000	(4,802,640)	624,411,545
Orion Knit Textiles Ltd.	Common director/ Share holding	Intercompany Current A/C	219,000,000	1,544,115	-	220,544,115
Orion Hospital Ltd.	Common director/ Share holding	Intercompany Current A/C	800,000	200,000	-	1,000,000

Transaction with Key Management Personnel:

Particulars	Value in BDT
Managerial Remuneration paid or payable during the period to the directors, including managing directors, a managing agent or manager	8,400,000
Expenses reimbursed to Managing Agent	-
Commission or Remuneration payable separately to a managing agent or his associate	-
Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company	-
The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the period	-
Any other perquisite or benefits in cash or in kind stating, approximate money value where applicable.	-
Other allowances and commission including guarantee commission	-
(i) Pensions	-
(ii) Gratuities	-
(iii) Payments from a provident funds, in excess of own subscription and interest thereon	-
Share Based payments	-

22 Capacity utilization

Licensed capacity	Installed capacity	Plant factor 2020	Plant factor 2019
		(% on licensed capacity)	(% on licensed capacity)
100.00 MW	106.80 MW	Average 21.00% Max. 71.00%	Average 21.00% Max. 62.00%

23 Employee details

During the period, there were 135 employees employed for the full year and the end of the year with remuneration of BDT 5400 per month and above.

24 Rounding off

Amounts appearing in these financial statements have been rounded off to the nearest BDT.

25 Authorisation of financial statements to issue

The financial statements were authorised for issue by the Board of Directors on 24 September 2020.

Sd/-
Chairman

Sd/-
Managing Director

Sd/-
Chief Financial Officer





ORION PHARMA LIMITED

153-154, Tejgaon Industrial Area, Dhaka-1208

PROXY FORM

I/We _____ of _____ being a member of Orion Pharma Limited hereby appoint Mr./Mrs. _____ having BO ID No. _____, e-mail _____, Phone No. _____, as my proxy to join and vote for me/us on my/our behalf at the 55th Annual General Meeting of the Company to be held on Wednesday, the December 23, 2020 at 4:00 p.m. on a digital platform and at any adjournment thereof.

As witness my/our hand this _____ day of _____ 2020 signed by the said in presence of _____

(Signature of the Proxy)

Revenue
Stamp
Tk. 20.00/-

Signature of the Shareholder(s)

BO ID No. _____

Signature of Witness

Dated _____

Note:

A member entitled to join and vote at the General Meeting may appoint a proxy to join and vote in his/her stead. The proxy form, duly stamped, must be sent to the Registered Office of the Company via registered post/e-mail (orion.share@orion-group.net) not later than 48 hours before the time appointed for the meeting.

Signature Verified

Authorised Signatory



ORION PHARMA LIMITED

153-154, Tejgaon Industrial Area, Dhaka-1208

SHAREHOLDERS' ATTENDANCE SLIP

I/We hereby record my joining in the 55th Annual General Meeting of the Company to be held on Wednesday, the December 23, 2020 at 4:00 p.m. on a digital platform.

Name of Member(s) _____ BO ID No. _____

holding of _____ ordinary Shares of Orion Pharma Limited.

(Signature of the Proxy)

Signature of the Shareholder(s)

N.B.

1. Please note that AGM can only be joined by the honourable shareholder or properly constituted proxy.
2. Please sent this slip via registered post/e-mail (orion.share@orion-group.net) to the Registered Office of the Company.





Corporate Office : Orion House, 153-154 Tejgaon I/A, Dhaka-1208, Bangladesh

Phone : PABX : +88 02 8870133 Fax : +88 02 8870130

E-mail : orion@orion-group.net

Web : www.orionpharmabd.com, www.orion-group.net